



Planet Depos®
We Make It *Happen™*

Transcript of Dr. Sheldon Park

Date: August 7, 2025

Case: Merck Sharp & Dohme LLC -v- Halozyme Inc. (PTAB)

Planet Depos

Phone: 888.433.3767 | **Email:** transcripts@planetdepos.com

www.planetdepos.com

Michigan #8598 | Nevada #089F | New Mexico #566

WORLDWIDE COURT REPORTING & LITIGATION TECHNOLOGY

Halozyme EX2077
Merck v. Halozyme
PGR2025-00050

1 UNITED STATES PATENT AND TRADEMARK OFFICE
2 BEFORE THE PATENT TRIAL AND APPEAL BOARD
3

4 MERCK SHARP & DOHME LLC,
5 Petitioner,

6 v.

7 HALOZYME INC.,
8 Patent Owner.

9 Case Nos. PGR2025-00003;
10 PGR2025-00004; PGR2025-00006;
11 PGR2025-00009

12 U.S. Patent No. 12,123,035
13

14 Videotaped Deposition of

15 DR. SHELDON PARK

16 Buffalo, New York

17 Thursday, August 7, 2025

18 8:45 a.m. EST
19

20 Job No.: 594918

21 Pages: 1 - 234

22 Reported By: Kadi A. Harmon

1 Deposition of DR. SHELDON PARK, held at
2 the offices of:

3
4 Hyatt Regency Buffalo

5 Two Fountain Plaza

6 Buffalo, NY 14202
7
8
9

10 Pursuant to notice, before Kadi A. Harmon,
11 Court Reporter and Notary Public in and for the
12 State of New York.
13
14
15
16
17
18
19
20
21
22

A P P E A R A N C E S

ON BEHALF OF PETITIONER:

JEFFREY P. KUSHAN, ESQUIRE

CHRISTINE ENGEN, ESQUIRE

KALEN SULLIVAN, ESQUIRE

CHELSEA M. HIMES, ESQUIRE

SIDLEY AUSTIN LLP

1501 K Street, N.W.

Washington, D.C. 20005

(202) 736-8000

BRIAN M. GOLDBERG, ESQUIRE

DECHERT LLP

Cira Centre

2929 Arch Street

Philadelphia, PA 19104

(215) 994-2143

A P P E A R A N C E S C O N T I N U E D

ON BEHALF OF PATENT OWNER:

LAUREN MARTIN, ESQUIRE

ELLIOT CHOI, ESQUIRE (New York)

ZACH SUMMERS, ESQUIRE (Los Angeles)

NANCY L. ZHANG, ESQUIRE (San Francisco)

QUINN EMANUEL URQUHART & SULLIVAN LLP

111 Huntington Avenue, Suite 520

Boston, MA 02199

(617) 712-7100

R. WILSON "TREY" POWERS III, Ph.D.

ELDORA L. ELLISON, Ph.D.

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

1101 K Street NW, 10th Floor

Washington, D.C. 20005

(202) 371-2600

A P P E A R A N C E S C O N T I N U E D

ALSO PRESENT:

Charlotte Forrest, Videographer

Raechel Meyerowich, Technician

Mark Stewart, Merck

Eric Majcherzak, Merck

Aubrey Hoddach, Halozyme

Joshua Mack, Halozyme

Dr. Michael Hecht

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

6

C O N T E N T S

EXAMINATION OF DR. SHELDON PARK	PAGE
By Attorney Martin	9

E X H I B I T S

(Attached to the Transcript.)

PARK DEPOSITION EXHIBIT	PAGE
Exhibit 2068 Errata	27

PREVIOUSLY MARKED EXHIBITS

(Retained by Counsel.)

EXHIBIT		PAGE
Exhibit 1004	PGR2025-00003	18
	US Patent No. 11,952,600	
Exhibit 1004	PGR2025-00004	18
	US Patent No. 1,218,298	
Exhibit 1004	PGR2025-00006	18
	US Patent No. 12,152,262	
Exhibit 1004	PGR2025-00009	19
	US Patent No. 12,123,035	
Exhibit 1054	BLAST Sequences	81
Exhibit 1057	Clustal Omega Alignment	81

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

7

P R O C E E D I N G S

THE VIDEOGRAPHER: Here begins Media
Number 1 in the videotaped deposition of
Dr. Sheldon Park, in the matter of Merck Sharp &
Dohme, LLC versus Halozyme Inc., in the United
States Patent and Trademark Office, before the
Patent Trial and Appeal Board; Case Numbers
PGR2025-00003, PGR2025-00004, PGR2025-00006, and
PGR2025-00009.

Today's date is Thursday, August 7th,
2025. The time on the video monitor is 8:45 a.m.,
Eastern time.

The videographer today is Charlotte
Forrest representing Planet Depos. This video
deposition is taking place at Two Fountain Plaza,
Buffalo, New York, 14202.

Would Counsel please voice-identify
themselves and state whom they represent?

ATTORNEY MARTIN: Lauren Martin from Quinn
Emanuel on behalf of Patent Owner, and with me I
have Elliot Choi, also from Quinn Emanuel, and
Trey Powers, from Sterne Kessler.

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

8

1	ATTORNEY KUSHAN: Jeff Kushan from Sidney	08:45:50
2	Austin on behalf of Petitioner, Merck. With me is	08:45:55
3	Christine Engen.	08:45:55
4	Also, remotely we have attendees Kalen	08:45:56
5	Sullivan and Chelsea Himes from Sidney Austin, and	08:46:02
6	I believe Mark Stewart from Merck and Eric	08:46:05
7	Majcherzak from Merck, and you'll have to get a	08:46:12
8	spelling on the last one.	08:46:15
9	I think that's it for us.	08:46:17
10	Do you want to announce your remote	08:46:18
11	participants?	08:46:22
12	ATTORNEY MARTIN: Yeah. Can someone	08:46:22
13	announce the remote participants?	08:46:23
14	ATTORNEY ELLISON: I can do it.	08:46:32
15	This is Eldora Ellison from Sterne,	08:46:37
16	Kessler, Goldstein & Fox on behalf of Halozyme.	08:46:38
17	And it looks like we're joined by Zach Summers	08:46:39
18	from Quinn Emanuel, Aubrey Hoddach from Halozyme,	08:46:40
19	Josh -- Joshua Mack from Halozyme, and I think	08:46:44
20	that's it. Thank you.	08:46:48
21	ATTORNEY MARTIN: Thank you.	08:46:50
22	THE VIDEOGRAPHER: All right. Thank you,	08:46:50

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

9

1	Counsel.	08:46:52
2	The Court Reporter today is Kadi Harmon	08:46:52
3	representing Planet Depos. The witness will now	08:46:55
4	be sworn.	08:46:58
5	THE COURT REPORTER: Okay. Would you	
6	raise your right hand, please?	
7	THE WITNESS: Yes.	
8	THE COURT REPORTER: Do you swear or	
9	affirm that the testimony you provide today will	
10	be the truth, the whole truth and nothing but the	
11	truth?	08:47:13
12	THE WITNESS: I do.	08:47:13
13	THE COURT REPORTER: Thank you.	08:47:16
14	E X A M I N A T I O N	08:47:17
15	BY ATTORNEY MARTIN:	
16	Q Good morning, Dr. Park.	08:47:18
17	A Good morning.	08:47:19
18	Q Can you please state your full name and	08:47:19
19	address for the record?	08:47:22
20	A Sheldon Park, at 4 Fawn Meadows Court,	08:47:22
21	Amherst, New York, 14068.	08:47:26
22	Q Where are you employed, Dr. Park?	08:47:28

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

10

1	A I am employed at the University at	08:47:30
2	Buffalo.	08:47:33
3	Q And how long have you been at the	08:47:33
4	University of Buffalo?	08:47:36
5	A I have been there since year 2006.	08:47:37
6	Q And what's your position at University of	08:47:40
7	Buffalo?	08:47:43
8	A I'm currently an associate professor of	08:47:44
9	chemical and biological engineering.	08:47:49
10	Q Do you have any interest in the outcome of	08:47:53
11	this litigation?	08:47:55
12	A No. I do not.	08:47:55
13	Q When were you first contacted about this	08:47:57
14	case?	08:47:59
15	A I was first contacted back in July 2024.	08:48:03
16	Q And do you recall who contacted you?	08:48:06
17	A Mr. Jeff Kushan contacted me.	08:48:09
18	Q Have you ever been deposed before?	08:48:14
19	A No. This is the first time.	08:48:16
20	Q So Dr. Park, if at any time during the	08:48:18
21	deposition you would like clarification on one of	08:48:26
22	my questions, please ask me for clarification, and	08:48:30

1	not your counsel.	08:48:33
2	A I will.	08:48:34
3	Q Thank you.	08:48:35
4	Dr. Park, do you understand that you	08:48:36
5	cannot discuss the substance of this deposition	08:48:40
6	with anyone until the deposition is over,	08:48:42
7	including during breaks?	08:48:46
8	A I understand that.	08:48:47
9	Q Thank you.	08:48:48
10	Your counsel may object to some of my	08:48:49
11	questions during the course of the deposition, but	08:49:00
12	you have to answer every question unless you're	08:49:02
13	instructed not to answer by your counsel.	08:49:05
14	Do you understand?	08:49:08
15	A Yes. I understand.	08:49:08
16	Q And if at any time you need to take a	08:49:09
17	break, just let me know and we can take a break.	08:49:13
18	But I do ask that if a question is pending, you'll	08:49:16
19	answer the question and then we can take a break.	08:49:19
20	A I understand.	08:49:22
21	Q All right. Have you collaborated with	08:49:22
22	Merck before in your -- in your career?	08:49:32

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

12

1	A No. I have not.	08:49:34
2	Q Has Merck funded any of your research?	08:49:35
3	A No.	08:49:43
4	Q Have you ever had any -- any type of the	08:49:44
5	relationship with Merck, other than this	08:49:55
6	litigation?	08:49:57
7	A No.	08:49:58
8	Q Do you know Dr. Michael Hecht?	08:49:58
9	A I don't know him personally. I know of	08:50:06
10	his name from his publication. I read his work.	08:50:10
11	That is the extent of my familiarity with	08:50:15
12	Dr. Hecht.	08:50:19
13	Q Have you ever collaborated with Dr. Hecht?	08:50:19
14	A He wrote a chapter for me in a book that I	08:50:23
15	was editing.	08:50:30
16	(Reporter clarification.)	08:50:32
17	Q Any other collaboration?	08:50:32
18	A No.	08:50:35
19	Q Did you speak with him about his book	08:50:36
20	chapter, or did you correspond with him about his	08:50:39
21	book chapter?	08:50:43
22	A I emailed him, invited him to contribute a	08:50:44

1	chapter, and he was nice enough to do that.	08:50:47
2	Q Why did you ask him to contribute the	08:50:47
3	chapter?	08:50:49
4	A Because he was an authority in the field.	08:50:50
5	Q Have you ever heard of the company	08:51:01
6	Alteogen?	08:51:05
7	A What company?	08:51:06
8	Q Alteogen.	08:51:08
9	A No, never.	08:51:10
10	Q Do you have any experience with	08:51:11
11	hyaluronidases?	08:51:27
12	A No.	08:51:28
13	Q Do you have experience with enzymes	08:51:29
14	generally?	08:51:34
15	A No.	08:51:34
16	Q Do you know how many human hyaluronidases	08:51:35
17	there are?	08:51:42
18	A Yes. I believe there are five versions of	08:51:45
19	hyaluronidases.	08:51:49
20	Q Do you know what they're called?	08:51:50
21	A Hyaluronidase 1 through 4, and PH20.	08:51:52
22	Q Do you know which ones cleave hyaluronic	08:51:58

1	acid?	08:52:04
2	A HYAL1 and 2, and PH20 are believed to be	08:52:04
3	hyaluronidases. HYAL4, I think is a -- got	08:52:10
4	something related, the name of which just escapes	08:52:20
5	me. And then Hyaluronidase 3, I don't think it	08:52:25
6	has a known activity.	08:52:34
7	(Reporter clarification.)	08:52:38
8	A Known enzymatic activity.	08:52:38
9	Q Have you done any work with PH20?	08:52:45
10	A No.	08:52:49
11	Q What's the function of PH20?	08:52:50
12	ATTORNEY KUSHAN: Objection. Form.	08:52:57
13	A PH20, based on my reading, is an enzyme	08:53:01
14	that cleaves hyaluronic acid.	08:53:06
15	(Reporter clarification.)	08:53:18
16	Q Do you know specifically how PH20 cleaves	08:53:18
17	hyaluronic acid, what the mechanism of action is?	08:53:26
18	A I read papers on that, so I have some	08:53:29
19	knowledge of it.	08:53:33
20	Q And did you read those papers in	08:53:34
21	connection with your work on this case?	08:53:38
22	A I did.	08:53:39

1 Q So outside of your work on this case, do 08:53:40
2 you have any -- strike that. 08:53:45

3 Before you started working on this case, 08:53:50
4 had you ever had any experience with PH20? 08:53:56

5 A No. 08:53:58

6 Q Before you started working on this case, 08:53:59
7 had you ever -- had you had any experience with 08:54:03
8 hyaluronidases? 08:54:08

9 A No. 08:54:09

10 Q Did you know how many human hyaluronidases 08:54:10
11 there were before you started working on this 08:54:14
12 case? 08:54:16

13 A No. 08:54:17

14 Q Did you know which human hyaluronidases 08:54:17
15 cleave hyaluronic acid before you started working 08:54:21
16 on this case? 08:54:26

17 A No. 08:54:27

18 Q So is it fair to say that all of your 08:54:27
19 hyaluronidase-related knowledge was learned in 08:54:31
20 connection with this case? 08:54:36

21 ATTORNEY KUSHAN: Objection to form. 08:54:37

22 A Much of what I know about hyaluronidase 08:54:43

1	comes from the reading that I initiated in	08:54:46
2	relation to this case.	08:54:52
3	Q Before you started working on this case,	08:55:05
4	had you examined any structures of hyaluronidase	08:55:08
5	proteins?	08:55:14
6	A No.	08:55:16
7	Q Before you started working on this case,	08:55:16
8	had you performed any sequence assignment analysis	08:55:19
9	for hyaluronidases?	08:55:26
10	A No.	08:55:26
11	Q Have you performed any structural analysis	08:55:30
12	on any other carbohydrate active enzyme?	08:55:39
13	ATTORNEY KUSHAN: Objection to foundation.	08:55:46
14	A Any carbohydrate enzymes?	08:55:47
15	Q Uh-huh.	08:55:52
16	A Yes. I was working on a project,	08:56:02
17	NIH-funded project.	08:55:58
18	Q And what enzyme was that?	08:55:59
19	A It was ST3GAL1.	08:56:14
20	(Reporter clarification.)	08:56:24
21	Q And what work did you do with ST3GAL1?	08:56:24
22	A It's an enzyme that transfers hyaluronic	08:56:26

1	acid to a glycan we were engineering. My -- my	08:56:30
2	collaborator and I were working on engineering	08:56:35
3	that enzyme into a glycan binding protein.	08:56:39
4	Q And did you succeed in transforming the	08:56:48
5	enzyme into a glycan binding protein?	08:56:54
6	A Yes. We did.	08:56:58
7	Q How did you do that?	08:56:59
8	A Combination of rational engineering and	08:57:01
9	directed evolution.	08:57:05
10	(Reporter clarification.)	08:57:15
11	Q And when -- when did you do that work?	08:57:15
12	A The work was funded around 2020. The	08:57:19
13	money might have started coming in 2021. I forget	08:57:27
14	the exact time. And for the last four or five	08:57:33
15	years, we've worked on it.	08:57:36
16	Q Have you done any work with any other --	08:57:46
17	sorry. Strike that.	08:57:51
18	Have you done any work with glycoside	08:57:52
19	hydrolase enzymes?	08:57:58
20	ATTORNEY KUSHAN: Objection. Form.	08:58:01
21	A I have not worked with any other glycoside	08:58:03
22	hydrolase enzyme.	08:58:09

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

18

1	ATTORNEY MARTIN: I'm going to introduce	08:58:11
2	the declaration -- your four declarations for the	08:58:13
3	four PGRs that we're talking about.	08:58:17
4	These have been -- these are of record in	08:58:22
5	the cases, so the first one is Exhibit 1004 to	08:58:27
6	PGR2025-00003, regarding US Patent Number	08:58:35
7	11,952,600.	08:58:44
8	THE WITNESS: Okay.	
9	(Previously marked Exhibit 1004 introduced	
10	and retained by counsel.)	08:58:54
11	ATTORNEY MARTIN: All right. The second	08:58:54
12	one is Exhibit 1004 for PGR2025-00004, regarding	08:58:55
13	US Patent Number 1,218,298.	08:59:03
14	THE WITNESS: Okay.	08:59:10
15	(Previously marked Exhibit 1004 introduced	
16	and retained by counsel.)	
17	ATTORNEY MARTIN: The third is	08:59:11
18	Exhibit 1004 for PGR2025-00006, regarding US	08:59:12
19	Patent Number 12,152,262.	08:59:23
20	(Previously marked Exhibit 1004 introduced	
21	and retained by counsel.)	08:59:27
22	ATTORNEY MARTIN: And then the fourth is	08:59:27

1	Exhibit 1004 for PGR2025-00009, regarding US	08:59:29
2	Patent Number 12,123,035.	08:59:39
3	(Previously marked Exhibit 1004 introduced	
4	and retained by counsel.)	
5	BY ATTORNEY MARTIN:	
6	Q Dr. Park, are these four the declarations	08:59:45
7	that you submitted in support of each of the four	08:59:48
8	PGRs?	08:59:52
9	A Yes. They are the four declarations I	09:01:16
10	submitted.	09:01:19
11	Q And you signed each of those four	09:01:20
12	declarations, correct?	09:01:23
13	A I did sign them.	09:01:24
14	Q So you have -- you have papers with you.	09:01:26
15	Can you explain what that is?	09:01:33
16	A Oh, yeah. Absolutely.	09:01:34
17	I wanted to identify some minor errors --	09:01:36
18	Q Okay.	
19	A -- that came in.	09:01:39
20	Q Uh-huh.	
21	A Should I give them to you first, or read	09:01:44
22	them to you? They're minor.	09:01:47

1	First one, which appears in	09:01:50
2	Paragraph 145(b) of the proceeding ending in 3, it	09:01:57
3	reads, somewhere in there, 134 rows. It should be	09:02:08
4	95 rows.	09:02:15
5	The reason that this error came in is	09:02:17
6	because initially the analysis was performed with	09:02:21
7	the sequences that were available by the end of	09:02:26
8	year 2012, December 2012. Afterwards, the	09:02:28
9	sequences were revised to end in December of 2011,	09:02:39
10	one year prior. As a result, the number of	09:02:49
11	sequences that were included in the sample was	09:02:54
12	reduced from 134 to 95. So that's what the first	09:02:58
13	errata indicates.	09:03:08
14	Q Okay. So to be clear, if you're on	09:03:08
15	Page 80 of the declaration for proceeding ending	09:03:11
16	in 3 --	09:03:17
17	A Uh-huh.	09:03:19
18	Q -- it says -- there's a sentence that says	09:03:19
19	there were 134 rows, and you're saying that the	09:03:27
20	number 134 should instead read 95?	09:03:32
21	A That is correct.	09:03:34
22	Q Thank you. Okay.	09:03:35

1	A And the corresponding errors in the other	09:03:39
2	proceedings are, in the proceeding ending in 4,	09:03:42
3	Paragraph 151(b); proceeding ending in 006,	09:03:46
4	Paragraph 147(b); and the final proceeding ending	09:03:53
5	in 9, Paragraph 127(b), the substance of the error	09:03:57
6	is the same.	09:04:02
7	Q So in each of those cases, the -- there	09:04:02
8	were 134 rows should read there were 95 rows?	09:04:05
9	A That is correct.	09:04:07
10	Q Okay.	09:04:08
11	A The next error is a typo, which is in	09:04:10
12	paragraph -- they're all in the same paragraph of	09:04:18
13	all four proceedings, Paragraph 97.	09:04:25
14	It reads, currently: Position 374 in	09:04:30
15	PH20.	09:04:37
16	It should read: Position 372 in PH20.	09:04:38
17	That's a typographical error.	09:04:43
18	Paragraph 42 should read, instead of	09:04:47
19	isoforms of PH20, the correct terminology should	09:04:53
20	have been: Homologs of PH20.	09:05:00
21	(Reporter clarification.)	
22	A Paragraph 12 --	09:05:05

1	Q	Sorry, what? Paragraph 42?	09:05:05
2	A	42. Yeah.	09:05:11
3		The last sentence of Paragraph 42 says:	09:05:23
4		At least four isoforms of PH20.	09:05:28
5	Q	Oh, okay. Okay.	
6	A	Should read: Homologs of PH20.	09:05:31
7	Q	Thank you.	09:05:36
8	A	And Paragraph 12, that's the ending of	09:05:37
9		Paragraph 12. I believe just prior to the	09:05:43
10		parentheses should read, instead of structure,	09:05:48
11		structure relationship, should simply read:	09:05:53
12		Structure.	09:05:59
13	Q	As well as with techniques and tools used	09:05:59
14		to analyze protein structure?	09:06:04
15	A	That is correct.	
16	Q	Period.	
17	A	Period.	
18	Q	Or, actually, it's: Protein structure,	09:06:10
19		parentheses.	09:06:10
20	A	That's correct.	09:06:11
21	Q	Got it.	09:06:11
22	A	There are errors unique to some of the	09:06:12

1	proceedings.	09:06:36
2	Proceeding ending in 03, Paragraph 109, it	09:06:16
3	lists a few amino acids in that paragraph.	09:06:23
4	109, yes. In the parentheses, it should	09:06:44
5	say: E31, P32 and D34, which is currently	09:06:51
6	missing. And L317, N321, E324.	09:06:57
7	Paragraph 100 in the same document also	09:07:06
8	lists several -- Paragraph 100, I think it should	09:07:20
9	have been in Paragraph 100. I don't see that. I	09:07:42
10	think the paragraph number is not correct.	09:07:49
11	Maybe I can -- I think that it should be	09:07:55
12	around -- let me see -- 109. So let me go there	09:08:00
13	and maybe I can find it. In fact, it's	09:08:04
14	Paragraph 110.	09:08:08
15	Q Oh, okay.	
16	A Yeah. Not 100.	09:08:09
17	Q Okay.	09:08:11
18	A Yeah. In the -- in there, there's a	09:08:12
19	parentheses that ends in M323. M323 should not be	09:08:15
20	there.	09:08:24
21	Q Okay.	
22	A So it ends in L319.	09:08:24

1	Okay. Appendix C in the same document,	09:08:30
2	Row Number 4, Column J, says: K320 has 9	09:08:39
3	neighbors.	09:08:45
4	It should read: K320 has 8 neighbors.	09:08:45
5	Moving on to the next document, proceeding	09:08:53
6	ending in 4, 004, Paragraph 134, typographical	09:08:57
7	error of 34.	09:09:07
8	It says: Glutamate at position 34.	09:09:12
9	It should say: Glutamate at position 31.	09:09:17
10	Oh, yes. Yes. Halfway through glutamate	09:09:32
11	at position 31.	
12	(Reporter clarification.)	
13	A Moving on to the next one.	09:09:53
14	Appendix C was cut off. It's a table of	09:09:54
15	evaluation. And in an Excel spreadsheet, it	09:09:59
16	should have been a wrap around, but the column got	09:10:04
17	cut off, so some of the words got left out. So	09:10:08
18	Appendix C -- yeah.	09:10:13
19	Okay. In this table, the column -- Row	09:10:28
20	Number 4, Column 1 -- I'm sorry -- Column I, not	09:10:34
21	Column 1, the comments column.	09:10:38
22	It should say: Hydrophobic contacts	

1	to F64.	
2	So that was left out.	09:10:45
3	Q Sorry. For which row?	09:10:45
4	A It says Row Number 4.	09:10:48
5	Q Number 4.	
6	A Column I. The comments column, it says:	09:10:50
7	Hydrophobic contacts to --	
8	(Reporter clarification.)	
9	A Hydrophobic contacts to F64.	09:11:00
10	Appendix -- the same appendix, Row	09:11:05
11	Number 5 this time, the same column: Potential	09:11:08
12	charge repulsion.	09:11:13
13	Row Number 8: Hydrophobic contacts to	09:11:18
14	F64.	09:11:26
15	Row Number 10: Increased hydrophobic	09:11:26
16	contacts, hydrophobic exposed.	09:11:31
17	Row Number 11: Increased hydrophobic	09:11:36
18	contacts.	
19	And finally, Row Number 13: Increased	09:11:39
20	hydrophobic contacts, Ncap.	09:11:45
21	So those are the minor errors I	09:11:49
22	identified. I wanted to bring them to your	09:11:54

1	attention.	09:11:56
2	Q Okay. Thank you.	09:11:57
3	Is that all the -- did we get all of them?	09:11:59
4	A Absolute yes.	
5	Q Okay. Thank you.	09:12:01
6	ATTORNEY KUSHAN: Those are just copies.	09:12:01
7	Can I get one?	09:12:04
8	THE WITNESS: Okay. Absolutely.	09:12:05
9	ATTORNEY KUSHAN: Do you want to introduce	09:12:06
10	this as an exhibit? It's up to you.	09:12:08
11	ATTORNEY MARTIN: Yeah. Actually, that's	09:12:09
12	probably a good idea.	09:12:15
13	So Park Exhibit 1 will be the Errata.	09:12:17
14	ATTORNEY KUSHAN: Do you happen to know,	
15	Trey, what the last exhibit...	09:12:23
16	ATTORNEY POWERS: 2037 [sic].	09:12:23
17	ATTORNEY KUSHAN: So why don't we -- do	09:12:25
18	you want to do a --	
19	ATTORNEY POWERS: Start at 2037.	09:12:29
20	ATTORNEY MARTIN: Okay. So 2037.	09:12:29
21	ATTORNEY KUSHAN: So this will be 2037.	09:12:30
22	ATTORNEY POWERS: Yeah.	

1 (Park Deposition Exhibit 2068 marked for
2 identification and attached to the transcript.)

3 ATTORNEY KUSHAN: Can you just --

4 THE WITNESS: Oh, okay. Yeah.

5 BY ATTORNEY MARTIN:

6 Q So Dr. Park, can you turn to the exhibit
7 list for --

8 A Exhibit list.

9 Q Well, I guess let's use the --

10 A Sure.

11 Q -- the one ending in 3.

12 So each of your declarations has an
13 exhibit list, correct?

14 A I believe so. Should I check?

15 I believe that they are the same. I see
16 exhibit list here. There we go, assuming they are
17 the same.

18 Yes. I see an exhibit list there too.

19 Q Okay. So there's an exhibit list in each
20 of the four declarations, correct?

21 A That is correct.

22 Q All right. And just as an example, you

09:13:18

09:13:18

09:13:20

09:13:23

09:13:23

09:13:23

09:13:24

09:13:28

09:13:31

09:13:32

09:13:46

09:13:49

09:14:02

09:14:02

09:14:05

09:14:08

09:14:09

09:14:10

1	can look at the exhibit list for PGR 3, and that's	09:14:13
2	on page -- starts on Page 99 of Exhibit 1004.	09:14:18
3	A Exhibit 1004?	
4	Q Yes.	09:14:32
5	A 1004.	
6	Q So that's the exhibit list?	09:14:34
7	A Yes. Yes. The declaration you mean.	09:14:35
8	Got it.	
9	(Reporter clarification.)	09:14:40
10	Q So the exhibit list on -- you're at the	09:14:40
11	exhibit list on Page 99 of the declaration on	09:14:44
12	PGR 3?	09:14:46
13	A That is correct. I am.	09:14:47
14	Q All right. And Dr. Park, you listed all	09:14:49
15	of the materials you considered forming your	09:14:56
16	opinions in that declaration on your exhibit list,	09:14:59
17	correct?	09:15:03
18	ATTORNEY KUSHAN: Objection.	09:15:04
19	A Yes.	09:15:07
20	ATTORNEY KUSHAN: Sorry.	09:15:08
21	Objection. Foundation.	09:15:11
22	Go ahead.	

1	A Yes. I included the references that I	09:15:12
2	read in preparation for this declaration.	09:15:13
3	Q Did you include all of the materials that	09:15:17
4	you considered in forming your opinions on your	09:15:19
5	exhibit list?	09:15:22
6	A I did.	09:15:27
7	Q Now your declaration in matter PGR 3, if	09:15:28
8	you go to the cover page for that declaration, you	09:15:47
9	see it says: Case Number PGR 2025-3, and then	09:15:51
10	under that, there's a patent number, US Patent	09:15:56
11	Number 11,952,600.	09:16:17
12	Do you see that?	09:16:05
13	A I see the patent number, yes.	09:16:05
14	Q Are you familiar with the '600 patent?	09:16:08
15	A No. I'm not familiar with this patent.	09:16:11
16	Q Have you ever seen the '600 patent?	09:16:13
17	A No. I have not seen this patent.	09:16:19
18	Q Did you consider the '600 patent in	09:16:21
19	forming your opinions for this matter?	09:16:25
20	A No. I did not.	09:16:27
21	Q Did -- as part of your analysis in this	09:16:33
22	case, did you go and look up the '600 patent?	09:16:35

1	A No. I did not look up the patent '600.	09:16:39
2	Q Have you ever read a patent?	09:16:43
3	A I read a patent that's listed in the	09:16:47
4	exhibit list for the first time.	09:16:51
5	Q And that patent is the '429 patent; is	09:16:54
6	that right? Exhibit 1005, US Patent Number	09:17:01
7	7,767,429?	09:17:09
8	A That's correct. '429 patent.	09:17:09
9	Q Is the '429 patent the first patent you	09:17:12
10	ever read?	09:17:15
11	A That is the first patent that I've ever	09:17:15
12	read. Yeah.	09:17:18
13	Q Okay.	09:17:19
14	A Except for my own patent, come to think of	09:17:31
15	it.	09:17:35
16	Q Uh-huh.	
17	A It was so long ago I forgot about it. The	09:17:36
18	patent was prepared by the lawyers, and I think I	09:17:39
19	read -- I wouldn't say I read the final patent,	09:17:44
20	but whatever was prepared at some point along the	09:17:50
21	process, I was involved in drafting that patent,	09:17:55
22	so you could say that might count as a patent.	09:18:04

1	Q Do you know if it issued as a patent?	09:18:10
2	A Say it again?	09:18:15
3	Q Do you know if your patent issued?	09:18:16
4	A Oh. It was issued, yes.	09:18:18
5	Q All right. But you don't know if you've	09:18:19
6	seen the issued patent?	09:18:20
7	A I have seen it, but I haven't read it.	09:18:20
8	Q Okay.	
9	A It was good enough to know that I was	09:18:23
10	granted a patent.	09:18:26
11	Q Understood.	09:18:27
12	All right. So is it fair to say that the	09:18:28
13	only issued patent that you've ever read is the	09:18:32
14	'429 patent?	09:18:35
15	A That is correct, yes.	09:18:37
16	Q Did you -- do you know what's claimed in	09:18:50
17	the '600 patent?	09:18:57
18	A I understand it's about a mutation in a	09:19:03
19	protein, which I assume is PH20. But that's about	09:19:09
20	it.	09:19:15
21	Q Have you ever seen the patent claims for	09:19:15
22	the '600 patent?	09:19:19

1	A No. I have not.	09:19:20
2	Q Do you know what's disclosed in the	09:19:21
3	specification for the '600 patent?	09:19:25
4	A No.	09:19:27
5	Q Do you know -- do you have any idea of	09:19:28
6	anything that's disclosed in the '600 patent?	09:19:31
7	A No.	09:19:35
8	Q When you read the '429 patent, did you	09:19:35
9	read the claims?	09:19:46
10	A Can I get a copy of the '429 patent to see	09:19:50
11	where the claim is listed?	09:19:54
12	Q Sure.	09:19:57
13	So while we wait for the '429 patent, you	09:20:36
14	cited everything that you considered in forming	09:21:03
15	your opinions in your declaration, correct?	09:21:05
16	A I cited all the references that I felt	09:21:10
17	relevant to the declaration, yes.	09:21:15
18	Q And if something was, in your opinion,	09:21:16
19	relevant to your analysis, then you would have	09:21:19
20	cited -- cited it in the declaration, correct?	09:21:22
21	A I would have cited any relevant	09:21:25
22	references.	09:21:30

1	Q So if there's a reference that's not cited	09:21:30
2	in your declaration, is it fair to assume that	09:21:33
3	that reference is not relevant to your analysis?	09:21:36
4	ATTORNEY KUSHAN: Objection. Form.	09:21:38
5	A I would have felt that that reference was	09:21:40
6	not directly relevant to my declaration.	09:21:44
7	Q All right. And so just quickly looking at	09:21:50
8	the other -- your other three declarations, so the	09:21:53
9	declaration for matter 4, do you see on the cover	09:21:59
10	page, it references US Patent Number 12,018,298?	09:22:05
11	So do you understand that your declaration	09:22:11
12	in PGR matter 4 was submitted with respect to the	09:22:16
13	proceeding concerning the '298 patent?	09:22:20
14	A That seems reasonable.	09:22:24
15	Q Have you ever seen the '298 patent?	09:22:26
16	A No. I have not.	09:22:31
17	Q Did you consider the '298 patent in	09:22:32
18	forming your opinions in PGR matter 4?	09:22:40
19	A No. I have not.	09:22:42
20	Q Do you know what's claimed in the '298	09:22:43
21	patent?	09:22:48
22	A I believe it's a mutation on a protein,	09:22:48

1	again probably PH20. Other than that, I'm not	09:22:55
2	familiar with the content of that patent.	09:22:58
3	Q Do you know what's disclosed in the '298	09:23:01
4	patent?	09:23:05
5	A No. I don't.	09:23:05
6	Q And then PGR -- your declaration in PGR	09:23:12
7	matter 6, on the cover page, lists US Patent	09:23:18
8	Number 12,152,262.	09:23:24
9	So do you understand that your declaration	09:23:27
10	in PGR matter 6 was submitted proceeding	09:23:30
11	concerning the '262 patent?	09:23:35
12	A It appears that way.	09:23:38
13	Q Have you ever seen the '262 patent?	09:23:39
14	A I have not seen that patent, '262.	09:23:44
15	Q Do you know what's claimed in the '262	09:23:47
16	patent?	09:23:50
17	A Again, I'm assuming it's a mutation on a	09:23:54
18	protein, PH20 perhaps. That's the extent of my	09:23:58
19	assumption.	09:24:03
20	Q So you don't know for sure. You're	09:24:04
21	just -- you're assuming that there's a mutation on	09:24:07
22	PH20 that's claimed?	09:24:11

1	A I do not know that for sure. I've never	09:24:12
2	seen the patent, so I don't know what's claimed in	09:24:17
3	it.	09:24:21
4	Q Did you ask for the patent when you were	09:24:21
5	performing your analysis?	09:24:24
6	A No. I did not.	09:24:28
7	Q Did you think that the patent was relevant	09:24:29
8	to your analysis?	09:24:31
9	A No. I didn't think so.	09:24:34
10	Q So you don't know what's disclosed in the	09:24:38
11	'262 patent?	09:24:41
12	A I don't know what's disclosed in that	09:24:42
13	patent.	09:24:44
14	Q All right. And then finally, your	09:24:50
15	declaration in PGR matter 9 lists US Patent Number	09:24:52
16	12,123,035.	09:25:02
17	So do you understand that your declaration	09:25:05
18	in PGR matter 9 was submitted with respect to the	09:25:07
19	'035 patent?	09:25:12
20	A That's my reading of it.	09:25:17
21	Q Have you ever seen the '035 patent?	09:25:18
22	A No. I have not seen the patent '035.	09:25:23

1	Q Do you know what's claimed in the '035	09:25:27
2	patent?	09:25:30
3	A Perhaps a mutation on PH20.	09:25:31
4	Q But you don't know for sure?	09:25:35
5	A I don't know it for sure.	09:25:37
6	Q And do you know what's disclosed in the	09:25:38
7	'035 patent?	09:25:42
8	A No. I don't know what's disclosed in that	09:25:42
9	patent.	09:25:46
10	Q All right. Dr. Park, do you know what a	09:25:47
11	patent claim is?	09:26:13
12	A Only in a lay term.	09:26:15
13	Q And what's your lay understanding of what	09:26:18
14	a patent claim is?	09:26:20
15	A You make a discovery, and you take	09:26:22
16	ownership of that discovery, and the government	09:26:26
17	gives you some authority, claims, for that	09:26:31
18	discovery over other people.	09:26:37
19	Q Do you know what a -- what the terms --	09:26:42
20	strike that.	09:26:46
21	Have you ever interpreted a patent claim?	09:26:47
22	A No. I have not.	09:27:01

1	Q Okay. Do you understand that trial has	09:27:02
2	been instituted in the four PGRs that we're	09:27:14
3	talking about today?	09:27:17
4	A No.	09:27:20
5	Q Okay. Have you seen the institution	09:27:21
6	decision for any of those -- any of these PGRs?	09:27:24
7	A What do you mean by institution decision?	09:27:28
8	Q It's a decision that was issued by the	09:27:31
9	Patent -- by the PTAB?	09:27:35
10	A By the patent?	09:27:38
11	Q By the Patent Office?	09:27:40
12	A By the Patent Office.	09:27:42
13	What did they issue?	09:27:44
14	Q It's called an institution decision.	09:27:46
15	A And what does the -- what does the	09:27:49
16	decision say?	09:27:51
17	Q I'm just asking if you've seen it.	09:27:51
18	A Oh, no. I've -- I have not seen it.	09:27:54
19	Q Okay. All right.	09:27:56
20	Okay. So Dr. Park, in your work, have you	09:28:22
21	attempted to predict the impact of substitutions	09:28:26
22	on protein function?	09:28:32

1	ATTORNEY KUSHAN: Objection. Form.	09:28:34
2	A In what work are you referring to?	09:28:35
3	Q Your work outside of this case. Just	09:28:37
4	your -- in your career.	09:28:40
5	A In my career?	09:28:42
6	Q Uh-huh.	09:28:44
7	A Yes.	09:28:44
8	Q Can you estimate how many -- for how many	09:28:47
9	proteins you've done this type of analysis, where	09:28:55
10	you're trying to impact -- predict the impact of	09:29:01
11	substitutions on protein function?	09:29:05
12	ATTORNEY KUSHAN: Objection. Form.	09:29:07
13	A The total number of proteins that I have	09:29:11
14	ever worked on? Is that what you're asking?	09:29:14
15	Q Yes.	09:29:17
16	A In my career?	09:29:18
17	Q Yes.	09:29:24
18	A I would say 10.	09:29:27
19	Q And what types of proteins were those	09:29:32
20	proteins that you worked on?	09:29:42
21	What was the function?	09:29:45
22	ATTORNEY KUSHAN: Objection. Form.	09:29:47

1	A They vary. They include binders, small	09:29:49
2	molecule binders, antibody, small proteins that	09:29:57
3	bind other proteins.	09:30:05
4	Q Anything else?	09:30:10
5	A Protein that binds DNA. Protein that	09:30:13
6	binds carbohydrate. I think that's it.	09:30:19
7	Q And what kind of work have you done on	09:30:35
8	antibodies?	09:30:38
9	A I use directed evolution to engineer an	09:30:43
10	antibody that binds an antigen in a pH dependant	09:30:49
11	manner.	09:30:57
12	Q When you say you used directed evolution,	09:31:02
13	do you mean that you screened a library of	09:31:07
14	antibodies to identify antibodies that had the	09:31:12
15	desired pH dependant binding profile?	09:31:15
16	ATTORNEY KUSHAN: Objection. Foundation.	09:31:17
17	A That is exactly what I did.	09:31:20
18	Q Okay. How did you generate -- or, sorry.	09:31:45
19	Strike that.	09:31:49
20	Did you generate the library of antibodies	09:31:49
21	that you screened?	09:31:51
22	A How did I generate the library?	09:31:51

1	Q Well, did you generate the library?	09:31:53
2	ATTORNEY KUSHAN: Objection. Foundation.	09:31:56
3	A We constructed the library ourselves.	09:32:00
4	Q And how --	09:32:03
5	A My students and I.	09:32:05
6	Q And how did you construct the library?	09:32:07
7	What -- I'll ask a better question.	09:32:14
8	What -- strike that.	09:32:15
9	Did you introduce specific mutations into	09:32:25
10	sequences when you generated the library, or was	09:32:43
11	it just a random library of antibodies?	09:32:46
12	ATTORNEY KUSHAN: Objection. Form.	09:32:51
13	Objection to foundation.	09:32:52
14	A It was a combination of both.	09:32:53
15	Q Okay. In the analysis that you performed	09:33:34
16	in these matters, you used several different	09:33:37
17	computational tools, correct?	09:33:43
18	A I used tools that involved computation in	09:33:46
19	the back -- background, yes.	09:33:52
20	Q And you -- specifically, you used PyMol,	09:33:54
21	SWISS-MODEL, Clustal Omega and BLAST; is that	09:33:58
22	right?	09:34:05

1	A	Those were the four major tools and web	09:34:05
2		services I used.	09:34:12
3	Q	Are there any other computational tools	09:34:13
4		that you used in your analysis for these PGRs?	09:34:17
5	A	No.	09:34:20
6	Q	And were all four of these tools known in	09:34:21
7		2011?	09:34:25
8	A	They were well-known, and widely used.	09:34:29
9	Q	In your work in the 2011 time frame, were	09:34:33
10		you using programs like PyMol, SWISS-MODEL,	09:34:49
11		Clustal Omega and BLAST?	09:35:02
12	A	I was using them actively, yes.	09:35:03
13	Q	Were there other computational tools that	09:35:08
14		were in use in the 2011 time frame that are	09:35:15
15		similar to PyMol, SWISS-MODEL, Clustal Omega and	09:35:20
16		BLAST?	09:35:25
17	ATTORNEY KUSHAN:	Objection. Form.	09:35:26
18		And objection. Foundation.	09:35:28
19	A	Are there alternative tools?	09:35:31
20	Q	Yes.	09:35:34
21	A	For some of them, there were alternative	09:35:35
22		tools.	09:35:44

1	Q And what are some examples of alternative	09:35:45
2	tools that were available in 2011?	09:35:48
3	A For instance, PyMol, which is a molecular	09:35:55
4	viewer. There was software, and even today there	09:36:00
5	is that software, that was written out of use in	09:36:05
6	San Francisco, Chimera, which does very similar	09:36:10
7	work as PyMol.	09:36:17
8	Q What about Coot? Was that available?	09:36:19
9	A Coot is a much more advanced tool used in	09:36:24
10	molecular modeling, determining X-ray crystal	09:36:31
11	structure. It's a more niche application compared	09:36:40
12	to PyMol or Chimera.	09:36:43
13	Q But in 2011, Chimera, PyMol and Coot were	09:36:43
14	all available?	09:36:56
15	A Yes.	09:36:56
16	Q And SWISS-MODEL is a -- strike that.	09:36:56
17	Were there alternatives to SWISS-MODEL	09:37:04
18	that were available in 2011?	09:37:09
19	A Yes. There were alternatives.	09:37:13
20	Q What were those?	09:37:16
21	A MODELLER, for instance. Perhaps Rosetta.	09:37:19
22	(Reporter clarification.)	09:37:33

1	Q Any others?	09:37:33
2	A There might have been. I don't remember.	09:37:35
3	Q In your work in 2011, were you using	09:37:38
4	structure prediction programs like SWISS-MODEL?	09:37:44
5	ATTORNEY KUSHAN: Objection. Form.	09:37:50
6	A Prior to 2011, I had used SWISS-MODEL.	09:37:55
7	Not in the year of 2011.	09:38:01
8	Q Okay. In that time frame, had you used	09:38:03
9	MODELLER?	09:38:10
10	A No. I did not use MODELLER.	09:38:12
11	Q And what about Rosetta? Did you use	09:38:15
12	Rosetta in that time frame?	09:38:18
13	A No.	09:38:21
14	Q How does SWISS-MODEL compare with MODELLER	09:38:23
15	and Rosetta?	09:38:30
16	ATTORNEY KUSHAN: Objection. Form.	09:38:31
17	A SWISS-MODEL is a web service, as opposed	09:38:33
18	to Rosetta and MODELLER that you need to run at	09:38:38
19	the command line. So one would have to be much	09:38:42
20	more sophisticated to be able to use them.	09:38:45
21	And they also required licensing	09:38:48
22	sometimes. Even if it's an academic licensing,	09:38:50

1	you would have to sign a form. So there was a lot	09:38:54
2	more involved in launching those programs, and not	09:38:57
3	many people had the -- the resources or the	09:39:01
4	capability to do it.	09:39:03
5	Q So is that why you used SWISS-MODEL as	09:39:05
6	opposed to MODELLER or Rosetta?	09:39:16
7	A That is correct.	09:39:17
8	Q And in the 2011 time frame, in your work	09:39:18
9	were you using PyMol?	09:39:22
10	A Yes. I was.	09:39:25
11	Q Did you use Chimera or Coot in that time	09:39:26
12	frame?	09:39:39
13	A I used Chimera sometimes, but in the end	09:39:39
14	we decided to go with PyMol because it was easier	09:39:46
15	to work with.	09:39:51
16	Q And do you have any experience with Coot?	09:39:59
17	A I have never used Coot.	09:40:03
18	Q Have you ever solved a protein crystal	09:40:13
19	structure?	09:40:17
20	A I solved a crystal structure in	09:40:21
21	collaboration with a crystallographer.	09:40:27
22	Q So --	09:40:33

1	A Two structures.	09:40:33
2	Q Two structures?	
3	A To be precise.	09:40:35
4	Q So and what was your involvement in	09:40:36
5	solving those structures?	09:40:40
6	A I made the protein, purify the protein,	09:40:41
7	and provide the protein to the crystallographer so	09:40:47
8	that they could crystalize and determine the	09:40:54
9	structure. And at the end, I interpreted the	09:40:58
10	structure and wrote the paper.	09:41:01
11	Q But you didn't actually -- you interpreted	09:41:03
12	the -- you interpreted the model once the	09:41:10
13	structure was solved; is that right?	09:41:12
14	ATTORNEY KUSHAN: Objection. Foundation.	09:41:14
15	A Once the structure has been determined by	09:41:16
16	the crystallographer, I interpreted it, compared	09:41:21
17	with the prediction, and ultimately wrote the	09:41:27
18	paper, which got published, as me as the leading	09:41:34
19	author.	09:41:43
20	(Reporter clarification.)	09:41:45
21	Q And what proteins were those when you were	09:41:45
22	involved in solving the structure?	09:41:49

1	A One is FK-506 binding protein. The second	09:41:52
2	is monomeric streptavidin.	09:42:00
3	Q And the papers that you wrote in	09:42:08
4	connection with those -- sorry. Strike that.	09:42:11
5	The papers that were published in	09:42:14
6	connection with that work, are those on your CV?	09:42:18
7	A Yes. They are.	09:42:22
8	ATTORNEY MARTIN: So we've probably been	09:42:27
9	going for an hour. Do you want to take a short	09:42:30
10	break?	09:42:34
11	THE WITNESS: Sounds great.	09:42:35
12	THE VIDEOGRAPHER: We are going off the	09:42:38
13	record. The time is 9:42 a.m.	09:42:40
14	(Recess from 9:42 a.m. until 9:54 a.m.)	09:42:44
15	THE VIDEOGRAPHER: We are back on the	09:54:23
16	record. The time is 9:54 a.m.	09:54:24
17	BY ATTORNEY MARTIN:	09:54:28
18	Q Welcome back, Dr. Park.	09:54:29
19	So in the 2011 time frame, had you used	09:54:31
20	the SWISS-MODEL program to predict protein	09:54:36
21	structure?	09:54:41
22	ATTORNEY KUSHAN: Objection. Form.	09:54:41

1	A	Predict a protein structure? I used	09:54:45
2		SWISS-MODEL to model a protein. Predict might be	09:54:50
3		a little over -- an overstatement.	09:54:57
4	Q	Okay. Let me ask a more clear question	09:54:59
5		then.	09:55:03
6		So in the 2011 time frame, had you used	09:55:04
7		the SWISS-MODEL program to model a protein	09:55:08
8		structure?	09:55:12
9	A	Yes. I have.	09:55:12
10	Q	Okay. So can you turn in your declaration	09:55:13
11		for the matter 3 case?	09:55:30
12	A	Which one?	09:55:32
13	Q	The one that you have opened right there.	09:55:33
14	A	Yes.	09:55:37
15	Q	So Paragraph 12, which is on Page 3.	09:55:37
16	A	Yes.	09:55:53
17	Q	And you said: Counsel for Merck provided	09:55:54
18		the following description of a person of ordinary	09:55:58
19		skill of the art in the 2011 time frame for you to	09:56:04
20		evaluate; is that right?	09:56:10
21	A	Yes.	09:56:12
22	Q	And your -- the definition that you	09:56:12

1 provided: A person of ordinary skill in the art
2 in the 2011 time frame would have had an
3 undergraduate degree, a Ph.D., and postdoctoral
4 experience in scientific fields relevant to the
5 study of protein structure and function, e.g.,
6 chemistry, biochemistry, biology, biophysics.
7 From training and experience, the person would
8 have been familiar with factors influencing
9 protein structure, folding inactivity, production
10 of modified proteins, using recombinant DNA
11 techniques, and use of biological assays to
12 characterize protein function, as well as
13 techniques and tools used to analyze protein
14 structure, i.e., sequence searching and
15 alignments, protein modeling software, et cetera;
16 is that right?

17 A That's correct. That was the description
18 provided by counsel.

19 Q Okay. And so throughout this deposition,
20 I'm going to use the term POSA to refer to person
21 of ordinary skill in the art.

22 A Okay.

09:56:14

09:56:17

09:56:20

09:56:24

09:56:27

09:56:28

09:56:33

09:56:34

09:56:36

09:56:41

09:56:44

09:56:49

09:56:49

09:56:52

09:56:55

09:56:59

09:57:00

09:57:03

09:57:05

09:57:08

09:57:15

09:57:17

1	Q Okay. In the 2011 time frame, were you a	09:57:17
2	person of ordinary skill in the art?	09:57:22
3	Did you meet this definition?	09:57:26
4	A In the year 2011, I was a POSA, yes.	09:57:29
5	Q And so in the 2011 time frame, a POSA	09:57:33
6	could have used the SWISS-MODEL program to model a	09:57:42
7	protein structure; is that right?	09:57:46
8	A That is correct.	09:57:47
9	Q And in the 2011 time frame, a POSA also	09:57:47
10	could have used MODELLER and Rosetta to model a	09:57:50
11	protein structure; is that right?	09:57:57
12	A If we say a POSA is a person of ordinary	09:57:59
13	skill, I do not think it would be reasonable to	09:58:05
14	expect a POSA to be able to use other software	09:58:10
15	that I mentioned earlier, including MODELLER or	09:58:14
16	Rosetta.	09:58:18
17	Q And is that because you would have to get	09:58:19
18	a license to use those programs, and the POSA	09:58:21
19	wouldn't necessarily have a license?	09:58:26
20	A No. The learning curve would have been	09:58:28
21	very steep.	09:58:32
22	Q Oh. Okay. They're just more	09:58:32

1	technically --	09:58:34
2	A Highly more --	09:58:36
3	Q Okay.	
4	A -- advanced.	09:58:38
5	Q Okay. So in your view, the POSA could	09:58:38
6	have used SWISS-MODEL, but not necessarily	09:58:41
7	MODELLER or Rosetta?	09:58:45
8	A That is correct.	09:58:48
9	Q Okay. Thanks.	09:58:49
10	All right. And then in the 2011 time	09:58:51
11	frame, had you used Clustal Omega for sequence	09:59:12
12	alignments?	09:59:17
13	A I did.	09:59:17
14	Q And the skilled person, or POSA, in 2011	09:59:17
15	could have used Clustal Omega to perform a	09:59:25
16	sequence alignment, correct?	09:59:28
17	A That's correct.	09:59:28
18	Q Were there other programs that the POSA	09:59:29
19	could have used in the 2011 time frame to run	09:59:34
20	sequence alignments?	09:59:38
21	A There were other sequence alignment	09:59:41
22	programs out there, but most of them were esoteric	09:59:46

1	in a way, not well-known. A person who	09:59:55
2	specializes in bioinformatics might know the	10:00:00
3	advantages of using different programs. But a	10:00:05
4	POSA would not be in a position to compare and	10:00:10
5	contrast different programs to see if there is a	10:00:14
6	benefit in using other program. And as such, they	10:00:18
7	would have used something like Clustal Omega as	10:00:24
8	opposed to other algorithms.	10:00:28
9	Q Okay. And would the skilled person have	10:00:30
10	been able to use BLAST to identify homologous	10:00:41
11	sequences in the 2011 time frame?	10:00:46
12	A A POSA would have been able to use BLAST	10:00:50
13	to find homologous sequences, yes.	10:00:55
14	Q Were there any other tools that a POSA	10:01:00
15	could have used in the 2011 time frame to identify	10:01:05
16	homologous sequences for alignment besides BLAST?	10:01:10
17	A I haven't used any other program besides	10:01:14
18	BLAST personally. I would think that there might	10:01:19
19	have been, but I'm not aware of any particular one	10:01:23
20	that would be equally versatile as BLAST, and an	10:01:26
21	ordinary person, a person of ordinary skill, would	10:01:36
22	have chosen BLAST as a search tool as opposed to	10:01:40

1	any other tools out there.	10:01:46
2	Q How many times in your career would you	10:01:49
3	say you've used SWISS-MODEL to generate a homology	10:02:14
4	model of a protein?	10:02:22
5	A How many times? That's a very difficult	10:02:24
6	estimate.	10:02:30
7	Q Okay.	10:02:30
8	A It's almost like asking how many times	10:02:33
9	have you gone to the bathroom in your lifetime. I	10:02:39
10	would say many. I don't know exactly how many.	10:02:43
11	Q Okay. So you used -- you've used	10:02:45
12	SWISS-MODEL frequently in your work to generate	10:02:51
13	homology models; is that right?	10:02:54
14	ATTORNEY KUSHAN: Objection. Form.	10:02:54
15	A At times, yes.	10:02:55
16	Q Okay. What's the purpose of generating --	10:02:57
17	well, actually strike that.	10:03:03
18	Like me make sure I'm using the right	10:03:05
19	terminology here.	10:03:09
20	So the model that you generate using	10:03:10
21	SWISS-MODEL, would you refer to that as a model,	10:03:14
22	or a homology model, or is there some other term?	10:03:15

1	A	You can use either one.	10:03:24
2	Q	Uh-huh.	
3	A	Unless the structure of the protein is	10:03:26
4		known, any time you have a model, it's going to be	10:03:28
5		a constructed model as opposed to an experimental	10:03:32
6		structure. So in this particular case, we're	10:03:38
7		talking about homology model.	10:03:41
8		Can one generate a model any other way? I	10:03:44
9		don't know. So homology model/model, I think	10:03:50
10		either one would work here.	10:03:54
11	Q	Okay.	10:03:56
12	A	And when you say model, I would understand	10:03:57
13		that to mean homology model going forward.	10:04:01
14	Q	Okay. Thank you.	10:04:04
15		So what's the purpose of generating a	10:04:05
16		homology model for a protein structure?	10:04:08
17	A	It allows you to look at the molecule, as	10:04:18
18		opposed to imagining it in your head.	10:04:22
19	Q	And it's useful to be able to look at the	10:04:27
20		molecule, right?	10:04:31
21	A	Absolutely.	10:04:32
22	Q	And you can use homology modeling to	10:04:38

1	predict the impact of substitutions in a protein?	10:04:42
2	ATTORNEY KUSHAN: Objection to foundation.	10:04:46
3	Also to form.	10:04:48
4	A A homology model can help you to evaluate	10:04:49
5	the impact of a substitution. Yes.	10:04:54
6	Q So can you turn in your declaration for	10:05:03
7	the -- the one that you have open for matter 3 --	10:05:08
8	turn to Paragraph 20?	10:05:12
9	A Okay.	10:05:26
10	Q And in the first sentence, you say that:	10:05:27
11	Proteins often can tolerate a single amino acid	10:05:32
12	substitution in non-essential regions of the	10:05:35
13	protein structure; is that right?	10:05:38
14	A That's the sentence, yes.	10:05:42
15	Q What is -- what do you mean when you say	10:05:44
16	non-essential regions of the protein structure?	10:05:50
17	A A non-essential region of the protein	10:05:58
18	structure is the part of the protein that is not	10:06:04
19	critical to the folding of the protein.	10:06:09
20	(Reporter clarification.)	10:06:34
21	Q How can you tell whether a region of a	10:06:34
22	protein is essential to the folding of the	10:06:42

1	protein?	10:06:45
2	A You can tell by looking at a bunch of	10:06:46
3	sequences that are related, homologous that is, to	10:06:50
4	one protein, and -- and have high sequence	10:06:58
5	similarity so that they all fold to the same	10:07:02
6	structure, and by comparing those sequences, you	10:07:07
7	can identify the amino acids that are important	10:07:12
8	for folding and the amino acids that are less	10:07:16
9	important for folding.	10:07:19
10	Q So wait. I'm going to unpack that.	10:07:22
11	So first -- and again, just to make sure	10:07:28
12	that we're aligned on terminology -- so you used	10:07:31
13	the word homologous. Can you explain what you	10:07:37
14	mean when you say homologous?	10:07:42
15	A Absolutely. Homologous or homology refers	10:07:43
16	to two or more genes in proteins that have a	10:07:51
17	common ancestor. Two proteins that have	10:07:55
18	originated from a common ancestral gene would have	10:08:01
19	homology, and therefore be homologous.	10:08:08
20	Q Can you use the term homology to refer	10:08:12
21	to -- strike that.	10:08:30
22	Does the term homology, as you're using	10:08:31

1 it, does that only refer to naturally occurring 10:08:35
2 proteins? 10:08:42

3 A Yes. That's how the word should be used, 10:08:42
4 and is used in practice. 10:08:46

5 Q Okay. And then you also talked about a 10:08:50
6 high sequence similarity. So what do you consider 10:09:00
7 to be a high sequence similarity? 10:09:04

8 A It's a spectrum. Similarity is something 10:09:13
9 that can be measured based on the sequence. You 10:09:17
10 can count the number of amino acids that are 10:09:23
11 identical between two sequences, plus the pairs of 10:09:26
12 amino acids, matching pairs, that are supposed to 10:09:32
13 be similar in some chemical aspects. That 10:09:38
14 definition can vary. Then you can count the 10:09:43
15 number of those positions and divide by the whole 10:09:46
16 length of the protein. That will give you a 10:09:49
17 number, which would be the similarity of that 10:09:51
18 protein, of those two proteins. 10:09:54

19 And now, getting back to high sequence 10:09:57
20 similarity. It's not a black and white thing. 10:10:00

21 It's more of a convention, perhaps used by 10:10:07
22 practitioners in the field to indicate that two 10:10:11

1 proteins have sequences that are fully similar, 10:10:15
2 and therefore have a similarity percentage above a 10:10:21
3 certain number. 10:10:27

4 That number is not set in stone, 10:10:31
5 unfortunately. However, practitioners would feel 10:10:34
6 comfortable saying that, say, 50 percent would be 10:10:38
7 a reasonable number to define high similarity. 10:10:42

8 Q Okay. And so if two sequences have, let's 10:10:48
9 say, 60 percent sequence similarity, and before -- 10:10:52
10 strike that. 10:10:57

11 Before we get there, I want to distinguish 10:10:57
12 between similarity and identity, right? 10:11:01

13 So when you say high sequence similarity, 10:11:04
14 you mean not necessarily identical, not 10:11:08
15 necessarily identity, but that allows for some 10:11:11
16 conservative substitutions or conservative 10:11:14
17 changes; is that right? 10:11:18

18 ATTORNEY KUSHAN: Objection. Form. 10:11:19

19 Also objection to foundation. 10:11:20

20 A Identity is a subset of similarity, yes. 10:11:24

21 And to go from identity to similarity, you do 10:11:28
22 allow some slight changes. What's debatable is 10:11:32

1 exactly what should be counted as an allowed 10:11:38
2 substitution. 10:11:42

3 Q Uh-huh.

4 A That -- I don't know the exact definition 10:11:43
5 of that. But accounting for those substitutions, 10:11:46
6 you would have a slightly higher number for 10:11:51
7 similarity, as opposed to identity. 10:11:54

8 Both terms are used. One doesn't stick to 10:11:57
9 one or the other religiously, but use the term 10:12:04
10 with the expectation that the reader or the 10:12:11
11 listener would understand what you mean by that. 10:12:15

12 Q Okay. So if a protein, or two proteins 10:12:19
13 have sequence -- strike that. Let me start over. 10:12:25

14 You have two sequences that are, let's 10:12:26
15 say, 60 percent similar. Would you consider those 10:12:36
16 two sequences to be -- to have high sequence 10:12:42
17 similarity? 10:12:46

18 ATTORNEY KUSHAN: Objection to foundation. 10:12:47

19 Objection as to form. 10:12:48

20 A Assuming certain conditions are met, I 10:12:53
21 would say that they are similar. 10:12:58

22 Q What conditions? 10:13:00

1	A The similarity has to extend over a	10:13:03
2	reasonable extent of the protein. In other words,	10:13:08
3	you can't have similarity within the first 50	10:13:12
4	amino acids out of 500 amino acids and call that	10:13:17
5	similar. Because the similarity would -- so you	10:13:23
6	have to factor that in, how much of -- of the	10:13:29
7	protein --	10:13:34

8 | 0 So --

```
9      A  -- would match.                                     10:13:37
```

10	Q Okay. So if the -- the sequence alignment	10:13:37
11	for the entire protein had, let's say, 60 percent	10:13:42
12	similarity, would you consider those two sequences	10:13:46
13	to be highly similar?	10:13:51

14	ATTORNEY KUSHAN: Objection. Foundation.	10:13:54
----	---	----------

15	Objection as to form.	10:13:55
----	-----------------------	----------

16	A If you're comparing just the sequence and	10:13:56
17	limit your discussion and interpretation to the	10:14:01
18	similarity alone? Yes. I would think that they	10:14:04
19	are similar.	10:14:09

20	Q Okay. So you mentioned that if you have a	10:14:16
21	bunch of sequences, a bunch of homologous	10:14:58
22	sequences that have a high sequence similarity so	10:15:05

1 that they all fold to the same structure, you can 10:15:09
2 compare those sequences and identify the amino 10:15:12
3 acids that are important for folding. 10:15:15

4 How -- and my question is: If you have a 10:15:18
5 bunch of sequences that are homologous, and have 10:15:22
6 high sequence similarity, how do you know that 10:15:26
7 they all fold to the same structure? 10:15:30

8 A That's the standard that the industry goes 10:15:36
9 by. If you ask a practitioner in the field: I 10:15:40
10 have two proteins that are homologous and have 10:15:50
11 high sequence similarity, would I expect them to 10:15:53
12 fold to the same structure, of course I would say 10:15:58
13 yes. 10:16:01

14 Q And why is that? 10:16:01

15 A It's a matter of protein evolution. 10:16:15
16 Protein structures, if one compares the folding 10:16:19
17 structure to an entire space of -- conformational 10:16:28
18 space that can be adopted by the polypeptide, it's 10:16:34
19 a very small fraction. 10:16:41

20 Now, if you have homologous proteins, 10:16:43
21 meaning they came from the same ancestor, and they 10:16:46
22 have maintained similar sequence similarity, they 10:16:51

1 would be obligated to explore that very small 10:16:56
2 sliver of the conformational space. They would 10:17:03
3 not be able to go and randomly find another island 10:17:08
4 of stability in that conformational space that can 10:17:13
5 be occupied by that particular sequence. So that 10:17:17
6 restricts what the protein can do. 10:17:19

7 So this is the foundation behind the 10:17:23
8 assumption that homologous highly similar 10:17:28
9 sequences would adopt the same conformational 10:17:33
10 three-dimensional structure. 10:17:38

11 Q So you said at the beginning of your 10:17:46
12 answer: If one compares folding structure to the 10:17:49
13 entire space of conformational space that can be 10:17:53
14 adopted by the polypeptides, it's a very small 10:18:06
15 fraction. 10:18:00

16 Can you explain what you mean by that, and 10:18:01
17 why that's the case? 10:18:03

18 A Conformational space, you can think of it 10:18:08
19 as the ensemble of all the shapes that a given 10:18:12
20 polypeptide can assume. It could be a folding 10:18:18
21 structure. It could be DNA structure, some random 10:18:23
22 structures. 10:18:28

1 The folding structure that one sees in a 10:18:29
2 crystal structure or model structure, that's just 10:18:34
3 a small fraction compared to whatever else, 10:18:38
4 whatever other shapes this -- this particular 10:18:42
5 polypeptide may assume. 10:18:46

6 Why is it a small fraction? Because 10:18:48
7 folding structure will be defined by a combination 10:18:52
8 of dihedral angles. And in a folded protein, you 10:18:55
9 would have pretty well-defined values of dihedral 10:19:03
10 angles, both main chain and side chains. The 10:19:04
11 entire conformational space would encompass all 10:19:09
12 the available values of all the dihedral angles. 10:19:15
13 Therefore, the folding structure would correspond 10:19:20
14 to a very small fraction of that entire ensemble.

15 (Reporter clarification.) 10:19:38

16 Q Okay. So the actual folded structure for 10:19:45
17 a given sequence corresponds to a very small 10:19:59
18 fraction of the potential conformational space 10:20:10
19 that that -- that could be occupied by -- that 10:20:14
20 could be occupied by folded protein structures? 10:20:17

21 ATTORNEY KUSHAN: Objection. Form. 10:20:17

22 Objection. Foundation. 10:21:54

1	A	Could you repeat that question, please?	10:20:20
2	Q	The actual folded structure for a given	10:20:23
3		sequence corresponds to a very small fraction of	10:21:46
4		the conformational space that -- that could be	10:20:28
5		occupied by that sequence?	10:20:35
6	ATTORNEY KUSHAN:	Objection. Form.	10:20:37
7		And objection to foundation.	10:20:39
8	A	Not by that sequence.	10:20:41
9	Q	Uh-huh.	
10	A	A polypeptide of that length.	10:20:43
11	Q	Oh, okay.	10:20:47
12	A	Or if you do not constrain the protein to	10:20:48
13		adopt a structure and do something in nature, and	10:20:58
14		you consider all theoretical possibilities that	10:21:02
15		can be adopted -- it doesn't mean that it will	10:21:07
16		be -- it can be adopted by a polypeptide of that	10:21:12
17		length, that space would be much, much bigger	10:21:14
18		compared to the folded space, folded conformation.	10:21:19
19	Q	Okay. All right.	10:21:26
20		And then going back to your previous	10:21:57
21		answer where you said that you compare the	10:22:00
22		sequences and identify the amino acids that are	10:22:03

1	important for folding, you're talking about amino	10:22:06
2	acids that are important for folding are the ones	10:22:10
3	that are conserved in the alignment, right?	10:22:13
4	A Yeah. Amino acids that are conserved in	10:22:18
5	the alignment are the residues that are important	10:22:22
6	for folding. Yes.	10:22:26
7	Q Okay. How many sequences do you need to	10:22:28
8	have in your alignment to know that you've	
9	identified residues that are important for	10:22:40
10	folding?	10:22:34
11	ATTORNEY KUSHAN: Objection. Foundation.	10:22:34
12	A The more sequences, the better. Since	10:22:44
13	you're trying to get a statistical sense of what	10:22:48
14	amino acids are conserved, a larger sample would	10:22:56
15	be better.	
16	There's no cut-off. You can do it with	10:22:59
17	smaller set. And the difference is with a smaller	10:23:02
18	set, it may look as if more residues are conserved	10:23:10
19	just because you are starting with a smaller set,	10:23:15
20	and you see less variation.	10:23:20
21	As you increase the sample size, you may	10:23:22
22	observe some of those positions that begin to	10:23:28

1 vary. But the sample size can be small I suppose. 10:23:27

2 There's no hard cut-off. 10:23:36

3 Q Okay. So we started this discussion by 10:23:57

4 looking at Paragraph 20, and I asked about what 10:24:01

5 are -- what you meant by non-essential regions of 10:24:07

6 the protein structure, and am I understanding 10:24:13

7 correctly that the non-essential regions of the 10:24:17

8 protein structure are identified based on a 10:24:20

9 sequence alignment, and specifically they are the 10:24:23

10 residues in the sequence alignment that are not 10:24:25

11 conserved? 10:24:30

12 A The positions, the residues, in a multiple 10:24:33

13 sequence alignment that are not conserved are 10:24:39

14 labeled as non-essential regions in this 10:24:48

15 declaration, and they may vary. And the fact that 10:24:54

16 they do vary among homologous high sequence 10:25:06

17 similarity sequences suggests that they may be 10:25:14

18 non-essential, although it's a quote/unquote 10:25:18

19 non-essential. 10:25:24

20 Q Uh-huh. So what do you mean when you say 10:25:24

21 quote/unquote non-essential? 10:25:26

22 A Meaning that it doesn't mean that 10:25:28

1	anything -- they're not anything goes residues.	10:25:32
2	You can't just randomly choose mutations at those	10:25:36
3	positions. They are still important, but they may	10:25:39
4	be qualitatively different than the residues that	10:25:43
5	are strictly conserved, or conserved to a very	10:25:46
6	high degree.	10:25:52
7	(Reporter clarification.)	10:25:54
8	Q So when you use the term non-essential,	10:25:54
9	non-essential region in -- in this declaration,	10:25:59
10	are you referring to positions in the sequence	10:26:01
11	that can potentially tolerate substitution, as	10:26:03
12	opposed to those that cannot tolerate	10:26:08
13	substitution?	10:26:11
14	A It -- it starts -- it starts with the --	10:26:16
15	with the definition of what non-essential residues	10:26:25
16	are. So these are definitions, meaning the	10:26:30
17	positions in the multiple sequence alignment where	10:26:34
18	we see variation, we label them as non-essential.	10:26:37
19	Whether they tolerate substitutions or not comes	10:26:42
20	later.	10:26:44
21	Q Okay. But why did you label them	10:26:45
22	non-essential?	10:26:48

1	A We label them as non-essential in the	10:26:51
2	sense that they are varied among homologous	10:26:54
3	sequences that bode the same structure, which	10:27:01
4	means those residues may allow variation. So in	10:27:07
5	that sense, they're not critical. The identity of	10:27:12
6	those amino acids are not critical to adopt this	10:27:20
7	common fold shared by all homologous proteins in	10:27:21
8	that group.	10:27:29
9	Q Did you use the term non-essential in your	10:27:30
10	work in 2011 to identify non-conserved residues in	10:27:35
11	sequence alignments?	10:27:41
12	ATTORNEY KUSHAN: Objection. Foundation.	10:27:42
13	A No. I did not use the term non-essential	10:27:47
14	when I used it for my purpose.	10:27:51
15	Q Have you ever used the phrase	10:27:53
16	non-essential region of a protein structure,	10:27:57
17	outside of your work in this case?	10:28:01
18	A No.	10:28:05
19	Q So why did you use the term non-essential	10:28:07
20	region to refer to non-conserved positions in	10:28:10
21	sequence alignment for this case?	10:28:21
22	A The task that I was given was to identify	10:28:25

1 non-essential positions in PH20 and identify 10:28:30
2 substitutions at those positions. So my task came 10:28:39
3 down to two things: One to identify what those 10:28:43
4 non-essential positions may be; and second, 10:28:48
5 evaluate various substitutions at those positions 10:28:50
6 to see if there are substitutions at non-essential 10:28:57
7 positions that would be tolerated. 10:29:04

8 And that is motivated by patent '427, 10:29:06
9 which I believe is quoted in Paragraph 32. We use 10:29:16
10 the term non-essential because that's what is in 10:29:26
11 the patent, and I was trying to see -- I was 10:29:31
12 tasked to identify the substitutions at 10:29:41
13 non-essential positions as described in the patent 10:29:48
14 to see where they are and what they may be. 10:29:50

15 Q Okay. 10:29:54

16 A That's why I went about defining 10:29:54
17 non-essential positions, whereas previously I did 10:29:58
18 not do that in my other studies. 10:30:01

19 Q So in your opinion, would a POSA who sees 10:30:05
20 the term non-essential position, would they 10:30:18
21 understand that to mean a position in the sequence 10:30:21
22 alignment that is not conserved? 10:30:25

1	A	The other way around. If they see	10:30:32
2		positions in a sequence alignment that is not	10:30:35
3		conserved, they would think it's non-essential.	10:30:40
4	Q	Oh.	
5	A	They wouldn't go, start with non-essential	10:30:43
6		and say: Oh, aha. It's sort of backwards.	10:30:45
7		If they were to identify -- if they were	10:30:48
8		tasked to identify non-essential positions, that	10:30:54
9		is how they would go about doing that.	10:30:57
10	Q	Okay. So if the POSA was tasked with	10:31:00
11		identifying non-essential regions in a protein	10:31:04
12		sequence, they would perform an alignment and	10:31:07
13		identify non-conserved -- non-conserved residues?	10:31:09
14	A	Yes. Since non-essential means opposite	10:31:16
15		of essential; therefore, if you identify	10:31:20
16		essential, you would have identified	10:31:25
17		non-essential.	10:31:27
18	Q	Okay. And the essential residues are	10:31:28
19		those that are conserved in the alignment, right?	10:31:32
20	A	That would be a reasonable interpretation.	10:31:35
21	Q	Okay. So let me make sure I got this	10:31:37
22		right. So a POSA tasked with identifying	10:31:41

1	essential residues in a protein sequence would	10:31:44
2	perform an alignment of homologous sequences and	10:31:48
3	identify those that are conserved, and that way	10:31:51
4	identify the essential residues. And then those	10:31:55
5	that are left, which are not conserved, are the	10:31:56
6	non-essential residues; is that right?	10:32:00
7	A That would be the correct logic, yes.	10:32:04
8	Q Thank you.	10:32:06
9	And I believe you mentioned the '427	10:32:07
10	patent, but it's '429 patent, right?	10:32:11
11	A Oh. Oh, I'm sorry. '429 patent, yes.	10:32:13
12	Q Okay. Thank you.	10:32:17
13	So let's turn to Paragraph 32 -- are we	10:33:01
14	already there -- in your declaration in matter 3?	10:33:05
15	And so the -- you have a block quote in	10:33:09
16	Paragraph 32 from the '429 patent, right?	10:33:13
17	A Yes.	10:33:17
18	Q And the second sentence of that block	10:33:17
19	quote says: Those of skill in this art recognize	10:33:32
20	that in general, single amino acid substitutions	10:33:35
21	in non-essential regions of a polypeptide do not	10:33:37
22	substantially alter biological activity; is that	10:33:41

1	right?	10:33:46
2	A That's correct.	10:33:46
3	Q So in the 2011 time frame, a POSA would	10:33:50
4	understand that if they performed a sequence	10:33:57
5	alignment of homologous sequences and identified	10:34:00
6	the non-conserved residues thereby giving them the	10:34:04
7	non-essential regions, that substitutions in those	10:34:14
8	non-essential positions would not substantially	10:34:18
9	alter biological activity; is that right?	10:34:20
10	ATTORNEY KUSHAN: Objection. Form.	10:34:24
11	A POSA in 2011 would have done that multiple	10:34:26
12	sequence alignment to identify non-essential	10:34:32
13	regions, and reasonably expect that the amino	10:34:35
14	acids found at those positions may be introduced	10:34:42
15	without substantially altering biological	10:34:48
16	activity, yes.	10:34:54
17	Q And how would -- what would the POSA	10:34:54
18	understand the phrase "substantially alter	10:34:57
19	biological activity" to mean?	10:34:59
20	A POSA would expect that sentence to mean	10:35:10
21	without loss of structure or function.	10:35:14
22	Q So loss of function, that means no -- that	10:35:18

1	means that -- sorry. Strike that.	10:35:21
2	When you say loss of function, do you mean	10:35:22
3	that you've eliminated the function?	10:35:26
4	ATTORNEY KUSHAN: Objection. Foundation.	10:35:29
5	Also objection as to form.	10:35:31
6	A It says: Substantially alter biological	10:35:34
7	activity.	10:36:09
8	A substantial drop in the enzyme activity	10:35:41
9	would be considered a substantial alteration.	10:35:46
10	Therefore, those need to be guarded against.	10:35:50
11	Q Uh-huh.	
12	A However, the way the sentence is written,	10:35:53
13	single amino acid substitutions may be introduced	10:35:57
14	without altering the biological activity	10:36:00
15	substantially.	10:36:07
16	Q If two highly similar polypeptides fold in	10:36:31
17	the same way, could a POSA predict that they will	10:36:39
18	function in the same way?	10:36:48
19	ATTORNEY KUSHAN: Objection. Form.	10:36:49
20	Also objection as to foundation.	10:36:50
21	A If two polypeptides, proteins, fold the	10:36:56
22	same way, can I -- can a person, POSA, expect them	10:37:00

1	to have the same activity? No.	10:37:04
2	Q Okay. Why is that?	10:37:07
3	A Because enzyme relating activity is a very	10:37:13
4	subtle thing. Things can happen in the active	10:37:18
5	site, which doesn't really alter the shape of the	10:37:21
6	molecule, but can change the -- the function of	10:37:27
7	the enzyme somewhat.	10:37:30
8	For instance, hyaluronidase 4 -- I	10:37:32
9	remember hyaluronidase, yes. It hydrolyzes it	10:37:40
10	from carbohydrate then PH20, which hydrolyzes	10:37:44
11	hyaluronic acid. And maybe because of differences	10:37:44
12	in the active site, for instance.	10:37:49
13	Q Uh-huh.	
14	A So they may look the same, but they may	10:37:52
15	act on different substrates, therefore, different	10:37:56
16	activities. So a POSA would understand that kind	10:38:00
17	of thing happens all the time.	10:38:02
18	Q Okay. Okay. So when you did your	10:38:06
19	homology sequence alignment for -- for PH20, did	10:38:13
20	you understand that all of the -- all of the	10:38:24
21	hyaluronidases that you included in your alignment	10:38:28
22	have -- I'm sorry. Strike that.	10:38:33

1	Your sequence alignment for PH20 includes,	10:38:34
2	for example, HYAL4, right?	10:38:39
3	A Yes.	10:38:48
4	Q And HYAL4 does not cleave HA, right?	10:38:49
5	A Not very well.	10:38:49
6	Q So why did you include HYAL4 in your	10:38:50
7	alignment for PH20 if they have different	10:39:00
8	functions?	10:39:02
9	A Because the question that we were	10:39:02
10	addressing was the -- the sequence structure	10:39:05
11	relationship in this family of proteins, and you	10:39:09
12	can learn by looking at all the sequences that	10:39:15
13	fold to the same structure, which include all	10:39:20
14	homologous sequences of PH20, regardless of how	10:39:26
15	they're labeled, or what their specific enzyme	10:39:30
16	activities may be, irrespective of their subtle	10:39:36
17	differences in substrate specificity or the	10:39:44
18	activity, enzymatic activity, doesn't change the	10:39:46
19	fact that yeah, they fold to the same structure;	10:39:51
20	therefore, the sequence -- all the sequences have	10:39:54
21	they share, common sequence in amino acid	10:39:57
22	restrictions and freedom, which can be beneficial	10:40:03

1 in our study. Therefore, it's important that we 10:40:09
2 include all the sequences, not just a subset of 10:40:13
3 highly similar sequences, for instance, by 10:40:18
4 limiting the analysis to PH20. 10:40:23

5 Q Okay. So you included hyaluronidases in 10:40:27
6 your alignment because you expect the homologous 10:40:32
7 hyaluronidases to all adopt the same fold, to all 10:40:41
8 fold in the same way, and as a result, that way 10:40:44
9 you're able to identify which residues are 10:40:47
10 essential for folding, as opposed to those which 10:40:53
11 are not; is that right? 10:40:54

12 A That is correct. 10:40:55

13 Q Okay.

14 A That is a fundamental assumption -- 10:40:56

15 Q Okay. 10:41:01

16 A -- in this discipline.

17 Q And so why would you expect all of the 10:41:02
18 hyaluronidases to fold the same way? 10:41:03

19 ATTORNEY KUSHAN: Objection. Foundation. 10:41:07

20 A In part for the reasons that I described 10:41:15
21 earlier. They are related sequences, and the 10:41:19
22 conformational space that can be explored by 10:41:23

1 related sequences will be clustered together into 10:41:28
2 a very small fraction of the old conformational 10:41:33
3 space that may be theoretically available to a 10:41:38
4 polypeptide of that size. 10:41:44

5 Now, if they do not fold, two 10:41:46
6 possibilities: One, they may fold to a completely 10:41:48
7 different structure, which is not possible, not 10:41:52
8 possible because they all came from the same 10:41:55
9 ancestral gene. That means they started in some 10:41:57
10 space, there would be no mechanism for them to go 10:42:02
11 to the next island, which may be light years away, 10:42:08
12 say.

13 Q Uh-huh.

14 A The other is they may not fold at all. If 10:42:12
15 that were the case, you wouldn't have those 10:42:16
16 concerned residues. Mutation would happen over 10:42:20
17 time that would eliminate those conserved 10:42:24
18 residues. 10:42:30

19 Evolution introduces mutations constantly 10:42:30
20 at some rate. And over time, once a protein loses 10:42:37
21 its benefit to the organism because it stopped 10:42:42
22 folding, then those sequences would very quickly 10:42:47

1	mutate away, drift away in the sequence space.	10:42:53
2	They would look very, very different than what	10:42:58
3	they started with.	10:43:01
4	So the fact that they do have conserved	10:43:03
5	residues guarantee that they're doing something,	10:43:06
6	even when you don't know what they are doing,	10:43:10
7	which I believe is the case with HYAL3, which has	10:43:18
8	unknown function. But they may do something.	10:43:18
9	They must be doing something. Otherwise, would	10:43:20
10	have gotten rid of over time. So this is the	10:43:22
11	reason that they would fold to the same structure.	10:43:29
12	Q Okay. So when you -- when you did your	10:43:33
13	alignment for PH20, did you include all of the	10:43:36
14	hyaluronidase sequences that were available in	10:43:40
15	2011, or did you use some other cut-off?	10:43:45
16	A Yes. I used the sequences that were	10:43:52
17	available as of the end of year 2011.	10:43:55
18	Q Okay. Can you explain how exactly you ran	10:44:01
19	your -- strike that.	10:44:06
20	You used BLAST to create the -- or, to	10:44:09
21	identify the sequences that would be in the	10:44:10
22	alignment; is that right?	10:44:14

1	A	I used BLAST to identify sequences that	10:44:15
2		are similar to the seed sequence, or the target	10:44:19
3		sequence, PH20 human.	10:44:25
4		(Reporter clarification.)	10:44:38
5	Q	And how exactly did you use BLAST?	10:44:38
6		Did you set any parameters?	10:44:42
7		Can you just walk me through what you did	10:44:44
8		in BLAST?	10:44:47
9	A	BLAST is a web service. You enter the	10:44:47
10		target sequence, in this case, human PH20, a	10:44:54
11		protein sequence, and you hit -- run a button.	10:44:59
12		In my case, I did one thing that changed	10:45:10
13		the default setting from the number return	10:45:14
14		sequences expected was changed from 100, which is	10:45:20
15		the default value, to the maximum that was allowed	10:45:27
16		through the web service, which is 5,000. Because	10:45:30
17		I wanted to see all the sequences that were	10:45:35
18		available, not just the top 100.	10:45:38
19	Q	Okay. Okay. And so then you then	10:45:41
20		whittled that down by -- by removing the sequences	10:45:51
21		that were only available after 2011 at the end?	10:45:56
22	A	Only the sequences --	10:45:59

1	ATTORNEY KUSHAN: Sorry.	10:46:02
2	Objection. Foundation.	10:46:02
3	Go ahead.	10:46:03
4	A Only the sequences that were available up	10:46:04
5	to the end of year 2011; that is correct.	10:46:07
6	Q Okay. And then you removed -- sorry.	10:46:45
7	So you obtained the 95 sequences after you	10:46:49
8	filtered out those available after December 29th,	10:46:54
9	2011, and then you removed 7 isoforms, leaving you	10:46:55
10	with 88 sequences; is that right?	10:46:57
11	A That is correct.	10:46:59
12	Q Can you explain what 7 isoforms are, and	10:47:00
13	why you removed them?	10:47:05
14	A Isoforms are different manifestations of	10:47:09
15	the same gene, resulting from alternative	10:47:14
16	splicing. They come from the same gene, but after	10:47:20
17	MRNA synthesize, they undergo splicing event. And	10:47:26
18	depending on where the splicing occurs, you get	10:47:28
19	slightly different forms.	10:47:33
20	Since they essentially come from the same	10:47:35
21	gene, having both of them represented in the final	10:47:37
22	set would introduce a bias. I wanted to eliminate	10:47:40

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

80

1	those redundancies by identifying isoforms and	10:47:45
2	ensuring that only one is represented in the final	10:47:49
3	set.	10:47:53
4	ATTORNEY MARTIN: Okay. So let's	10:48:06
5	introduce Exhibit 1054 and Exhibit 1057.	10:48:07
6	ATTORNEY KUSHAN: Lauren, do you want to	10:48:17
7	take a break?	10:48:19
8	We've been going for an hour and twenty,	10:48:20
9	or something. It's up to you.	10:48:23
10	ATTORNEY MARTIN: Yeah. That's fine.	10:48:26
11	THE WITNESS: Okay. Yeah. That would be	10:48:27
12	great. Yes. Yes.	10:48:29
13	THE VIDEOGRAPHER: We are going off the	10:48:30
14	record. The time is 10:48 a.m.	10:48:32
15	(Recess from 10:48 a.m. until 11:04 a.m.)	10:48:36
16	THE VIDEOGRAPHER: We are back on the	11:04:07
17	record. The time is 11:04 a.m.	11:04:11
18	ATTORNEY KUSHAN: We -- Brian Goldberg,	11:04:15
19	can you just announce yourself?	11:04:20
20	ATTORNEY GOLDBERG: Yes. Hi. This is	11:04:21
21	Brian Goldberg from Dechert LLP, and with me is	11:04:23
22	Dr. Michael Hecht, just listening in.	11:04:26

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

81

1	ATTORNEY MARTIN: All right. So welcome	11:04:48
2	back, Dr. Park.	11:04:49
3	Right before we left, we were introducing	11:04:51
4	Exhibits 1054 and 1057.	11:04:55
5	(Previously marked Exhibit 1054 introduced	
6	and retained by counsel.)	11:05:35
7	(Previously marked Exhibit 1057 introduced	11:05:35
8	and retained by counsel.)	
9	BY ATTORNEY MARTIN:	
10	Q Did you prepare --	11:05:35
11	A Yes.	
12	Q -- 1054 and 1057?	11:05:37
13	A I did prepare both documents, yes.	11:05:38
14	Q Can you explain what Exhibit 1054 is?	11:05:41
15	A This is the header portion of the BLAST	11:06:06
16	result that has been filtered based on the	11:06:12
17	publication date of the individual sequences to	11:06:19
18	correspond to pre-2011 set.	11:06:24
19	Q Okay. And so Exhibit 1054 includes the 88	11:06:25
20	sequences that you used in your sequence	11:06:29
21	alignment; is that right?	11:06:33
22	A 1054 is a -- is a set of 95 sequences.	11:06:36

1	Q Oh. It's the 95? Okay.	11:06:41
2	A That's correct.	11:06:46
3	Q Okay. So Exhibit 1054 is the set of 95	11:06:51
4	sequences that you obtained from BLAST, and then	11:06:57
5	you removed this 7 isoforms to arrive at the 88	11:07:01
6	sequences in your alignment; is that right?	11:07:02
7	A That is correct.	11:07:05
8	Q Okay. And so in Exhibit 1054, the first	11:07:18
9	sequence listed is: Hyaluronidase PH20 isoform 2	11:07:29
10	Homo sapiens; is that right?	11:07:36
11	A That is correct.	11:07:41
12	Q Is that the sequence that you entered into	11:07:45
13	BLAST?	11:07:49
14	A That is the sequence that was entered to	11:07:52
15	do a BLAST search. Yes.	11:07:57
16	Q And so Exhibit 1054 identifies the protein	11:08:06
17	in question, hyaluronidase PH20 versus --	11:08:19
18	actually, strike that.	11:08:28
19	So in Exhibit 1054, you can see which all	11:08:29
20	of the proteins that are included in the	11:08:33
21	alignment, and they include hyaluronidase PH20;	11:08:36
22	sperm adhesion molecule 1 precursor;	11:08:43

1 hyaluronidase-5-like; sperm adhesion molecule 1; 11:08:47
2 hyaluronidase-4; LOW-QUALITY PROTEIN 11:08:52
3 hyaluronidase-4; hyaluronoglucosaminidase -- I 11:09:03
4 really butchered that -- 6. 11:09:03
5 This one is just hyaluronidase; 11:09:08
6 hyaluronidase-2; hyaluronidase PH20-like; 11:09:12
7 hyaluronidase-1; hyaluronidase PH20 precursor. 11:09:19
8 Let's see. Hyaluronidase-2 precursor; 11:09:27
9 hyaluronoglucosaminidase 6 precursor; 11:09:44
10 hyaluronidase-like; hyaluronidase-4-like; 11:09:53
11 hyaluronidase-3 precursor. 11:09:59
12 I think I've got them; is that right? 11:10:01
13 ATTORNEY KUSHAN: Objection. Foundation. 11:10:04
14 A I wasn't sure what you were doing. Are 11:10:06
15 you reading the entire table, or are you selecting 11:10:10
16 some of them for some reasons? 11:10:14
17 Q I'm trying to filter as I go through and 11:10:16
18 just read out -- 11:10:20
19 A Filter based on what? 11:10:21
20 Q The first row or the first column. 11:10:23
21 A Yes. But what are you filtering for? 11:10:27
22 Q So I'm not reading hyaluronidase-4 eight 11:10:31

1	times. I'm just saying hyaluronidase --	11:10:35
2	A Oh. I see what you're saying. Okay.	11:10:35
3	Q Yeah.	11:10:36
4	A So you're just saying that there are	
5	different hyaluronidases here?	
6	Q Yes.	11:10:36
7	A Okay. Yes.	11:10:37
8	Q Okay.	
9	A I agree with that.	11:10:38
10	Q Okay. And then several columns over, is	11:10:41
11	there -- is that a percent identity or a percent	11:10:46
12	similarity that's given?	11:10:49
13	ATTORNEY KUSHAN: Objection. Foundation.	11:11:01
14	A I have to look back to the original file,	11:11:04
15	but my recollection says identity.	11:11:07
16	Q Okay. And so that field would give the	11:11:10
17	percent identity to the sequence that you entered,	11:11:14
18	which is the -- the first sequence, the	11:11:19
19	hyaluronidase PH20 isoform 2?	11:11:21
20	ATTORNEY KUSHAN: I'm sorry, Counsel.	11:11:23
21	Which -- which column are you referring to in the	11:11:28
22	exhibit? Maybe go from the far right, heading off	11:11:31

1	from the far right?	11:11:35
2	ATTORNEY MARTIN: Oh. From the far right.	11:11:35
3	Five. Right, so --	11:11:38
4	THE WITNESS: In fact, yes. I do	11:11:39
5	apologize. There seems to be different numbers.	11:11:41
6	I do get confused. One of them does have a	11:11:47
7	percentage sign, but I'm not sure what the heading	11:11:51
8	of that is.	
9	So perhaps I take back whatever I said	11:11:56
10	earlier, whether it was identity. I'll -- I'll	11:11:58
11	have to look at the original file with the	11:12:00
12	explanation of what each column means.	11:12:04
13	BY ATTORNEY MARTIN:	11:12:05
14	Q Okay. So you don't know if that's	11:12:05
15	identity or similarity?	11:12:07
16	A That I don't know right at this moment.	11:12:09
17	Yes.	11:12:12
18	Q Do you think it's either identity or	11:12:12
19	similarity, or is there another option?	11:12:15
20	A It makes me think that the one that says	11:12:17
21	percentage is not the identity or similarity. The	11:12:21
22	reason I say that is because I know the set of 88	11:12:24

1	or 95 sequences have sequences with similarity	11:12:29
2	down to about 40 percent. Land that column	11:12:34
3	doesn't seem to go down to 40 percent, so that	11:12:37
4	makes me think it's a coverage. Coverage.	11:12:43
5	Q Oh. I see.	11:12:46
6	A The identity I think may be the third from	11:12:47
7	the last column.	11:14:32
8	Q Okay. Okay. I got it.	11:12:51
9	Okay. So the column with the percentage	
10	sign is potentially coverage?	11:12:52
11	A Coverage.	11:12:52
12	Q Meaning what portion of the -- what	11:12:53
13	portion of the -- is it the starting sequence	11:12:59
14	is...	11:13:03
15	A I believe so.	11:13:04
16	Q What percentage of the starting sequence	11:13:05
17	is being aligned with the test sequence?	11:13:08
18	A That's right.	11:13:12
19	Q Okay. Okay. And then -- and then the	11:13:13
20	column that's three columns in from the far right,	11:13:14
21	that number is potentially percent identity or	11:13:20
22	similarity?	11:13:24

1	A Identity or similarity. I want to say	11:13:24
2	identity.	11:13:27
3	Q Okay.	11:13:27
4	A Because I believe the similarities are --	11:13:28
5	most of them were 50 percent and higher, and	11:13:32
6	identity here goes down to around 40 percent or	11:13:36
7	just below. I think the lowest percentage that I	11:13:41
8	remember was about 36 percent. So that seems to	11:13:45
9	match that value. That column seems to be the	11:13:49
10	identity.	11:13:53
11	Q Okay. And do you consider all of the	11:13:54
12	sequences in this BLAST result to be -- to have a	11:13:59
13	high sequence similarity, high degree of sequence	11:14:05
14	similarity?	11:14:11
15	A Yes. I do.	11:14:12
16	Q And do you consider that all of the 95	11:14:14
17	sequences in this BLAST result to be homologous	11:14:17
18	sequences?	11:14:20
19	A Yes. From the label of the individual	11:14:33
20	entries, they do suggest that they're homologous	11:14:36
21	proteins.	11:14:46
22	(Reporter clarification.)	11:14:49

1	THE VIDEOGRAPHER: Dr. Park, can you move	11:14:49
2	your microphone up just a bit?	11:14:52
3	THE WITNESS: Sure.	11:14:57
4	THE VIDEOGRAPHER: Thank you.	11:14:58
5	BY ATTORNEY MARTIN:	11:15:09
6	Q When you say the label of the individual	11:15:21
7	entry, what are you referring to?	11:15:23
8	A I mean the names that were given to the	11:15:29
9	individual sequences. The first column that you	11:15:34
10	were reading.	11:15:37
11	Q In other words, the hyaluronidases?	11:15:37
12	A That is correct.	11:15:41
13	Q Okay. The fact that they are all	11:15:42
14	hyaluronidases suggests that they are homologous	11:15:44
15	proteins?	11:15:49
16	ATTORNEY KUSHAN: Objection. Foundation.	11:15:50
17	A No.	11:15:51
18	Q Okay.	11:15:53
19	A If it's just a -- if I'm just focusing on	11:15:53
20	the name, I would find other hyaluronidase enzymes	11:15:57
21	out there that are not homologous to PH20. But in	11:16:01
22	this set, the combination of the sequence identity	11:16:07

1	and the names do indicate that I'm looking at	11:16:11
2	homologous proteins.	11:16:14
3	Q Okay. Okay. And when you say the	11:16:16
4	combination of the sequence identity, so is it the	11:16:18
5	sequence identity that is between 30 -- 36, 37 and	11:16:23
6	100, that combination, plus the name hyaluronidase	11:16:32
7	indicates that they're homologous?	11:17:45
8	ATTORNEY KUSHAN: Objection. Form.	11:16:42
9	Also objection to foundation.	11:16:43
10	A Yes. That would be the case.	11:16:44
11	BLAST doesn't know what it's returning.	11:16:47
12	It will return any sequence that looks similar to	11:16:50
13	the target sequence, and it will give you the	11:16:54
14	identity percentage.	11:16:57
15	So theoretically, one shouldn't be able to	11:16:59
16	tell whether they're homologous or not. But	11:17:03
17	combining that sequence identity with the names of	11:17:06
18	the enzymes would convince you that they are	11:17:10
19	homologous proteins. And the coverage. Identity	11:17:14
20	plus coverage and the names.	11:17:17
21	Q Okay. Sequence identity plus sequence	11:17:19
22	coverage plus the name indicates that they're	11:17:25

1	homologous?	11:17:29
2	A Yes.	11:17:31
3	Q Is there a range for sequence coverage	11:17:32
4	that you look for to determine whether two	11:17:35
5	proteins are homologous?	11:17:38
6	A No. Homologous proteins can have a wide	11:17:47
7	range of sequence identity. There's high sequence	11:17:52
8	similarity identity. There is a slightly lower	11:17:57
9	range of percentage, sometimes referred to as the	11:18:01
10	twilight zone, or you can have even lower	11:18:07
11	percentage, which may be detected using some very	11:18:12
12	sophisticated algorithms to establish some sort of	11:18:20
13	relationship, but at a very, very low percentage.	11:18:24
14	This is outside the realm of BLAST. BLAST would	11:18:27
15	not return those sequences.	11:18:32
16	Q Okay. What do you mean when you said the	11:18:33
17	twilight zone?	11:18:37
18	A Twilight zone refers to a range of	11:18:39
19	sequence identity, somewhere between 20 to 35	11:18:44
20	percent, which is sort of a grey area in a way, in	11:18:51
21	terms of interpreting sequence comparison.	11:18:54
22	Some sequences are very easy to interpret	11:18:58

1 because they are similar. Once a sequence 11:19:01
2 identity drops below a certain number, it gets to 11:19:09
3 be difficult. And even making the assumption that 11:19:12
4 they would fold to the same structure can be 11:19:16
5 questionable, and that would correspond to the 11:23:54
6 twilight zone that I mentioned, or the midnight 11:19:53
7 zone, that's even lower. So these are terms that 11:19:29
8 people use to refer to different levels of 11:19:34
9 sequence activity. 11:19:38

10 Q Do you know why they -- why it's called 11:19:39
11 twilight zone? 11:19:42

12 A Because you can't really see very well. 11:19:44

13 Q Okay. Got it. 11:19:49

14 And then midnight zone because you can't 11:19:58
15 really see? 11:20:01

16 A Too dark. Yeah. Pretty dark down there. 11:20:01

17 Q Okay. Got it. 11:20:02

18 So for the 95 sequences that are in 11:20:05
19 Exhibit 1054, you expect them to all fold the same 11:20:09
20 way? 11:20:14

21 A I do. 11:20:15

22 Q Would you expect that you could generate a 11:20:16

1	model of any of the sequences in Exhibit 1054	11:20:29
2	using the SWISS-MODEL?	11:20:33
3	ATTORNEY KUSHAN: Objection. Foundation.	11:20:41
4	A Generate a homology model of the sequences	11:20:42
5	in this list?	11:20:46
6	Q Yes.	11:20:47
7	A Using SWISS-MODEL?	11:20:47
8	Q Yes.	11:20:50
9	A That depends on the sequence identity	11:20:55
10	between the individual sequences and the model,	11:21:01
11	which is from HYAL1. In the case of PH20, the	11:21:05
12	identity is sufficiently high. 41 percent, 45	11:21:15
13	percent, somewhere around there.	11:21:17
14	For other sequences, once you do the	11:21:19
15	comparison with HYAL1, I don't know what that	11:21:24
16	sequence percentage is. The percentage that's	11:21:30
17	listed here is an identity to PH20 doesn't	11:21:30
18	guarantee that they would similarly have high	11:21:33
19	percent -- percentage identity with respect to	11:21:37
20	HYAL1, and that would determine whether a reliable	11:21:40
21	homology model can be generated for these entries.	11:21:47
22	Q Okay. I understand.	11:21:53

1	So you said 45-ish percent sequence	11:21:54
2	identity for PH -- between PH20 and HYAL1, that's	11:22:00
3	sufficiently high to use SWISS-MODEL to generate a	11:22:01
4	homology model; is that right?	11:22:07
5	ATTORNEY KUSHAN: Objection. Foundation.	11:22:09
6	A That will give you a structure model that	11:22:11
7	is overall reliable and can be used for subsequent	11:22:19
8	studies, yes.	11:22:25
9	Q Is there a minimum amount of sequence	11:22:30
10	identity that you need to satisfy in order to use	11:22:33
11	SWISS-MODEL to generate a homology model?	11:22:37
12	ATTORNEY KUSHAN: Objection. Foundation.	11:22:44
13	A This is another one of those questions	11:22:46
14	where one doesn't have a solid number, except a	11:22:50
15	number that's commonly used and understood. A 30	11:22:54
16	percent identity between two proteins that are	11:23:00
17	homologous would be assumed to fold the same	11:23:07
18	structure.	11:23:10
19	Q Okay.	11:23:11
20	A So if it's 31 percent, I don't know. But	11:23:12
21	if it's 45 percent, that seems like a pretty safe	11:23:16
22	place to be.	11:23:21

1	Q Okay. Got it.	11:23:22
2	And so the 30 percent identity between two	11:23:26
3	proteins that are homologous, they would be	11:23:31
4	assumed to fold the same structure? Is that 30	11:23:35
5	percent number, is that well-known in the field?	11:23:38
6	ATTORNEY KUSHAN: Objection. Foundation.	11:23:42
7	A If you ask a POSA to put a number on that,	11:23:43
8	I think they would name 30 percent.	11:23:48
9	Q Okay. And was that the case in 2011?	11:23:51
10	A The understanding of 30 percent being sort	11:23:57
11	of the cut-off has been around for a long, long	11:24:01
12	time, including 2011, yes.	11:24:05
13	Q Okay. Would you consider proteins that	11:24:08
14	have more than 40 percent sequence identity to be	11:24:33
15	highly homologous?	11:24:37
16	ATTORNEY KUSHAN: Objection. Form.	11:24:39
17	A No. Those are unrelated issues.	11:24:43
18	Similarity is a similarity. Homology --	11:24:47
19	homologous -- homologous proteins.	11:24:52
20	Q Oh, okay.	11:24:54
21	A You know, homology and homologous proteins	11:24:55
22	are -- that's a separate issue. They tend to go	11:25:00

1	hand in hand, but there's no direct correlation	11:25:04
2	between the two.	11:25:08
3	Q Okay. I understand.	11:25:10
4	Because you could have proteins that are	11:25:11
5	more similar in sequence that are completely	
6	evolutionarily unrelated, so those would not be	11:25:15
7	homologous proteins; is that what you're saying?	11:25:17
8	A Yes. Although that might be difficult	11:25:20
9	to -- to -- I don't know. It may be difficult to	11:25:24
10	imagine. I don't know.	11:25:32
11	Q Okay.	11:25:33
12	A But again, those two are separate issues.	11:25:34
13	They should not be mixed.	11:25:38
14	Q Okay. Understood.	11:25:40
15	Okay. All right. So then looking at	11:25:47
16	10 -- Exhibit 1057.	11:25:48
17	A 57. Yes.	11:25:57
18	Q So Exhibit 1057 is the alignment that you	11:25:57
19	generated using Clustal Omega, right?	11:26:03
20	A This is the alignment that was produced by	11:26:04
21	Clustal Omega, yes.	11:26:09
22	Q And you generated the alignment -- you	11:26:11

1	used Clustal Omega to generate the alignment,	11:26:12
2	right?	11:26:15
3	A That's how I generated the sequence	11:26:16
4	alignment, yes.	11:26:20
5	Q And I believe I asked earlier about other	11:26:24
6	programs that could have been used for sequence	11:26:28
7	alignments, and I believe you said that a POSA in	11:26:31
8	2011 would have used Clustal Omega.	11:26:35
9	Is that the case just for multiple	11:26:38
10	sequence alignments?	11:26:41
11	A Clustal Omega is -- it's an algorithm	11:26:44
12	that's designed to align multiple sequences.	11:26:50
13	Q If a POSA wanted to do a pairwise	11:26:54
14	alignment, what would they have used in 2011?	11:26:58
15	A They would have used BLAST.	11:27:02
16	Q Okay.	11:27:04
17	A BLAST does have a feature that allows you	11:27:05
18	to submit two sequences and do pairwise alignment.	11:27:10
19	Q Okay. And you can match the sequences	11:27:16
20	that are in Exhibit 1057 with the sequences that	11:27:30
21	are in Exhibit 1054 based on the designation?	11:27:35
22	I'm not sure what the right term for that	11:27:42

1	is, but in the left-hand most column on 1057; is	11:27:46
2	that right?	11:27:50
3	A The accession numbers are --	11:27:50
4	Q Accession numbers. Thank you.	11:27:54
5	A Yes.	
6	Q Okay. So yeah. You use the accession	11:27:56
7	number -- you can use the accession numbers in	11:27:57
8	Exhibit 1057, which are in the left-hand most	11:28:02
9	column to match the sequences in Exhibit 1057 with	11:28:05
10	the sequences in 1054; is that right?	11:28:09
11	A Yes.	11:28:09
12	Q So the first -- the sequence at the very	11:28:15
13	top in Exhibit 1057 has accession number	11:28:19
14	NP003108.2, and that sequence in Exhibit 1054,	11:28:29
15	that's the third sequence on the list.	11:28:33
16	It's PH20 isoform number 1; is that right?	11:28:39
17	A That is correct. Yes.	11:28:42
18	Q Do you know why you used the isoform	11:28:43
19	number 1 as your lead sequence in the alignment in	11:28:49
20	1057, as opposed to the isoform 2 that you entered	11:28:52
21	into BLAST in Exhibit 1054?	11:28:57
22	A Yeah. That's a byproduct of the	11:29:04

1 processing steps that I took in order to reduce 11:29:11
2 the set of 95 sequences to 88 by illuminating 11:29:15
3 redundancy. 11:29:22

4 At the time I assumed that the longest 11:29:25
5 sequence might be what we want. Given that two -- 11:29:29
6 given two sequences that are from the same gene, I 11:29:35
7 decided to go with the longest isoform. That was 11:29:42
8 the logic in the script that I developed in order 11:29:46
9 to identify redundancy and filter it down to 88. 11:29:49

10 It turned out that isoform 1 has 511 amino 11:29:57
11 acids; whereas isoform 2 has 9 -- 509 amino acids. 11:30:04
12 So the program picked isoform 1 as opposed to 11:30:10
13 isoform 2 as the sequence to keep in the final 88. 11:30:15

14 They are different in the final 14 amino 11:30:20
15 acids of isoform 2. They are identical up to 495, 11:30:25
16 but afterwards they deviate. And for that reason, 11:30:32
17 isoform 1 ended up being included in the final 11:30:43
18 set. And because I didn't -- yeah. So that was 11:30:49
19 that. 11:30:50

20 Q Okay. Okay. So you selected the longest 11:30:50
21 isoform, which is isoform 1, which has the 511 11:30:56
22 amino acids as the lead sequence in your 11:31:01

1	alignment?	11:31:02
2	A That's correct. Yes.	11:31:02
3	Q Okay. All right.	
4	A 511, minus the ones that didn't match to	11:31:05
5	isoform 2. In other words, the sequences that	11:31:09
6	were used in the multiple sequence alignment are	11:31:13
7	the portions of the sequences that were matched by	11:31:17
8	BLAST.	11:31:22
9	Q Okay.	11:31:24
10	A So comparing isoform 2 and 1, that	11:31:25
11	alignment went up to 495. So only the first 495	11:31:29
12	amino acids of isoform 1 was used in the final	11:31:36
13	multiple sequence alignment, which incidentally is	11:31:42
14	exactly the same as isoform 2.	11:31:46
15	Q Okay. I understand.	11:31:49
16	A So despite the fact that it has a	11:31:49
17	different accession number, the results would have	11:31:52
18	been identical. But I used...	11:31:57
19	Q Okay. Okay. I see. Okay. I understand.	11:31:58
20	All right. So let's turn in your	11:32:39
21	declaration to Paragraph 30.	11:32:40
22	A Okay.	11:33:07

1	Q All right. So in Paragraph 30, you say:	11:33:10
2	Using the alignment identified 68 largely	11:33:13
3	invariant residues that a skilled artisan would	11:33:17
4	have deemed essential residues in PH20 based on	11:33:23
5	the sequence alignment, and then you have the	11:33:29
6	table, right?	11:33:28
7	A Yes.	11:33:29
8	Q Can you explain what you mean by the term	11:33:31
9	invariant in that sentence?	11:33:36
10	A By invariant, I mean that once the	11:33:45
11	sequences have been aligned by Clustal Omega,	11:33:49
12	there are certain positions where the identity of	11:33:55
13	the amino acid does not change at all, or it	11:33:58
14	changes only ever so slightly.	11:34:02
15	Q And the cut-off that you used to identify	11:34:09
16	invariant residues is 95 percent; is that right?	11:34:12
17	A I used 95 percent as the cut-off, yes.	11:34:21
18	Q And how did you arrive at the 95 percent	11:34:25
19	number?	11:34:29
20	A Well, there are two ways to think about	11:34:37
21	it. I wanted to ensure that the preference of the	11:34:43
22	wild-type amino acid at that position is	11:34:50

1	statistically significant compared to other amino	11:34:55
2	acids that may occur at that position. And 95	11:35:01
3	percent seemed pretty convincing.	11:35:02
4	(Reporter clarification.)	11:35:11
5	A That would be a simple explanation.	11:35:11
6	Q Had you used a 95 percent cut-off in your	11:35:17
7	work before to identify invariant residues?	11:35:21
8	ATTORNEY KUSHAN: Objection. Form.	11:35:27
9	A Never had the occasion to having to	11:35:31
10	identify invariant residues before. So no, I have	11:35:36
11	not used 95 percent per se.	11:35:44
12	Q So in your work, when you perform sequence	11:35:46
13	alignments, you never identified invariant	11:35:50
14	residues in those alignments?	11:35:56
15	ATTORNEY KUSHAN: Objection. Foundation.	11:36:01
16	A I do identify. However, the focus of my	11:36:02
17	past studies have not been on invariant residues.	11:36:07
18	Therefore, having to put a number on where the	11:36:20
19	cut-off needs to be has never occurred.	11:36:24
20	Q So are you saying that in your work, when	11:36:28
21	you would perform a sequence alignment like this,	11:36:32
22	you would identify residues that were conserved,	11:36:35

1 but you never had to go through the exercise of 11:36:40
2 categorizing residues, as invariant versus not 11:36:43
3 invariant, and so that's why you haven't -- you 11:36:50
4 didn't use a cut-off? 11:36:52

5 ATTORNEY KUSHAN: Objection. Form. 11:36:53

6 A Right. My goals were different and did 11:36:54
7 not require having to identify invariant residues 11:36:58
8 and having to put a number on the conservation. 11:37:05

9 Q So in your work in 2011, did you perform 11:37:10
10 BLAST searches and then form sequence alignments 11:37:15
11 of homologous proteins, like you did here? 11:37:19

12 ATTORNEY KUSHAN: Objection. Foundation. 11:37:22

13 A Are you referring to my independent work? 11:37:23

14 Q Yes. 11:37:27

15 A That might have happened in 2011? 11:37:28

16 Q Yes. 11:37:31

17 A Which, by the way, I haven't done any in 11:37:31
18 2011, I don't think. 11:37:35

19 But prior to that, perhaps? 11:37:36

20 Q Uh-huh. Yeah. In your independent work. 11:37:39

21 A Yeah. What about it? 11:37:40

22 Q Had you used BLAST to identify homologous 11:37:42

1	sequences and then perform the multiple sequence	11:37:46
2	alignment?	11:37:50
3	A That I have, yes.	11:37:53
4	Q Okay. And why did you do that? What was	11:37:54
5	the goal?	11:37:57
6	A The goal was to identify what other amino	11:37:58
7	acids we might try at various positions in the	11:38:02
8	protein that we're working with.	11:38:06
9	Q So you were -- you performed this	11:38:10
10	alignment to identify potential candidates for	11:38:13
11	substitution in the protein that you were working	11:38:17
12	with?	11:38:21
13	A That is correct.	11:38:21
14	Q Okay. Did you already -- did you know	11:38:22
15	what residues were essential for function in that	11:38:30
16	protein?	11:38:34
17	ATTORNEY KUSHAN: Objection. Foundation.	11:38:35
18	A Essential residues weren't of interest to	11:38:39
19	us. It was actually a non-essential residue, a	11:38:43
20	residue that actually varied quite a bit from one	11:38:47
21	protein to another that we were interested in. We	11:38:52
22	wanted to see whether we could introduce a	11:38:56

1 mutation at that variable position in order to 11:39:02
2 improve the function of that protein that we were 11:39:05
3 working with. 11:39:06

4 Q And why were you focussed on that one 11:39:06
5 specific position? 11:39:10

6 A There have been a lot of studies on this 11:39:12
7 protein. This is a well-known protein. And the 11:39:15
8 amino acids important for function were also well 11:39:22
9 known, so we paid our attention to those positions 11:39:27
10 more than amino acids. 11:39:32

11 Q Okay. What protein? 11:39:37

12 A Streptavidin. 11:39:39

13 Q So you were trying to improve the function 11:39:58
14 in streptavidin by introducing mutations at a 11:40:02
15 particular position; is that right? 11:40:08

16 A That is correct. 11:40:08

17 Q And how did you arrive at the particular 11:40:09
18 position that you wanted to change in 11:40:13
19 streptavidin? 11:40:17

20 A That position was known to be important. 11:40:17

21 Q Was it known to be important through 11:40:24
22 studies in the literature? 11:40:29

1	A Yes.	11:40:28
2	Q When you say important, what do you mean?	11:40:39
3	A The residue at that position seems to be	11:40:45
4	involved in ligand binding.	11:40:52
5	(Reporter clarification.)	11:41:03
6	Q And were you able to improve streptavidin	11:41:03
7	activity by introducing mutations at that	11:41:13
8	position?	11:41:12
9	A Yes. It did improve.	11:41:14
10	Q Did you do the work in your lab that	11:41:23
11	identified that position as important in ligand	11:41:25
12	binding?	11:41:32
13	A Did we do the work in the lab?	11:41:33
14	Repeat that question, please.	11:41:37
15	Q Let me try to ask a different question.	11:41:38
16	How do you know that that position was --	11:41:42
17	that that position was important in ligand	11:41:47
18	binding?	11:41:49
19	A As I said, previous studies by other labs	11:41:50
20	have identified that position to be involved in	11:41:56
21	ligand binding.	11:42:02
22	Q Was that position that you were trying to	11:42:32

1	change in streptavidin, was that position	11:42:36
2	essential to the protein folding?	11:42:39
3	A No. I don't think so.	11:42:46
4	Q Okay. In your -- in your work, in terms	11:42:51
5	of introducing substitutions into proteins, have	11:42:59
6	you ever tried introducing substitutions into a	11:43:04
7	position that is essential for protein folding?	11:43:06
8	ATTORNEY KUSHAN: Objection. Form.	11:43:10
9	A No. I have never tried to introduce a	11:43:14
10	mutation at a position that is known to be	11:43:17
11	important for folding.	11:43:21
12	Q Would you expect that if you tried to	11:43:22
13	introduce a mutation into a position known to be	11:43:25
14	important for folding, that the -- that the	11:43:28
15	protein would not be able to fold correctly?	11:43:29
16	A I would expect that; therefore, I would	11:43:36
17	not try that.	11:43:39
18	Q Is it fair to say that a person skilled in	11:43:49
19	the art would expect that if you introduced	11:43:54
20	positions into residues that are important for	11:43:58
21	folding, the resulting protein will not be	11:44:02
22	properly folded?	11:44:06

1	ATTORNEY KUSHAN: Objection. Foundation.	11:44:08
2	A I think you may have garbled up words	11:44:12
3	there.	11:44:17
4	Q That's possible. Let me try to ask that	11:44:17
5	better.	11:44:20
6	A Okay.	11:44:20
7	Q So okay. So would persons skilled in the	11:44:20
8	art understand that if you try to introduce a	11:44:28
9	substitution into a position known to be important	11:44:32
10	for folding, the protein would not be able to fold	11:44:36
11	correctly?	11:44:39
12	ATTORNEY KUSHAN: Objection. Foundation.	11:44:40
13	Objection as to form.	11:44:41
14	A That really depends on the nature of the	11:44:43
15	conservation. Some amino acids and residues are	11:44:49
16	important for reasons other than folding itself.	11:44:55
17	If it's an enzyme, for instance, the residue may	11:45:00
18	be important for catalysis.	
19	(Reporter clarification.)	11:45:15
20	A And mutating those residues would abrogate	11:45:15
21	enzyme function; however, it would have minimal	11:45:23
22	impact on the folding of the protein.	11:45:27

1	So knowing what the conservation is for	11:45:27
2	would be relevant to calibrate one's expectation.	11:45:32
3	Q Okay. So along those lines, the skilled	11:45:37
4	person would expect that if you make a	11:45:43
5	substitution in a residue that's essential for	11:45:46
6	catalysis, the skilled person would expect that	11:45:51
7	you're going to inactivate the protein; is that	11:45:53
8	right?	11:45:57
9	ATTORNEY KUSHAN: Objection. Foundation.	11:45:57
10	Objection as to form.	11:45:58
11	A Introducing a mutation at a position that	11:46:01
12	is catalytically important often abrogates the	11:46:06
13	enzyme function. That would be the expectation.	11:46:14
14	Q So let's turn to Appendix D-1.	11:46:26
15	A D-1?	
16	Q D-1, yeah. Which starts on Page 126.	11:46:41
17	Okay. You have it.	11:46:44
18	A I'm on that.	11:46:44
19	Q Can you explain what you have -- what	11:46:46
20	you've set forth in exhibit -- or, Appendix D-1,	11:47:11
21	Appendix D, Part 1, rather?	11:46:57
22	A D, Part 1. Yes.	11:46:59

1 This is the output of the analysis of the 11:47:06
2 multiple sequence alignment from Clustal Omega 11:47:14
3 that we saw earlier in Exhibit 1057. I developed 11:47:18
4 a script that took this as an input, and for each 11:47:27
5 amino acid in PH20 -- that's the top line -- I 11:47:33
6 would give it a residue number -- that's 11:47:46
7 wild-type 1, wild-type 2 -- corresponding to the 11:47:51
8 first amino acid, second amino acid, of PH20. And 11:47:54
9 for that position, from the alignment, I counted 11:48:00
10 the appearance of various amino acids and computed 11:48:05
11 the actual number, as well as the percentage, 11:48:10
12 which is divided by -- which is obtained by 11:48:16
13 dividing that number by 88. 11:48:20
14 So for the first position, you have 11:48:24
15 methionine, M, wild-type position number 1, 11:48:33
16 methionine. If you look at the alignment, you see 11:48:34
17 some sequences that have methionine at the 11:48:38
18 beginning. But then there are a lot of sequences 11:48:41
19 that don't have any matching residue. The absence 11:48:45
20 of a matching residue is indicated by dashes. 11:48:48
21 So there are a lot of dashes. So the dash 11:48:51
22 appears 72 times. Methionine appears 16 times, 11:48:53

1 divided by 88, will give you 18.18. So the top 11:48:59
2 line says: Methionine appears 18.18 percentage, 11:49:00
3 but the most frequent residue, in this case a 11:49:05
4 dash, appears 81.81 percentage. 11:49:15

5 Then you will do that for every position 11:49:18
6 of PH20, all the way down to the last amino acid, 11:49:21
7 which I believe is 495 -- yeah, 495 -- for the 11:49:28
8 reasons that I explained earlier. 11:49:35

9 Q Okay. And the sequence that you used 11:49:37
10 includes the 35 amino acid signal peptide, right? 11:49:40

11 A It does include the 35 signal sequence at 11:49:45
12 the beginning, yes. 11:49:50

13 Q Okay. So we start with position -- let's 11:49:51
14 see. Actually, let's just do -- so you refer to 11:49:57
15 position 320, or in the full length sequence it's 11:50:05
16 position 355, right? 11:50:09

17 A The full length sequence number would be 11:50:11
18 355. That is correct. 11:50:15

19 Q So in Appendix D-1, the residue in 11:50:16
20 question is residue 355? 11:50:22

21 A That is correct. 11:50:24

22 Q And that's on Page 146? 11:50:26

1	A	Okay.	11:50:31
2	Q	Okay. So it says: Wild-type 355 is D,	11:50:34
3		right?	11:50:40
4		Did you get it?	11:50:42
5	A	I thought I did.	11:50:43
6	Q	Wild-type residue position 355 is D,	11:50:45
7		right?	11:50:50
8	A	Yes.	11:50:51
9	Q	And if I'm understanding this correctly,	11:50:51
10		then D appears 10.22 percent of the time?	11:50:54
11	A	Yes. 10.22 percent of the time, out of	11:50:59
12		the 88 sequences.	11:51:02
13	Q	Okay. And the most common residue at that	11:51:03
14		position is K, right?	11:51:07
15	A	That is correct.	11:51:09
16	Q	And K appears 57.95 percent of the time?	11:51:10
17	A	That's right. It appears 51 times out of	11:51:15
18		88, corresponding to 57.95 percent. Yes.	11:51:20
19	Q	Okay. So why does it say, like, res394?	11:51:24
20	A	Okay. One, you can ignore that number.	11:51:29
21	Q	Okay.	
22	A	It's just a bookkeeping number.	11:51:32

1	Q Okay.	11:51:36
2	A Including all the dashes in the alignment.	11:51:37
3	Yeah. So I didn't know what I was using this	11:51:41
4	output for, ultimately when I was developing the	11:51:44
5	algorithm. So I just kept track of all the	11:51:48
6	positions. Because of the dashes, the wild-type	11:51:52
7	number actually corresponds to the amino acid	11:51:58
8	number in PH20.	11:52:02
9	Q Uh-huh.	
10	A But res394, that's just a position in this	11:52:03
11	particular format.	11:52:09
12	Q Oh, okay. Okay. Got it. Thanks.	11:52:10
13	Okay. So in -- at the position 355, in	11:52:14
14	your alignment then all of the residues that	11:52:21
15	appear there, which are K, D, H, R, N, Q, S, G, E,	11:52:30
16	those are all of the amino acids that appear at	11:52:38
17	position 355 in the alignment; is that right?	11:53:10
18	A Yeah. The position corresponding to	11:52:44
19	wild-type residue in PH20, 355, yes.	11:52:50
20	Q Yes. Okay.	11:53:04
21	All right. So can you turn to	11:54:06
22	Paragraph 31?	11:54:07

1	A	Okay.	11:54:18
2	Q	So -- oh, actually. Sorry.	11:54:19
3		So we've talked about Paragraph 30, which	11:54:29
4		is where you have the 95 percent cut-off, right,	11:54:32
5		the essential residues?	11:54:38
6	A	Yes.	11:54:40
7	Q	Okay. And then you have a chart on	11:54:40
8		Page 14, and that gives all of the essential	11:54:42
9		residues; is that right?	11:54:47
10	A	Page 14 lists essential residues, yes.	11:54:50
11	Q	Okay. And so you have the residue number,	11:54:53
12		which is the -- the position in the wild-type	11:54:58
13		sequence that includes the signal sequence, right?	11:55:03
14	A	Yes. Residue number -- yes.	11:55:11
15	Q	Okay. And then the mature residue number	11:55:15
16		is the position in the sequence that does not	11:55:18
17		include the signal sequence? In other words, you	11:55:21
18		just subtract 35 from the residue number?	11:55:23
19	A	That's correct.	11:55:27
20	Q	Okay. And then the PH20 residue, and then	11:55:28
21		you have residue percent. So is the residue	11:55:34
22		percent the frequency with which the PH20 residue	11:55:40

1 occurs in the alignment of that position? 11:55:44

2 A That is correct. The residue percentage 11:55:47

3 corresponds to the wile type residue of PH20. 11:55:50

4 Q Okay. So for example, the first entry in 11:55:57

5 your chart is mature residue position 14, and it's 11:56:00

6 PH20 residue F, and the residue appears 95.5 11:56:09

7 percent of the time. So is it the case then 11:56:16

8 that -- am I understanding this correctly, that in 11:56:18

9 the alignment at mature residue position 14, 95.5 11:56:20

10 percent of the time there is an F? 11:56:26

11 A That is correct. 11:56:27

12 Q Okay. So then -- and there are 68 11:56:37

13 residues that you identified as essential, right? 11:56:44

14 A There are 68 residues in this table 11:56:49

15 labeled essential, yes. 11:56:53

16 Q And those 68 residues are the residues 11:56:56

17 that the skilled person would understand to be 11:57:01

18 essential to protein folding? 11:57:05

19 ATTORNEY KUSHAN: Objection. Foundation. 11:57:06

20 A Essential, not necessarily for folding. 11:57:11

21 Again, some residues may be conserved for other 11:57:16

22 reasons besides folding a cell. For this class of 11:57:22

1	proteins, that really comes down to the catalatic	11:57:26
2	residue. So catalatically important residues also	
3	be conserved, and therefore included in this list.	11:57:32
4	Q So -- okay. So is the 68 residue list	11:57:35
5	then, does that include residues that are	11:57:40
6	essential for folding and/or catalytic activity?	11:57:41
7	ATTORNEY KUSHAN: Objection. Foundation.	11:57:47
8	A One would think that.	11:57:48
9	Q Okay. All right.	11:57:50
10	So now let's go to Paragraph 31 on the	11:57:53
11	next page.	11:57:56
12	So the second and third -- I'm looking at	11:58:07
13	the second and third sentence in Paragraph 31.	11:58:13
14	A I did get it.	11:58:17
15	Q Nice. Okay.	11:58:18
16	The second and third sentence in	11:58:21
17	Paragraph 31: The existence of evolutionary	11:58:24
18	segregation at these positions indicates that the	11:58:30
19	homologous proteins have tolerated different amino	11:58:32
20	acids at those positions.	11:58:34
21	And so am I understanding correctly that	11:58:35
22	because the positions that you've labeled as	11:58:46

1 non-essential, because there's variation in the 11:58:48
2 amino acid at that position in the sequence, for 11:58:52
3 homologous proteins, that would indicate to a POSA 11:58:56
4 that the POSA could potentially introduce 11:59:00
5 substitutions at those positions? 11:59:05

6 A Because there is variation among naturally 11:59:13
7 occurring homologous proteins, a POSA would be 11:59:17
8 justified in thinking that a mutation may be made 11:59:22
9 at those positions without damaging the enzyme. 11:59:28

10 Q Okay. And then you say: Amino acids at 11:59:33
11 these positions in the different hyaluronidase 11:59:36
12 proteins would be considered non-essential 11:59:38
13 residues because the proteins presumably still 11:59:41
14 exhibit hyaluronidase activity when they are 11:59:43
15 mutated; is that right? 11:59:51

16 A They are considered non-essential, given 11:59:53
17 that there is variation. In other words, the 11:59:57
18 wild-type residue identity is not strictly 12:00:01
19 required, and that makes it non-essential from 12:00:06
20 that sense. 12:00:09

21 Again, it doesn't mean that it's anything 12:00:12
22 goes. One has to be careful. But from that 12:00:15

1	definition, yes.	12:00:19
2	Q But there are -- there are proteins in the	12:00:24
3	alignment that don't exhibit hyaluronidase	12:00:28
4	activity, right?	12:00:32
5	A That is correct. Yes. HYAL3, as I	12:00:33
6	mentioned earlier, doesn't seem to have known	12:00:38
7	activity. It must still be folded, and must be	12:00:41
8	doing something. Otherwise, there's no reason to	12:00:44
9	keep those amino acids where they are. It's so	12:00:48
10	easy to mutate them away.	12:00:49
11	In fact, hyaluronidase 6 in human is	12:00:51
12	supposed to be a pseudo gene, but it has diversified	12:00:53
13	so much you can't even find it, actually. It's	12:01:00
14	not easy to find.	
15	The same fate would have happened to	
16	hyaluronidase 3. The fact that it's around and	12:01:05
17	has all those conserved residues suggests that it	12:01:07
18	must be doing something. And in order to do be	12:01:11
19	doing something for a protein, it has to be	12:01:14
20	folded.	12:01:18
21	So one can deduce based on those	12:01:18
22	observations that -- yeah. So they are doing	12:01:23

1 something. They might not have strictly the 12:01:24
2 hyaluronidase activity. However, what's important 12:01:28
3 is that they do have a structure that is 12:01:31
4 sufficient to support activity. 12:01:35

5 That's what one would take away from this 12:01:40
6 multiple sequence alignment. Not a strict reading 12:01:45
7 that these enzymes exist because in the group, 12:01:47
8 they exhibit hyaluronidase activity, which we know 12:01:50
9 to be not true, with 3 and 4, for instance. 12:01:54

10 Q Okay. So the person of ordinary skill in 12:02:09
11 the art would understand that amino acids at those 12:02:12
12 non-essential positions and the different 12:02:30
13 hyaluronidase proteins -- actually, strike that. 12:02:23
14 It's going to be garbled. 12:02:24

15 I mean, the skilled person would 12:02:24
16 understand that the non-essential residues are 12:02:27
17 potentially amenable to change because different 12:02:35
18 amino acids are allowed at those positions and the 12:02:40
19 resulting proteins are folded and exhibit whatever 12:02:45
20 activity it is that they do? 12:02:48

21 A That was a long sentence. If you could 12:02:55
22 repeat some part of that sentence? 12:03:00

1	Q Uh-huh.	12:03:02
2	So the amino acids at the -- at the	12:03:06
3	positions that you termed non-essential would be	12:03:09
4	considered non-essential because the protein --	12:03:13
5	the resulting protein is still folded and exhibits	12:03:15
6	some activity?	12:03:21
7	A They must have activity. Some activity, a	12:03:27
8	lot of activity, that's hard to say. But they	12:03:30
9	must have activity, and you still see a variation	12:03:35
10	in those individual sequences. Coupling those two	12:03:41
11	things was -- would lead one to believe that you	12:03:47
12	can have variation at these positions without	12:03:53
13	compromising the activity of the protein, which in	12:03:57
14	turn assumes that the protein would be folded.	12:04:02
15	ATTORNEY MARTIN: So it's 12:05. Is now a	12:04:13
16	good time to break for lunch?	12:04:17
17	ATTORNEY KUSHAN: Sure.	12:04:22
18	THE WITNESS: Okay.	12:04:23
19	THE VIDEOGRAPHER: We are going off the	12:04:23
20	record. The time is 12:04 p.m.	12:04:27
21	(Recess from 12:04 p.m. until 1:06 p.m.)	12:04:32
22	THE VIDEOGRAPHER: We are back on the	13:06:31

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

120

1	record. The time is 1:06 p.m.	13:06:35
2	BY ATTORNEY MARTIN:	13:06:38
3	Q Welcome back, Dr. Park.	13:06:40
4	Did you discuss the substance of your	13:06:42
5	deposition with anyone during the break?	13:06:44
6	A No. I did not.	13:06:47
7	ATTORNEY MARTIN: Okay. So can I ask, is	13:06:48
8	Dr. Hecht still on the Zoom?	13:06:51
9	ATTORNEY KUSHAN: I don't know.	13:06:55
10	Brian, are you on the Zoom?	13:06:58
11	ATTORNEY GOLDBERG: Sorry. I was just	13:07:02
12	unmuting.	13:07:05
13	Yes. Dr. Hecht and I are on the Zoom.	13:07:06
14	ATTORNEY MARTIN: Okay. So we object to	13:07:09
15	Dr. Hecht listening in to this deposition because	13:07:11
16	we believe it's improper witness coaching.	13:07:15
17	And so we're going to ask Dr. Hecht to	13:07:20
18	stop listening to the deposition.	13:07:21
19	ATTORNEY KUSHAN: How is this witness	13:07:21
20	coaching?	13:07:24
21	ATTORNEY MARTIN: Because he's listening	13:07:26
22	to the deposition, presumably to prepare for his	

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

121

1	own deposition.	13:07:27
2	ATTORNEY KUSHAN: He can review the	13:07:27
3	deposition transcript, too.	13:07:29
4	ATTORNEY MARTIN: But it's different to	13:07:29
5	listen in to the deposition of another expert in	13:07:32
6	the same case and then --	13:07:33
7	ATTORNEY KUSHAN: How?	13:07:33
8	ATTORNEY MARTIN: -- see how depositions	13:07:33
9	go so that you can understand, you know, what to	13:07:35
10	do for your deposition.	13:07:37
11	ATTORNEY KUSHAN: Look, I've been in	13:07:38
12	depositions where an expert who is not being	13:07:40
13	deposed is attending, and never been the basis for	13:07:43
14	objection.	13:10:06
15	ATTORNEY MARTIN: I have never had a	13:07:48
16	deposition where another -- an expert for the same	13:07:50
17	side is listening to -- who has not yet been	13:07:53
18	deposed is listening to another expert be deposed	13:07:55
19	before him. I have never had that, ever.	13:08:00
20	ATTORNEY KUSHAN: Well, you can object. I	13:08:03
21	don't know how long he's going to be on. You	13:08:08
22	know, he can remove himself. If you want to	13:08:10

1	consult with this -- with me on this, we can do	13:08:11
2	that on the next break.	13:08:15
3	ATTORNEY MARTIN: Okay. So our objection	13:08:15
4	is noted on the record, and understand that you're	13:08:17
5	not willing to remove Dr. Hecht from the	13:08:20
6	deposition.	13:08:23
7	ATTORNEY KUSHAN: Correct.	13:08:23
8	ATTORNEY MARTIN: All right. And to be	13:08:24
9	clear, the objection is witness coaching under	13:08:29
10	FRE-615.	13:08:37
11	BY ATTORNEY MARTIN:	13:08:49
12	Q Okay. So at the beginning -- at the very	13:08:50
13	beginning of this deposition, Dr. Park, you	13:08:54
14	gave -- you gave me a chart that had the	13:08:58
15	corrections to your declarations, right?	13:09:01
16	A Yeah.	13:09:03
17	Q So when did -- when did those corrections	13:09:04
18	first come to your attention?	13:09:06
19	A I noticed these errors while I was reading	13:09:21
20	the declarations in preparation for today's	13:09:27
21	deposition.	13:09:30
22	Q Okay. And when did that -- when did that	13:09:30

1	happen?	13:09:37
2	A The past three weeks, I would say.	13:09:41
3	Q Okay. And when was the chart prepared?	13:09:44
4	A This chart?	13:09:49
5	Q Yes.	13:09:50
6	A This was given to me this morning.	13:09:56
7	Q Got it.	13:09:59
8	Dr. Park, what did -- what did you do to	13:10:15
9	prepare for this deposition?	13:10:17
10	A To prepare for this deposition, I read the	13:10:22
11	declarations over. I read the articles over. I	13:10:29
12	went over the data to make sure that I was	13:10:34
13	familiar with the content of each file that was	13:10:38
14	being submitted.	13:10:42
15	Q When you said the data, you mean the data	13:10:47
16	in the appendices, or the exhibits to your	13:10:50
17	declaration?	13:10:54
18	A That's correct.	13:10:54
19	Q Okay. Did --	
20	A I wanted to know what was exactly in that	13:10:55
21	file. I think I knew what it was, but wanted to	13:10:59
22	go over that one more time.	13:11:02

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

124

1	Q Did you meet with anyone to prepare for	13:11:03
2	this deposition?	13:11:06
3	A I met with counsel.	13:11:10
4	Q Was there anyone present who was not a	13:11:12
5	lawyer?	13:11:15
6	A No.	13:11:20
7	Q Okay. Have you had any communications	13:11:21
8	with Dr. Hecht regarding this case?	13:11:32
9	A We had Zoom meetings together.	13:11:40
10	Q About how many Zoom meetings?	13:11:43
11	A I want to say maybe four. I know it was	13:11:51
12	less than seven for sure, because I elaborated on	13:11:59
13	some of the positions, and there were seven of	13:12:06
14	them.	13:12:12
15	At some of the meetings, I discussed more	13:12:12
16	than one position, so it was definitely less than	13:12:15
17	seven. I don't remember exactly how many I	13:12:19
18	discussed at which days. My feeling is doubling	13:12:21
19	up -- doubling up on some of the days. It might	13:12:27
20	have been four meetings, say.	13:12:30
21	Q And approximately when did those meetings	13:12:33
22	take place?	13:12:37

1 A I think it was toward the end of last year 13:12:44
2 and beginning of this year. 13:12:48

3 Q Approximately how long were those 13:12:54
4 meetings? 13:12:57

5 A Those Zoom meetings lasted an hour and a 13:13:02
6 half to two hours each. 13:13:07

7 Q Did you -- did you ask to speak to 13:13:16
8 Dr. Hecht, or did he ask to speak to you, do you 13:13:20
9 know? 13:13:26

10 A During the Zoom meeting you mean? 13:13:26

11 Q Did you initiate -- in order to initiate 13:13:29
12 the meeting, did you request to speak with 13:13:31
13 Dr. Hecht? 13:13:37

14 A To initiate the meeting? 13:13:37

15 Q Yes. 13:13:40

16 A No. Those meetings were set up by 13:13:40
17 Mr. Kushan. 13:13:47

18 Q Okay. Got it. 13:13:48

19 Was any -- was anyone else present -- 13:13:49
20 strike that. 13:13:51

21 Was counsel present during the meetings 13:13:51
22 with Dr. Hecht? 13:13:54

1	A Yes.	13:13:55
2	Q Okay. Did you communicate with Dr. Hecht	13:13:57
3	about the substance of your declarations after you	13:14:23
4	signed them?	13:14:30
5	A After I signed them? I'm afraid I can't	13:14:28
6	tell which happened first, signing or the	13:14:39
7	discussion.	13:14:42
8	Q Okay. So let's turn -- did you -- did you	13:14:43
9	read Dr. Hecht's declarations?	13:15:43
10	A No.	13:15:45
11	Q Do you know what Dr. Hecht opined on in	13:15:45
12	connection with these PGRs?	13:15:51
13	A Pardon?	13:15:53
14	Q Do you know what the substance of	13:15:54
15	Dr. Hecht's testimony is?	13:15:56
16	A No.	13:15:58
17	Q Did you ask doctor -- or, sorry. Strike	13:15:58
18	that.	13:16:00
19	So let's turn to Paragraph 85.	13:16:00
20	ATTORNEY KUSHAN: I'm sorry, Counsel.	13:16:35
21	Before you proceed, we're going to have	13:16:36
22	Dr. Hecht leave this Zoom. We, of course,	13:16:39

1 disagree with your objection, but as of respect of 13:16:43
2 your request, we're going to honor your request 13:16:47
3 and have him leave. 13:16:51

4 ATTORNEY MARTIN: Thank you. 13:16:52

5 BY ATTORNEY MARTIN: 13:17:07

6 Q Okay. So in this section -- so, yeah. 13:17:09

7 Are you in Paragraph 85? 13:17:28

8 A I am in Paragraph 85. I wanted to see 13:17:30
9 where Paragraph 85 comes in, in the overall scheme 13:17:34
10 of things as I'm flipping through here. 13:17:39

11 Okay. I'll listen to your question first. 13:17:43

12 Q Okay. So the second sentence in 13:17:48
13 Paragraph 85, you say: I balanced the type of 13:17:52
14 impact of the substitutions based on the magnitude 13:17:55
15 of each interaction may have on the protein 13:18:00
16 structure. 13:18:03

17 Can you explain what you mean by the 13:18:04
18 impact of the substitutions, like, what -- what 13:18:06
19 you mean by impact, I guess? 13:18:09

20 A When a substitution is made, changes 13:19:00
21 happen. Some are favorable changes. Others are 13:19:04
22 unfavorable changes, and those changes are listed 13:19:09

1 in the paragraphs before this. There are many of 13:19:14
2 them. 13:19:17

3 Q Uh-huh. 13:19:18

4 A I was just looking through them. Many of 13:19:21
5 them are enumerated. I am factoring all of those 13:19:24
6 positive and negative changes trying to come up 13:19:32
7 with an estimate of where the net effects falls. 13:19:37

8 (Reporter clarification.) 13:19:44

9 Q Okay. So is it fair to say that you're 13:19:44
10 analyzing all the potential effects of a 13:19:50
11 substitution, and then trying to arrive at the 13:19:54
12 overall net effect? 13:19:58

13 A That would be a correct summary, yes. 13:19:59

14 Q Okay. And when you reference the 13:20:04
15 magnitude of each interaction, what do you mean -- 13:20:06
16 what do you mean by magnitude? 13:20:10

17 A It's more of a perception. When there are 13:20:19
18 two conflicting changes, I need to decide whether 13:20:25
19 there are of equivalent magnitude, meaning is one 13:20:30
20 as positive as the other one is negative, or is 13:20:36
21 one factor more significant than the other. And 13:20:41
22 if so, what would be the sum of all those number 13:20:44

1	of interactions.	13:20:51
2	So without putting a number on the	13:20:54
3	magnitude, which obviously cannot be done, based	13:20:58
4	on visual inspection, I try to apply my experience	13:21:03
5	and my viewpoint as a POSA, to determine whether	13:21:09
6	the net change would be in favor of the protein	13:21:22
7	structure and stability and function, or the other	13:21:27
8	way around, whether it would negatively impact the	13:21:31
9	structure and function.	13:21:34
10	Q And so based on that assessment, you used	13:21:45
11	a scoring system of -- using the numbers 1, 2	13:21:54
12	and 3, right?	13:21:58
13	A I did use a system of 1, 2 and 3. Yes.	13:21:58
14	Q Had you used that scoring system before in	13:22:01
15	your work, outside of this case?	13:22:05
16	A Maybe implicitly, but not in those terms.	13:22:11
17	Q So is it fair to say that in your work	13:22:17
18	outside of this case, you had perhaps looked at	13:22:22
19	potential substitution and determine whether you	13:22:25
20	would expect it to improve the stability or have a	13:22:29
21	neutral effect or have a negative effect, but you	13:22:33
22	wouldn't necessarily give it a 1, 2 or 3 rating?	13:22:37

1	ATTORNEY KUSHAN: Objection. Form.	13:22:41
2	A That is correct. I never had the need to	13:22:45
3	put a number on what I see.	13:22:49
4	Q And why did you need to put a number on	13:22:55
5	what you see in your analysis in this case?	13:22:58
6	A In order to put those substitutions in 2/3	13:23:08
7	bins so that I can say whether a mutation would be	13:23:12
8	likely to be tolerated or not tolerated. I had to	13:23:20
9	make that qualitative decision for the purpose of	13:23:27
10	this declaration, and that required me to classify	13:23:34
11	the substitutions in different bins. There could	13:23:37
12	have been two, yes or no. But as I was looking	13:23:42
13	through the substitutions, some stood out and I	13:23:45
14	felt comfortable classifying some of them as a	13:23:48
15	favorable mutation, not just acceptable mutual	13:23:55
16	mutations.	13:24:22
17	Q So did you arrive at the 1, 2, 3 scoring	13:24:02
18	system as you were doing your analysis in this	13:24:06
19	case?	13:24:11
20	A Yes. I developed the system 1, 2 and 3 as	13:24:11
21	I was looking at the substitutions.	13:24:16
22	Q Okay. So is it fair to say that a score	13:24:39

1	of 3 would be expected to be a favorable	13:24:42
2	substitution; is that right?	13:24:47
3	A That's how the system is set up, yes.	13:24:50
4	Q Okay.	13:24:53
5	A By classification. System is set up, so	13:24:53
6	that 3 indicates a favorable substitution.	13:24:58
7	Q And then is 2, is that a neutral	13:25:01
8	substitution?	13:25:05
9	A Neutral plus/minus delta. In other words,	13:25:06
10	I -- if there's a change in stability in either	13:25:14
11	direction, I thought it would be minor change, not	13:25:18
12	really worthy of separate classification, but	13:25:22
13	something equivalent to wild-type.	13:25:30
14	Q Okay. And 1, is that a disfavored	13:25:35
15	substitution, or unfavorable substitution?	13:25:43
16	A 1 corresponds to substitutions for which I	13:25:47
17	had real reservation. Something about the	13:25:51
18	substitution, say, worried me, then I would put	13:25:56
19	that substitution in the category of 1.	13:25:59
20	Q And when you say it worried you, does	13:26:01
21	that -- does that mean that you would expect it to	13:26:05
22	potentially have a detrimental impact on protein	13:26:08

1	structure or function?	13:26:19
2	A Yes. That's what I mean.	13:26:19
3	Q Okay. And for a neutral change, would you	13:26:21
4	expect that change to not have a meaningful effect	13:26:24
5	on protein structure and function?	13:26:28
6	A That's correct. There may be a change,	13:26:32
7	but I didn't think the change would be meaningful	13:26:35
8	enough.	13:26:38
9	Q So for those residues where you scored the	13:26:39
10	mutation as a 2, you would expect those changes	13:26:43
11	not to meaningfully impact the protein structure	13:26:48
12	and function?	13:26:54
13	A That would be the correct way to interpret	13:26:55
14	a score of 2.	13:26:57
15	Q And for a score of 3, you would expect	13:26:59
16	that the substitution potentially would improve	13:27:02
17	function, or would have no effect on function?	13:27:08
18	ATTORNEY KUSHAN: Objection. Foundation.	13:27:11
19	A Score of 3 is a substitution that I can	13:27:15
20	get excited about. Yes. So those are	13:27:20
21	substitutions I had high hopes for.	13:27:26
22	Q And when you say you have high hopes for	13:27:31

1	them, what would you expect to see with those	13:27:34
2	substitutions?	13:27:38
3	A I would expect those substitutions to	13:27:39
4	improve the stability and perhaps function of the	13:27:41
5	enzyme.	13:27:45
6	Q How could you tell if a mutation improves	13:27:46
7	the stability of an enzyme?	13:27:51
8	A There are a number of things one needs to	13:27:55
9	consider when entertaining a substitution. If the	13:27:59
10	individual factors are favorable, then I would	13:28:06
11	expect the net effect of the substitution would be	13:28:11
12	overall favorable. And if I see several such	13:28:15
13	effects, combined with an absence of any	13:28:21
14	noticeable negative effect, I would think that	13:28:27
15	that substitution would improve the protein, not	13:28:32
16	necessarily the enzyme, but a protein in terms of	13:28:37
17	stability.	13:28:40
18	Q Okay. So you mentioned that in your work	13:28:41
19	outside of this case you would analyze potential	13:29:09
20	substitution and determine whether it would be	13:29:12
21	favorable, unfavorable or neutral. Was that the	13:29:14
22	case in the 2011 time frame?	13:29:18

1 A Again, in 2011, I don't think I was doing 13:29:24
2 that particularly. But if you're referring to 13:29:29
3 time before then, I was looking at various 13:29:32
4 substitutions. Most of the time, I wouldn't care 13:29:36
5 for substitutions that are 2 or 1. Neutral 13:29:40
6 substitutions are not that interesting from my 13:29:44
7 perspective.

8 My ultimate goal as an academic person is 13:29:46
9 to publish. You need to have an exciting 13:29:50
10 discovery to publish. A neutral substitution does 13:29:53
11 not constitute an exciting discovery that deserves 13:29:59
12 a publication. As such, I wouldn't care much 13:30:02
13 about substitutions that are 2, much less 1. It 13:30:06
14 would have to be 3, and plus. 13:30:09

15 So those are the substitutions that I 13:30:11
16 would care mostly about. There were many 13:30:14
17 substitutions that would be in the groups of 2's 13:30:19
18 and 1's. I wouldn't care much about them. 13:30:21

19 Q So if you were looking to make a 13:30:40
20 substitution into a -- into a protein, you 13:30:43
21 wouldn't be looking for a substitution that would 13:30:47
22 have no effect. You would be looking for a 13:30:50

1 substitution that would have an improved effect, 13:30:55
2 or at least some difference in effect; is that 13:30:56
3 right? 13:30:58

4 ATTORNEY KUSHAN: Objection. Foundation. 13:30:58

5 Also objection as to form. 13:31:00

6 A We're talking about a different situation, 13:31:03
7 different scenario. My goal as an independent 13:31:08
8 researcher would not necessarily be aligned with 13:31:12
9 the goals of this particular declaration. My 13:31:16
10 objective is quite different. 13:31:20

11 As you said, I would be interested in 13:31:23
12 improving the enzyme, not necessarily finding a 13:31:25
13 substitution that would be neutral and doesn't 13:31:30
14 really change the protein per se. That is not 13:31:34
15 really the mandate for this work. 13:31:40

16 As I understand it, I was instructed to go 13:31:47
17 find substitutions that would be tolerated at 13:31:49
18 non-essential positions in this enzyme, and that's 13:31:54
19 what I did. 13:31:57

20 Q Okay. And when you say tolerated, you 13:31:58
21 mean substitutions that were neutral or 13:32:17
22 beneficial; is that right? 13:32:05

1	ATTORNEY KUSHAN: Objection. Foundation.	13:32:07
2	A I define the word tolerate in the	13:32:08
3	declaration.	13:32:14
4	Q Uh-huh.	
5	A It's in the terminology used in the	13:32:19
6	declaration, Page 5 I believe.	13:32:22
7	Q Oh. It's actually in Paragraph 20.	13:32:33
8	A Oh, is it. Okay. The following, yes.	13:32:35
9	I use the word tolerate -- it should be in	13:32:40
10	quotation -- here to mean that the presence of a	13:32:44
11	single amino acid at a particular position of the	13:32:47
12	protein's amino acid sequence does not materially	13:32:50
13	alter the local structure around that position in	13:32:55
14	the protein, and thus does not meaningfully alter	13:32:55
15	the biological activity of the protein.	
16	In terms of ranking, that would correspond	13:32:59
17	to 2 and 3 of the classification.	13:33:02
18	Q Okay. So going back to -- let's see.	13:33:08
19	So do you -- would you expect that	13:33:29
20	mutations that you've scored as 2 or 3, would you	13:33:42
21	expect those to impact protein function?	13:33:47
22	A Hard to say. I have not considered that	13:33:59

1 aspect much. I was mostly concerned with the 13:34:03
2 compatibility of the substitution in terms of the 13:34:09
3 structure, whether the substitution would be 13:34:18
4 tolerated by the structure of the PH20. 13:34:20

5 If those substitutions are within the 13:34:24
6 active site, which I can roughly guess based on 13:34:28
7 the shape of the molecule. However, precisely 13:34:32
8 what residues are involved in catalysis is not 13:34:37
9 well known, so that would at best, an educated 13:34:42
10 guess. If I see a position that is close to where 13:34:45
11 I would expect the ligand or the substrate would 13:34:49
12 be, then I would try to include that in the 13:34:53
13 consideration. But I was mostly interested in the 13:34:59
14 compatibility of the substitution with the 13:35:04
15 structure of the enzyme more than anything else. 13:35:08

16 Q Okay. So did you -- did you evaluate 13:35:11
17 whether you would expect the change to impact the 13:35:16
18 function of the protein? 13:35:19

19 A I did not address that question directly. 13:35:23
20 However, when it was apparent to me that the 13:35:27
21 substrate would be near that particular position, 13:35:36
22 I tried to model that as much as possible. 13:35:39

1 However, the substrate bound structure of the 13:35:45
2 enzyme is not known. Therefore, those 13:35:49
3 considerations may not be very accurate. 13:35:55

4 Fortunately, there weren't that many positions, 13:36:00
5 because the active site residues are fewer than 13:36:04
6 the rest of the protein. 13:36:14

7 In other words, there are more amino acids 13:36:16
8 away from the active site than at the active site. 13:36:19
9 So a fraction of the residues might be in the 13:36:25
10 active site, and I would, if I can, fold that into 13:36:28
11 the consideration, but not actively. If I get 13:36:33
12 the -- the role of the enzymatic function 13:36:38
13 incorrect, I do not worry about that aspect much. 13:36:43

14 Q So you say in Paragraph 20, in the context 13:37:04
15 of your definition of tolerate, that the -- it 13:37:38
16 doesn't materially alter the local structure, and 13:37:25
17 thus does not meaningfully alter the biological 13:37:28
18 activity of the protein, right? 13:37:35

19 ATTORNEY KUSHAN: Objection. Foundation. 13:37:39

20 A Does not meaningfully alter the biological 13:37:42
21 activity in the way of structural preservations. 13:37:48

22 In other words, a substitution that doesn't 13:37:55

1 change the structure of a protein, it would not 13:37:59
2 affect the activity of the enzyme unless, of 13:38:05
3 course that residue happens to be involved in 13:38:09
4 catalysis. 13:38:16

5 Some of them are known. We know from 13:38:18
6 other publications that there are catalytic 13:38:22
7 residues. If you mutate them, you would lose the 13:38:26
8 activity 100 percent, and those positions are also 13:38:31
9 unlikely to be structurally important. 13:38:34

10 Based on the structure, one can surmise 13:38:38
11 that some of those substitutions are important for 13:38:44
12 catalyst, but not necessarily for the folding of 13:38:51
13 the protein. So here, what is meant is it doesn't 13:38:56
14 affect the biological activity because the 13:39:32
15 structure will be maintained upon substitution. 13:39:07

16 Q So you expect that after the substitution 13:39:10
17 is made, that the -- the protein structure -- the 13:39:15
18 protein will maintain the same structure, and so 13:39:20
19 therefore it will also maintain the same function; 13:39:23
20 is that right? 13:39:26

21 ATTORNEY KUSHAN: Objection. Foundation. 13:39:26

22 Also objection as to form. 13:39:28

1 A Given that the structure of the protein is 13:39:34
2 critical for its activity, if you introduce a 13:39:38
3 substitution that leaves a structure untouched, it 13:39:44
4 would be reasonable to think that the biological 13:39:50
5 activity would remain the same. 13:39:54

6 Q And so is it your opinion that a person of 13:40:04
7 ordinary skill in the art would expect that if you 13:40:08
8 leave a structure untouched that the biological 13:40:12
9 activity would remain the same? 13:40:16

10 ATTORNEY KUSHAN: Objection. Foundation. 13:40:19

11 Also objection as to form. 13:40:23

12 A To a degree that would be true, as long 13:40:26
13 as, as I said earlier, the mutation does not 13:40:37
14 affect known catalytically important residues. In 13:40:45
15 this case, you can keep the structure the same and 13:40:51
16 you would lose activity. So all bets are off in 13:40:55
17 those cases. 13:40:58

18 Q Okay. When you look at the model, the 13:40:59
19 structural model, are you able to identify 13:41:04
20 residues that are important for protein folding? 13:41:09

21 A From the structure alone, no. That would 13:41:17
22 be hard. 13:41:22

1 Q In connection with the -- are you able to 13:41:28
2 use the structure in connection with the alignment 13:41:31
3 to identify residues that important for protein 13:41:34
4 folding? 13:41:37

5 A I think the alignment can help you 13:41:40
6 greatly. It will help you identify a significant 13:41:45
7 number of residues that are important for folding. 13:41:50

8 Q I'm just trying to understand what is it 13:41:55
9 about a residue that makes it important for 13:41:58
10 protein folding? 13:42:01

11 ATTORNEY KUSHAN: Objection to form. 13:42:03

12 A That's the essence of protein folding. If 13:42:09
13 I knew the answer, it would be great. I don't 13:42:14
14 think anybody does, unfortunately. 13:42:18

15 Q Okay. So when you designed the scoring 13:42:20
16 system that you used in this declaration, you were 13:42:56
17 approaching the issue from the perspective of a 13:43:01
18 POSA; is that right? 13:43:05

19 A Yes. 13:43:07

20 Q Okay. 13:43:12

21 Okay. So can we turn to Appendix C? 13:43:35

22 A I am at Appendix C. 13:43:59

1	Q Okay. So Appendix C has your analysis for	13:44:02
2	position 320; is that right?	13:44:12
3	A That is correct.	13:44:18
4	Q And is it correct that the alternate --	13:44:21
5	strike that.	13:44:29
6	So for position 320, the alternative	13:44:29
7	residues that you considered are those alternative	13:44:36
8	residues that appear at position 320 in the	13:44:40
9	alignment; is that right?	13:44:43
10	ATTORNEY KUSHAN: Objection.	13:44:46
11	A Yes.	13:44:47
12	ATTORNEY KUSHAN: Objection to foundation.	13:44:48
13	Go ahead.	13:44:51
14	Q So the only residues that you consider as	13:44:51
15	alternative residues are those that appear in the	13:44:54
16	alignment at that position, right?	13:44:58
17	ATTORNEY KUSHAN: Objection. Foundation.	13:45:00
18	A I only consider the residues that appeared	13:45:04
19	in the multiple sequence alignment for	13:45:07
20	consideration at this position, yes.	13:45:10
21	Q Why did you only consider the residues	13:45:12
22	that appear in the multiple sequence alignment at	13:45:15

1 that position? 13:45:18

2 A That goes back to the assumption that was 13:45:25
3 stated earlier in the declaration, that the 13:45:28
4 residues that appear among homologous sequences 13:45:31
5 have been tested by evolution and proven to be 13:45:40
6 compatible with the structure. Therefore, looking 13:45:44
7 at those possibilities would make sense. 13:45:48

8 And so that is in the Paragraph 31, I 13:46:07
9 think, which is the one that you referred to 13:46:09
10 earlier. Maybe... 13:46:11

11 The existence of evolutionary variation at 13:46:29
12 these positions indicates that the homologous 13:46:31
13 proteins have tolerated different amino acids at 13:46:38
14 those positions, including 320. Those proteins 13:46:42
15 presumably exhibit hyaluronidase activity when 13:46:44
16 they are mutated. 13:46:54

17 So in other words, the homologous 13:46:56
18 sequences that are part of the multiple sequence 13:46:57
19 alignment, they are -- they have explored other 13:46:59
20 possible substitutions at various non-essential 13:47:04
21 positions, including 320, and somehow they have 13:47:08
22 survived. They continue to exhibit activities, if 13:47:15

1 necessary, or at a minimum, managed to stay 13:47:20
2 folded, which, as we discussed earlier, is 13:47:26
3 supported by the fact that conserved residues are 13:47:30
4 conserved, and they're conserved for a reason. 13:47:37
5 Without a reason, there is no reason for them to 13:47:42
6 be conserved. 13:47:46

7 So that is the evidence that they would 13:47:51
8 fold to the same structure. So that's the reason 13:47:51
9 for testing these residues, as opposed to other
10 residues that are not listed in the -- 13:47:55

11 Q Okay. 13:48:00

12 A -- in the multiple sequence alignment. 13:48:01

13 Q A POSA would understand that they could 13:48:07
14 also -- that they could, for example, at 13:48:10
15 position 320, that the aspartic acid could be 13:48:15
16 mutated to one of the other -- another amino acid
17 that's not listed here; is that right?

18 (Reporter clarification.) 13:48:33

19 A Could you repeat the question? What a 13:48:33
20 POSA might assume again? 13:48:36

21 Q Oh. A POSA would understand that if they 13:48:36
22 were looking to substitution position 320 -- 13:48:39

1	A Yes.	13:48:42
2	Q -- they could change position 320	13:48:42
3	theoretically to any of the other 19 amino acids,	13:48:46
4	right?	13:48:49
5	A Not if they have any hope of finding an	13:48:53
6	acceptable mutant. If they're looking for an	13:48:59
7	acceptable substitution, a POSA who's familiar	13:49:03
8	with the literature wouldn't just try any amino	13:49:07
9	acid. There has to be a foundation for what they	13:49:10
10	try, and this would give them the foundation. The	13:49:14
11	other substitutions wouldn't make any sense, so	13:49:18
12	they wouldn't try. Yeah. That's not what a POSA	13:49:22
13	would do.	13:49:27
14	Q So a POSA wouldn't just make random	13:49:34
15	changes and kind of hope for the best?	13:49:37
16	ATTORNEY KUSHAN: Objection. Foundation.	13:49:39
17	Also objection as to form.	13:49:42
18	A Not a POSA. A person off the street, yes.	13:49:43
19	But a person who is supposed to be	13:49:48
20	educated in the field and understand the factors	13:49:51
21	that contribute to protein folding, stability, no.	13:49:55
22	They wouldn't randomly try a substitution. No.	13:50:01

1	They wouldn't.	13:50:07
2	Q So in exhibit -- I'm sorry -- Appendix C,	13:50:38
3	the far right of Appendix C in your chart, you	13:50:43
4	have factors, hydrophobicity, secondary structure	13:50:49
5	and interactions, and there's the Number 1, for	13:50:51
6	some of them, but not all of them.	13:50:55
7	Can you just explain how you -- what this	13:50:57
8	means -- what that means?	13:50:59
9	A First of all, 1 is meant to be a check.	13:51:03
10	So you can understand 1 as a substitute for a	13:51:10
11	check.	13:51:16
12	(Reporter clarification.)	13:51:16
13	A Checkmark. I was doing this in Excel	13:51:16
14	spreadsheet, and it's easier to enter 1, as	13:51:24
15	opposed to a checkmark.	13:51:27
16	The three columns, which have the labels	13:51:28
17	of: Hydrophobicity, secondary structure, and then	13:51:33
18	I forget what the third one says.	13:51:36
19	Q Interactions.	13:51:38
20	A Interactions -- are the three main	13:51:39
21	categories of interactions, attributes that I	13:51:41
22	should consider during a substitution, and they	13:51:46

1	correspond to the intrinsic properties of that	13:51:51
2	amino acid, which is supposed to be the first	13:51:56
3	column.	13:51:59
4	I labeled it as hydrophobicity, but it	13:52:00
5	should really be hydrophobicity/hydrophilicity,	13:52:07
6	lots of other things that one might think of,	13:52:07
7	that's -- that belongs to that amino acid.	13:52:10
8	The second column is the secondary	13:52:13
9	structure, meaning the compatibility of this amino	13:52:17
10	acid with the underlying secondary structure of	13:52:21
11	that protein.	
12	And the third column is the interaction,	13:52:21
13	meaning the interaction of the wild-type and	13:52:25
14	mutant residue with its neighbors.	13:52:29
15	So these are the three aspects that I	13:52:32
16	consider as a personal note, as I was scoring	13:52:34
17	different substitutions. It is important to note	13:52:38
18	that I considered all three for every	13:52:42
19	substitution, but sometimes I'd make a checkmark	13:52:47
20	as an -- as an indication to myself, oh, pay	13:52:50
21	attention to that, what just sort of jumped out,	13:52:54
22	that kind of a thing.	13:52:58

1 Q So does the check mean, for example, for 13:52:59
2 secondary -- you have a check for R, for secondary 13:53:03
3 structure, does that mean that the R gene at that 13:53:07
4 position is compatible with the secondary 13:53:13
5 structure; is that what that means? 13:53:17

6 A One shouldn't look at it as a 13:53:18
7 compatibility, but rather secondary structure is 13:53:23
8 an aspect that I considered and it jumped out as 13:53:27
9 one of the factors that would affect the final 13:53:32
10 decision. 13:53:37

11 Q Okay. I'm just trying to understand if 13:53:38
12 the check is good -- a good thing or a bad thing, 13:53:40
13 or just a note to yourself? 13:53:42

14 A Just a note. 13:53:44

15 Q Just a note. 13:53:45

16 A Yes.

17 Q Okay. Got it. Okay. 13:53:45

18 And so when you said the hydrophobicity 13:53:47
19 should really be the properties of the amino acid, 13:53:50
20 is that looking to see if the two amino acids are 13:53:53
21 comparable in terms of, like, size and chemistry, 13:53:56
22 or is that something else? 13:54:00

1	ATTORNEY KUSHAN: Objection. Foundation.	13:54:04
2	A All of them.	13:54:05
3	Q Okay.	13:54:06
4	A All of them. It could be a hydrophilic	13:54:06
5	amino acid being substituted with a hydrophilic	13:54:15
6	amino acid. Well, I took that into consideration.	13:54:18
7	Checkmark.	13:54:21
8	Q Okay.	13:54:22
9	A That's what it means.	13:54:23
10	Q Okay. Can you explain the FSASA?	13:54:24
11	A Oh. The FSASA.	13:54:48
12	(Reporter clarification.)	13:54:50
13	A I call it accessible surface area --	13:54:50
14	Q Uh-huh. Okay.	
15	A -- as a way of quantifying how much a	13:54:54
16	given amino acid is exposed to the solvent. So	13:54:57
17	that pulls information regarding the -- the	13:55:05
18	neighbor, the environment where this residue	13:55:09
19	appears. If that residue is solvent exposed, then	13:55:11
20	this accessible surface area, fraction of	13:55:16
21	accessible surface area, would approach 1, because	13:55:20
22	the measured value at that position in this	13:55:23

1 protein is nearly as great as the maximum solvent 13:55:27
2 accessible surface area for that amino acid. 13:55:35

3 Q So in order to calculate the fractional 13:55:38
4 solvent accessible surface area, are you 13:55:46
5 determining the solvent accessible surface area in 13:55:49
6 the PyMol for that residue, and then dividing by 13:55:52
7 the maximum solvent accessible surface area for 13:55:57
8 that residue? 13:56:07

9 A That is correct, yes. 13:56:09

10 Q Okay. So the wild-type had -- the 13:56:29
11 wild-type, you have a fractional solvent 13:56:33
12 accessible surface area of .17. 13:56:39

13 Would you consider that to be varied? 13:56:42

14 ATTORNEY KUSHAN: Objection. Foundation. 13:56:45

15 A It is somewhat varied for that amino acid, 13:56:49
16 aspartic acid. 13:56:54

17 The important quantity to bear in mind is 13:56:58
18 not just the number that's listed here, but a 13:57:01
19 comparison of that number to the typical value for 13:57:04
20 that amino acid. For instance, the aspartic acid 13:57:10
21 has a much higher median fractional accessible 13:57:19
22 surface area, which I think is listed further down 13:57:22

1	in appendix -- which is page -- this is	13:57:25
2	Appendix E. This is an output from PyMol.	13:57:41
3	As I consider wild-type on each	13:57:47
4	substitution, I would look at the numbers that are	13:57:49
5	reported back to me, and I get this information	13:57:56
6	because it's written into the script that I	13:58:00
7	developed.	13:58:05
8	And this one says, on Page 192: For	13:58:05
9	aspartic acid at 355, position 355, the relative	13:58:13
10	area, or relative solvent accessible surface area,	13:58:20
11	0.17, whereas the mean is 0.388.	13:58:23
12	So on average, this amino acid is much	13:58:30
13	more solvent exposed, but at this position, it has	13:58:33
14	much smaller solvent accessible surface area. So	13:58:39
15	it gives you an idea of what kind of position	13:58:41
16	we're looking at, because not every position is	13:58:45
17	equal.	13:58:49
18	Q Can you turn to Page 178, Appendix D,	13:58:57
19	Part 5, solvent accessible surface area?	13:59:04
20	A Page 178?	13:59:10
21	Q Yeah.	13:59:15
22	A Okay. Sure.	13:59:15

1	Q Yeah. The chart is on 179.	13:59:16
2	A Sure. Sure.	
3	Q Can you just explain the chart that's on	13:59:22
4	Page 179?	13:59:26
5	A Uh-huh.	13:59:27
6	So this is the normalizing factor,	13:59:28
7	normalization factor, that you mentioned earlier.	13:59:31
8	You measure the surface area of that amino acid	13:59:34
9	at position 320 in the structure, and divide that	13:59:38
10	number by something else. And that something else	13:59:43
11	is the maximum area possible for that amino acid,	13:59:48
12	which has been published.	13:59:53
13	Q Oh, okay. So am I understanding right	13:59:55
14	that the max solvent accessible surface area and	13:59:58
15	the median solvent accessible surface area have --	
16	are published values from the Lins paper, and then	14:00:05
17	you've calculated the median solvent accessible	14:00:09
18	surface area fraction based on those numbers, and	14:00:16
19	that's in the third column?	14:00:18
20	A That is correct. Yes.	14:00:21
21	Q Okay. Got it.	14:00:23
22	Okay. So going back to Appendix C,	14:00:40

1	Page 125, so for N, you just have neutral in the	14:00:53
2	comments. What does -- and also for E, you have	14:01:11
3	neutral in the comment, and that's it.	14:01:17
4	Can you explain what that means?	14:01:20
5	A Yes. I consider that substitution to be	14:01:22
6	so unremarkable that there was nothing to say	14:01:29
7	about it. Oftentimes, D to N substitution is done	14:01:33
8	because they are similar in size, both	14:01:40
9	hydrophilic, and often no substitutions are made.	14:01:46
10	When I make that substitution in the	14:01:50
11	structure, I don't see a great deal of change one	14:01:53
12	way or another. Not -- nothing much. As a	14:01:57
13	result, I just give it a score of 2 with very	14:02:01
14	little comment. Nonetheless, I do consider all	14:02:08
15	three factors listed in the last three columns,	14:02:14
16	which includes intrinsic properties of the	14:02:18
17	individual amino acids, compatibility with the	14:02:22
18	secondary structure, and how that residue	14:02:25
19	wild-type and mutant might interact with its	14:02:31
20	neighbors.	14:02:34
21	So these are done, but in this case its so	14:02:35
22	automatic and it's so quick, really nothing stood	14:02:39

1 out, so I didn't really felt the urge to mark it 14:02:43
2 in anyway, other than noting that it's a very 14:02:46
3 neutral substitution with a score of 2. 14:02:51

4 Q Okay. So you analyzed eight different 14:02:55
5 potential alternative residues, right, for 14:03:06
6 position 320? 14:03:11

7 A There are eight alternative potential 14:03:12
8 substitutions at this position, yes. 14:03:18

9 Q And you conclude that all but one -- so 14:03:19
10 seven of them -- would be tolerated, right? 14:03:24

11 A Yes. Seven substitutions are listed here 14:03:27
12 with a score of 2 or 3, would be tolerated at this 14:03:31
13 position of 320. 14:03:37

14 Q And you would expect that one glycine 14:03:38
15 would be not tolerated, right? 14:03:43

16 A I had a strong feeling that it would not 14:03:45
17 be tolerated. 14:03:49

18 Q So what do you expect would happen if you 14:03:53
19 put glycine in position 320? 14:03:59

20 Do you think the protein wouldn't fold? 14:04:03

21 A It may fold. Its stability may be 14:04:06
22 significantly lower than that of wild-type, thus 14:04:12

1	resulting in a substantial loss of activity.	14:04:19
2	Q Okay. So you would expect that if you put	14:04:22
3	glycine in position 320, you would have a	14:04:26
4	substantial loss in activity?	14:04:31
5	A That is my expectation, yes.	14:04:32
6	Q But for the other seven amino acids that	14:04:32
7	you considered, you would expect the activity to	14:04:35
8	be comparable or better than wild-type; is that	14:04:36
9	right?	14:04:40
10	A That's correct.	14:04:40
11	ATTORNEY MARTIN: All right. We've been	14:04:45
12	going for another hour.	14:04:48
13	Want to take another short break?	14:04:51
14	THE WITNESS: That would be great.	14:04:54
15	Thank you.	14:04:56
16	THE VIDEOGRAPHER: We are going off the	14:04:56
17	record. The time is 2:04 p.m.	14:04:58
18	(Recess from 2:05 p.m. until 2:15 p.m.)	14:05:03
19	THE VIDEOGRAPHER: We are back on the	14:15:26
20	record. The time is 2:15 p.m.	14:15:29
21	BY ATTORNEY MARTIN:	14:15:32
22	Q Welcome back, Dr. Park.	14:15:33

1	Did you discuss the substance of your	14:15:36
2	deposition during the break with anyone?	14:15:39
3	A No.	14:15:41
4	Q So the principles that we've been talking	14:15:42
5	about in terms of -- in terms of protein structure	14:15:46
6	and function in your analysis, that all applies to	14:15:52
7	the 2011 time frame, right?	14:16:03
8	ATTORNEY KUSHAN: Objection. Form.	14:16:06
9	A Obviously the principles are timeless, but	14:16:08
10	the analysis was based on the sample that was	14:16:12
11	gathered with the time frame of 2011 in mind.	14:16:16
12	Q Okay. And the analysis that you performed	14:16:20
13	was done from the perspective of the skilled	14:16:23
14	person in 2011, right?	14:16:31
15	(Reporter clarification.)	14:16:34
16	A Yes. It was.	14:16:34
17	Q Okay. All right. If you have -- if you	14:16:35
18	had homologous proteins that were 90 percent	14:16:45
19	identical in sequence, would you expect that those	14:16:52
20	proteins share the same structure and function?	14:16:55
21	ATTORNEY KUSHAN: Objection. Foundation.	14:16:58
22	A Two proteins that are homologous and have	14:17:05

1 a sequence identity/similarity, 90 percent, do I 14:17:11
2 expect them to adopt the same structure? If these 14:17:18
3 are naturally occurring sequences, yes. 14:17:23

4 Q Would you expect them to have the same 14:17:32
5 function? 14:17:35

6 A No. They may have subtly or dramatically 14:17:38
7 different functions, depending on what's going on 14:17:48
8 at the active site. 14:17:51

9 Q Okay. 14:17:53

10 A Although that may be less likely once you 14:17:53
11 have 90 percent. Was that the percentage you 14:17:57
12 mentioned? 14:17:59

13 Q Yes. 90 percent. 14:18:00

14 A 90 percent? Yes. Chances are they would 14:18:02
15 have very similar functions. 14:18:05

16 Q Okay. And I believe you mentioned earlier 14:18:27
17 this morning that you had done work with 14:18:29
18 antibodies? 14:18:32

19 A Yes. 14:18:33

20 Q Do you know whether changes in the 14:18:33
21 framework region of an antibody can impact 14:18:35
22 binding? 14:18:40

1	ATTORNEY KUSHAN: Objection. Foundation.	14:18:41
2	A Yes. It can.	14:18:44
3	Q Is it possible to make changes in the	14:18:49
4	framework region of an antibody that will	14:18:51
5	eliminate the ability of the antibody to bind the	14:19:12
6	antigen?	14:19:02
7	A It can, too.	14:19:03
8	Q Let's go to Paragraph 88 in your	14:19:08
9	declaration.	14:19:20
10	All right. So Paragraph 88 is under the	14:19:37
11	header that reads: Analysis of published results	14:19:40
12	for mutations of hyaluronidase proteins; is that	14:19:45
13	right?	14:19:49
14	A That is correct.	14:19:49
15	Q And in Paragraph 88, you say: In my	14:19:51
16	evaluation of single amino acid substitutions, I	14:19:53
17	considered biochemical and structural data	14:19:57
18	reported in the scientific literature before	14:20:00
19	December of 2011, particularly those reported in	14:20:00
20	Chao, Zhang, Stern and Arming; is that right?	14:20:08
21	A That's correct.	14:20:15
22	Q Why did you consider biochemical and	14:20:16

1 structural data as part of your analysis? 14:20:21

2 A Structural data as reported in, say, Chao 14:20:42

3 paper is very useful in terms of developing our 14:20:59

4 own model for evaluation of individual 14:20:52

5 substitutions. 14:20:55

6 Biochemical data reported in other papers, 14:20:55

7 they're useful because they report the 14:21:01

8 consequences of introducing the mutations at 14:21:05

9 various places in the protein. Some conserved, 14:21:10

10 some less conserved. So they are useful. 14:21:15

11 Q So why are -- why is it that biochemical 14:21:20

12 data that reports the consequences of introducing 14:21:24

13 substitutions into a protein, why is that useful? 14:21:31

14 ATTORNEY KUSHAN: Objection. Foundation. 14:21:34

15 Also objection as to form. 14:21:36

16 A They are useful because they help you 14:21:39

17 identify what amino acids are important, and in 14:21:42

18 some cases, it can even be used to deduce whether 14:21:46

19 a protein would fold. 14:21:53

20 For instance, if you introduce a mutation 14:21:57

21 and you get very little protein expressed in the 14:22:00

22 same expression system, that may be because the 14:22:05

1 protein has unfolded, and as a result is no longer 14:22:08
2 soluble. So this would be the standard way of 14:22:13
3 interpreting mutational effects. 14:22:18

4 Q And are mutation data for both 14:22:25
5 conservative and non-conservative changes useful? 14:22:31

6 ATTORNEY KUSHAN: Objection. Foundation. 14:22:36

7 A They are useful because they say different 14:22:45
8 things. 14:22:48

9 Q Can you explain that? 14:22:48

10 A If you introduce mutation at a conserved 14:22:52
11 position and you lose activity, function, 14:22:58
12 expression, then it confirms that those conserved 14:23:00
13 residues are important. 14:23:04

14 If you introduce a mutation at a 14:23:06
15 non-conserved position and nothing happens, the 14:23:09
16 protein maintains the same activity, then you know 14:23:12
17 those mutations are interchangeable to a degree 14:23:17
18 and they would tolerate substitutions. 14:23:21

19 So they hold different information, all of 14:23:24
20 which can be useful, and some, in some ways 14:23:27
21 support our findings. 14:23:32

22 Q Okay. How did you identify the Chao, 14:23:45

1	Zhang, Stern and Arming references?	14:23:50
2	A I did a public search with some keywords.	14:23:57
3	I don't remember exactly what. Hyaluronidase	14:24:04
4	would be a good starting point, or PH20.	14:24:11
5	Sometimes I would look up bibliography references	14:24:13
6	at the end of a paper and move backwards in time	14:24:21
7	and find earlier examples.	14:25:11
8	Q Okay. Can you turn to Paragraph 91?	14:25:11
9	A Yes. I'm at Paragraph 91.	14:25:20
10	Q So in Paragraph 91, you state: Chao	14:25:22
11	identified the residues in the active site of	14:25:24
12	HYAL1 that are involved in catalysis as Asp129,	14:25:29
13	Glu131, and Tyr202, which correspond to Asp146,	14:25:33
14	Glu148, and Tyrosine 219 in PH20. It also	14:25:41
15	identified a number of other residues in a cleft	14:25:47
16	where the ligand binds.	
17	And I'm not going to read them out.	14:25:49
18	So the question is: Do you understand --	14:25:55
19	sorry. Strike that.	14:26:03
20	Is it correct that Aspartic Acid 146,	14:26:04
21	Glutamate 148, and Tyrosine 219 in PH20 are	14:26:12
22	involved in catalysis based on the Chao paper?	14:26:18

1	ATTORNEY KUSHAN: Objection. Foundation.	14:26:21
2	A Yes. I would think so.	14:26:25
3	Q Okay. And do you know if the residues	14:26:29
4	that are listed -- listed in the cleft, those	14:26:36
5	are -- are those the HYAL1 residue numbers, or	14:26:40
6	you're not sure?	14:26:47
7	A I'm pretty sure there are -- those are	14:26:48
8	HYAL1 residues.	14:26:51
9	Q Okay. So you'd have to go and convert to	14:26:52
10	figure out what the residues are in PH20?	14:26:56
11	A Yes. There is a table at the end that --	14:27:01
12	Q Oh, okay.	14:27:05
13	A -- in those amino acids to PH20 residues.	14:27:07
14	Q Okay.	
15	A It's on paragraph -- Page 170 -- it goes	14:27:07
16	on for a while. 168. It's Appendix D, Part 4.	14:27:14
17	Q Appendix D, Part 4.	
18	A Page 7 -- starting at Page 167.	14:27:20
19	Q Oh. I got it.	
20	A It allows the mapping of PH20 to HYAL1.	14:27:23
21	Q Okay. Great.	14:27:28
22	Okay. And so would you expect that in	14:27:55

1	PH20 those residues -- the PH20 version of those	14:27:59
2	residues are also in the cleft where the ligand	14:28:00
3	binds?	14:28:04
4	A Yes.	14:28:05
5	Q Okay. And so if you turn to -- can you	14:28:10
6	please turn to Paragraph 95?	14:28:37
7	A Yes. I'm at Paragraph 95.	14:28:54
8	Q So in Paragraph 95, you reference the	14:28:56
9	testing in Zhang of single mutant HYAL1 proteins;	14:29:00
10	is that right?	14:29:06
11	A These are mutational results from single	14:29:11
12	point mutations, yes.	14:29:14
13	Q And in the -- the Zhang paper, am I	14:29:18
14	understanding correctly that the mutations at the	14:29:23
15	D129N, E131Q, Y202F, Y247F, and R265L mutations,	14:29:30
16	have little or no activity?	14:29:47
17	A The figure shows that, yes.	14:29:54
18	Q Okay.	14:29:58
19	Okay. And so then the -- the results from	14:30:16
20	Zhang, from the mutagenesis in Zhang, those are	14:30:20
21	shown in a table in Paragraph 99 in your	14:30:26
22	declaration, right?	14:30:30

1	A Paragraph 99? All right. Okay.	14:30:31
2	Q So just the -- in Paragraph 99, you've	14:30:43
3	reproduced the chart from the Zhang paper that has	14:30:49
4	the results of the mutagenesis testing?	14:30:52
5	A That is correct.	14:30:58
6	Q Do you know what the distinction is	14:31:03
7	between catalytic mutants, substrate binding	14:31:05
8	mutants, and punitive structural mutants?	14:31:10
9	ATTORNEY KUSHAN: Objection. Foundation.	14:31:17
10	A My reading of that table with those three	14:31:27
11	classifications would be catalytic mutants are	14:31:31
12	mutants where catalytic residues or residues that	14:31:37
13	are directly involved in catalysis have been	14:31:39
14	mutated.	14:31:42
15	Substrate binding mutants are the	14:31:42
16	mutations where an amino acid involved in	14:31:45
17	substrate recognition and binding has been	14:31:48
18	mutated.	14:31:52
19	And punitive structural mutants would be	14:31:52
20	mutations that affect the enzyme in some other	14:32:01
21	ways.	14:32:03
22	Q Okay. And then can you turn to	14:32:03

1	Paragraph 101?	14:32:29
2	So and in Paragraph 101, you list the	14:32:38
3	results from Arming, where Arming identified five	14:32:43
4	single mutations that greatly reduced PH20	14:32:48
5	activity, right?	14:32:52
6	A Yes.	14:32:53
7	Q And then, as well as four conserved	14:32:53
8	cysteine residues that formed disulfide bonds, and	14:32:58
9	that PH20 truncated at position 341 exhibited no	14:33:02
10	activity, right?	14:33:07
11	A That's correct.	14:33:07
12	Q So how is the Arming data, how did you use	14:33:08
13	that in your analysis?	14:33:12
14	A I use these biochemical data to confirm	14:33:23
15	the finding from the multiple sequence alignment,	14:33:27
16	which suggested conservation of certain positions,	14:33:32
17	and they track the biochemical data, in that if	14:33:37
18	you mutate those residues, you lose activity.	14:33:40
19	Q So the biochemical data, consistent with	14:33:48
20	the multiple sequence alignment, and confirmed	14:33:53
21	that certain residues are essential for activity;	14:33:54
22	is that right?	14:33:58

1	A Yes.	14:33:58
2	ATTORNEY KUSHAN: Objection. Foundation.	14:33:58
3	And also objection as to form.	14:34:00
4	A Yes. That's how the biochemical data	14:34:02
5	would be useful to our analysis.	14:34:07
6	Q So would you expect based on the	14:34:16
7	biochemical data, for example in Arming, that if	14:34:18
8	you change position 113, that you're likely to	14:34:25
9	reduce PH20 activity?	14:34:33
10	ATTORNEY KUSHAN: Objection. Foundation.	14:34:41
11	Also objection as to form.	14:34:43
12	A These note that -- these note that	14:34:44
13	glutamine 113 is not wild-type. This is the	14:34:49
14	mutant --	14:34:52
15	Q Oh, oh. Sorry.	14:34:53
16	A Yes.	14:34:55
17	Q Okay. So if you change position 113 to	14:34:55
18	glutamine --	14:35:01
19	A That is correct.	14:35:01
20	Q -- then you will -- okay.	14:35:02
21	A That is correct.	14:35:03
22	Q Okay. Thank you.	14:35:04

1	A Yes.	14:35:05
2	Q Would you expect based on the Arming	14:35:06
3	results that if you change the four conserved	14:35:13
4	cysteine residues that you would reduce PH20	14:35:20
5	activity?	14:35:24
6	ATTORNEY KUSHAN: Objection. Foundation.	14:35:24
7	Also objection as to form.	14:35:26
8	(Reporter clarification.)	14:35:42
9	A Yes. I would totally expect mutating any	14:35:42
10	of the conserved cysteine residues involved in	14:35:46
11	that sulfuric bond would result in total loss of	14:35:51
12	protein activity.	14:35:56
13	Q All right. So let's turn to	14:36:09
14	Paragraph 102.	14:36:11
15	So in Paragraphs 102 and 103, you describe	14:36:28
16	your unbiased scoring system, right?	14:36:33
17	A That's correct.	14:36:44
18	Q And you said that it's necessary for you	14:36:45
19	to evaluate a lot of different types of	14:36:49
20	substitutions, and through that process you	14:36:52
21	developed a consistent methodology; is that right?	14:37:00
22	A That's correct.	14:37:05

1 Q So why was it necessary to evaluate a lot 14:37:06
2 of different types of substitutions? 14:37:08

3 A It gives you a breadth in your analysis. 14:37:17
4 It tells you how to deal with different types of 14:37:23
5 substitutions. Some conserved, some not 14:37:27
6 conserved, small to large, large to small, all 14:37:31
7 kinds of differences. You want to be familiar 14:37:35
8 with different types of substitutions that can 14:37:37
9 happen so that you can develop a more consistent 14:37:40
10 methodology that can be applied to all 14:37:46
11 substitutions in your data set. 14:37:54

12 Q So when you say -- so did, as part of your 14:37:58
13 analysis, did you evaluate a lot of different 14:38:06
14 types of substitutions? 14:38:10

15 A I did. I mapped the types of 14:38:14
16 substitutions by tabulating different combinations 14:38:18
17 of from and to amino acids, and it was pretty well 14:38:25
18 populated in that distribution. 14:38:33

19 Q How many different types of substitutions 14:38:36
20 did you consider? 14:38:39

21 A I haven't counted, so out of the 20 by 20 14:38:43
22 minus 20, 380 types of substitutions that can 14:38:52

1	exist, a pretty significant fraction of them were	14:38:59
2	found to exist in this PH20 data set.	14:39:05
3	(Reporter clarification.)	14:39:14
4	Q And what are you referring to when you	14:39:14
5	talk about the PH20 data set?	14:39:18
6	A That's the multiple sequence on	14:39:22
7	alignment --	14:39:26
8	Q Okay.	14:39:26
9	A -- data set that I am speaking of.	14:39:27
10	Q Okay. Did you consider substitutions at	14:39:30
11	every position in PH20?	14:39:35
12	A I considered as many substitutions as	14:39:38
13	possible. There were approximately 3,000	14:39:42
14	substitutions suggested by the multiple sequence	14:39:49
15	alignment. That was too many for me to consider.	14:39:52
16	I considered about one quarter of them.	14:39:57
17	Q Okay. And have you provided -- when you	14:40:01
18	say you considered them, can you explain what you	14:40:05
19	did for each one of those?	14:40:09
20	A Absolutely. For each substitution that	14:40:11
21	was suggested by the sequence alignment, starting	14:40:18
22	from those substitutions involving amino acids	14:40:23

1 that appear with decent frequency, which I started 14:40:27
2 with 10 percent, but ultimately went down to 5 14:40:35
3 percent. 14:40:39

4 So in the end, any substitutions to an 14:40:39
5 amino acid that occur with a frequency 5 or 14:40:42
6 greater percentage, I considered the wild-type 14:40:45
7 residue in the context of the modeled PH20 14:40:50
8 structure, as well as the individual substitutions 14:40:55
9 listed in the multiple sequence alignment. And 14:40:59
10 for each substitution, I scored the substitution 14:41:03
11 on a scale of 1 to 3, using the metric that was 14:41:09
12 demonstrated in Appendix C earlier. 14:41:16

13 Q And did you record -- did you record the 14:41:20
14 results of that analysis for every substitution 14:41:24
15 that you analyzed? 14:41:27

16 A Yes. I created a spreadsheet and provided 14:41:29
17 that to counsel. 14:41:35

18 Q You provided a spreadsheet with your 14:41:36
19 analysis for every single residue that you 14:41:40
20 considered to counsel? 14:41:44

21 A Yes. I did. 14:41:44

22 Q So you said that when you went through the 14:41:45

1 analysis, you would revisit the scores for each 14:42:10
2 position multiple times to make sure that the way 14:42:12
3 you assigned scores was consistent. 14:42:13

4 Can you explain what you mean by that? 14:42:17

5 A Yes. I would look at a substitution, give 14:42:20
6 it a score, move on to the next position, consider 14:42:28
7 substitutions at the next position, finish them, 14:42:31
8 move on to the next position, consider 14:42:36
9 substitutions. 14:42:38

10 I finished this exercise all the way to 14:42:39
11 the end of the structure, and just to be 14:42:42
12 consistent, I went back to the beginning, and 14:42:46
13 repeated that exercise to either confirm what I 14:42:49
14 had found the first time around, or I might have 14:42:54
15 decided, perhaps I was a bit too harsh here, and I 14:42:58
16 would update the score a little bit. This I did 14:43:05
17 twice for the whole set. 14:43:09

18 Q So you looked at every single substitution 14:43:10
19 twice? 14:43:15

20 A Every single substitution which amounted 14:43:16
21 to roughly one quarter of the complete set of 14:43:21
22 possible substitutions, which as I said was 14:43:26

1 about 3,000 substitutions. 14:43:29

2 Q Okay. And did your analysis in total for 14:43:47
3 all of those positions, did you rely on that 14:43:35
4 analysis in forming the opinions that you set 14:43:39
5 forth in your declaration? 14:43:42

6 A That analysis was the backbone of the 14:43:48
7 current declaration. 14:43:52

8 Q And was it important for you to consider 14:43:54
9 every single position and substitution that you 14:43:56
10 considered in order to validate your scoring 14:44:00
11 system? 14:44:04

12 ATTORNEY KUSHAN: Objection to form. 14:44:05

13 A Was it necessary? Maybe not. I suppose I 14:44:09
14 could have done less work. I wanted to be 14:44:17
15 thorough about my analysis and be as rigorous as 14:44:22
16 possible. If I had looked at only 10 14:44:31
17 substitutions, it's hard to know that I am doing 14:44:34
18 it objectively. 14:44:37

19 It's only through repetition that I 14:44:38
20 developed confidence in my scoring system and can 14:44:42
21 vouch that I am being objective when evaluating 14:44:49
22 the substitution. So for that reason I thought it 14:44:51

1 was important that I do a bit of a blind study in 14:44:52
2 a way, look at the substitutions without paying 14:44:54
3 attention to, you know, why they may be important. 14:44:59

4 Look at it as cleanly as possible and 14:45:03
5 score it and see if I can come back at a later 14:45:07
6 time and arrive at the same score. This was the 14:45:11
7 objective. And for that I thought it was 14:45:17
8 important that I start with a very large set, or 14:45:21
9 set a goal for a larger set as what's practical. 14:45:24

10 Q Okay. And do you know, did you change the 14:45:27
11 score when you went back and revisited some of the 14:45:31
12 substitutions? 14:45:34

13 A Yes. I wasn't surprised that this 14:45:35
14 happened. It's not unlike looking at students' 14:45:39
15 exams. You start grading them, and once you get 14:45:43
16 to the end of it and you realize that maybe I was 14:45:48
17 a bit too harsh on this question. Let me go back 14:45:53
18 and try to do a slightly different job. 14:45:56

19 I found that a fraction of the 14:46:01
20 substitutions which I had previously scored could 14:46:03
21 have been interpreted differently, and I updated 14:46:07
22 them. In the process, I think it helped really to 14:46:13

1 refine my methodology, became more consistent, 14:46:19
2 which then led to more confidence in how I was 14:46:25
3 evaluating individual substitutions. 14:46:32

4 Q So did you rely on the -- the spreadsheet 14:47:08
5 that you provided to counsel for your analysis for 14:47:10
6 each of the declarations that you submitted? 14:47:13

7 ATTORNEY KUSHAN: Objection to form. 14:47:18

8 A The -- the complete set of analysis, which 14:47:19
9 was recorded in a spreadsheet, formed the 14:47:26
10 foundation for these four sets of declarations. 14:47:29

11 ATTORNEY MARTIN: Okay. So counsel, we 14:47:33
12 would like to request the spreadsheet, since it 14:47:48
13 was the foundation for all four declarations. 14:47:53

14 ATTORNEY KUSHAN: Okay. Do you want to 14:47:57
15 have a conversation on the break about that? 14:47:58

16 ATTORNEY MARTIN: Sure. 14:48:00

17 BY ATTORNEY MARTIN: 14:48:07

18 Q So you've mentioned that when you went 14:48:08
19 back and did your analysis again, the second 14:48:11
20 analysis, you noticed that you were too harsh for 14:48:15
21 some of the substitutions. 14:48:20

22 Can you just explain what you meant by 14:48:21

1	that?	14:48:24
2	A Being too harsh was an example. I	14:48:24
3	wouldn't say that the correction was always in one	14:48:30
4	direction. It might have gone both directions, 1	14:48:32
5	going to 2, 2 going into 3, vice-versa. So they	14:48:36
6	did move around.	14:48:40
7	So based on the follow-up examination,	14:48:42
8	where I either noticed other interactions which I	14:48:44
9	had missed earlier, or I have seen similar	14:48:49
10	interactions elsewhere, which then led me to one	14:48:55
11	score, which I then felt should be applied	14:49:02
12	similarly at a different position.	14:49:06
13	So that influenced my thinking, and hence	14:49:10
14	the final score. And the score got updated in	14:49:15
15	some of the cases, but it wasn't always	14:49:21
16	improvement. Sometimes it could have been the	14:49:27
17	other way around.	14:49:30
18	Q So in the 2011 time frame, if a POSA is	14:49:39
19	trying to determine the impact of a potential	14:49:42
20	substitution, would they have done the similar	14:49:45
21	analysis where they look at -- where they look at	14:49:49
22	the substitution and determine if it's potentially	14:49:54

1 going to favorable, neutral or unfavorable? 14:49:58

2 A In the year 2011, to consider a mutation, 14:50:02
3 it would have been very common and expected for a 14:50:08
4 POSA to generate a model and consider the 14:50:15
5 substitution in that structural context. 14:50:27

6 Q So you said that you looked at about -- I 14:50:41
7 think you said you looked at about a quarter of 14:50:44
8 the 3,000 and some; is that right? 14:50:51

9 A About a quarter, yes. 820 or 830. 14:50:51
10 (Reporter clarification.) 14:51:03

11 A I don't know exactly. Somewhere around 14:51:03
12 there, slightly over 800 substitutions. 14:51:05

13 Q How did you pick those 800-some -- how did 14:51:05
14 you pick the ones that you looked at? 14:51:12

15 A I started with substitutions that appeared 14:51:15
16 with high frequency. Ultimately I looked at all 14:51:19
17 substitutions that involved amino acids that 14:51:26
18 appeared with a frequency of 5 or greater 14:51:30
19 percentage. So I started at the top. After doing 14:51:59
20 10 percent, I think I had about 450. 14:51:37

21 I said: Okay. 450's not bad but I can do 14:51:40
22 better. So let's do additional 5 percent. That 14:51:44

1	added another 400.	14:51:50
2	Q Okay. Got it.	14:51:53
3	Okay. So can you turn to Paragraph 149?	14:52:32
4	A I'm at Paragraph 149.	14:52:57
5	Q So starting on Paragraph 149 is how you --	14:52:58
6	is where you explain how you generated the	14:53:01
7	homology model using the SWISS-MODEL, right?	14:53:03
8	A That's correct.	14:53:08
9	Q So can you just explain kind of	14:53:08
10	step-by-step how you went about generating the	14:53:12
11	homology model using the SWISS-MODEL?	14:53:16
12	A Okay. SWISS-MODEL is a web service which	14:53:46
13	makes it very convenient for somebody who's not an	14:53:52
14	expert or a specialist in structural	14:53:55
15	bioinformatics to use the structure of a known	14:54:00
16	homologous protein as the starting point to	14:54:05
17	generate a model for a protein of interest, such	14:54:09
18	as PH20.	14:54:14
19	You visit the website, enter PH20	14:54:15
20	sequence. The website will take the sequence,	14:54:19
21	compare the sequence with the structures in their	14:54:22
22	database. And based on the matching, it will give	14:54:27

1 you a list of potential templates that you can use 14:54:31
2 with a QME score -- that's quality of model 14:54:36
3 estimate -- QME score. The higher the better. So 14:54:43
4 it gives you idea of which template you might want 14:54:45
5 to use. 14:54:48

6 At that point, you have a choice of 14:54:49
7 choosing one or more template, and submit the job. 14:54:51
8 And the job runs in the background, at the end of 14:54:55
9 which you will be notified and then you'll be able 14:55:00
10 to download the homology model of your protein. 14:55:02

11 That's it. 14:55:08

12 Q Okay. So you entered -- so you went to 14:55:09
13 the SWISS-MODEL website and you entered the 14:55:15
14 sequence for PH20, and then you asked the program 14:55:17
15 to identify potential templates; is that right? 14:55:22

16 A That is correct. 14:55:27

17 ATTORNEY KUSHAN: Or, sorry. 14:55:28

18 Objection to form. 14:55:31

19 Q And so then it give you potential 14:55:32
20 templates and then you selected the HYAL1 as the 14:55:35
21 template; is that right? 14:55:37

22 A Yes. 14:55:38

1	Q Okay. So you selected HYAL1 as the	14:55:43
2	template to use for the homology model?	14:55:48
3	ATTORNEY KUSHAN: Objection to form.	14:55:55
4	A I used the HYAL1 structure as the template	14:55:56
5	for my homology model, yes.	14:56:01
6	Q Why did you use HYAL1 as the template?	14:56:03
7	A That was really the only template that was	14:56:07
8	viable. When I read the service, only two	14:56:11
9	structures came back as actually: HYAL1	14:56:15
10	structure, and another structure that had nothing	14:56:20
11	to do with this protein.	14:56:25
12	Q Okay.	14:56:27
13	A Apparently there was some similarity over a	14:56:27
14	span of, perhaps 50 amino acids, which is not even	14:56:32
15	a protein. So it was pretty clear that I don't	14:56:36
16	have a whole lot of options, other than HYAL1. So	14:56:41
17	you pick that, and the rest is automated.	14:56:47
18	Q Okay. And so on Page 84, you have the	14:56:50
19	SWISS-MODEL result; is that right?	14:57:10
20	A Yes. This is the result of homology	14:57:19
21	modeling. Yes.	14:57:29
22	(Reporter clarification.)	14:57:30

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

180

1	Q And can you explain what the GMQE is?	14:57:30
2	A Yes. G -- GMQE stands for global model	14:57:39
3	quality estimate. It give you an idea of how good	14:57:44
4	the template is so that you can choose the right	14:57:48
5	template among several that are returned	14:57:56
6	initially, so that way you don't waste your time	14:58:00
7	modeling it against a template that's not even	14:58:05
8	appropriate.	14:58:10
9	So higher the better. Here it's 0.69.	14:58:15
10	The second template that came back I think had	
11	a 0.1 or something.	
12	Q Okay.	
13	A So pretty clear cut.	14:58:16
14	Q Is 0.69, is that a -- is that a good	14:58:26
15	value, in your experience?	14:58:24
16	A I don't know actually. I think 0.69 is a	14:58:27
17	reasonable score based on the publication. I	14:58:44
18	don't have a lot of experience working with a	14:58:36
19	template that has lower QM -- GMQE value, so I	14:58:39
20	can't quite say.	14:58:43
21	Q Okay.	14:58:53
22	A But what's comforting is that we know	14:58:53

1	HYAL1 and PH20 are pretty similar based on the	14:58:58
2	sequence alignment. So if that high sequence	14:59:03
3	identity translates into 0.69, I think it's	14:59:04
4	reasonable to assume that that is an acceptable	14:59:09
5	value.	14:59:12
6	Q And the sequence identity is given as	14:59:12
7	40.24 percent; is that right?	14:59:18
8	A Yes. That's what this website says.	14:59:20
9	Q And then there's also a QMEAN DisCo	14:59:26
10	Global. Can you explain what that is?	14:59:35
11	A QMEAN DisCo Local stands for qualitative	14:59:39
12	model energy analysis, distance correlation local,	14:59:44
13	meaning individual analysis.	14:59:47
14	Q And the value is given as .75 plus or	14:59:49
15	minus .05.	14:59:58
16	What does that mean?	14:59:59
17	ATTORNEY KUSHAN: Objection. Foundation.	15:00:02
18	A In this graph, 0.75 I think is the average	15:00:04
19	or mean, and anything above that is colored blue.	15:00:09
20	Anything below that is colored red.	15:00:16
21	The critical number is 0.6, according to	15:00:19
22	publication. It says 0.6 and up, you would have	15:00:22

1 some confidence in that modeling structure at that 15:00:30
2 residue position, and sometimes it falls below 15:00:34
3 because the sequence identity might be low in that 15:00:38
4 region. 15:00:49

5 (Reporter clarification.) 15:00:59

6 Q Okay. And so when you did your analysis, 15:00:59
7 did you -- at the positions that you looked at, 15:01:04
8 did you consider what the -- what the value was at 15:01:06
9 that -- at that position for the QMEAN DisCo? 15:01:11

10 A Yes. 15:01:16

11 Q Okay.

12 A I checked it and it was about .6. I 15:01:17
13 forget the exact value, but -- 15:01:29

14 Q Okay.

15 A -- above that threshold. 15:01:25

16 Q Okay. 15:01:27

17 Okay. And so then you have -- on Page 86, 15:01:39
18 you have: The relative QMEAN assessment for the 15:01:52
19 entire protein and the local QMEAN quality 15:02:03
20 assessment; is that right? 15:02:06

21 A That is correct. 15:02:07

22 Q Can you explain the graph on the left on 15:02:08

1	Page 86?	15:02:14
2	A QMEAN 4, or quality model energy analysis,	15:02:19
3	is a statistical energy comprised of four	15:02:26
4	independent terms, including torsion energy,	15:02:32
5	solvent interaction, secondary structure and	15:02:38
6	atomic interaction. Those four terms are added up	15:02:41
7	some way to give a total score of QMEAN 4.	15:02:47
8	And what's plotted on this graph is a Z	15:02:54
9	score, which indicates the multiples of the	15:03:02
10	standard deviation for our structure compared to	15:03:05
11	the average energy expected for a protein of that	15:03:14
12	size.	15:03:19
13	Q And so what does this graph tell you about	15:03:37
14	the model that you generated?	15:03:40
15	A The graph tells you that the model is	15:03:43
16	reasonable.	15:03:47
17	Q Okay. And what about the graph on the	15:03:53
18	right?	15:03:57
19	A The graph on the right is the -- the local	15:04:00
20	quality estimate, which is the expanded view of	15:04:06
21	the earlier tiny graph where 0.6 is the number to	15:04:11
22	watch out for. And the position where the local	15:04:19

1	quality estimate is about .6 is a place where one	15:04:24
2	can trust the model and carry on with the	15:04:28
3	analysis.	15:04:32
4	Q Okay.	15:04:32
5	(Reporter clarification.)	15:04:47
6	Q And you also, above those graphs at the	15:04:47
7	very top of Page 86, you mention that the whole	15:04:56
8	protein had an overall QMEAN score of minus 2.83,	15:05:02
9	which is the -- which is below the threshold of	15:05:08
10	minus 4, indicative of acceptable quality.	
11	So what is the QMEAN score of minus 2.83?	15:05:17
12	A Right. So QMEAN stands for qualitative	15:05:21
13	model energy analysis. That's the aggregate sum	15:05:25
14	of the four terms that I mentioned earlier --	15:05:30
15	torsion energy, solvent exposure, blah, blah --	15:05:33
16	and minus 2.83 corresponds to the multiple of the	15:05:35
17	standard deviation from the average energy	15:05:44
18	expected for a protein of that size. So that is	15:05:46
19	what's shown on the left of the figure.	15:05:51
20	The star is our model, and what this graph	15:05:53
21	says is that that star is minus 2.83 standard	15:05:57
22	deviation away from the median, or median or	15:06:06

1	average, of the energy at that protein size, for	15:06:11
2	that protein size, which is the X axis.	15:06:17
3	Q Oh, okay. Okay. Got it. Okay. Thanks.	15:06:21
4	So in Paragraph 153, you refer to B factor	15:06:49
5	scores?	15:06:58
6	(Reporter clarification.)	15:07:00
7	Q And you equate a local QMEAN reliability	15:07:00
8	to a B factor score?	15:07:06
9	A Yes.	15:07:09
10	Q Is that right?	15:07:09
11	A Yes.	15:07:10
12	Q Okay. And so the graph on the right, in	15:07:12
13	the local quality estimate graph on the right on	15:07:19
14	Page 86, is that a graph of B factor scores?	15:07:23
15	A That is correct.	15:07:28
16	Q Okay.	
17	A The values shown on the right side of that	15:07:30
18	graph is recorded in the B factor column of the	15:07:34
19	PDB file. You can extract that value.	15:07:45
20	(Reporter clarification.)	15:07:48
21	Q Okay. So the PDB file that you download	15:07:48
22	from SWISS-MODEL, in the B factor column, it has	15:07:54

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

186

1	the numbers that are -- for each atom, right?	15:07:54
2	A Residue.	15:07:56
3	Q For each residue?	15:07:58
4	A Yes.	
5	Q That provides the local QMEAN reliability?	15:08:00
6	A That's correct, yes. So you can extract	15:08:02
7	that information from that B factor column.	15:08:05
8	ATTORNEY MARTIN: Okay. Okay. Got it.	15:08:34
9	All right. We've probably been going for	15:08:34
10	another an hour.	15:08:39
11	Do you want to take another break?	15:08:40
12	THE WITNESS: Yes, yes, yes.	15:08:43
13	ATTORNEY KUSHAN: Why don't we stay on the	15:08:44
14	record for a minute, and let Dr. Park step out.	15:08:46
15	THE WITNESS: Okay.	
16	ATTORNEY KUSHAN: So we can discuss an	
17	issue you raised.	15:08:51
18	THE VIDEOGRAPHER: Do you want to stay on	15:08:51
19	the video record as well?	15:08:53
20	ATTORNEY KUSHAN: You can take the video	15:08:56
21	off.	15:08:57
22	THE VIDEOGRAPHER: We are going off the	15:09:00

1 video record. The time is 3:08 p.m.

15:09:02

2 ATTORNEY KUSHAN: So we're willing to
3 entertain a request to produce the spreadsheet
4 that he referred to. I want to make clear that,
5 you know, you've had these declarations since
6 November/December.

15:09:06

15:09:10

15:09:14

15:09:19

15:09:20

7 You filed Patent Owner response,
8 preliminary responses. We filed replies. And
9 what we pointed out in our replies was that you
10 were misreading paragraphs of the declaration.

15:09:21

15:09:24

15:09:27

15:09:27

11 We pointed you to Paragraphs 102 and 103
12 in our replies to the Board, and what we said was
13 your characterization that we had directed him to
14 specific residues to consider only, was false. We
15 made it very clear, and we also pointed out this
16 additional explanation in the declaration, that he
17 had -- he's telling you he evaluated lots of
18 positions. That's what he just confirmed in his
19 testimony.

15:09:30

15:09:34

15:09:38

15:09:41

15:09:44

15:09:48

15:09:51

15:09:54

15:09:59

20 So I want to make it clear, you had a
21 chance to ask for this many months ago, and we
22 don't expect that you should, you know, seek to

15:09:59

15:10:02

15:10:05

1 get an additional deposition of him or anything 15:10:08
2 like that, claiming prejudice, because you've had 15:10:11
3 the opportunity, you've had the knowledge, you've 15:10:14
4 had our position about him doing more work than 15:10:14
5 what was limited to each individual declaration as 15:10:15
6 specific position. 15:10:18

7 So we're happy -- like I said, we can work 15:10:19
8 to produce this spreadsheet. We can add it in as 15:10:23
9 an exhibit if you want, and we can provide it to 15:10:28
10 you. 15:10:30

11 ATTORNEY MARTIN: So a couple of things. 15:10:31

12 There's no way from his declaration that 15:10:32
13 one could extract that he looked at 820 to 830 15:10:35
14 different substitutions, and gave you a 15:10:41
15 spreadsheet with the data. It's not clear from 15:10:44
16 this declaration at all how many positions he 15:10:47
17 looked at, and then how many substitutions he 15:10:50
18 looked at in each position. 15:10:53

19 He could have looked at 10, right? He 15:10:55
20 could have looked at, you know, 10 different 15:10:58
21 positions of like, a handful of different 15:11:01
22 substitutions, maybe, like, 10 at each position. 15:11:03

1 That's very different from what he just said, 15:11:04
2 which is 100 and -- 820 to 830. 15:11:07

3 There are like -- this is purely 15:11:09
4 qualitative. There -- there is no way for us to 15:11:12
5 know, based on the declaration, what he did. And 15:11:15
6 so there's no -- there's no way -- there is no 15:11:17
7 possible way that we could have predicted that he 15:11:21
8 gave you a spreadsheet with 820 to 830 15:11:25
9 substitutions in it, and then asked for it and 15:11:27
10 then considered it. We just did not have that 15:11:29
11 level of information. 15:11:32

12 You guys are you ones who -- hold on. I 15:11:33
13 listened to you go on for a very long time, so let 15:11:35
14 me -- 15:11:39

15 ATTORNEY KUSHAN: Go ahead. 15:11:40

16 ATTORNEY MARTIN: -- say my piece and 15:11:42
17 then, you know, you can respond. 15:11:44

18 You know, you guys had the opportunity to 15:11:45
19 make clear what he did or didn't do. You had the 15:11:47
20 opportunity to frame what he did and didn't do. 15:11:51
21 And that's what you did in your declaration. We 15:11:55
22 read it. Literally, we read it, and we understood 15:11:55

1 the best that we could. And if it's the case that 15:11:57
2 he considered 800 and some positions, you should 15:12:00
3 have told us that, right, as opposed to trying to 15:12:04
4 put it on us to somehow psychically extrapolate 15:12:06
5 out of this declaration what it was that he did, 15:12:09
6 and put the onus on us to go and ask you. 15:12:11

7 And also, I mean, you guys have been 15:12:15
8 serially filing PGRs over time, right, where you 15:12:16
9 come up with new tables with new positions. Like 15:12:20
10 when you filed the first one, how could we possibly 15:12:25
11 know what positions he looked at. We get no 15:12:30
12 information or positions he looked at because 15:12:34
13 you're filing more PGRs, but there was no way that 15:12:35
14 we could have known that at the very beginning. 15:12:36
15 It's just totally unreasonable. 15:12:39

16 So it's really -- like, it's really, 15:12:41
17 really not clear from anything that you guys 15:12:42
18 have -- maybe it's clear for you because you know 15:12:44
19 that there's a spreadsheet. It was not clear from 15:12:46
20 our perspective that there was this spreadsheet 15:12:47
21 that we should have known to ask about. We just 15:12:49
22 didn't know. 15:12:52

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

191

1	And so in terms of asking for another	15:12:53
2	deposition, I haven't seen the spreadsheet, right?	15:12:54
3	We need to see the spreadsheet, and then we can go	15:12:57
4	from there. But as an initial matter, we would	15:13:00
5	like the spreadsheet.	15:13:03
6	ATTORNEY KUSHAN: So I'll be very brief.	15:13:04
7	The point I made was that when you read	15:13:06
8	Paragraphs 102 and 103, and you see him explain	15:13:09
9	that he did a lot of different types of --	15:13:13
10	evaluated a lot of different types of	15:13:15
11	substitutions. He conducted an analysis that did	15:13:17
12	not focus on any particular position.	15:13:20
13	And the natural thing would have been	
14	to -- if you had a question or you thought this	15:13:24
15	was relevant information, would be to drop an	15:13:27
16	email to me saying: Hey, you appear to be relying	15:13:27
17	on additional information that you haven't	15:13:31
18	included in the record.	15:13:33
19	ATTORNEY POWERS: Jeff, that's why we have	15:13:34
20	a deposition.	15:13:36
21	ATTORNEY KUSHAN: What?	15:13:37
22	ATTORNEY POWERS: That's why we have a	15:13:38

1 deposition, so we can ask him these questions. 15:13:39

2 ATTORNEY KUSHAN: No. You chose to tell a 15:13:40

3 narrative where you said we, you know, you've 15:13:41

4 invented -- you've basically ignored these 15:13:43

5 passages, and misquoted and mischaracterized the 15:13:47

6 scope of work he was asked to do.

7 And then you went to the Board, and you 15:13:52

8 said: Deny these institutions because they 15:13:55

9 directed him to review only position 320. So it 15:13:56

10 was advancing that narrative you were going for. 15:13:58

11 I have done this in many, many cases, 15:14:00

12 where if we have an expert do analytical work, the 15:14:03

13 other side can read the explanation that work has 15:14:08

14 been done, and if you feel there's an incomplete 15:14:09

15 record or you need more information about what he 15:14:13

16 did, we would have responded, and we would have, 15:14:16

17 you know, we could have provided or explained what 15:14:17

18 additional information existed. That's my point. 15:14:19

19 And the Board obviously wants us to 15:14:22

20 cooperate and not bring things to them that are, 15:14:23

21 you know, going to waste their time. So that's 15:14:26

22 why in a normal setting, you can contact opposing 15:14:28

1 counsel and ask questions.

2 Is there more evidence? Is there more 15:14:32
3 work product of this expert? And we would have 15:14:37
4 then had this conversation three months ago, and 15:14:40
5 then maybe you wouldn't have filed, you know, all 15:14:41
6 those arguments. 15:14:41

7 But the point of it is, you could have 15:14:42
8 gotten -- you could have explored -- 15:14:45

9 ATTORNEY POWERS: Well, you withheld them. 15:14:45

10 ATTORNEY KUSHAN: We didn't withhold the 15:14:48
11 document.

12 ATTORNEY POWERS: Certainly seems like it. 15:14:49

13 ATTORNEY KUSHAN: We made clear -- you can 15:14:49
14 read the -- look, we've told you he didn't limit 15:14:51
15 his analysis. We've told you that evaluated lots 15:14:54
16 of positions, and we would have, you know, 15:14:57
17 responded if you had contacted us about this. 15:14:59

18 So bottom line, we are going to go back 15:15:02
19 and we will work to get this over to you as 15:15:06
20 rapidly as we can. I think the question that you 15:15:10
21 guys should think about is, you know, why did -- 15:15:12
22 why did you wait? 15:15:15

1	And that's my point. So I'm happy to --	15:15:16
2	ATTORNEY MARTIN: Yeah. We -- you've said	15:15:20
3	your piece. I've said my piece. Trey has said	15:15:21
4	his piece.	15:15:24
5	We didn't wait, right? Like, you guys had	15:15:25
6	the burden under the rules to provide the	15:15:28
7	information that your expert is relying on that	15:15:29
8	forms the backbone of the declarations that he	15:15:32
9	submitted. So you should have given us the	15:15:34
10	spreadsheet.	15:15:36
11	You can give us the spreadsheet now.	15:15:37
12	You're going to give us the spreadsheet, so...	15:15:37
13	ATTORNEY KUSHAN: Do you want it, like,	15:15:39
14	right now?	15:15:41
15	ATTORNEY MARTIN: We can move forward.	15:15:42
16	As soon as possible would be great.	15:15:43
17	ATTORNEY KUSHAN: I don't think we can	15:15:46
18	create -- I don't think we can turn it into paper	15:15:52
19	now, so that's the point.	15:15:55
20	ATTORNEY MARTIN: I mean, I would hope	15:15:56
21	that you would give it in, like, an electronic	15:15:57
22	format. I mean, if you hand me like -- if you	15:15:59

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

195

1	hand me something that's this big, you know, a	15:16:01
2	foot-tall stack of paper with 800 and some rows,	15:16:05
3	I'm going to be a little unhappy, so please just	
4	give me a PDF, or...	15:16:09
5	ATTORNEY KUSHAN: You'll get -- yeah.	15:16:12
6	You'll get an electronic version.	15:16:13
7	ATTORNEY MARTIN: Okay. Thank you.	
8	ATTORNEY KUSHAN: All right. So we'll...	15:16:16
9	ATTORNEY MARTIN: Want to take a break?	15:16:18
10	ATTORNEY KUSHAN: Yeah.	15:16:20
11	ATTORNEY MARTIN: Okay.	15:16:21
12	ATTORNEY KUSHAN: Now we can go off the	15:16:22
13	record.	15:16:24
14	(Recess from 3:16 p.m. until 3:34 p.m.)	15:16:27
15	THE VIDEOGRAPHER: We are back on the	15:34:51
16	record. The time is 3:34 p.m.	15:35:03
17	BY ATTORNEY MARTIN:	15:35:10
18	Q All right. Okay. Can you turn --	15:35:11
19	Dr. Park, can you turn to Paragraph 161?	15:35:25
20	A I'm at Paragraph 161.	15:35:34
21	Q Okay. Oh, actually. Let's look at 160.	15:35:37
22	A 160.	15:35:47

1	Q So you said that protein structure models	15:35:50
2	generated by SWISS-MODEL, similar tools in 2011	15:35:55
3	would have been reliable for evaluating single	15:36:01
4	amino acid substitutions that are in regions of	15:36:04
5	PH20 where there is a sufficiently reliable local	15:36:04
6	QMEAN score, right?	15:36:06
7	A Yes. That is correct.	15:36:09
8	Q And then you say: This is possible	15:36:10
9	because only one residue is being changed and the	15:36:17
10	remainder of the protein is still based on the	15:36:20
11	reliable experimentally determined structure,	15:36:24
12	right?	15:36:28
13	A Correct.	15:36:28
14	Q So when you say only one residue is being	15:36:29
15	changed, are you referring to the fact that you're	15:36:33
16	using the mutagenesis feature in PyMol to change	15:36:41
17	one amino acid in the protein?	15:36:41
18	ATTORNEY KUSHAN: Objection. Foundation.	15:36:45
19	A Introducing a mutation in PyMol is for	15:36:46
20	convenience only. You can see it in realtime in a	15:36:51
21	matter of seconds. I do it so I can see the	15:36:55
22	mutation quickly. However, if I want to generate	15:37:00

1 a more reliable model, I would generate a mutant 15:37:04
2 sequence of PH20, resubmit it to SWISS-MODEL, and 15:37:10
3 generate PyMol's model again. So I do this in 15:37:15
4 parallel. 15:37:17

5 Q Okay. And is that because PyMol does 15:37:18
6 not -- does not do an energy minimization when it 15:37:21
7 does the mutagenesis? 15:37:26

8 ATTORNEY KUSHAN: Objection. Foundation. 15:37:29

9 A It does not do minimization, energy 15:37:31
10 minimization. That's part of the answer. But 15:37:34
11 it's also because when you introduce a mutation 15:37:39
12 using PyMol, you're using PH20 as the template for 15:37:43
13 generating mutant structure. It would be more 15:37:50
14 fair if that mutant structure were generated using 15:37:54
15 HYAL1 structure as the template, just so that you 15:37:58
16 can treat wild-type and mutant the same way. 15:38:03

17 Q Okay. So hypothetically, you could take 15:38:06
18 the PH20 sequence and introduce two substitutions, 15:38:10
19 and then put that sequence -- put the two 15:38:15
20 substitutions into SWISS-MODEL and generate a 15:38:19
21 homology model using HYAL1 as the template, right? 15:38:27

22 ATTORNEY KUSHAN: Objection. Form. 15:38:28

1 A Yes. If you submit a sequence containing 15:38:29
2 two substitutions through SWISS-MODEL, it will 15:38:32
3 generate a homology model corresponding to that 15:38:34
4 mutant structure. That is true. 15:38:39

5 Unfortunately, that's not the end of the 15:38:45
6 story. Because modeling is not just a matter of 15:38:47
7 generating a PDB file. It also involves the -- 15:38:53
8 the subsequent aspect, which involves an expert 15:38:58
9 looking at the structure and making sense of it, 15:39:02
10 and that's where the problem occurs. 15:39:05

11 Q And what's the problem? 15:39:08

12 A The problem is when you're looking at one 15:39:11
13 substitution, there are only so many interactions 15:39:15
14 that a single amino acid can make, and those are 15:39:21
15 relatively straightforward to discern for an 15:39:29
16 expert. They look at the substitution. They can 15:39:35
17 estimate the three properties that I mentioned: 15:39:42
18 The intrinsic property of the amino acid, 15:39:45
19 secondary structure compatibility and 15:39:47
20 interactions. Those are relatively 15:39:48
21 straightforward, relatively speaking. 15:39:52

22 Once you start introducing the mutations, 15:39:55

1	more than one mutation, and if those mutations	15:40:01
2	happen to be -- to say, one, if they're close, or	15:40:11
3	if they're far away.	15:40:14
4	If they're far away, you can treat them --	15:40:15
5	treat them as independent mutations so you can	15:40:19
6	evaluate them one at a time. That's fine.	15:40:23
7	However, if those substitutions happen to be very	15:40:25
8	close to each other, what happens is now suddenly	15:40:29
9	you have to deal with many more possible changes	15:40:33
10	in the interactions, because the individual	15:40:36
11	substitutions would now alter their interactions	15:40:40
12	with their neighbor, and there would be	15:40:45
13	interactions between them as well.	15:40:47
14	So now that results in both positive and	15:40:50
15	negative interactions, all of which need to be	15:40:53
16	tracked and estimated. Unfortunately, a person	15:40:56
17	viewing the structure would not be able to	15:41:02
18	differentiate many of these subtle changes,	15:41:05
19	especially if there are multiple mutations nearby.	15:41:11
20	Q Okay. So let's say you have your PH20	15:41:16
21	structure, and you introduce two substitutions	15:41:21
22	that are far apart in the structure.	15:41:25

1	Am I understanding correctly that you	15:41:29
2	could -- you could evaluate those -- you could	15:41:31
3	evaluate those substitutions using the model, the	15:41:34
4	homology model that you generate, because they're	15:41:39
5	far away from each other and so you're not going	15:41:43
6	to have this neighbor effect?	15:41:46
7	ATTORNEY KUSHAN: Objection. Foundation.	15:41:48
8	Objection as to form.	15:41:49
9	A One can make an approximation and say	15:41:50
10	because they are spatially far apart from each	15:41:54
11	other, their interactions would be minimal.	15:42:01
12	Therefore, they can be treated independently, yes.	15:42:01
13	(Reporter clarification.)	15:42:08
14	Q And so when you say they can be treated	15:42:08
15	independently, you mean that you can go and look	15:42:11
16	in the structure at -- at the effect of the	15:42:13
17	substitution at each position independently and	15:42:17
18	see how that substitution is impacting the local	15:42:20
19	environment, and it would be two different	15:42:28
20	analyses because they're far apart in the protein;	15:42:33
21	is that right?	15:42:37
22	A Yes. That would be the case.	15:42:37

1	Q Okay.	15:42:39
2	A That would be an approximation, but I	15:42:39
3	would think it would be a reasonable	15:42:43
4	approximation. Distant residues are known to be	
5	coupled in some cases, but they're not very	15:42:47
6	common.	15:42:49
7	So if you introduce a mutation that are	15:42:50
8	far apart from each other, then each mutation can	15:42:52
9	be treated independently and evaluated	15:42:57
10	independently, and one may be able to estimate the	15:42:59
11	combined effect of the two or more mutations, if	15:43:06
12	necessary, and include whether the mutant would be	15:43:11
13	better or worse than wild-type.	15:43:17
14	(Reporter clarification.)	15:43:26
15	Q Okay. So then if you have two	15:43:26
16	substitutions that are close together, am I	15:43:30
17	understanding correctly that if you make two	15:43:33
18	substitutions that are close together, then they	15:43:36
19	could interact with each other, and if you're	15:43:41
20	going through and identifying and cataloging every	15:43:44
21	single interaction that -- every single	15:43:47
22	interaction at a particular position, when you	15:43:50

1	then make a change, let's say right next to that	15:43:54
2	position, you then have to go through and catalog	15:43:58
3	every single one of the interactions at the second	15:44:01
4	substitution, and so then it becomes difficult to	15:44:02
5	tease out the effects of the combination, as	15:44:06
6	opposed to just making the single substitution?	15:44:11
7	ATTORNEY KUSHAN: Objection to form.	15:44:15
8	Also objection to foundation.	15:44:16
9	A It does come down to the number game. As	15:44:20
10	you introduce more and more mutations, the number	15:44:25
11	of possible favorable and unfavorable interactions	15:44:28
12	increases exponentially, and can quickly overwhelm	15:44:35
13	a person's ability to evaluate them.	15:44:43
14	And many of the combinations may be very	15:44:47
15	nuanced. In other words, the differences between	15:44:53
16	different conformations and different combinations	15:44:58
17	of mutations would be very nuanced, to be able	15:45:02
18	to -- for a person to be able to -- to say whether	15:45:08
19	one would be better than another set of mutants,	15:45:10
20	mutations.	15:45:16
21	Q Okay. So let's say you're mutating two	15:45:17
22	residues that are right next to each other in the	15:45:23

1 protein. Okay? Just the two. I'm trying to 15:45:26
2 understand why it is that -- why it is that that 15:45:30
3 creates an issue when you're doing your 15:45:38
4 comparison? 15:45:41

5 So you have your PH20 sequence and you 15:45:44
6 mutate two residues right next to each other, and
7 you compare that model with the wild-type PH20 15:45:48
8 model. So what is it about the fact that the 15:45:53
9 residues are right next to each other that is 15:45:58
10 making the analysis difficult? 15:46:01

11 ATTORNEY KUSHAN: Objection. Form. 15:46:03

12 A Yeah. Again, the problem is not the 15:46:06
13 generation of the model, per se. But here I'm 15:46:11
14 using the word modeling, not only to indicate the 15:46:14
15 mechanics of going through the SWISS-MODEL portal 15:46:19
16 downloading PBD, which can be done regardless of 15:46:22
17 what you put in, but the subsequent step -- the 15:46:26
18 human intervention portion of the modeling, which 15:46:32
19 involves interpretation of the mutations, becomes 15:46:36
20 very quickly intractable. 15:46:40

21 And the reason for that is because of 15:46:45
22 the -- the very large number of changes that occur 15:46:49

1	following multiple simultaneous mutations. They	15:46:54
2	can't be broken down. In other words, the number	15:47:02
3	of interactions they need to keep track of does	15:47:05
4	not grow linearly, as you would expect if those	15:47:05
5	sites are independent, but they would grow	15:47:12
6	exponentially.	15:47:15
7	Q Okay. So you agree that technically you	15:47:16
8	can introduce multiple mutations into a	15:47:21
9	sequence -- into a sequence, and then you could	15:47:27
10	submit that sequence for PH20 into SWISS-MODEL,	15:47:30
11	and you download a PBD file with the resulting	15:47:33
12	homology model, right?	15:47:38
13	A Well, I don't --	15:47:40
14	ATTORNEY KUSHAN: Sorry.	15:47:40
15	Objection. Foundation.	15:47:41
16	A I don't argue that you can do it. If you	15:47:45
17	have many combinations, it might take a while.	15:47:53
18	But you can generate a PBD file, files.	15:47:56
19	Unfortunately, it doesn't really get you anywhere,	15:48:00
20	because SWISS-MODEL doesn't put a number on -- it	15:48:04
21	doesn't tell you anything about the energetics of	15:48:10
22	those substitutions. All it does is -- it's going	15:48:14

1 to give you the best structure it can, given the 15:48:20
2 sequence. 15:48:24

3 It may be a horrendous combination of 15:48:24
4 mutations. SWISS-MODEL would not know the 15:48:30
5 difference between that and the best sequence. It 15:48:32
6 just gives you the best structure it can by going 15:48:35
7 through the set of routines that it's designed to 15:48:38
8 do, and you generate a PBD file. 15:48:44

9 And sure, you can download it. But what 15:48:49
10 do you do with it? The problem is you can't do 15:48:51
11 anything, and there's no methodology that will 15:48:55
12 allow you to compare two structures containing 15:49:01
13 substitutions that are near each other if it's a 15:49:06
14 large number. There's no proven and accepted 15:49:10
15 methodology that one can go through systemically 15:49:14
16 to evaluate and compare those sets of structures 15:49:17
17 and sequences, which I consider still part of the 15:49:23
18 modeling. 15:49:27

19 Q Uh-huh. 15:49:28

20 A Because modeling is not just generating 15:49:29
21 the PBD file, but also looking at it and making 15:49:32
22 sense of it. And you will -- one will run into a 15:49:36

1 combinatorial, combinatorially intractable 15:49:44
2 situation very quickly if mutations occur close to 15:49:48
3 each other. 15:49:53

4 Q And the combinatorially intractability is 15:49:54
5 because of all of the -- all of the new 15:50:00
6 interactions that are forming, and you can't keep 15:50:02
7 track of all of the new interactions that are 15:50:06
8 forming when you're making multiple changes close 15:50:09
9 together in the protein; is that right? 15:50:11

10 A That is true. Two parts: One, to share a 15:50:14
11 number of interactions that one needs to keep 15:50:20
12 track of increases very quickly, as I pointed out, 15:50:22
13 exponentially, and that will expose the 15:50:29
14 fundamental shortfalls, shortcomings of the energy 15:50:36
15 field that is used to evaluate different 15:50:39
16 substitutions. Those energy fields are 15:50:43
17 incomplete. Incomplete. 15:50:47

18 And I think I got it. 15:50:51

19 They are unfortunately incomplete. There 15:50:54
20 are many effects that are overlooked by the -- the 15:50:57
21 force field, and those errors would compound as 15:51:02
22 you begin to change more interactions, and now the 15:51:07

1 uncertainty that results from those shortcomings 15:51:12
2 in the force -- force field would essentially 15:51:18
3 prevent one to make a meaningful comparison 15:51:23
4 between structures. 15:51:28

5 Q So is the problem that you're -- is the 15:51:30
6 problem the comparison, that you're comparing the 15:51:31
7 wild-type structure with the structure that has, 15:51:35
8 let's say, two changes that are right next to each 15:51:37
9 other, and you're trying to account for, let's 15:51:40
10 take position 320 -- you're trying to account for 15:51:43
11 all of the interactions at position 320, and then 15:51:46
12 in the wild-type structure, and then if you make 15:51:53
13 two changes -- well actually, wait. 15:51:59

14 Let me start over. Let me try this a
15 different way. 15:52:04

16 All right. So you have your wild-type 15:52:04
17 PH20 model. Let's say you make your position, 15:52:08
18 your change at position 320, right? And you make 15:52:11
19 your SWISS-MODEL model at position 320. 15:52:13

20 Could you then make a change at 15:52:15
21 position 321, and then compare that model to the 15:52:18
22 model at position in which you changed 15:52:22

1	position 320?	15:52:26
2	A Both mutations, or just one mutation?	15:52:28
3	Q So the -- wait. You have your wild-type,	15:52:32
4	and you have your mutant 320, and then you have	15:52:41
5	your mutant 320 and 321.	15:52:42
6	A Okay. Single point mutant versus double	15:52:43
7	mutant?	15:52:47
8	Q Yes. Could you do that -- could you do	15:52:47
9	that comparison, I guess three-way comparison --	15:52:50
10	ATTORNEY KUSHAN: Objection.	15:52:54
11	Q -- to evaluate the -- to model the	15:52:55
12	mutation at positions 320 and 321?	15:52:59
13	ATTORNEY KUSHAN: Objection. Foundation.	15:53:02
14	Objection to form.	15:53:03
15	A It depends on the types of mutations that	15:53:05
16	you would introduce. Some combinations are more	15:53:08
17	straightforward than others. If one mutation is	15:53:12
18	outright bad, then no matter what you do at the	15:53:16
19	other position, you may just kill the protein. So	15:53:21
20	that -- that's an easy combination.	15:53:25
21	There may be scenarios where it's not	15:53:28
22	clear what happens. And now if you increase it to	15:53:31

1 three and four and five positions which are all 15:53:38
2 simultaneously changing, and now all of a sudden, 15:53:44
3 a lot of things are changing. 15:53:48

4 So you have to -- one has to compare the 15:53:50
5 initial wild-type set of interactions with the 15:53:54
6 interactions that you see in a single point mutant 15:53:58
7 or a quintuple mutant, and a lot of things have 15:54:04
8 changed, and unfortunately the energy function 15:54:11
9 that is used and needed to evaluate these 15:54:16
10 different changes and interactions are not very 15:54:19
11 accurate. 15:54:23

12 And those errors would compound as you 15:54:25
13 begin to introduce more and more, and there are 15:54:28
14 other missing components to the force field which 15:54:33
15 may not have been very important initially, for a 15:54:38
16 single point mutant, will become very apparent as 15:54:42
17 you -- it would become more significant because 15:54:48
18 they individually introduce uncertainties, and 15:54:53
19 errors so that it becomes nearly impossible to 15:54:58
20 make any meaningful statement comparing one set of 15:55:03
21 five mutants versus another set of five mutants, 15:55:08
22 or a single mutant. That's the challenge. 15:55:15

1 Q So the challenge is that -- I'm trying to 15:55:16
2 understand if the challenge is that you have to 15:55:21
3 count all of the different interactions that have 15:55:23
4 changed, and that's just a lot of interactions 15:55:25
5 that have changed when you have, like, five 15:55:27
6 mutations right next to each other on a protein, 15:55:30
7 or if the problem is that you don't know if 15:55:33
8 those -- let's say you're making five changes, if 15:55:35
9 those replaced residues are in the correct 15:55:40
10 position in the model, because there's an issue 15:55:43
11 with the energetics that the computer program is 15:55:46
12 using to build the homology model. 15:55:51

13 I'm trying to understand if which one of 15:55:54
14 those two things it is that you're -- 15:55:56

15 A Oh, absolutely. 15:55:57

16 ATTORNEY KUSHAN: Objection. Foundation. 15:55:58

17 Objection to form. 15:56:00

18 A SWISS-MODEL does side chain modeling, 15:56:05
19 meaning after the backbone structure has been 15:56:12
20 determined, it would go through different rotamer 15:56:17
21 states and identify the set of rotamers that the 15:56:21
22 minimize the energy. 15:56:30

1	(Reporter clarification.)	15:56:32
2	A That it does pretty well, because it uses	15:56:32
3	an external algorithm actually, SCWRL, I think	15:56:36
4	that's called.	
5	It's known to be pretty good at side chain	15:56:43
6	modeling. And it will find the best combination	15:56:48
7	of rotamers. So internally consistent. So	15:56:53
8	comparing one rotamer set for that quintuple	15:57:00
9	mutant to another rotamer set containing exactly	
10	the same mutations, in other words, if you change	15:57:05
11	the conformations of the five residues, SCWRL will	15:57:05
12	know how to do it.	15:57:12
13	So it will give you the best rotamer.	15:57:13
14	However, it doesn't give you a method of comparing	15:57:17
15	that mutant with another mutant containing	15:57:20
16	different amino acids at the same positions. That	15:57:26
17	requires different analysis, post-model	15:57:29
18	generation. You generate the model, and then	15:57:33
19	comes the analysis. How does one analyze that?	15:57:38
20	For a single point mutant, visual	15:57:42
21	inspection is often sufficient. That has been	15:57:43
22	known to be very successful. And that's also	15:57:48

1	proven by publication. People have done that.	15:57:52
2	For multiple point mutations, it becomes	15:57:56
3	very difficult for a human to juggle many	15:58:00
4	different possible interactions.	15:58:07
5	But that's only the problem. As I said,	
6	there are two parts to it: One is the sheer	15:58:09
7	number of conformations, or combinatorial	15:58:10
8	interactions that we -- we need to keep track of.	15:58:16
9	But even if we were to do that diligently	15:58:19
10	and somehow tabulate all 5,000 interactions that	15:58:25
11	have changed, it still doesn't give you the answer	15:58:26
12	because the force field, energy field, that is	15:58:31
13	needed to estimate the energies for those	15:58:34
14	individual interactions is not there. It's	15:58:38
15	incomplete.	15:58:43
16	And that is a struggle that the whole	15:58:43
17	community has to deal with, and was not a solved	15:58:47
18	problem back in 2011. I don't think it's a solved	15:58:59
19	problem as of today.	15:58:56
20	Q Okay. Okay. So I think that what I'm	15:58:58
21	struggling with is that PH20 is -- PH20 is 40	15:59:07
22	percent-ish identical to HYAL1, the template	15:59:17

1	structure, right?	15:59:26
2	A Yes.	15:59:26
3	Q Okay.	
4	A It is.	15:59:27
5	Q Human PH20. Let's say Rhesus monkey PH20	15:59:27
6	is, I don't know, like 37 percent -- I'm just	15:59:37
7	making up a number -- 37 percent identical to	15:59:42
8	HYAL1, right?	15:59:46
9	Presumably there's more than one change,	15:59:47
10	one difference between Rhesus monkey PH20 and	15:59:52
11	human PH20 that presumably you could still	15:59:53
12	generate a Rhesus monkey model using SWISS-MODEL	15:59:54
13	for Rhesus monkey PH20, the same way you could for	15:59:58
14	human PH20.	16:00:01
15	And if based on what you're saying about	16:00:02
16	the multiple mutation issue, I don't understand	16:00:04
17	why it's okay to use SWISS-MODEL to generate a	16:00:09
18	human PH20 model, and that's okay, but somehow	16:00:13
19	there's no force field and you're going to get	16:00:20
20	gibberish if you try to generate a model for	
21	Rhesus monkey PH20, despite the fact that the	16:00:24
22	Rhesus monkey PH20 and the human PH20 have	16:00:27

1 multiple differences in their sequences? 16:00:31

2 That's -- that's what I'm not 16:00:33

3 understanding. Because the template sequence that 16:00:35

4 you're using has more than one change, right, to 16:00:38

5 PH20? The HYAL1 sequence is more than one amino 16:00:42

6 acid off of PH20, and you're still able to use 16:00:47

7 that as a template, so -- 16:00:50

8 A Absolutely. No problem with the Rhesus 16:00:51

9 monkey. It can generate a model. 16:00:55

10 Q Okay. 16:00:56

11 A What you cannot do is compare the Rhesus 16:00:57

12 monkey PH20, compare that to human PH20. 16:01:00

13 Q Okay. Okay. It's the comparison that 16:01:01

14 we're talking about? 16:01:04

15 A It's the comparison that you cannot do. 16:01:05

16 Q Okay. 16:01:08

17 A That's what -- that's what comes down to 16:01:10

18 the mutant analysis. 16:01:11

19 Q Okay. 16:01:12

20 A If you introduce the mutation in PH20, the 16:01:16

21 model will not tell you how to compare the two 16:01:22

22 structures.

1	Q Okay. All right. I am now following.	16:01:18
2	Thank you for that.	16:01:24
3	A I'm sorry for that very long-winded and	16:01:24
4	somewhat confusing answer.	16:01:30
5	Q No. I'm now following. Thank you.	16:01:30
6	All right. So let's turn to	16:03:00
7	Paragraph 107.	16:03:02
8	A Okay. I'm at Paragraph 107.	16:03:22
9	Q So you say: I visualized position 320 --	16:03:41
10	(Reporter clarification.)	
11	Q Paragraph 107: I visualized position 320	16:03:52
12	within the PH20 model using PyMol. First, I	16:03:52
13	confirmed that position 320 was not near the	16:03:58
14	active site, right?	16:04:01
15	A That's correct.	16:04:02
16	Q How did you confirm that position 320 was	16:04:04
17	not near the active site?	16:04:07
18	A I built a model of PH20 with the substrate	16:04:15
19	in the binding pocket, and that substrate was	
20	imported from the bee venom hyaluronidase. And	16:04:26
21	through superposition and transferring of the	16:04:27
22	glycan, I could see where the substrate would sit	16:04:31

1 in the binding pocket, and 320 was not near that 16:04:35
2 binding pocket. 16:04:40

3 Q When you say not near, I'm just trying to 16:04:41
4 understand what that means. Is that a 16:04:44
5 quantitative or qualitative? 16:04:46

6 A Sure. I don't have an exact number in 16:04:49
7 terms of the distance in angstroms, but it was 16:04:52
8 sufficiently far away from where the bound 16:04:56
9 substrate is, which led me to believe that it's 16:05:00
10 unlikely that this residue 320, regardless of what 16:05:05
11 that amino acids is, I didn't think that that 16:05:10
12 would be in a position to interact with a 16:05:14
13 substrate in any significant way. 16:05:16

14 Q And why is that evaluation as to whether 16:05:19
15 position 320 is near the active site, why is that 16:05:23
16 important in your analysis? 16:05:28

17 A When you start mutating residues in the 16:05:33
18 binding pocket, now you have to worry about the 16:05:37
19 impact of the substitution on catalysis directly, 16:05:41
20 in addition to its potential impact on the 16:05:47
21 structure. I wanted to isolate those two effects 16:05:53
22 and consider only the structural aspect, not the 16:05:56

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

217

1	functional aspect.	16:06:02
2	Q Okay.	16:06:05
3	ATTORNEY KUSHAN: Can we take a one-minute	16:06:08
4	break so I can let Christine in?	16:06:11
5	ATTORNEY MARTIN: Oh, yeah.	16:06:14
6	THE VIDEOGRAPHER: We are going off the	16:06:16
7	record. The time is 4:06 p.m.	16:06:18
8	(Recess from 4:06 p.m. until 4:08 p.m.)	16:06:22
9	THE VIDEOGRAPHER: We are back on the	16:08:48
10	record. The time is 4:08 p.m.	16:08:50
11	BY ATTORNEY MARTIN:	16:08:59
12	Q Okay. Dr. Park, can you please turn to	16:09:00
13	Paragraph 52?	16:09:05
14	A Paragraph 52? I am at Paragraph 52.	16:09:26
15	Q So in Paragraph 52, you say that the Yue	16:09:39
16	paper also pointed out that there was a better	16:09:44
17	correlation between substitutions and	16:09:47
18	destabilizing changes when the nature of an	16:09:50
19	interaction was combined with this location.	16:09:54
20	Do you agree that the location of a	16:09:58
21	residue is an important factor to consider when	16:10:04
22	evaluating the impact of a substitution?	16:10:08

1	Actually, strike that.	16:10:30
2	If you turn to Paragraph 53 --	16:10:33
3	A Okay.	
4	Q -- in the last sentence, it looks like you	
5	address this.	
6	You say: The location of the amino acid	16:10:36
7	being changed within the protein structure is an	16:10:37
8	important consideration in assessing whether a	16:10:39
9	single amino acid substitution will be tolerated	16:10:42
10	or not, right?	16:10:50
11	A That's correct.	16:10:50
12	Q So do you agree that the location of the	16:10:50
13	amino acid is an important consideration when	16:10:54
14	you're evaluating substitutions?	16:10:56
15	A Was the question: Is the location an	16:10:57
16	important consideration?	16:10:59
17	Q Yes. Yes.	16:10:59
18	A The location of the substitution is an	16:11:05
19	important consideration, yes.	16:11:08
20	Q So why -- why is the location of an amino	16:11:09
21	acid an important consideration?	16:11:11
22	A There are many factors that go in. It's	16:11:20

1 listed in that Paragraph 52 as well, where it 16:11:24
2 says, for example: Proteins are more consistently 16:11:30
3 destabilized by a single amino acid change that 16:11:37
4 introduced a large side chain that caused a steric 16:11:41
5 clash within a buried position of the protein. 16:11:43

6 (Reporter clarification.) 16:11:55

7 A That's because in a buried position, many 16:11:55
8 structural constraints of what can go in, in terms 16:11:57
9 of size, the shape, in addition to the 16:12:02
10 hydrophobicity/hydrophilicity. 16:12:05

11 So the constraints are different whether a 16:12:09
12 position is buried as opposed to, say, solvent 16:12:16
13 exposed. In a solvent exposed position, there's a 16:12:23
14 lot of freedom. You still need to satisfy some 16:12:26
15 constraints, but having done that, there's a lot 16:12:32
16 of freedom in terms of choosing an amino acid, 16:12:38
17 just because there are fewer structural 16:12:43
18 constraints. 16:12:48

19 Q What are -- what do you mean when you say 16:12:49
20 structural constraints? 16:12:51

21 A Structural constraints that I refer to 16:12:53
22 include the ones that I mentioned earlier, say, 16:12:58

1 the volume or the shape. The amino acids at a 16:13:01
2 buried position will force the choice of amino 16:13:11
3 acid to be introduced to be a certain way. It not 16:13:17
4 only has to fit into that space, but it also needs 16:13:22
5 to have the right shape. 16:13:27

6 Those constraints are not as prominent at 16:13:30
7 a solvent exposed position. The amino acid will 16:13:35
8 have to satisfy some constraint, for instance, 16:13:42
9 based on hydrophilicity/hydrophobicity. 16:13:46

10 (Reporter clarification.) 16:13:57

11 A But beyond that, there is much liberty. 16:13:57

12 Q So as a -- is it correct that as a general 16:14:05
13 matter, a buried hydrophobic residue is going to 16:14:09
14 be less amenable to substitution than a solvent 16:14:16
15 exposed hydrophilic residue? 16:14:21

16 A It's always dangerous to generalize, but 16:14:26
17 in many cases, buried positions are harder to 16:14:30
18 mutate properly, compared to a solvent exposed 16:14:37
19 position. Yes. 16:14:41

20 Q Did you look -- did you identify where on 16:14:46
21 the structure -- strike that. 16:14:50

22 If you were to introduce a single amino 16:15:23

1 acid change that introduced a large side chain, 16:15:26
2 let's say a large charged side chain, into a 16:15:29
3 buried hydrophobic pocket in the protein, would 16:15:33
4 you expect that to cause problems for your 16:15:38
5 protein? 16:15:43

6 ATTORNEY KUSHAN: Objection. Foundation. 16:15:44

7 A That's a very complicated scenario, 16:15:48
8 introducing a large charged residue into a buried 16:15:54
9 position, was it? 16:15:58

10 Q Uh-huh. 16:15:59

11 A It's hard to imagine a scenario where that 16:16:00
12 would happen. The large side chain would have to 16:16:05
13 be the right size to fit into it, first of all. 16:16:09
14 And having a charge that's buried is a no-no when 16:16:15
15 you're doing important engineering. This, I 16:16:22
16 think, would be one of the worst combination of 16:16:26
17 position versus amino acid choice. 16:16:31

18 Q Okay. 16:16:35

19 A Yes. So it would be a pretty bad mutation 16:16:35
20 in general. Now, can one think of a scenario 16:16:41
21 where this is not the case, well, anything is 16:16:45
22 possible. But I think in general, that would be 16:16:47

1	challenging.	16:16:51
2	Q Okay. Would you expect -- would you	16:16:52
3	expect to get a misfolded protein, or an inactive	16:16:54
4	protein, if you did something like that?	16:17:01
5	A In all likelihood, and very high	16:17:06
6	probability, I think the -- that substitution	16:17:10
7	would be highly destabilizing.	16:17:13
8	(Reporter clarification.)	16:17:19
9	Q So if you -- let's say you change	16:17:19
10	multiple -- multiple buried hydrophobic residues	16:17:24
11	to large charged residues all at the same time,	16:17:33
12	would you expect to get a functional protein, or	16:17:36
13	would you expect to get not -- an inactive	16:17:40
14	protein?	16:17:43
15	ATTORNEY KUSHAN: Objection. Foundation.	16:17:44
16	Objection as to form.	16:17:46
17	A We're talking about a very highly	16:17:48
18	coordinated and orchestrated mutation, which I	16:17:58
19	think would be extremely difficult to pull off.	16:18:03
20	Q So you would expect that it would not --	16:18:04
21	you would not get a functional protein out of	16:18:06
22	that, right?	16:18:10

1	ATTORNEY KUSHAN: Objection. Form.	16:18:10
2	A If I were a betting man, I would not bet	16:18:11
3	in favor of that mutation.	16:18:15
4	Q Okay. And you don't need a SWISS-MODEL	16:18:25
5	homology model to predict that that's not going to	16:18:21
6	work, right?	16:18:24
7	ATTORNEY KUSHAN: Objection. Foundation.	16:18:26
8	A SWISS-MODEL can generate a model that one	16:18:31
9	can expect to see whether such combination might	16:18:36
10	be possible, and being able to see the model with	16:18:41
11	your own eye might be very helpful.	16:18:47
12	What I am objecting earlier is that the	16:18:53
13	likelihood of finding a pair of charge mutations,	16:18:55
14	I think that was the scenario?	16:19:01
15	Q For multiple -- multiple charge.	16:19:03
16	A Multiple charge, no less.	16:19:04
17	Q Uh-huh.	
18	A To fit into hydrophobic pocket and somehow	16:19:06
19	make everybody happy and keep the protein	16:19:15
20	functional, would be a very difficult task, with	16:19:19
21	or without SWISS-MODEL.	16:19:23
22	(Reporter clarification.)	16:19:29

1	ATTORNEY KUSHAN: Can we just -- whoever	16:19:29
2	has joined, announce themselves?	16:19:33
3	THE VIDEOGRAPHER: It looks like	16:19:37
4	Mr. Goldberg signed in again.	16:19:39
5	ATTORNEY KUSHAN: Brian, can you hear us?	16:19:42
6	ATTORNEY GOLDBERG: I can.	16:19:45
7	ATTORNEY KUSHAN: Are you by yourself?	16:19:47
8	ATTORNEY GOLDBERG: Yes.	16:19:49
9	ATTORNEY KUSHAN: Okay. Just wanted to	16:19:50
10	make sure.	16:19:52
11	ATTORNEY MARTIN: Thank you.	16:19:53
12	ATTORNEY GOLDBERG: Yeah.	16:19:53
13	BY ATTORNEY MARTIN:	16:20:08
14	Q So you used a distance cut-off of 5	16:20:08
15	angstroms to identify neighbors in your analysis;	16:20:15
16	is that right?	16:20:17
17	A I did.	16:20:17
18	Q Why did you use 5 angstroms as the	16:20:18
19	cut-off?	16:20:22
20	A It's a number that's commonly used.	16:20:24
21	Q So is that a typical cut-off in the art to	16:20:30
22	identify neighbors for a particular residue?	16:20:33

1	A I would say so.	16:20:39
2	Q And was that the case in 2011?	16:20:41
3	A Yes. The cut-off hasn't changed.	16:20:46
4	Q Okay. Let's turn to Paragraph 70.	16:20:51
5	A I'm at Paragraph 70.	16:22:02
6	Q And in Paragraph 70, you say that: The	16:22:04
7	propensity of different amino acids to support	16:22:10
8	helix or beta sheet formation was generally known;	16:22:12
9	is that right?	16:22:13
10	A That's correct.	16:22:16
11	Q And was that generally known in 2011?	16:22:17
12	A Yes.	16:22:25
13	Q And you have a chart under Paragraph 70	16:22:25
14	that identifies good and poor alpha helix and beta	16:22:29
15	sheet formers, right?	16:22:38
16	(Reporter clarification.)	16:22:41
17	A Yes. There's a chart.	16:22:41
18	Q Did you prepare this chart?	16:22:43
19	A Yes. I did.	16:22:49
20	Q And was this chart created based on what	16:22:50
21	the skilled person would understand in 2011?	16:22:57
22	A Yes.	16:23:00

1	Q Okay.	16:23:05
2	A This would be regularly understood by a	16:23:06
3	POSA.	16:23:09
4	Q So we had talked about the various	16:24:07
5	interactions that you considered in your analysis	16:24:11
6	to determine whether a substitution would be	16:24:16
7	favorable or neutral or unfavorable, and you used	16:24:19
8	two publications -- the Wang publication and the	16:24:24
9	Yue publication -- for the -- to identify or list	16:24:29
10	those interactions; is that right?	16:24:33
11	ATTORNEY KUSHAN: Objection. Foundation.	16:24:38
12	A Yes. I used those two publications as a	16:24:40
13	demonstration that there were other precedents	16:24:46
14	doing similar things.	16:24:55
15	Q And how did you identify those two papers?	16:24:56
16	A I don't remember the exact steps I took,	16:24:59
17	but it must have been a combination of PubMed	16:25:09
18	search and Google search.	16:25:20
19	(Reporter clarification.)	16:25:28
20	Q And those papers evaluate SNPs, right,	16:25:28
21	single nucleotide polymorphisms; is that right?	16:25:38
22	A That's correct.	16:25:44

1	Q And in particular, they evaluate SNPs that	16:25:44
2	are known to cause disease, right?	16:25:50
3	A That's right.	16:25:52
4	Q And they try to identify the molecular	16:25:53
5	mechanism of action for why that particular SNP	16:25:57
6	causes disease?	16:25:58
7	A That's correct.	16:26:00
8	Q So is it fair to say that those two	16:26:01
9	papers, the Wang and the Yue paper, are evaluating	16:26:04
10	the relationship between structure and function in	16:26:07
11	terms of the impact on protein structure of a	16:26:11
12	particular mutation, and the function being a	16:26:18
13	destabilization and then the resulting disease?	16:26:23
14	ATTORNEY KUSHAN: Objection. Foundation.	16:26:27
15	A That's what they found in the paper. They	16:26:28
16	reported that 90 percent of the time, SNPs cause	16:26:32
17	instability in the protein, which is the -- the	16:26:38
18	direct cause of the disease.	16:26:41
19	Q So are those papers evaluating structure	16:26:41
20	function correlations for those various SNPs?	16:26:44
21	ATTORNEY KUSHAN: Objection. Foundation.	16:26:50
22	A Not structure function, but sequence	16:26:51

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

228

1	structure/stability.	16:26:53
2	ATTORNEY MARTIN: Okay. So we've been	16:26:55
3	going for a long time. Do you want to take a	16:27:03
4	quick break?	16:27:05
5	THE WITNESS: Sure.	16:27:09
6	ATTORNEY KUSHAN: Sure.	16:27:09
7	ATTORNEY MARTIN: See how much I have.	16:27:11
8	THE VIDEOGRAPHER: We are going off the	16:27:14
9	record. The time is 4:27 p.m.	16:27:23
10	(Recess from 4:27 p.m. until 4:50 p.m.)	16:27:30
11	THE VIDEOGRAPHER: We are back on the	16:50:24
12	record. The time is 4:50 p.m.	16:50:25
13	ATTORNEY MARTIN: All right. I just have	16:50:29
14	one more question, and then some things to read on	16:50:31
15	the record.	16:50:36
16	BY ATTORNEY MARTIN:	16:50:39
17	Q So -- so Dr. Park, you mentioned that you	16:50:40
18	had several conversations with Dr. Hecht in	16:50:41
19	connection with your analysis in this case.	16:50:45
20	So the question is: Did you rely on -- on	16:50:48
21	anything that you learned from Dr. Hecht in -- in	16:50:51
22	your analyses that are set forth in your	16:50:57

1 declarations?

16:51:02

2 A No. The conversation was more or less one
3 directional, me explaining to him what I had done,
4 and Dr. Hecht mostly agreeing with what I said.

16:51:03

16:51:11

16:51:14

5 ATTORNEY MARTIN: Okay. All right. So
6 let me just say what I'm going to say.

16:51:24

16:51:27

7 All right. So for the spreadsheet, we
8 object to the late production of the spreadsheet
9 under Rule 42.65. It's highly prejudicial that we
10 got the spreadsheet during the deposition, the
11 afternoon of the deposition.

16:51:30

16:51:34

16:51:38

16:51:45

16:51:49

12 And you know, it's very -- we appreciate
13 that you got us the spreadsheet, but at the same
14 time, right, I mean, it's a very small fonted,
15 large document with, like, 2,800 rows.

16:51:52

16:51:55

16:52:00

16:52:04

16 And it's in black and white, and there's a
17 figure that looks like it should be in color in
18 here, and we still don't have a color version of
19 it.

16:52:08

16:52:11

16:52:15

16:52:17

20 So it's obviously highly prejudicial that
21 we just got this now. We haven't been able to
22 talk to our experts about it. Obviously we can't

16:52:18

16:52:21

16:52:26

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

230

1 be expected to depose Dr. Park on it now, and so 16:52:29
2 we reserve the right to request a further 16:52:31
3 deposition and potentially other relief, so... 16:52:34

4 And we also object to the fact that 16:52:45
5 Dr. Hecht attended a portion of this deposition, 16:52:51
6 and we object to the potential -- we object to 16:52:53
7 Dr. Hecht reading the transcript from this 16:52:58
8 deposition because we think that it's witness 16:53:02
9 coaching. So we're going to put that on the 16:53:05
10 record as well. 16:53:08

11 And we object to, under Federal Rule of 16:53:11
12 Evidence 615 specifically, that Dr. Hecht listened 16:53:17
13 in on the deposition. We object to Dr. Hecht 16:53:22
14 reviewing the transcript under Federal Rule of 16:53:25
15 Evidence 615, and we object to the extent that 16:53:26
16 Dr. Hecht relies on any of today's testimony. 16:53:30

17 Okay. All right. So I think I'm done, 16:53:49
18 and pass the witness. 16:53:51

19 ATTORNEY KUSHAN: Can we have a 16:53:52
20 five-minute break, and then we can proceed? 16:53:58

21 Before we do that, we, of course, disagree 16:54:01
22 with the basis and propriety of the objections 16:54:04

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

231

1	you've raised about Dr. Hecht.	16:54:07
2	We also disagree with your arguments	16:54:09
3	regarding the late production -- or, supposedly	16:54:15
4	late production -- of this exhibit. And we are in	16:54:17
5	the process of emailing you the version of that	16:54:19
6	file with page numbers, which you should get	16:54:23
7	shortly.	16:54:27
8	But why don't we take our break?	16:54:28
9	THE VIDEOGRAPHER: We are going off the	16:54:32
10	record. The time is 4:54 p.m.	16:54:34
11	(Recess from 4:54 p.m. until 5:07 p.m.)	16:54:37
12	THE VIDEOGRAPHER: We are back on the	17:07:58
13	record. The time is 5:07 p.m.	17:08:01
14	ATTORNEY KUSHAN: Just before the break,	17:08:09
15	you made a number of comments, and my brief	17:08:12
16	response to that -- and we obviously can reserve	17:08:15
17	our ability to address other issues at a	17:08:18
18	subsequent point.	17:08:21
19	Promptly after you asked that Dr. Hecht	17:08:23
20	terminate his participation in this deposition, we	17:08:26
21	complied. And we don't think -- believe there's	17:08:26
22	any improper nature in his participation in the	17:08:30

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

232

1 deposition or, you know, watching it, and we don't
2 think there's been any prejudice as a consequence
3 of that. So we don't think there's any issue to
4 address in the future.

5 And that's -- at this point, we have no
6 questions for the witness, so we can end the
7 deposition.

8 ATTORNEY MARTIN: Okay. Great.

9 THE VIDEOGRAPHER: This marks the end of
10 the deposition of Dr. Sheldon Park.

11 We are going off the record at 5:08 p.m.

12 (The videotaped deposition of DR. SHELDON
13 PARK was concluded at 5:09 p.m.)
14
15
16
17
18
19
20
21
22

17:08:34

17:08:39

17:08:41

17:08:45

17:08:48

17:08:51

17:08:53

17:08:54

17:08:55

17:08:59

17:09:01

1 CERTIFICATE OF SHORTHAND REPORTER - NOTARY PUBLIC

2
3 I, Kadi A. Harmon, Certified Reporter and
4 Notary Public within and for the State of New York
5 do hereby certify:

6
7 That Dr. Sheldon Park, the witness whose
8 deposition is hereinbefore set forth, was duly
9 sworn by me before the commencement of such
10 deposition and that such deposition was taken
11 before me and is a true record of the testimony
12 given by such witness.

13
14 I further certify that the adverse party,
15 Merck Sharp & Dohme, was represented by counsel at
16 the deposition.

17
18 I further certify that the deposition of
19 Dr. Sheldon Park, occurred at the offices of the
20 Hyatt Regency Buffalo on Thursday, the 7th day of
21 August, 2025, commencing at 8:45 a.m. to 5:09 p.m.

1 I further certify that I am not related to any
2 of the parties to this action by blood or
3 marriage, I am not employed by or an attorney to
4 any of the parties to this action, and that I am
5 in no way interested, financially or otherwise, in
6 the outcome of this matter.

7
8 IN WITNESS WHEREOF, I have hereunto set my hand
9 this 11th day of August, 2025.

10
11 My commission expires:

12 December 18, 2026

13
14 
15 _____

16 NOTARY PUBLIC IN AND FOR THE

17 STATE OF NEW YORK
18
19
20
21
22

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

235

A			
ability 158:5, 202:13, 231:17 able 43:20, 49:14, 51:10, 51:12, 53:19, 61:3, 75:9, 89:15, 105:6, 106:15, 107:10, 140:19, 141:1, 178:9, 199:17, 201:10, 202:17, 202:18, 214:6, 223:10, 229:21 about 10:13, 12:19, 12:20, 15:22, 18:3, 30:17, 31:18, 31:19, 37:3, 42:8, 43:11, 53:7, 56:5, 64:1, 65:4, 68:16, 69:9, 86:2, 87:8, 96:5, 100:20, 102:21, 113:3, 124:10, 126:3, 131:17, 132:20, 134:13, 134:16, 134:18, 135:6, 138:13, 141:9, 153:7, 156:5, 169:5, 169:16, 172:1, 172:15, 174:15, 176:6, 176:7, 176:9, 176:20, 177:10, 182:12, 183:13, 183:17, 184:1, 188:4, 190:21, 192:15, 193:17, 193:21, 203:8, 204:21, 213:15, 214:14, 216:18, 222:17,	226:4, 229:22, 231:1 above 57:2, 181:19, 182:15, 184:6 abrogate 107:20 abrogates 108:12 absence 109:19, 133:13 absolute 26:4 absolutely 19:16, 26:8, 53:21, 55:15, 169:20, 210:15, 214:8 academic 43:22, 134:8 acceptable 130:15, 145:6, 145:7, 181:4, 184:10 accepted 205:14 accessible 149:13, 149:20, 149:21, 150:2, 150:4, 150:5, 150:7, 150:12, 150:21, 151:10, 151:14, 151:19, 152:14, 152:15, 152:17 accession 97:3, 97:4, 97:6, 97:7, 97:13, 99:17 according 181:21 account 207:9, 207:10 accounting 58:5 accurate 138:3, 209:11 acid 14:1, 14:14,	14:17, 15:15, 17:1, 54:11, 70:20, 72:13, 73:11, 74:21, 100:13, 100:22, 109:5, 109:8, 110:6, 110:10, 112:7, 116:2, 136:11, 136:12, 144:15, 144:16, 145:9, 147:2, 147:7, 147:10, 148:19, 149:5, 149:6, 149:16, 150:2, 150:15, 150:16, 150:20, 151:9, 151:12, 152:8, 152:11, 158:16, 161:20, 164:16, 170:5, 196:4, 196:17, 198:14, 198:18, 214:6, 218:6, 218:9, 218:13, 218:21, 219:3, 219:16, 220:3, 220:7, 221:1, 221:17 acids 23:3, 55:7, 55:8, 56:10, 56:12, 59:4, 60:3, 63:22, 64:2, 64:4, 64:14, 67:6, 71:14, 98:11, 98:15, 98:22, 99:12, 101:2, 103:7, 104:8, 104:10, 107:15, 109:10, 112:16, 115:20, 116:10, 117:9, 118:11, 118:18, 119:2, 138:7, 143:13, 145:3, 148:20, 153:17, 155:6, 159:17, 162:13,	168:17, 169:22, 176:17, 179:14, 211:16, 216:11, 220:1, 225:7 act 73:15 action 14:17, 227:5, 234:2, 234:4 active 16:12, 73:4, 73:12, 137:6, 138:5, 138:8, 138:10, 157:8, 161:11, 215:14, 215:17, 216:15 actively 41:12, 138:11 activities 73:16, 74:16, 143:22 activity 14:6, 14:8, 70:22, 71:9, 71:16, 71:19, 72:7, 72:8, 72:14, 73:1, 73:3, 74:18, 91:9, 105:7, 115:6, 116:14, 117:4, 117:7, 118:2, 118:4, 118:8, 118:20, 119:6, 119:7, 119:8, 119:9, 119:13, 136:15, 138:18, 138:21, 139:2, 139:8, 139:14, 140:2, 140:5, 140:9, 140:16, 143:15, 155:1, 155:4, 155:7, 160:11, 160:16, 163:16, 165:5, 165:10, 165:18, 165:21, 166:9, 167:5, 167:12

actual 62:16, 63:2, 109:11 actually 22:18, 26:11, 45:11, 52:17, 82:18, 103:19, 103:20, 110:14, 112:7, 113:2, 117:13, 118:13, 136:7, 179:9, 180:16, 195:21, 207:13, 211:3, 218:1 add 188:8 added 177:1, 183:6 addition 216:20, 219:9 additional 176:22, 187:16, 188:1, 191:17, 192:18 address 9:19, 137:19, 218:5, 231:17, 232:4 addressing 74:10 adhesion 82:22, 83:1 adopt 61:9, 63:13, 67:6, 75:7, 157:2 adopted 60:18, 61:14, 63:15, 63:16 advanced 42:9, 50:4 advancing 192:10 advantages 51:3 adverse 233:14 affect 139:2, 139:14,	140:14, 148:9, 164:20 affirm 9:9 afraid 126:5 after 78:21, 79:7, 79:8, 79:16, 126:3, 126:5, 139:16, 176:19, 210:19, 231:19 afternoon 229:11 afterwards 20:8, 98:16 again 31:2, 34:1, 34:17, 55:11, 95:12, 114:21, 116:21, 134:1, 144:20, 174:19, 197:3, 203:12, 224:4 against 72:10, 180:7 aggregate 184:13 ago 30:17, 187:21, 193:4 agree 84:9, 204:7, 217:20, 218:12 agreeing 229:4 aha 69:6 ahead 28:22, 79:3, 142:13, 189:15 algorithm 96:11, 112:5, 211:3 algorithms 51:8, 90:12 align 96:12	aligned 55:12, 86:17, 100:11, 135:8 alignment 6:22, 50:16, 50:21, 51:16, 59:10, 64:3, 64:5, 64:8, 65:9, 65:10, 65:13, 66:17, 67:21, 68:22, 69:2, 69:12, 69:19, 70:2, 71:5, 71:12, 73:19, 73:21, 74:1, 74:7, 75:6, 77:13, 77:22, 81:21, 82:6, 82:21, 95:18, 95:20, 95:22, 96:1, 96:4, 96:14, 96:18, 97:19, 99:1, 99:6, 99:11, 99:13, 100:2, 100:5, 101:21, 103:2, 103:10, 109:2, 109:9, 109:16, 112:2, 112:14, 112:17, 114:1, 114:9, 117:3, 118:6, 141:2, 141:5, 142:9, 142:16, 142:19, 142:22, 143:19, 144:12, 165:15, 165:20, 169:7, 169:15, 169:21, 170:9, 181:2 alignments 48:15, 50:12, 50:20, 67:11, 96:7, 96:10, 101:13, 101:14, 102:10 allow 57:22, 67:4,	205:12 allowed 58:1, 78:15, 118:18 allows 53:17, 57:15, 96:17, 162:20 almost 52:8 alone 59:18, 140:21 along 30:20, 108:3 alpha 225:14 already 70:14, 103:14 also 5:3, 7:21, 8:4, 23:7, 43:21, 49:9, 54:3, 56:5, 57:19, 72:5, 72:20, 89:9, 104:8, 115:2, 135:5, 139:8, 139:19, 139:22, 140:11, 144:14, 145:17, 153:2, 159:15, 161:14, 163:2, 166:3, 166:11, 167:7, 181:9, 184:6, 187:15, 190:7, 197:11, 198:7, 202:8, 205:21, 211:22, 217:16, 220:4, 230:4, 231:2 alteogen 13:6, 13:8 alter 70:22, 71:9, 71:18, 72:6, 73:5, 136:13, 136:14, 138:16, 138:17, 138:20, 199:11 alteration 72:9
--	--	---	---

altering 71:15, 72:14 alternate 142:4 alternative 41:19, 41:21, 42:1, 79:15, 142:6, 142:7, 142:15, 154:5, 154:7 alternatives 42:17, 42:19 although 65:18, 95:8, 157:10 always 175:3, 175:15, 220:16 amenable 118:17, 220:14 amherst 9:21 amino 23:3, 54:11, 55:7, 55:8, 56:10, 56:12, 59:4, 60:2, 63:22, 64:1, 64:4, 64:14, 67:6, 70:20, 71:13, 72:13, 74:21, 98:10, 98:11, 98:14, 98:22, 99:12, 100:13, 100:22, 101:1, 103:6, 104:8, 104:10, 107:15, 109:5, 109:8, 109:10, 110:6, 110:10, 112:7, 112:16, 115:19, 116:2, 116:10, 117:9, 118:11, 118:18, 119:2, 136:11, 136:12, 138:7, 143:13, 144:16, 145:3, 145:8,	147:2, 147:7, 147:9, 148:19, 148:20, 149:5, 149:6, 149:16, 150:2, 150:15, 150:20, 151:12, 152:8, 152:11, 153:17, 155:6, 158:16, 159:17, 162:13, 164:16, 168:17, 169:22, 170:5, 176:17, 179:14, 196:4, 196:17, 198:14, 198:18, 211:16, 214:5, 216:11, 218:6, 218:9, 218:13, 218:20, 219:3, 219:16, 220:1, 220:2, 220:7, 220:22, 221:17, 225:7 among 65:16, 67:2, 116:6, 143:4, 180:5 amount 93:9 amounted 171:20 analyses 200:20, 228:22 analysis 16:8, 16:11, 20:6, 29:21, 32:19, 33:3, 35:5, 35:8, 38:9, 40:15, 41:4, 75:4, 109:1, 130:5, 130:18, 142:1, 156:6, 156:10, 156:12, 158:11, 159:1, 165:13, 166:5, 168:3, 168:13, 170:14, 170:19, 171:1, 172:2, 172:4,	172:6, 172:15, 174:5, 174:8, 174:19, 174:20, 175:21, 181:12, 181:13, 182:6, 183:2, 184:3, 184:13, 191:11, 193:15, 203:10, 211:17, 211:19, 214:18, 216:16, 224:15, 226:5, 228:19 analytical 192:12 analyze 22:14, 48:13, 133:19, 211:19 analyzed 154:4, 170:15 analyzing 128:10 ancestor 55:17, 60:21 ancestral 55:18, 76:9 angeles 4:7 angles 62:8, 62:10, 62:12 angstroms 216:7, 224:15, 224:18 announce 8:10, 8:13, 80:19, 224:2 another 61:3, 85:19, 93:13, 103:21, 121:5, 121:16, 121:18, 144:16, 153:12, 155:12, 155:13, 177:1, 179:10, 186:10, 186:11, 191:1, 202:19, 209:21, 211:9, 211:15 answer 11:12, 11:13,	11:19, 61:12, 63:21, 141:13, 197:10, 212:11, 215:4 antibodies 39:8, 39:14, 39:20, 40:11, 157:18 antibody 39:2, 39:10, 157:21, 158:4, 158:5 antigen 39:10, 158:6 any 10:10, 10:20, 11:16, 12:2, 12:4, 12:17, 13:10, 14:9, 15:2, 15:4, 15:7, 16:4, 16:8, 16:11, 16:12, 16:14, 17:16, 17:18, 17:21, 32:5, 32:21, 37:6, 41:3, 43:1, 44:16, 51:14, 51:17, 51:19, 52:1, 53:4, 53:8, 78:6, 89:12, 92:1, 102:17, 109:19, 124:7, 125:19, 133:13, 145:3, 145:5, 145:8, 145:11, 167:9, 170:4, 191:12, 209:20, 216:13, 230:16, 231:22, 232:2, 232:3, 234:1, 234:4 anybody 141:14 anyone 11:6, 120:5, 124:1, 124:4, 125:19, 156:2
---	---	---	---

anything 32:6, 39:4, 66:1, 116:21, 137:15, 181:19, 181:20, 188:1, 190:17, 204:21, 205:11, 221:21, 228:21 anyway 154:2 anywhere 204:19 apart 199:22, 200:10, 200:20, 201:8 apologize 85:5 apparent 137:20, 209:16 apparently 179:13 appeal 1:3, 7:7 appear 112:15, 112:16, 142:8, 142:15, 142:22, 143:4, 170:1, 191:16 appearance 109:10 appeared 142:18, 176:15, 176:18 appears 20:1, 34:12, 109:22, 110:2, 110:4, 111:10, 111:16, 111:17, 114:6, 149:19 appendices 123:16 appendix 24:1, 24:14, 24:18, 25:10, 108:14, 108:20, 108:21, 110:19, 141:21, 141:22, 142:1, 146:2,	146:3, 151:1, 151:2, 151:18, 152:22, 162:16, 162:17, 170:12 application 42:11 applied 168:10, 175:11 applies 156:6 apply 129:4 appreciate 229:12 approach 149:21 approaching 141:17 appropriate 180:8 approximately 124:21, 125:3, 169:13 approximation 200:9, 201:2, 201:4 arch 3:18 area 90:20, 149:13, 149:20, 149:21, 150:2, 150:4, 150:5, 150:7, 150:12, 150:22, 151:10, 151:14, 151:19, 152:8, 152:11, 152:14, 152:15, 152:18 argue 204:16 arguments 193:6, 231:2 arming 158:20, 161:1, 165:3, 165:12, 166:7, 167:2 around 17:12, 23:12,	24:16, 69:1, 87:6, 92:13, 94:11, 117:16, 129:8, 136:13, 171:14, 175:6, 175:17, 176:11 arrive 82:5, 100:18, 104:17, 128:11, 130:17, 173:6 art 47:19, 48:1, 48:21, 49:2, 70:19, 106:19, 107:8, 118:11, 140:7, 224:21 articles 123:11 artisan 100:3 asked 65:4, 96:5, 178:14, 189:9, 192:6, 231:19 asking 37:17, 38:14, 52:8, 191:1 asp 161:12, 161:13 aspartic 144:15, 150:16, 150:20, 151:9, 161:20 aspect 137:1, 138:13, 148:8, 198:8, 216:22, 217:1 aspects 56:13, 147:15 assays 48:11 assessing 218:8 assessment 129:10, 182:18, 182:20 assigned 171:3	assignment 16:8 associate 10:8 assume 31:19, 33:2, 61:20, 62:5, 144:20, 181:4 assumed 93:17, 94:4, 98:4 assumes 119:14 assuming 27:16, 34:17, 34:21, 58:20 assumption 34:19, 61:8, 75:14, 91:3, 143:2 atom 186:1 atomic 183:6 attached 6:6, 27:2 attempted 37:21 attended 230:5 attendees 8:4 attending 121:13 attention 26:1, 104:9, 122:18, 147:21, 173:3 attributes 146:21 aubrey 5:9, 8:18 august 1:21, 7:10, 233:21, 234:9 austin 3:9, 8:2, 8:5 author 45:19
---	---	---	--

authority 13:4, 36:17 automated 179:17 automatic 153:22 available 20:7, 42:2, 42:8, 42:14, 42:18, 62:12, 76:3, 77:14, 77:17, 78:18, 78:21, 79:4, 79:8 avenue 4:10 average 151:12, 181:18, 183:11, 184:17, 185:1 aware 51:19 away 76:11, 77:1, 117:10, 118:5, 138:8, 184:22, 199:3, 199:4, 200:5, 216:8 axis 185:2	174:19, 179:9, 180:10, 193:18, 195:15, 212:18, 217:9, 228:11, 231:12 backbone 172:6, 194:8, 210:19 background 40:19, 178:8 backwards 69:6, 161:6 bad 148:12, 176:21, 208:18, 221:19 balanced 127:13 based 14:13, 56:9, 65:8, 81:16, 83:19, 96:21, 100:4, 117:21, 127:14, 129:3, 129:10, 137:6, 139:10, 152:18, 156:10, 161:22, 166:6, 167:2, 175:7, 177:22, 180:17, 181:1, 189:5, 196:10, 213:15, 220:9, 225:20 basically 192:4 basis 121:13, 230:22 bathroom 52:9 bear 150:17 became 174:1 because 13:4, 20:6, 44:14, 49:17, 59:5, 62:6, 64:19, 68:10, 73:3, 73:11,	74:9, 75:6, 76:8, 76:21, 78:16, 85:22, 87:4, 91:1, 91:12, 91:14, 95:4, 98:18, 112:6, 115:22, 116:1, 116:6, 116:13, 118:7, 118:17, 119:4, 120:15, 120:21, 124:12, 138:5, 139:14, 149:21, 151:6, 151:16, 153:8, 159:7, 159:16, 159:22, 160:7, 182:3, 188:2, 190:12, 190:18, 192:8, 196:9, 197:5, 197:11, 198:6, 199:10, 200:4, 200:10, 200:20, 203:21, 204:20, 205:20, 206:5, 209:17, 210:10, 211:2, 212:12, 214:3, 219:7, 219:17, 230:8 become 209:16, 209:17 becomes 202:4, 203:19, 209:19, 212:2 bee 215:20 been 10:3, 10:5, 10:18, 18:4, 21:20, 23:9, 24:16, 37:2, 43:2, 45:15, 46:8, 48:8, 49:20, 51:10, 51:12, 51:19, 80:8, 81:16, 94:11, 96:6, 99:18, 100:11,	101:17, 104:6, 121:11, 121:13, 121:17, 124:20, 130:12, 143:5, 152:12, 155:11, 156:4, 164:13, 164:17, 173:21, 175:16, 176:3, 186:9, 190:7, 191:13, 192:14, 196:3, 209:15, 210:19, 211:21, 226:17, 228:2, 229:21, 232:2 before 1:3, 2:10, 7:6, 10:18, 11:22, 15:3, 15:6, 15:11, 15:15, 16:3, 16:7, 57:9, 57:11, 81:3, 101:7, 101:10, 121:19, 126:21, 128:1, 129:14, 134:3, 158:18, 230:21, 231:14, 233:9, 233:11 begin 64:22, 206:22, 209:13 beginning 61:11, 109:18, 110:12, 122:12, 122:13, 125:2, 171:12, 190:14 begins 7:2 behalf 3:3, 4:3, 7:20, 8:2, 8:16 behind 61:7 being 86:17, 94:10, 98:17, 121:12, 123:14, 149:5, 172:21, 175:2,
---	---	---	--

196:9, 196:14, 218:7, 223:10, 227:12 believe 8:6, 13:18, 22:9, 27:14, 27:15, 33:22, 68:9, 70:9, 77:7, 86:15, 87:4, 96:5, 96:7, 110:7, 119:11, 120:16, 136:6, 157:16, 216:9, 231:21 believed 14:2 belongs 147:7 below 87:7, 91:2, 181:20, 182:2, 184:9 beneficial 74:22, 135:22 benefit 51:6, 76:21 besides 51:16, 51:17, 114:22 best 137:9, 145:15, 190:1, 205:1, 205:5, 205:6, 211:6, 211:13 bet 223:2 beta 225:8, 225:14 bets 140:16 better 40:7, 64:12, 64:15, 107:5, 155:8, 176:22, 178:3, 180:9, 201:13, 202:19, 217:16 betting 223:2	between 56:11, 57:12, 89:5, 90:19, 92:10, 93:2, 93:16, 94:2, 95:2, 164:7, 199:13, 202:15, 205:5, 207:4, 213:10, 217:17, 227:10 beyond 220:11 bias 79:22 bibliography 161:5 big 195:1 bigger 63:17 bind 39:3, 158:5 binders 39:1, 39:2 binding 17:3, 17:5, 39:15, 46:1, 105:4, 105:12, 105:18, 105:21, 157:22, 164:7, 164:15, 164:17, 215:19, 216:1, 216:2, 216:18 binds 39:5, 39:6, 39:10, 161:16, 163:3 bins 130:7, 130:11 biochemical 158:17, 158:22, 159:6, 159:11, 165:14, 165:17, 165:19, 166:4, 166:7 biochemistry 48:6 bioinformatics 51:2, 177:15	biological 10:9, 48:11, 70:22, 71:9, 71:15, 71:19, 72:6, 72:14, 136:15, 138:17, 138:20, 139:14, 140:4, 140:8 biology 48:6 biophysics 48:6 bit 88:2, 103:20, 171:15, 171:16, 173:1, 173:17 black 56:20, 229:16 blah 184:15 blast 6:21, 40:21, 41:11, 41:16, 51:10, 51:12, 51:16, 51:18, 51:20, 51:22, 77:20, 78:1, 78:5, 78:8, 78:9, 81:15, 82:4, 82:13, 82:15, 87:12, 87:17, 89:11, 90:14, 96:15, 96:17, 97:21, 99:8, 102:10, 102:22 blind 173:1 block 70:15, 70:18 blood 234:2 blue 181:19 board 1:3, 7:7, 187:12, 192:7, 192:19	bode 67:3 bond 167:11 bonds 165:8 book 12:14, 12:19, 12:21 bookkeeping 111:22 boston 4:11 both 40:14, 58:8, 62:10, 79:21, 81:13, 153:8, 160:4, 175:4, 199:14, 208:2 bottom 193:18 bound 138:1, 216:8 breadth 168:3 break 11:17, 11:19, 46:10, 80:7, 119:16, 120:5, 122:2, 155:13, 156:2, 174:15, 186:11, 195:9, 217:4, 228:4, 230:20, 231:8, 231:14 breaks 11:7 brian 3:15, 80:18, 80:21, 120:10, 224:5 brief 191:6, 231:15 bring 25:22, 192:20 broken 204:2 buffalo 1:20, 2:4, 2:6,
--	--	--	--

7:16, 10:2, 10:4, 10:7, 233:20 build 210:12 built 215:18 bunch 55:2, 59:21, 60:5 burden 194:6 buried 219:5, 219:7, 219:12, 220:2, 220:13, 220:17, 221:3, 221:8, 221:14, 222:10 butchered 83:4 button 78:11 byproduct 97:22 C calculate 150:3 calculated 152:17 calibrate 108:2 call 59:4, 149:13 called 13:20, 37:14, 91:10, 211:4 came 19:19, 20:5, 60:21, 68:2, 76:8, 179:9, 180:10 can't 59:3, 66:2, 91:12, 91:14, 117:13, 126:5, 180:20, 204:2, 205:10, 206:6,	229:22 candidates 103:10 cannot 11:5, 66:12, 129:3, 214:11, 214:15 capability 44:4 carbohydrate 16:12, 16:14, 39:6, 73:10 care 134:4, 134:12, 134:16, 134:18 career 11:22, 38:4, 38:5, 38:16, 52:2 careful 116:22 carry 184:2 case 1:12, 7:7, 10:14, 14:21, 15:1, 15:3, 15:6, 15:12, 15:16, 15:20, 16:2, 16:3, 16:7, 29:9, 29:22, 38:3, 47:11, 53:6, 61:17, 67:17, 67:21, 76:15, 77:7, 78:10, 78:12, 89:10, 92:11, 94:9, 96:9, 110:3, 114:7, 121:6, 124:8, 129:15, 129:18, 130:5, 130:19, 133:19, 133:22, 140:15, 153:21, 190:1, 200:22, 221:21, 225:2, 228:19 cases 18:5, 21:7,	140:17, 159:18, 175:15, 192:11, 201:5, 220:17 catalatic 115:1 catalatically 115:2 catalog 202:2 cataloging 201:20 catalysis 107:18, 108:6, 137:8, 139:4, 161:12, 161:22, 164:13, 216:19 catalyst 139:12 catalytic 115:6, 139:6, 164:7, 164:11, 164:12 catalytically 108:12, 140:14 categories 146:21 categorizing 102:2 category 131:19 cause 221:4, 227:2, 227:16, 227:18 caused 219:4 causes 227:6 cell 114:22 centre 3:17 certain 57:3, 58:20, 91:2, 100:12, 165:16, 165:21, 220:3 certainly 193:12	certificate 233:1 certified 233:3 certify 233:5, 233:14, 233:18, 234:1 cetera 48:15 chain 62:10, 210:18, 211:5, 219:4, 221:1, 221:2, 221:12 chains 62:10 challenge 209:22, 210:1, 210:2 challenging 222:1 chance 187:21 chances 157:14 change 73:6, 74:18, 100:13, 104:18, 106:1, 118:17, 129:6, 131:10, 131:11, 132:3, 132:4, 132:6, 132:7, 135:14, 137:17, 139:1, 145:2, 153:11, 166:8, 166:17, 167:3, 173:10, 196:16, 202:1, 206:22, 207:18, 207:20, 211:10, 213:9, 214:4, 219:3, 221:1, 222:9 changed 78:12, 78:14, 196:9, 196:15, 207:22, 209:8, 210:4, 210:5,
---	---	---	--

212:11, 218:7, 225:3 changes 57:17, 57:22, 100:14, 127:20, 127:21, 127:22, 128:6, 128:18, 132:10, 145:15, 157:20, 158:3, 160:5, 199:9, 199:18, 203:22, 206:8, 207:8, 207:13, 209:10, 210:8, 217:18 changing 209:2, 209:3 chao 158:20, 159:2, 160:22, 161:10, 161:22 chapter 12:14, 12:20, 12:21, 13:1, 13:3 characterization 187:13 characterize 48:12 charge 25:12, 221:14, 223:13, 223:15, 223:16 charged 221:2, 221:8, 222:11 charlotte 5:5, 7:13 chart 113:7, 114:5, 122:14, 123:3, 123:4, 146:3, 152:1, 152:3, 164:3, 225:13, 225:17, 225:18, 225:20 check 27:14, 146:9, 146:11, 148:1,	148:2, 148:12 checked 182:12 checkmark 146:13, 146:15, 147:19, 149:7 chelsea 3:8, 8:5 chemical 10:9, 56:13 chemistry 48:6, 148:21 chimera 42:6, 42:12, 42:13, 44:11, 44:13 choi 4:6, 7:21 choice 178:6, 220:2, 221:17 choose 66:2, 180:4 choosing 178:7, 219:16 chose 192:2 chosen 51:22 christine 3:6, 8:3, 217:4 cira 3:17 cited 32:14, 32:16, 32:20, 32:21, 33:1 claim 32:11, 36:11, 36:14, 36:21 claimed 31:16, 33:20, 34:15, 34:22, 35:2, 36:1 claiming 188:2 claims 31:21, 32:9,	36:17 clarification 10:21, 10:22, 12:16, 14:7, 14:15, 16:20, 17:10, 21:21, 24:12, 25:8, 28:9, 42:22, 45:20, 54:20, 62:15, 66:7, 78:4, 87:22, 101:4, 105:5, 107:19, 128:8, 144:18, 146:12, 149:12, 156:15, 167:8, 169:3, 176:10, 179:22, 182:5, 184:5, 185:6, 185:20, 200:13, 201:14, 211:1, 215:10, 219:6, 220:10, 222:8, 223:22, 225:16, 226:19 clash 219:5 class 114:22 classification 131:5, 131:12, 136:17 classifications 164:11 classify 130:10 classifying 130:14 cleanly 173:4 clear 20:14, 47:4, 122:9, 179:15, 180:13, 187:4, 187:15, 187:20, 188:15, 189:19, 190:17, 190:18, 190:19, 193:13, 208:22	cleave 13:22, 15:15, 74:4 cleaves 14:14, 14:16 cleft 161:15, 162:4, 163:2 close 137:10, 199:2, 199:8, 201:16, 201:18, 206:2, 206:8 clustal 6:22, 40:21, 41:11, 41:15, 50:11, 50:15, 51:7, 95:19, 95:21, 96:1, 96:8, 96:11, 100:11, 109:2 clustered 76:1 coaching 120:16, 120:20, 122:9, 230:9 collaborated 11:21, 12:13 collaboration 12:17, 44:21 collaborator 17:2 color 229:17, 229:18 colored 181:19, 181:20 column 24:2, 24:16, 24:19, 24:20, 24:21, 25:6, 25:11, 83:20, 84:21, 85:12, 86:2, 86:7, 86:9, 86:20, 87:9, 88:9, 97:1, 97:9, 147:3, 147:8, 147:12, 152:19,
--	--	--	--

185:18, 185:22, 186:7 columns 84:10, 86:20, 146:16, 153:15 combination 17:8, 40:14, 62:7, 88:22, 89:4, 89:6, 202:5, 205:3, 208:20, 211:6, 221:16, 223:9, 226:17 combinations 168:16, 202:14, 202:16, 204:17, 208:16 combinatorial 206:1, 212:7 combinatorially 206:1, 206:4 combined 133:13, 201:11, 217:19 combining 89:17 come 30:14, 79:16, 79:20, 122:18, 128:6, 173:5, 190:9, 202:9 comes 16:1, 66:19, 115:1, 127:9, 211:19, 214:17 comfortable 57:6, 130:14 comforting 180:22 coming 17:13 command 43:19 commencement 233:9 commencing 233:21 comment 153:3, 153:14	comments 24:21, 25:6, 153:2, 231:15 commission 234:11 common 55:17, 55:18, 67:7, 74:21, 111:13, 176:3, 201:6 commonly 93:15, 224:20 communicate 126:2 communications 124:7 community 212:17 company 13:5, 13:7 comparable 148:21, 155:8 compare 43:14, 51:4, 60:2, 63:21, 177:21, 203:7, 205:12, 205:16, 207:21, 209:4, 214:11, 214:12, 214:21 compared 42:11, 45:16, 62:3, 63:18, 101:1, 183:10, 220:18 compares 60:16, 61:12 comparing 55:6, 59:16, 99:10, 207:6, 209:20, 211:8, 211:14 comparison 90:21, 92:15, 150:19, 203:4, 207:3, 207:6, 208:9, 214:13, 214:15	compatibility 137:2, 137:14, 147:9, 148:7, 153:17, 198:19 compatible 143:6, 148:4 complete 171:21, 174:8 completely 76:6, 95:5 complicated 221:7 complied 231:21 components 209:14 compound 206:21, 209:12 comprised 183:3 compromising 119:13 computation 40:18 computational 40:17, 41:3, 41:13 computed 109:10 computer 210:11 concerned 76:16, 137:1 concerning 33:13, 34:11 conclude 154:9 concluded 232:13 conditions 58:20, 58:22 conducted 191:11 confidence 172:20, 174:2, 182:1 confirm 165:14, 171:13,	215:16 confirmations 211:11 confirmed 165:20, 187:18, 215:13 confirms 160:12 conflicting 128:18 conformation 63:18 conformational 60:17, 61:2, 61:4, 61:9, 61:13, 61:18, 62:11, 62:18, 63:4, 75:22, 76:2 conformations 202:16, 212:7 confused 85:6 confusing 215:4 connection 14:21, 15:20, 46:4, 46:6, 126:12, 141:1, 141:2, 228:19 consequence 232:2 consequences 159:8, 159:12 conservation 102:8, 107:15, 108:1, 165:16 conservative 57:16, 160:5 conserved 64:3, 64:4, 64:14, 64:18, 65:11, 65:13, 66:5, 68:22, 69:3, 69:19, 70:3, 70:5, 76:17, 77:4, 101:22, 114:21,
---	--	--	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

244

115:3, 117:17, 144:3, 144:4, 144:6, 159:9, 159:10, 160:10, 160:12, 165:7, 167:3, 167:10, 168:5, 168:6 consider 29:18, 33:17, 56:6, 58:15, 59:12, 63:14, 87:11, 87:16, 94:13, 133:9, 142:14, 142:18, 142:21, 146:22, 147:16, 150:13, 151:3, 153:5, 153:14, 158:22, 168:20, 169:10, 169:15, 171:6, 171:8, 172:8, 176:2, 176:4, 182:8, 187:14, 205:17, 216:22, 217:21 consideration 137:13, 138:11, 142:20, 149:6, 218:8, 218:13, 218:16, 218:19, 218:21 considerations 138:3 considered 28:15, 29:4, 32:14, 72:9, 116:12, 116:16, 119:4, 136:22, 142:7, 147:18, 148:8, 155:7, 158:17, 169:12, 169:16, 169:18, 170:6, 170:20, 172:10, 189:10, 190:2, 226:5 consistent 165:19, 167:21, 168:9, 171:3,	171:12, 174:1, 211:7 consistently 219:2 constantly 76:19 constitute 134:11 constrain 63:12 constraint 220:8 constraints 219:8, 219:11, 219:15, 219:18, 219:20, 219:21, 220:6 construct 40:6 constructed 40:3, 53:5 consult 122:1 contact 192:22 contacted 10:13, 10:15, 10:16, 10:17, 193:17 contacts 24:22, 25:7, 25:9, 25:13, 25:16, 25:18, 25:20 containing 198:1, 205:12, 211:9, 211:15 content 34:2, 123:13 context 138:14, 170:7, 176:5 continue 143:22 contrast 51:5 contribute 12:22, 13:2,	145:21 convenience 196:20 convenient 177:13 convention 56:21 conversation 174:15, 193:4, 229:2 conversations 228:18 convert 162:9 convince 89:18 convincing 101:3 cooperate 192:20 coordinated 222:18 coot 42:8, 42:9, 42:13, 44:11, 44:16, 44:17 copies 26:6 copy 32:10 correct 19:12, 20:21, 21:9, 21:19, 22:15, 22:20, 23:10, 27:13, 27:20, 27:21, 28:13, 28:17, 30:8, 31:15, 32:15, 32:20, 40:17, 44:7, 48:17, 49:8, 50:8, 50:16, 50:17, 70:7, 71:2, 75:12, 79:5, 79:11, 82:2, 82:7, 82:11, 88:12, 97:17, 99:2,	103:13, 104:16, 110:18, 110:21, 111:15, 113:19, 114:2, 114:11, 117:5, 122:7, 123:18, 128:13, 130:2, 132:6, 132:13, 142:3, 142:4, 150:9, 152:20, 155:10, 158:14, 158:21, 161:20, 164:5, 165:11, 166:19, 166:21, 167:17, 167:22, 177:8, 178:16, 182:21, 185:15, 186:6, 196:7, 196:13, 210:9, 215:15, 218:11, 220:12, 225:10, 226:22, 227:7 correction 175:3 corrections 122:15, 122:17 correctly 65:7, 106:15, 107:11, 111:9, 114:8, 115:21, 163:14, 200:1, 201:17 correlation 95:1, 181:12, 217:17 correlations 227:20 correspond 12:20, 62:13, 81:18, 91:5, 136:16, 147:1, 161:13 corresponding 21:1, 109:7, 111:18, 112:18, 198:3 corresponds 62:17, 63:3,
--	--	--	--

112:7, 114:3, 131:16, 184:16 could 30:22, 45:8, 49:6, 49:10, 50:5, 50:15, 50:19, 51:15, 61:20, 61:21, 62:19, 62:20, 63:1, 63:4, 72:17, 91:22, 95:4, 96:6, 103:22, 116:4, 118:21, 130:11, 133:6, 144:13, 144:14, 144:15, 144:19, 145:2, 149:4, 172:14, 173:20, 175:16, 188:13, 188:19, 188:20, 189:7, 190:1, 190:10, 190:14, 192:17, 193:7, 193:8, 197:17, 200:2, 201:19, 204:9, 207:20, 208:8, 213:11, 213:13, 215:22 counsel 6:11, 7:17, 9:1, 11:1, 11:10, 11:13, 18:10, 18:16, 18:21, 19:4, 47:17, 48:18, 81:6, 81:8, 84:20, 124:3, 125:21, 126:20, 170:17, 170:20, 174:5, 174:11, 193:1, 233:15 count 30:22, 56:10, 56:14, 210:3 counted 58:1, 109:9, 168:21	couple 188:11 coupled 201:5 coupling 119:10 course 11:11, 60:12, 126:22, 139:3, 230:21 court 2:11, 9:2, 9:5, 9:8, 9:13, 9:20 cover 29:8, 33:9, 34:7 coverage 86:4, 86:10, 86:11, 89:19, 89:20, 89:22, 90:3 create 77:20, 194:18 created 170:16, 225:20 creates 203:3 critical 54:19, 67:5, 67:6, 140:2, 181:21 crystal 42:10, 44:18, 44:20, 62:2 crystalize 45:8 crystallographer 44:21, 45:7, 45:16 current 172:7 currently 10:8, 21:14, 23:5 curve 49:20 cut 24:14, 24:17,	180:13 cut-off 64:16, 65:2, 77:15, 94:11, 100:15, 100:17, 101:6, 101:19, 102:4, 113:4, 224:14, 224:19, 224:21, 225:3 cv 46:6 cysteine 165:8, 167:4, 167:10 D d-1 108:14, 108:15, 108:16, 108:20, 110:19 damaging 116:9 dangerous 220:16 dark 91:16 dash 109:21, 110:4 dashes 109:20, 109:21, 112:2, 112:6 data 123:12, 123:15, 158:17, 159:1, 159:2, 159:6, 159:12, 160:4, 165:12, 165:14, 165:17, 165:19, 166:4, 166:7, 168:11, 169:2, 169:5, 169:9, 188:15 database 177:22 date 7:10, 81:17 day 233:20, 234:9	days 124:18, 124:19 deal 153:11, 168:4, 199:9, 212:17 debatable 57:22 december 20:8, 20:9, 79:8, 158:19, 187:6, 234:12 decent 170:1 dechert 3:16, 80:21 decide 128:18 decided 44:14, 98:7, 171:15 decision 37:6, 37:7, 37:8, 37:14, 37:16, 130:9, 148:10 declaration 18:2, 20:15, 28:7, 28:11, 28:16, 29:2, 29:7, 29:8, 32:15, 32:17, 32:20, 33:2, 33:6, 33:9, 33:11, 34:6, 34:9, 35:15, 35:17, 47:10, 54:6, 65:15, 66:9, 70:14, 99:21, 123:17, 130:10, 135:9, 136:3, 136:6, 141:16, 143:3, 158:9, 163:22, 172:5, 172:7, 187:10, 187:16, 188:5, 188:12, 188:16, 189:5, 189:21, 190:5
--	---	--	---

declarations 18:2, 19:6, 19:9, 19:12, 27:12, 27:20, 33:8, 122:15, 122:20, 123:11, 126:3, 126:9, 174:6, 174:10, 174:13, 187:5, 194:8, 229:1 deduce 117:21, 159:18 deemed 100:4 default 78:13, 78:15 define 57:7, 136:2 defined 62:7 defining 68:16 definitely 124:16 definition 47:22, 49:3, 56:14, 58:4, 66:15, 117:1, 138:15 definitions 66:16 degree 48:3, 66:6, 87:13, 140:12, 160:17 delta 131:9 demonstrated 170:12 demonstration 226:13 deny 192:8 dependant 39:10, 39:15 depending 79:18, 157:7 depends 92:9, 107:14,	208:15 depos 7:14, 9:3 depose 230:1 deposed 10:18, 121:13, 121:18 deposition 1:18, 2:1, 6:7, 7:3, 7:15, 10:21, 11:5, 11:6, 11:11, 27:1, 48:19, 120:5, 120:15, 120:18, 120:22, 121:1, 121:3, 121:5, 121:10, 121:16, 122:6, 122:13, 122:21, 123:9, 123:10, 124:2, 156:2, 188:1, 191:2, 191:20, 192:1, 229:10, 229:11, 230:3, 230:5, 230:8, 230:13, 231:20, 232:1, 232:7, 232:10, 232:12, 233:8, 233:10, 233:16, 233:18 depositions 121:8, 121:12 describe 167:15 described 68:13, 75:20 description 47:18, 48:17 deserves 134:11 designation 96:21 designed 96:12, 141:15, 205:7 desired 39:15	despite 99:16, 213:21 destabilization 227:13 destabilized 219:3 destabilizing 217:18, 222:7 detected 90:11 determine 45:8, 90:4, 92:20, 129:5, 129:19, 133:20, 175:19, 175:22, 226:6 determined 45:15, 196:11, 210:20 determining 42:10, 150:5 detrimental 131:22 develop 168:9 developed 98:8, 109:3, 130:20, 151:7, 167:21, 172:20 developing 112:4, 159:3 deviate 98:16 deviation 183:10, 184:17, 184:22 difference 64:17, 135:2, 205:5, 213:10 differences 73:11, 74:17, 168:7, 202:15, 214:1 different 40:16, 51:3, 51:5, 66:4, 73:15, 74:7, 76:7, 77:2,	79:14, 79:19, 84:5, 85:5, 91:8, 98:14, 99:17, 102:6, 105:15, 115:19, 116:11, 118:12, 118:17, 121:4, 130:11, 135:6, 135:7, 135:10, 143:13, 147:17, 154:4, 157:7, 160:7, 160:19, 167:19, 168:2, 168:4, 168:8, 168:13, 168:16, 168:19, 173:18, 175:12, 188:14, 188:20, 188:21, 189:1, 191:9, 191:10, 200:19, 202:16, 206:15, 207:15, 209:10, 210:3, 210:20, 211:16, 211:17, 212:4, 219:11, 225:7 differentiate 199:18 differently 173:21 difficult 52:5, 91:3, 95:8, 95:9, 202:4, 203:10, 212:3, 222:19, 223:20 dihedral 62:8, 62:9, 62:12 diligently 212:9 direct 95:1, 227:18 directed 17:9, 39:9, 39:12, 187:13, 192:9 direction 131:11, 175:4
--	--	---	--

directional 229:3 directions 175:4 directly 33:6, 137:19, 164:13, 216:19 disagree 127:1, 230:21, 231:2 discern 198:15 discipline 75:16 disclosed 32:2, 32:6, 34:3, 35:10, 35:12, 36:6, 36:8 disco 181:9, 181:11, 182:9 discovery 36:15, 36:16, 36:18, 134:10, 134:11 discuss 11:5, 120:4, 156:1, 186:16 discussed 124:15, 124:18, 144:2 discussion 59:17, 65:3, 126:7 disease 227:2, 227:6, 227:13, 227:18 disfavored 131:14 distance 181:12, 216:7, 224:14 distant 201:4 distinction 164:6 distinguish 57:11	distribution 168:18 disulfide 165:8 diversed 117:12 divide 56:15, 152:9 divided 109:12, 110:1 dividing 109:13, 150:6 dn 163:15 dna 39:5, 48:10, 61:21 doctor 126:17 document 23:7, 24:1, 24:5, 193:11, 229:15 documents 81:13 dohme 1:6, 7:5, 233:15 doing 69:9, 77:5, 77:6, 77:9, 83:14, 117:8, 117:18, 117:19, 117:22, 130:18, 134:1, 146:13, 172:17, 176:19, 188:4, 203:3, 221:15, 226:14 done 14:9, 17:16, 17:18, 38:9, 39:7, 71:11, 102:17, 129:3, 153:7, 153:21, 156:13, 157:17, 172:14, 175:20, 192:11, 192:14, 203:16, 212:1,	219:15, 229:3, 230:17 double 208:6 doubling 124:18, 124:19 down 68:3, 78:20, 86:2, 86:3, 87:6, 91:16, 98:9, 110:6, 115:1, 150:22, 170:2, 202:9, 204:2, 214:17 download 178:10, 185:21, 204:11, 205:9 downloading 203:16 dr 1:19, 2:1, 5:11, 6:2, 7:4, 9:16, 9:22, 10:20, 11:4, 12:8, 12:12, 12:13, 19:6, 27:6, 28:14, 36:10, 37:20, 46:18, 80:22, 81:2, 88:1, 120:3, 120:8, 120:13, 120:15, 120:17, 122:5, 122:13, 123:8, 124:8, 125:8, 125:13, 125:22, 126:2, 126:9, 126:11, 126:15, 126:22, 155:22, 186:14, 195:19, 217:12, 228:17, 228:18, 228:21, 229:4, 230:1, 230:5, 230:7, 230:12, 230:13, 230:16, 231:1, 231:19, 232:10, 232:12, 233:7,	233:19 drafting 30:21 dramatically 157:6 drift 77:1 drop 72:8, 191:15 drops 91:2 duly 233:8 during 10:20, 11:7, 11:11, 120:5, 125:10, 125:21, 146:22, 156:2, 229:10 E each 19:7, 19:11, 21:7, 27:12, 27:19, 85:12, 109:4, 123:13, 125:6, 127:15, 128:15, 151:3, 169:19, 169:20, 170:10, 171:1, 174:6, 186:1, 186:3, 188:5, 188:18, 188:22, 199:8, 200:5, 200:10, 200:17, 201:8, 201:19, 202:22, 203:6, 203:9, 205:13, 206:3, 207:8, 210:6 earlier 49:15, 75:21, 85:10, 96:5, 109:3, 110:8, 117:6, 140:13, 143:3, 143:10, 144:2, 152:7, 157:16, 161:7,
---	--	--	---

170:12, 175:9, 183:21, 184:14, 219:22, 223:12 easier 44:14, 146:14 eastern 7:12 easy 90:22, 117:10, 117:14, 208:20 editing 12:15 educated 137:9, 145:20 effect 128:12, 129:21, 132:4, 132:17, 133:11, 133:14, 134:22, 135:1, 135:2, 200:6, 200:16, 201:11 effects 128:7, 128:10, 133:13, 160:3, 202:5, 206:20, 216:21 eight 83:22, 154:4, 154:7 either 53:1, 53:10, 85:18, 131:10, 171:13, 175:8 elaborated 124:12 eldora 4:16, 8:15 electronic 194:21, 195:6 eliminate 76:17, 79:22, 158:5 eliminated 72:3 elliott 4:6, 7:21 ellison 4:16, 8:14,	8:15 else 39:4, 62:3, 125:19, 137:15, 148:22, 152:10 elsewhere 175:10 email 191:16 emailed 12:22 emailing 231:5 emanuel 4:9, 7:20, 7:21, 8:18 employed 9:22, 10:1, 234:3 encompass 62:11 end 20:7, 20:9, 44:13, 45:9, 77:17, 78:21, 79:5, 125:1, 161:6, 162:11, 170:4, 171:11, 173:16, 178:8, 198:5, 232:6, 232:9 ended 98:17 ending 20:2, 20:15, 21:2, 21:3, 21:4, 22:8, 23:2, 24:6, 27:11 ends 23:19, 23:22 energetics 204:21, 210:11 energies 212:13 energy 181:12, 183:2, 183:3, 183:4,	183:11, 184:13, 184:15, 184:17, 185:1, 197:6, 197:9, 206:14, 206:16, 209:8, 210:22, 212:12 engen 3:6, 8:3 engineer 39:9 engineering 10:9, 17:1, 17:2, 17:8, 221:15 enough 13:1, 31:9, 132:8 ensemble 61:19, 62:14 ensure 100:21 ensuring 80:2 enter 78:9, 146:14, 177:19 entered 82:12, 82:14, 84:17, 97:20, 178:12, 178:13 entertain 187:3 entertaining 133:9 entire 59:11, 60:17, 61:13, 62:11, 62:14, 83:15, 182:19 entries 87:20, 92:21 entry 88:7, 114:4 enumerated 128:5 environment 149:18, 200:19 enzymatic 14:8, 74:18,	138:12 enzyme 14:13, 16:12, 16:18, 16:22, 17:3, 17:5, 17:22, 72:8, 73:3, 73:7, 74:15, 107:17, 107:21, 108:13, 116:9, 133:5, 133:7, 133:16, 135:12, 135:18, 137:15, 138:2, 139:2, 164:20 enzymes 13:13, 16:14, 17:19, 88:20, 89:18, 118:7 eq 163:15 equal 151:17 equally 51:20 equate 185:7 equivalent 128:19, 131:13 eric 5:8, 8:6 errata 6:8, 20:13, 26:13 error 20:5, 21:5, 21:11, 21:17, 24:7 errors 19:17, 21:1, 22:22, 25:21, 122:19, 206:21, 209:12, 209:19 escapes 14:4 esoteric 50:22 especially 199:19
--	---	--	--

esquire 3:5, 3:6, 3:7, 3:8, 3:15, 4:5, 4:6, 4:7, 4:8 essence 141:12 essential 54:22, 69:15, 69:16, 69:18, 70:1, 70:4, 75:10, 100:4, 103:15, 103:18, 106:2, 106:7, 108:5, 113:5, 113:8, 113:10, 114:13, 114:15, 114:18, 114:20, 115:6, 165:21 essentially 79:20, 207:2 est 1:22 establish 90:12 estimate 38:8, 52:6, 128:7, 178:3, 180:3, 183:20, 184:1, 185:13, 198:17, 201:10, 212:13 estimated 199:16 et 48:15 evaluate 47:20, 54:4, 68:5, 137:16, 167:19, 168:1, 168:13, 199:6, 200:2, 200:3, 202:13, 205:16, 206:15, 208:11, 209:9, 226:20, 227:1 evaluated 187:17, 191:10, 193:15, 201:9	evaluating 172:21, 174:3, 196:3, 217:22, 218:14, 227:9, 227:19 evaluation 24:15, 158:16, 159:4, 216:14 even 42:4, 43:22, 77:6, 90:10, 91:3, 91:7, 117:13, 159:18, 179:14, 180:7, 212:9 event 79:17 ever 10:18, 12:4, 12:13, 13:5, 15:4, 15:7, 29:16, 30:2, 30:10, 30:11, 31:13, 31:21, 33:15, 34:13, 35:21, 36:21, 38:14, 44:18, 67:15, 100:14, 106:6, 121:19 every 11:12, 110:5, 147:18, 151:16, 169:11, 170:14, 170:19, 171:18, 171:20, 172:9, 201:20, 201:21, 202:3 everybody 223:19 everything 32:14 evidence 144:7, 193:2, 230:12, 230:15 evolution 17:9, 39:9, 39:12, 60:15, 76:19, 143:5	evolutionarily 95:6 evolutionary 115:17, 143:11 exact 17:14, 58:4, 182:13, 216:6, 226:16 exactly 39:17, 52:10, 58:1, 77:18, 78:5, 99:14, 123:20, 124:17, 161:3, 176:11, 211:9 examination 6:2, 175:7 examined 16:4 example 27:22, 74:2, 114:4, 144:14, 148:1, 166:7, 175:2, 219:2 examples 42:1, 161:7 exams 173:15 excel 24:15, 146:13 except 30:14, 93:14 excited 132:20 exciting 134:9, 134:11 exercise 102:1, 171:10, 171:13 exhibit 6:7, 6:8, 6:12, 6:13, 6:15, 6:17, 6:19, 6:21, 6:22, 18:5, 18:9, 18:12, 18:15, 18:18, 18:20, 19:1, 19:3,	26:10, 26:13, 26:15, 27:1, 27:6, 27:8, 27:13, 27:16, 27:18, 27:19, 28:1, 28:2, 28:3, 28:6, 28:10, 28:11, 28:16, 29:5, 30:4, 30:6, 80:5, 81:5, 81:7, 81:14, 81:19, 82:3, 82:8, 82:16, 82:19, 84:22, 91:19, 92:1, 95:16, 95:18, 96:20, 96:21, 97:8, 97:9, 97:13, 97:14, 97:21, 108:20, 109:3, 116:14, 117:3, 118:8, 118:19, 143:15, 143:22, 146:2, 188:9, 231:4 exhibited 165:9 exhibits 6:10, 81:4, 119:5, 123:16 exist 118:7, 169:1, 169:2 existed 192:18 existence 115:17, 143:11 expanded 183:20 expect 49:14, 60:11, 71:13, 71:20, 72:22, 75:6, 75:17, 91:19, 91:22, 106:12, 106:16, 106:19, 108:4, 108:6,
---	---	--	--

129:20, 131:21, 132:4, 132:10, 132:15, 133:1, 133:3, 133:11, 136:19, 136:21, 137:11, 137:17, 139:16, 140:7, 154:14, 154:18, 155:2, 155:7, 156:19, 157:2, 157:4, 162:22, 166:6, 167:2, 167:9, 187:22, 204:4, 221:4, 222:2, 222:3, 222:12, 222:13, 222:20, 223:9 expectation 58:10, 108:2, 108:13, 155:5 expected 78:14, 131:1, 176:3, 183:11, 184:18, 230:1 experience 13:10, 13:13, 15:4, 15:7, 44:16, 48:4, 48:7, 129:4, 180:15, 180:18 experimental 53:5 experimentally 196:11 expert 121:5, 121:12, 121:16, 121:18, 177:14, 192:12, 193:3, 194:7, 198:8, 198:16 experts 229:22 expires 234:11 explain 19:15, 55:13, 61:16, 77:18, 79:12, 81:14,	100:8, 108:19, 127:17, 146:7, 149:10, 152:3, 153:4, 160:9, 169:18, 171:4, 174:22, 177:6, 177:9, 180:1, 181:10, 182:22, 191:8 explained 110:8, 192:17 explaining 229:3 explanation 85:12, 101:5, 187:16, 192:13 explore 61:1 explored 75:22, 143:19, 193:8 exponentially 202:12, 204:6, 206:13 expose 206:13 exposed 25:16, 149:16, 149:19, 151:13, 219:13, 220:7, 220:15, 220:18 exposure 184:15 expressed 159:21 expression 159:22, 160:12 extend 59:1 extent 12:11, 34:18, 59:2, 230:15 external 211:3 extract 185:19, 186:6, 188:13 extrapolate 190:4	extremely 222:19 eye 223:11 F fact 23:13, 65:15, 74:19, 77:4, 85:4, 88:13, 99:16, 117:11, 117:16, 144:3, 196:15, 203:8, 213:21, 230:4 factor 59:6, 128:21, 152:6, 152:7, 185:4, 185:8, 185:14, 185:18, 185:22, 186:7, 217:21 factoring 128:5 factors 48:8, 133:10, 145:20, 146:4, 148:9, 153:15, 218:22 fair 15:18, 31:12, 33:2, 106:18, 128:9, 129:17, 130:22, 197:14, 227:8 falls 128:7, 182:2 false 187:14 familiar 29:14, 29:15, 34:2, 48:8, 123:13, 145:7, 168:7 familiarity 12:11 family 74:11 far 84:22, 85:1,	85:2, 86:20, 146:3, 199:3, 199:4, 199:22, 200:5, 200:10, 200:20, 201:8, 216:8 fate 117:15 favor 129:6, 223:3 favorable 127:21, 130:15, 131:1, 131:6, 133:10, 133:12, 133:21, 176:1, 202:11, 226:7 fawn 9:20 feature 96:17, 196:16 federal 230:11, 230:14 feel 57:5, 192:14 feeling 124:18, 154:16 felt 32:16, 33:5, 130:14, 154:1, 175:11 few 23:3 fewer 138:5, 219:17 field 13:4, 56:22, 60:9, 84:16, 94:5, 145:20, 206:15, 206:21, 207:2, 209:14, 212:12, 213:19 fields 48:4, 206:16 figure 162:10, 163:17, 184:19, 229:17 file 84:14, 85:11,
--	---	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

251

123:13, 123:21, 185:19, 185:21, 198:7, 204:11, 204:18, 205:8, 205:21, 231:6 filed 187:7, 187:8, 190:10, 193:5 files 204:18 filing 190:8, 190:13 filter 83:17, 83:19, 98:9 filtered 79:8, 81:16 filtering 83:21 final 21:4, 30:19, 79:21, 80:2, 98:13, 98:14, 98:17, 99:12, 148:9, 175:14 finally 25:19, 35:14 financially 234:5 find 23:13, 51:13, 61:3, 88:20, 117:13, 117:14, 135:17, 161:7, 211:6 finding 135:12, 145:5, 165:15, 223:13 findings 160:21 fine 80:10, 199:6 finish 171:7 finished 171:10 first 10:13, 10:15,	10:19, 18:5, 19:21, 20:1, 20:12, 30:4, 30:9, 30:11, 54:10, 55:11, 59:3, 82:8, 83:20, 84:18, 88:9, 97:12, 99:11, 109:8, 109:14, 114:4, 122:18, 126:6, 127:11, 146:9, 147:2, 171:14, 215:12, 221:13 fist 190:10 fit 220:4, 221:13, 223:18 five 13:18, 17:14, 85:3, 165:3, 209:1, 209:21, 210:5, 210:8, 211:11 five-minute 230:20 fk 46:1 flipping 127:10 floor 4:18 focus 101:16, 191:12 focusing 88:19 focussed 104:4 fold 55:5, 60:1, 60:7, 60:12, 67:7, 72:16, 72:21, 74:13, 74:19, 75:7, 75:8, 75:18, 76:5, 76:6, 76:14, 77:11,	91:4, 91:19, 93:17, 94:4, 106:15, 107:10, 138:10, 144:8, 154:20, 154:21, 159:19 folded 62:8, 62:16, 62:20, 63:2, 63:18, 106:22, 117:7, 117:20, 118:19, 119:5, 119:14, 144:2 folding 48:9, 54:19, 54:22, 55:8, 55:9, 60:3, 60:16, 61:12, 61:20, 62:1, 62:7, 62:13, 64:1, 64:2, 64:6, 64:10, 75:10, 76:22, 106:2, 106:7, 106:11, 106:14, 106:21, 107:10, 107:16, 107:22, 114:18, 114:20, 114:22, 115:6, 139:12, 140:20, 141:4, 141:7, 141:10, 141:12, 145:21 follow-up 175:7 following 47:18, 136:8, 204:1, 215:1, 215:5 fonted 229:14 foot-tall 195:2 force 206:21, 207:2, 209:14, 212:12, 213:19, 220:2 forget 17:13, 146:18,	182:13 forgot 30:17 form 14:12, 15:21, 17:20, 33:4, 38:1, 38:12, 38:22, 40:12, 41:17, 43:5, 43:16, 44:1, 46:22, 52:14, 54:3, 57:18, 58:19, 59:15, 62:21, 63:6, 71:10, 72:5, 72:19, 89:8, 94:16, 101:8, 102:5, 102:10, 106:8, 107:13, 108:10, 130:1, 135:5, 139:22, 140:11, 141:11, 145:17, 156:8, 159:15, 166:3, 166:11, 167:7, 172:12, 174:7, 178:18, 179:3, 197:22, 200:8, 202:7, 203:11, 208:14, 210:17, 222:16, 223:1 format 112:11, 194:22 formation 225:8 formed 165:8, 174:9 formers 225:15 forming 28:15, 29:4, 29:19, 32:14, 33:18, 172:4, 206:6, 206:8 forms 79:19, 194:8 forrest 5:5, 7:14
--	---	--	---

forth 108:20, 172:5, 228:22, 233:8 fortunately 138:4 forward 53:13, 194:15 found 71:14, 169:2, 171:14, 173:19, 227:15 foundation 16:13, 28:21, 39:16, 40:2, 40:13, 41:18, 45:14, 54:2, 57:19, 58:18, 59:14, 61:7, 62:22, 63:7, 64:11, 67:12, 72:4, 72:20, 75:19, 79:2, 83:13, 84:13, 88:16, 89:9, 92:3, 93:5, 93:12, 94:6, 101:15, 102:12, 103:17, 107:1, 107:12, 108:9, 114:19, 115:7, 132:18, 135:4, 136:1, 138:19, 139:21, 140:10, 142:12, 142:17, 145:9, 145:10, 145:16, 149:1, 150:14, 156:21, 158:1, 159:14, 160:6, 162:1, 164:9, 166:2, 166:10, 167:6, 174:10, 174:13, 181:17, 196:18, 197:8, 200:7, 202:8, 204:15, 208:13, 210:16, 221:6, 222:15, 223:7, 226:11,	227:14, 227:21 fountain 2:5, 7:15 four 17:14, 18:2, 18:3, 19:6, 19:7, 19:9, 19:11, 21:13, 22:4, 27:20, 37:2, 41:1, 41:6, 124:11, 124:20, 165:7, 167:3, 174:10, 174:13, 183:3, 183:6, 184:14, 209:1 fourth 18:22 fox 4:17, 8:16 fraction 60:19, 61:15, 62:3, 62:6, 62:14, 62:18, 63:3, 76:2, 138:9, 149:20, 152:18, 169:1, 173:19 fractional 150:3, 150:11, 150:21 frame 41:9, 41:14, 43:8, 43:12, 44:8, 44:12, 46:19, 47:6, 47:19, 48:2, 49:1, 49:5, 49:9, 50:11, 50:19, 51:11, 51:15, 71:3, 133:22, 156:7, 156:11, 175:18, 189:20 framework 157:21, 158:4 francisco 4:8, 42:6	fre 122:10 freedom 74:22, 219:14, 219:16 frequency 113:22, 170:1, 170:5, 176:16, 176:18 frequent 110:3 frequently 52:12 fsasa 149:10, 149:11 full 9:18, 110:15, 110:17 fully 57:1 function 14:11, 37:22, 38:11, 38:21, 48:5, 48:12, 71:21, 71:22, 72:2, 72:3, 72:18, 73:6, 77:8, 103:15, 104:2, 104:8, 104:13, 107:21, 108:13, 129:7, 129:9, 132:1, 132:5, 132:12, 132:17, 133:4, 136:21, 137:18, 138:12, 139:19, 156:6, 156:20, 157:5, 160:11, 209:8, 227:10, 227:12, 227:20, 227:22 functional 217:1, 222:12, 222:21, 223:20 functions 74:8, 157:7, 157:15 fundamental 75:14, 206:14	funded 12:2, 17:12 further 150:22, 230:2, 233:14, 233:18, 234:1 future 232:4 G game 202:9 garbled 107:2, 118:14 gathered 156:11 gave 122:14, 188:14, 189:8 gene 55:18, 76:9, 79:15, 79:16, 79:21, 98:6, 117:12, 148:3 general 70:20, 220:12, 221:20, 221:22 generalize 220:16 generally 13:14, 225:8, 225:11 generate 39:18, 39:20, 39:22, 40:1, 52:3, 52:12, 52:20, 53:8, 91:22, 92:4, 93:3, 93:11, 96:1, 176:4, 177:17, 196:22, 197:1, 197:3, 197:20, 198:3, 200:4, 204:18, 205:8, 211:18, 213:12, 213:17, 213:20, 214:9, 223:8
--	--	---	---

generated 40:10, 92:21, 95:19, 95:22, 96:3, 177:6, 183:14, 196:2, 197:14 generating 52:16, 53:15, 177:10, 197:13, 198:7, 205:20 generation 203:13, 211:18 genes 55:16 getting 56:19 gibberish 213:20 give 19:21, 56:16, 84:16, 89:13, 93:6, 109:6, 110:1, 129:22, 145:10, 153:13, 171:5, 177:22, 178:19, 180:3, 183:7, 194:11, 194:12, 194:21, 195:4, 205:1, 211:13, 211:14, 212:11 given 61:19, 62:17, 63:2, 67:22, 84:12, 88:8, 98:5, 98:6, 116:16, 123:6, 140:1, 149:16, 181:6, 181:14, 194:9, 205:1, 233:12 gives 36:17, 113:8, 151:15, 168:3, 178:4, 205:6 giving 71:6 global 180:2, 181:10	glu 161:13, 161:14 glutamate 24:8, 24:9, 24:10, 161:21 glutamine 166:13, 166:18 glycan 17:1, 17:3, 17:5, 215:22 glycine 154:14, 154:19, 155:3 glycoside 17:18, 17:21 gmqe 180:1, 180:2, 180:19 go 23:12, 27:16, 28:22, 29:8, 29:22, 44:14, 57:21, 61:3, 69:5, 69:9, 76:10, 79:3, 83:17, 84:22, 86:3, 94:22, 98:7, 102:1, 115:10, 121:9, 123:22, 135:16, 142:13, 158:8, 162:9, 173:17, 189:13, 189:15, 190:6, 191:3, 193:18, 195:12, 200:15, 202:2, 205:15, 210:20, 218:22, 219:8 goal 103:5, 103:6, 134:8, 135:7, 173:9 goals 102:6, 135:9 goes 60:8, 66:1, 87:6, 116:22, 143:2, 162:15	going 18:1, 46:9, 46:12, 48:20, 53:4, 53:13, 55:10, 63:20, 80:8, 80:13, 108:7, 118:14, 119:19, 120:17, 121:21, 126:21, 127:2, 136:18, 152:22, 155:12, 155:16, 157:7, 161:17, 175:5, 176:1, 186:9, 186:22, 192:10, 192:21, 193:18, 194:12, 195:3, 200:5, 201:20, 203:15, 204:22, 205:6, 213:19, 217:6, 220:13, 223:5, 228:3, 228:8, 229:6, 230:9, 231:9, 232:11 goldberg 3:15, 80:18, 80:20, 80:21, 120:11, 224:4, 224:6, 224:8, 224:12 goldstein 4:17, 8:16 gone 52:9, 175:4 good 9:16, 9:17, 26:12, 31:9, 119:16, 148:12, 161:4, 180:3, 180:14, 211:5, 225:14 google 226:18 gotten 77:10, 193:8 government 36:16	grading 173:15 granted 31:10 graph 181:18, 182:22, 183:8, 183:13, 183:15, 183:17, 183:19, 183:21, 184:20, 185:12, 185:13, 185:14, 185:18 graphs 184:6 great 46:11, 80:12, 141:13, 150:1, 153:11, 155:14, 162:21, 194:16, 232:8 greater 170:6, 176:18 greatly 141:6, 165:4 grey 90:20 group 67:8, 118:7 groups 134:17 grow 204:4, 204:5 guarantee 77:5, 92:18 guarded 72:10 guess 27:9, 127:19, 137:6, 137:10, 208:9 guys 189:12, 189:18, 190:7, 190:17, 193:21, 194:5 H ha 74:4
--	---	---	---

half 125:6 halfway 24:10 halozyme 1:9, 5:9, 5:10, 7:5, 8:16, 8:18, 8:19 hand 9:6, 95:1, 194:22, 195:1, 234:8 handful 188:21 happen 26:14, 73:4, 76:16, 123:1, 127:21, 154:18, 168:9, 199:2, 199:7, 221:12 happened 102:15, 117:15, 126:6, 173:14 happens 73:17, 139:3, 160:15, 199:8, 208:22 happy 188:7, 194:1, 223:19 hard 65:2, 119:8, 136:22, 140:22, 172:17, 221:11 harder 220:17 harmon 1:26, 2:10, 9:2, 233:3 harsh 171:15, 173:17, 174:20, 175:2 head 53:18 header 81:15, 158:11 heading 84:22, 85:7	hear 224:5 heard 13:5 hecht 5:11, 12:8, 12:12, 12:13, 80:22, 120:8, 120:13, 120:15, 120:17, 122:5, 124:8, 125:8, 125:13, 125:22, 126:2, 126:11, 126:22, 228:18, 228:21, 229:4, 230:5, 230:7, 230:12, 230:13, 230:16, 231:1, 231:19 hecht's 126:9, 126:15 held 2:1 helix 225:8, 225:14 help 54:4, 141:5, 141:6, 159:16 helped 173:22 helpful 223:11 hence 175:13 here 7:2, 27:16, 52:19, 53:10, 84:5, 87:6, 92:17, 102:11, 127:10, 136:10, 139:13, 144:17, 150:18, 154:11, 171:15, 180:9, 203:13, 229:18 hereby 233:5 hereinbefore 233:8	hereunto 234:8 hey 191:16 hi 80:20 high 55:4, 56:6, 56:7, 56:19, 57:7, 57:13, 58:16, 59:22, 60:6, 60:11, 65:16, 66:6, 87:13, 90:7, 92:12, 92:18, 93:3, 132:21, 132:22, 176:16, 181:2, 222:5 higher 58:6, 87:5, 150:21, 178:3, 180:9 highly 50:2, 59:13, 61:8, 72:16, 75:3, 94:15, 222:7, 222:17, 229:9, 229:20 himes 3:8, 8:5 himself 121:22 hit 78:11 hoddach 5:9, 8:18 hold 160:19, 189:12 homo 82:10 homologous 51:10, 51:13, 51:16, 55:3, 55:13, 55:14, 55:15, 55:19, 59:21, 60:5, 60:10, 60:20, 61:8, 65:16,	67:2, 67:7, 70:2, 71:5, 74:14, 75:6, 87:17, 87:20, 88:14, 88:21, 89:2, 89:7, 89:16, 89:19, 90:1, 90:5, 90:6, 93:17, 94:3, 94:15, 94:19, 94:21, 95:7, 102:11, 102:22, 115:19, 116:3, 116:7, 143:4, 143:12, 143:17, 156:18, 156:22, 177:16 homologs 21:20, 22:6 homology 52:3, 52:13, 52:22, 53:7, 53:9, 53:13, 53:16, 53:22, 54:4, 55:15, 55:19, 55:20, 55:22, 73:19, 92:4, 92:21, 93:4, 93:11, 94:18, 94:21, 177:7, 177:11, 178:10, 179:2, 179:5, 179:20, 197:21, 198:3, 200:4, 204:12, 210:12, 223:5 honor 127:2 hope 145:5, 145:15, 194:20 hopes 132:21, 132:22 horrendous 205:3 hour 46:9, 80:8, 125:5, 155:12,
--	---	---	---

186:10 hours 125:6 however 57:5, 72:12, 101:16, 107:21, 118:2, 137:7, 137:20, 138:1, 196:22, 199:7, 211:14 human 13:16, 15:10, 15:14, 78:3, 78:10, 117:11, 203:18, 212:3, 213:5, 213:11, 213:14, 213:18, 213:22, 214:12 huntington 4:10 hyall 14:2, 92:11, 92:15, 92:20, 93:2, 161:12, 162:5, 162:8, 162:20, 163:9, 178:20, 179:1, 179:4, 179:6, 179:9, 179:16, 181:1, 197:15, 197:21, 212:22, 213:8, 214:5 hyal3 77:7, 117:5 hyal4 14:3, 74:2, 74:4, 74:6 hyaluronic 13:22, 14:14, 14:17, 15:15, 16:22, 73:11 hyaluronidase 13:21, 14:5, 15:22, 16:4, 73:8, 73:9, 77:14, 82:9, 82:17, 82:21, 83:5, 83:6,	83:7, 84:1, 84:19, 88:20, 89:6, 116:11, 116:14, 117:3, 117:11, 117:16, 118:2, 118:8, 118:13, 143:15, 158:12, 161:3, 215:20 hyaluronidase-1 83:7 hyaluronidase-2 83:6, 83:8 hyaluronidase-3 83:11 hyaluronidase-4 83:2, 83:3, 83:22 hyaluronidase-4-- like 83:10 hyaluronidase-5-- like 83:1 hyaluronidase-li- ke 83:10 hyaluronidase-re- lated 15:19 hyaluronidases 13:11, 13:16, 13:19, 14:3, 15:8, 15:10, 15:14, 16:9, 73:21, 75:5, 75:7, 75:18, 84:5, 88:11, 88:14 hyaluronoglucosa- minidase 83:3, 83:9 hyatt 2:4, 233:20 hydrolase 17:19, 17:22 hydrolyzes 73:9, 73:10	hydrophilic 149:4, 149:5, 153:9, 220:15 hydrophilicity 147:5, 219:10, 220:9 hydrophobic 24:22, 25:7, 25:9, 25:13, 25:15, 25:16, 25:17, 25:20, 220:13, 221:3, 222:10, 223:18 hydrophobicity 146:4, 146:17, 147:4, 147:5, 148:18, 219:10, 220:9 hypothetically 197:17 I idea 26:12, 32:5, 151:15, 178:4, 180:3 identical 56:11, 57:14, 98:15, 99:18, 156:19, 212:22, 213:7 identification 27:2 identified 25:22, 64:9, 65:8, 69:16, 71:5, 100:2, 101:13, 105:11, 105:20, 114:13, 161:11, 161:15, 165:3 identifies 82:16, 225:14 identify 19:17, 39:14, 51:10, 51:15, 55:7, 60:2, 63:22, 67:10,	67:22, 68:1, 68:3, 68:12, 69:7, 69:8, 69:13, 69:15, 70:3, 70:4, 71:12, 75:9, 77:21, 78:1, 98:9, 100:15, 101:7, 101:10, 101:16, 101:22, 102:7, 102:22, 103:6, 103:10, 140:19, 141:3, 141:6, 159:17, 160:22, 178:15, 210:21, 220:20, 224:15, 224:22, 226:9, 226:15, 227:4 identifying 69:11, 69:22, 80:1, 201:20 identity 57:12, 57:15, 57:20, 57:21, 58:7, 67:5, 84:11, 84:15, 84:17, 85:10, 85:15, 85:18, 85:21, 86:6, 86:21, 87:1, 87:2, 87:6, 87:10, 88:22, 89:4, 89:5, 89:14, 89:17, 89:19, 89:21, 90:7, 90:8, 90:19, 91:2, 92:9, 92:12, 92:17, 92:19, 93:2, 93:10, 93:16, 94:2, 94:14, 100:12, 116:18, 157:1, 181:3, 181:6, 182:3 ignore 111:20
---	--	---	---

ignored 192:4 iii 4:15 illuminating 98:2 imagine 95:10, 221:11 imagining 53:18 impact 37:21, 38:10, 54:1, 54:5, 107:22, 127:14, 127:18, 127:19, 129:8, 131:22, 132:11, 136:21, 137:17, 157:21, 175:19, 216:19, 216:20, 217:22, 227:11 impacting 200:18 implicitly 129:16 important 55:7, 55:9, 60:3, 64:1, 64:2, 64:5, 64:9, 66:3, 75:1, 104:8, 104:20, 104:21, 105:2, 105:11, 105:17, 106:11, 106:14, 106:20, 107:9, 107:16, 107:18, 108:12, 115:2, 118:2, 139:9, 139:11, 140:14, 140:20, 141:3, 141:7, 141:9, 147:17, 150:17, 159:17, 160:13, 172:8, 173:1, 173:3, 173:8, 209:15, 216:16, 217:21, 218:8, 218:13,	218:16, 218:19, 218:21, 221:15 imported 215:20 impossible 209:19 improper 120:16, 231:22 improve 104:2, 104:13, 105:6, 105:9, 129:20, 132:16, 133:4, 133:15 improved 135:1 improvement 175:16 improves 133:6 improving 135:12 inactivate 108:7 inactive 222:3, 222:13 inactivity 48:9 inc 1:9, 7:5 incidentally 99:13 include 29:3, 39:1, 74:6, 74:13, 75:2, 77:13, 82:21, 110:11, 113:17, 115:5, 137:12, 201:12, 219:22 included 20:11, 29:1, 73:21, 75:5, 82:20, 98:17, 115:3, 191:18 includes 74:1, 81:19, 110:10, 113:13, 153:16	including 11:7, 49:15, 94:12, 112:2, 143:14, 143:21, 183:4 incomplete 192:14, 206:17, 206:19, 212:15 incorrect 138:13 increase 64:21, 208:22 increased 25:15, 25:17, 25:19 increases 202:12, 206:12 independent 102:13, 102:20, 135:7, 183:4, 199:5, 204:5 independently 200:12, 200:15, 200:17, 201:9, 201:10 indicate 56:22, 89:1, 116:3, 203:14 indicated 109:20 indicates 20:13, 89:7, 89:22, 115:18, 131:6, 143:12, 183:9 indication 147:20 indicative 184:10 individual 81:17, 87:19, 88:6, 88:9, 92:10, 119:10, 133:10, 153:17, 159:4, 170:8, 174:3, 181:13, 188:5, 199:10, 212:14	individually 209:18 industry 60:8 influenced 175:13 influencing 48:8 information 149:17, 151:5, 160:19, 186:7, 189:11, 190:12, 191:15, 191:17, 192:15, 192:18, 194:7 initial 191:4, 209:5 initially 20:6, 180:6, 209:15 initiate 125:11, 125:14 initiated 16:1 input 109:4 inspection 129:4, 211:21 instability 227:17 instance 42:3, 42:21, 73:8, 73:12, 75:3, 107:17, 118:9, 150:20, 159:20, 220:8 instead 20:20, 21:18, 22:10 instituted 37:2 institution 37:5, 37:7, 37:14 institutions 192:8 instructed 11:13, 135:16
--	---	---	--

interact 153:19, 201:19, 216:12 interaction 127:15, 128:15, 147:12, 147:13, 183:5, 183:6, 201:21, 201:22, 217:19 interactions 129:1, 146:5, 146:19, 146:20, 146:21, 175:8, 175:10, 198:13, 198:20, 199:10, 199:11, 199:13, 199:15, 200:11, 202:3, 202:11, 204:3, 206:6, 206:7, 206:11, 206:22, 207:11, 209:5, 209:6, 209:10, 210:3, 210:4, 212:4, 212:8, 212:10, 212:14, 226:5, 226:10 interchangeable 160:17 interest 10:10, 103:18, 177:17 interested 103:21, 135:11, 137:13, 234:5 interesting 134:6 internally 211:7 interpret 90:22, 132:13 interpretation 59:17, 69:20, 203:19 interpreted 36:21, 45:9, 45:11, 45:12, 45:16, 173:21	interpreting 90:21, 160:3 intervention 203:18 intractability 206:4 intractable 203:20, 206:1 intrinsic 147:1, 153:16, 198:18 introduce 18:1, 26:9, 40:9, 79:22, 80:5, 103:22, 106:9, 106:13, 107:8, 116:4, 140:2, 159:20, 160:10, 160:14, 197:11, 197:18, 199:21, 201:7, 202:10, 204:8, 208:16, 209:13, 209:18, 214:20, 220:22 introduced 18:9, 18:15, 18:20, 19:3, 71:14, 72:13, 81:5, 81:7, 106:19, 219:4, 220:3, 221:1 introduces 76:19 introducing 81:3, 104:14, 105:7, 106:5, 106:6, 108:11, 159:8, 159:12, 196:19, 198:22, 221:8 invariant 100:3, 100:9, 100:10, 100:16, 101:7, 101:10, 101:13, 101:17, 102:2, 102:3, 102:7	invented 192:4 invited 12:22 involved 30:21, 40:18, 44:2, 45:22, 105:4, 105:20, 137:8, 139:3, 161:12, 161:22, 164:13, 164:16, 167:10, 176:17 involvement 45:4 involves 198:7, 198:8, 203:19 involving 169:22 irrespective 74:16 ish 93:1 island 61:3, 76:11 isoform 82:9, 84:19, 97:16, 97:18, 97:20, 98:7, 98:10, 98:11, 98:12, 98:13, 98:15, 98:17, 98:21, 99:5, 99:10, 99:12, 99:14 isoforms 21:19, 22:4, 79:9, 79:12, 79:14, 80:1, 82:5 isolate 216:21 issue 37:13, 94:22, 141:17, 186:17, 203:3, 210:10, 213:16, 232:3 issued 31:1, 31:3,	31:4, 31:6, 31:13, 37:8 issues 94:17, 95:12, 231:17 itself 107:16 J jeff 8:1, 10:17, 191:19 jeffrey 3:5 job 1:24, 173:18, 178:7, 178:8 joined 8:17, 224:2 josh 8:19 joshua 5:10, 8:19 juggle 212:3 july 10:15 jumped 147:21, 148:8 justified 116:8 K kadi 1:26, 2:10, 9:2, 233:3 kalen 3:7, 8:4 keep 98:13, 117:9, 140:15, 204:3, 206:6, 206:11, 212:8, 223:19 kept 112:5 kessler 4:17, 7:22, 8:16
---	---	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

258

keywords 161:2 kill 208:19 kind 39:7, 73:16, 145:15, 147:22, 151:15, 177:9 kinds 168:7 knew 123:21, 141:13 know 11:17, 12:8, 12:9, 13:16, 13:20, 13:22, 14:16, 15:10, 15:14, 15:22, 26:14, 31:1, 31:3, 31:5, 31:9, 31:16, 32:2, 32:5, 33:20, 34:3, 34:15, 34:20, 35:1, 35:2, 35:10, 35:12, 36:1, 36:4, 36:5, 36:6, 36:8, 36:10, 36:19, 51:2, 52:10, 53:9, 58:4, 60:6, 64:8, 77:6, 85:14, 85:16, 85:22, 89:11, 91:10, 92:15, 93:20, 94:21, 95:9, 95:10, 97:18, 103:14, 105:16, 112:3, 118:8, 120:9, 121:9, 121:21, 121:22, 123:20, 124:11, 125:9, 126:11, 126:14, 139:5, 157:20, 160:16, 162:3, 164:6, 172:17,	173:3, 173:10, 176:11, 180:16, 180:22, 187:5, 187:22, 188:20, 189:5, 189:17, 189:18, 190:11, 190:18, 190:22, 192:3, 192:17, 192:21, 193:5, 193:16, 193:21, 195:1, 205:4, 210:7, 211:12, 213:6, 229:12, 232:1 knowing 108:1 knowledge 14:19, 15:19, 188:3 known 14:6, 14:8, 41:6, 53:4, 104:9, 104:20, 104:21, 106:10, 106:13, 107:9, 117:6, 137:9, 138:2, 139:5, 140:14, 177:15, 190:14, 190:21, 201:4, 211:5, 211:22, 225:8, 225:11, 227:2 L lab 105:10, 105:13 label 66:18, 66:21, 67:1, 87:19, 88:6 labeled 65:14, 74:15, 114:15, 115:22, 147:4 labels 146:16 labs 105:19	land 86:2 large 168:6, 173:8, 203:22, 205:14, 219:4, 221:1, 221:2, 221:8, 221:12, 222:11, 229:15 largely 100:2 larger 64:14, 173:9 last 8:8, 17:14, 22:3, 26:15, 86:7, 110:6, 125:1, 153:15, 218:4 lasted 125:5 late 229:8, 231:3, 231:4 later 66:20, 173:5 launching 44:2 lauren 4:5, 7:19, 80:6 lawyer 124:5 lawyers 30:18 lay 36:12, 36:13 lead 97:19, 98:22, 119:11 leading 45:18 learn 74:12 learned 15:19, 228:21 learning 49:20 least 22:4, 135:2	leave 126:22, 127:3, 140:8 leaves 140:3 leaving 79:9 led 174:2, 175:10, 216:9 left 24:17, 25:2, 70:5, 81:3, 182:22, 184:19 left-hand 97:1, 97:8 length 56:16, 63:10, 63:17, 110:15, 110:17 less 55:8, 64:20, 124:12, 124:16, 134:13, 157:10, 159:10, 172:14, 220:14, 223:16, 229:2 let's 27:9, 57:8, 58:14, 59:11, 70:13, 80:4, 83:8, 99:20, 108:14, 110:13, 110:14, 115:10, 126:8, 126:19, 136:18, 158:8, 167:13, 176:22, 195:21, 199:20, 202:1, 202:21, 207:8, 207:9, 207:17, 210:8, 213:5, 215:6, 221:2, 222:9, 225:4 level 189:11 levels 91:8
--	---	---	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

259

liberty 220:11 library 39:13, 39:20, 39:22, 40:1, 40:3, 40:6, 40:10, 40:11 license 49:18, 49:19 licensing 43:21, 43:22 lifetime 52:9 ligand 105:4, 105:11, 105:17, 105:21, 137:11, 161:16, 163:2 light 76:11 likelihood 222:5, 223:13 likely 130:8, 157:10, 166:8 limit 59:17, 193:14 limited 188:5 limiting 75:4 line 43:19, 109:5, 110:2, 193:18 linearly 204:4 lines 108:3 lins 152:16 list 27:7, 27:8, 27:13, 27:16, 27:18, 27:19, 28:1, 28:6, 28:10, 28:11, 28:16, 29:5, 30:4, 92:5,	97:15, 115:3, 115:4, 165:2, 178:1, 226:9 listed 28:14, 30:3, 32:11, 82:9, 92:17, 127:22, 144:10, 144:17, 150:18, 150:22, 153:15, 154:11, 162:4, 170:9, 219:1 listen 121:5, 127:11 listened 189:13, 230:12 listener 58:11 listening 80:22, 120:15, 120:18, 120:21, 121:17, 121:18 lists 23:3, 23:8, 34:7, 35:15, 113:10 literally 189:22 literature 104:22, 145:8, 158:18 litigation 10:11, 12:6 little 47:3, 153:14, 159:21, 163:16, 171:16, 195:3 llc 1:6, 7:5 llp 3:9, 3:16, 4:9, 80:21 local 136:13, 138:16, 181:11, 181:12, 182:19, 183:19, 183:22, 185:7, 185:13, 186:5,	196:5, 200:18 location 217:19, 217:20, 218:6, 218:12, 218:15, 218:18, 218:20 logic 70:7, 98:8 long 10:3, 30:17, 94:11, 118:21, 121:21, 125:3, 140:12, 189:13, 228:3 long-winded 215:3 longer 160:1 longest 98:4, 98:7, 98:20 look 28:1, 29:22, 30:1, 53:17, 53:19, 64:18, 73:14, 77:2, 84:14, 85:11, 90:4, 109:16, 121:11, 140:18, 148:6, 151:4, 161:5, 171:5, 173:2, 173:4, 175:21, 193:14, 195:21, 198:16, 200:15, 220:20 looked 129:18, 171:18, 172:16, 176:6, 176:7, 176:14, 176:16, 182:7, 188:13, 188:17, 188:18, 188:19, 188:20, 190:11, 190:12 looking 33:7, 55:2, 65:4, 74:12, 89:1, 95:15,	115:12, 128:4, 130:12, 130:21, 134:3, 134:19, 134:21, 134:22, 143:6, 144:22, 145:6, 148:20, 151:16, 173:14, 198:9, 198:12, 205:21 looks 8:17, 89:12, 218:4, 224:3, 229:17 los 4:7 lose 139:7, 140:16, 160:11, 165:18 loses 76:20 loss 71:21, 71:22, 72:2, 155:1, 155:4, 167:11 lot 44:1, 104:6, 109:18, 109:21, 119:8, 167:19, 168:1, 168:13, 179:16, 180:18, 191:9, 191:10, 209:3, 209:7, 210:4, 219:14, 219:15 lots 147:6, 187:17, 193:15 low 90:13, 182:3 low-quality 83:2 lower 90:8, 90:10, 91:7, 154:22, 180:19 lowest 87:7 lunch 119:16
---	---	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

260

M			
ma	making	8:12, 8:21,	47:11, 54:7,
4:11	91:3, 198:9,	9:15, 18:1,	60:15, 70:14,
mack	202:6, 203:10,	18:11, 18:17,	191:4, 196:21,
5:10, 8:19	205:21, 206:8,	18:22, 19:5,	198:6, 208:18,
made	210:8, 213:7	26:11, 26:20,	220:13, 234:6
45:6, 116:8,	man	27:5, 46:8,	matters
127:20, 139:17,	223:2	46:17, 80:4,	40:16
153:9, 187:15,	managed	80:10, 81:1,	mature
191:7, 193:13,	144:1	81:9, 85:2,	113:15, 114:5,
231:15	mandate	85:13, 88:5,	114:9
magnitude	135:15	119:15, 120:2,	max
127:14, 128:15,	manifestations	120:7, 120:14,	152:14
128:16, 128:19,	79:14	120:21, 121:4,	maximum
129:3	manner	121:8, 121:15,	78:15, 150:1,
main	39:11	122:3, 122:8,	150:7, 152:11
62:10, 146:20	many	122:11, 127:4,	maybe
maintain	13:16, 15:10,	127:5, 155:11,	23:11, 23:13,
139:18, 139:19	38:8, 44:3,	155:21, 174:11,	73:11, 84:22,
maintained	52:2, 52:5,	174:16, 174:17,	124:11, 129:16,
60:22, 139:15	52:8, 52:10,	186:8, 188:11,	143:10, 172:13,
maintains	64:7, 124:10,	189:16, 194:2,	173:16, 188:22,
160:16	124:17, 128:1,	194:15, 194:20,	190:18, 193:5
majcherzak	128:4, 134:16,	195:7, 195:9,	meadows
5:8, 8:7	138:4, 168:19,	195:11, 195:17,	9:20
major	169:12, 169:15,	217:5, 217:11,	mean
41:1	187:21, 188:16,	224:11, 224:13,	28:7, 37:7,
make	188:17, 192:11,	228:2, 228:7,	39:13, 53:13,
36:15, 52:18,	198:13, 199:9,	228:13, 228:16,	54:15, 55:14,
55:11, 69:21,	199:18, 202:14,	229:5, 232:8	57:14, 58:11,
108:4, 123:12,	204:17, 206:20,	match	61:16, 63:15,
130:9, 134:19,	212:3, 218:22,	59:9, 87:9,	65:20, 65:22,
143:7, 145:11,	219:7, 220:17	96:19, 97:9,	68:21, 71:19,
145:14, 147:19,	mapped	99:4	71:20, 72:2,
153:10, 158:3,	168:15	matched	88:8, 90:16,
171:2, 187:4,	mapping	99:7	100:8, 100:10,
187:20, 189:19,	162:20	matching	105:2, 116:21,
198:14, 200:9,	mark	56:12, 109:19,	118:15, 123:15,
201:17, 202:1,	5:7, 8:6, 154:1	109:20, 177:22	125:10, 127:17,
207:3, 207:12,	marked	materially	127:19, 128:15,
207:17, 207:18,	6:10, 18:9,	136:12, 138:16	128:16, 131:21,
207:20, 209:20,	18:15, 18:20,	materials	132:2, 135:21,
223:19, 224:10	19:3, 27:1,	28:15, 29:3	136:10, 148:1,
makes	81:5, 81:7	matter	148:3, 151:11,
85:20, 86:4,	marks	7:4, 29:7,	171:4, 181:16,
116:19, 141:9,	232:9	29:19, 33:9,	181:19, 190:7,
177:13	marriage	33:12, 33:18,	194:20, 194:22,
	234:3	34:7, 34:10,	200:15, 219:19,
	martin	35:15, 35:18,	229:14
	4:5, 6:3, 7:19,		

meaning 60:21, 65:22, 66:16, 86:12, 128:19, 147:9, 147:13, 181:13, 210:19 meaningful 132:4, 132:7, 207:3, 209:20 meaningfully 132:11, 136:14, 138:17, 138:20 means 67:4, 69:14, 71:22, 72:1, 76:9, 85:12, 146:8, 148:5, 149:9, 153:4, 216:4 meant 65:5, 139:13, 146:9, 174:22 measure 152:8 measured 56:9, 149:22 mechanics 203:15 mechanism 14:17, 76:10, 227:5 media 7:2 median 150:21, 152:15, 152:17, 184:22 meet 49:3, 124:1 meeting 125:10, 125:12, 125:14 meetings 124:9, 124:10, 124:15, 124:20, 124:21, 125:4, 125:5, 125:16, 125:21 mention 184:7	mentioned 49:15, 59:20, 70:9, 91:6, 117:6, 133:18, 152:7, 157:12, 157:16, 174:18, 184:14, 198:17, 219:22, 228:17 merck 1:6, 5:7, 5:8, 7:4, 8:2, 8:6, 8:7, 11:22, 12:2, 12:5, 47:17, 233:15 met 58:20, 124:3 methionine 109:15, 109:16, 109:17, 109:22, 110:2 method 211:14 methodology 167:21, 168:10, 174:1, 205:11, 205:15 metric 170:11 meyerowich 5:6 michael 5:11, 12:8, 80:22 microphone 88:2 midnight 91:6, 91:14 might 17:13, 30:22, 43:2, 47:2, 51:2, 51:18, 95:8, 98:5, 102:15, 103:7, 118:1, 124:19, 138:9, 144:20, 147:6, 153:19, 171:14, 175:4, 178:4, 182:3,	204:17, 223:9, 223:11 mind 150:17, 156:11 minimal 107:21, 200:11 minimization 197:6, 197:9, 197:10 minimize 210:22 minimum 93:9, 144:1 minor 19:17, 19:22, 25:21, 131:11 minus 99:4, 131:9, 168:22, 181:15, 184:8, 184:10, 184:11, 184:16, 184:21 minute 186:14 mischaracterized 192:5 misfolded 222:3 misquoted 192:5 misreading 187:10 missed 175:9 missing 23:6, 209:14 mixed 95:13 model 45:12, 47:2, 47:7, 49:6, 49:10, 52:4, 52:20, 52:21, 52:22, 53:4, 53:5, 53:7, 53:8, 53:9, 53:12, 53:13, 53:16, 54:4,	62:2, 92:1, 92:4, 92:10, 92:21, 93:4, 93:6, 93:11, 137:22, 140:18, 140:19, 159:4, 176:4, 177:7, 177:11, 177:17, 178:2, 178:10, 179:2, 179:5, 180:2, 181:12, 183:2, 183:14, 183:15, 184:2, 184:13, 184:20, 197:1, 197:3, 197:21, 198:3, 200:3, 200:4, 203:7, 203:8, 203:13, 204:12, 207:17, 207:19, 207:21, 207:22, 208:11, 210:10, 210:12, 211:18, 213:12, 213:18, 213:20, 214:9, 214:21, 215:12, 215:18, 223:5, 223:8, 223:10 modeled 170:7 modeling 42:10, 48:15, 53:22, 179:21, 180:7, 182:1, 198:6, 203:14, 203:18, 205:18, 205:20, 210:18, 211:6 modeller 42:21, 43:9, 43:10, 43:14, 43:18, 44:6, 49:10, 49:15, 50:7 models 52:13, 196:1 modified 48:10
---	---	---	--

molecular 42:3, 42:10, 227:4 molecule 39:2, 53:17, 53:20, 73:6, 82:22, 83:1, 137:7 moment 85:16 money 17:13 monitor 7:11 monkey 213:5, 213:10, 213:12, 213:13, 213:21, 213:22, 214:9, 214:12 monomeric 46:2 months 187:21, 193:4 more 42:9, 42:11, 43:20, 44:2, 47:4, 49:22, 50:2, 55:16, 56:21, 64:12, 64:18, 94:14, 95:5, 104:10, 123:22, 124:15, 128:17, 128:21, 137:15, 138:7, 151:13, 168:9, 174:1, 174:2, 178:7, 188:4, 190:13, 192:15, 193:2, 197:1, 197:13, 199:1, 199:9, 201:11, 202:10, 206:22, 208:16, 209:13, 209:17, 213:9, 214:4, 214:5, 219:2, 228:14, 229:2 morning 9:16, 9:17,	123:6, 157:17 most 50:22, 87:5, 97:1, 97:8, 110:3, 111:13, 134:4 mostly 134:16, 137:1, 137:13, 229:4 motivated 68:8 move 88:1, 161:6, 171:6, 171:8, 175:6, 194:15 moving 24:5, 24:13 mrna 79:17 much 15:22, 42:9, 43:19, 59:6, 63:17, 117:13, 134:12, 134:13, 134:18, 137:1, 137:22, 138:13, 149:15, 150:21, 151:12, 151:14, 153:12, 220:11, 228:7 multiple 65:12, 66:17, 71:11, 96:9, 96:12, 99:6, 99:13, 103:1, 109:2, 118:6, 142:19, 142:22, 143:18, 144:12, 165:15, 165:20, 169:6, 169:14, 170:9, 171:2, 184:16, 199:19, 204:1, 204:8, 206:8, 212:2, 213:16, 214:1, 222:10, 223:15, 223:16 multiples 183:9	must 77:9, 117:7, 117:18, 119:7, 119:9, 226:17 mutagenesis 163:20, 164:4, 196:16, 197:7 mutant 145:6, 147:14, 153:19, 163:9, 166:14, 197:1, 197:13, 197:14, 197:16, 198:4, 201:12, 208:4, 208:5, 208:6, 208:7, 209:6, 209:7, 209:16, 209:22, 211:9, 211:15, 211:20, 214:18 mutants 164:7, 164:8, 164:11, 164:12, 164:15, 164:19, 202:19, 209:21 mutate 77:1, 117:10, 139:7, 165:18, 203:6, 220:18 mutated 116:15, 143:16, 144:16, 164:14, 164:18 mutating 107:20, 167:9, 202:21, 216:17 mutation 31:18, 33:22, 34:17, 34:21, 36:3, 76:16, 104:1, 106:10, 106:13, 108:11, 116:8, 130:7, 130:15, 132:10, 133:6, 140:13, 159:20, 160:4, 160:10, 160:14, 176:2, 196:19,	196:22, 197:11, 199:1, 201:7, 201:8, 208:2, 208:12, 208:17, 213:16, 214:20, 221:19, 222:18, 223:3, 227:12 mutational 160:3, 163:11 mutations 40:9, 66:2, 76:19, 104:14, 105:7, 130:16, 136:20, 158:12, 159:8, 160:17, 163:12, 163:14, 163:15, 164:16, 164:20, 165:4, 198:22, 199:1, 199:5, 199:19, 201:11, 202:10, 202:17, 202:20, 203:19, 204:1, 204:8, 205:4, 206:2, 208:2, 208:15, 210:6, 211:10, 212:2, 223:13 mutual 130:15 myself 147:20 N name 9:18, 12:10, 14:4, 88:20, 89:6, 89:22, 94:8 names 88:8, 89:1, 89:17, 89:20 nancy 4:8 narrative 192:3, 192:10 natural 191:13
---	---	--	---

naturally 56:1, 116:6, 157:3 nature 63:13, 107:14, 217:18, 231:22 ncap 25:20 near 137:21, 205:13, 215:13, 215:17, 216:1, 216:3, 216:15 nearby 199:19 nearly 150:1, 209:19 necessarily 49:19, 50:6, 57:14, 57:15, 114:20, 129:22, 133:16, 135:8, 135:12, 139:12 necessary 144:1, 167:18, 168:1, 172:13, 201:12 need 11:16, 43:18, 64:7, 72:10, 93:10, 128:18, 130:2, 130:4, 134:9, 191:3, 192:15, 199:15, 204:3, 212:8, 219:14, 223:4 needed 209:9, 212:13 needs 101:19, 133:8, 206:11, 220:4 negative 128:6, 128:20, 129:21, 133:14, 199:15 negatively 129:8 neighbor 149:18, 199:12,	200:6 neighbors 24:3, 24:4, 147:14, 153:20, 224:15, 224:22 net 128:7, 128:12, 129:6, 133:11 neutral 129:21, 131:7, 131:9, 132:3, 133:21, 134:5, 134:10, 135:13, 135:21, 153:1, 153:3, 154:3, 176:1, 226:7 never 13:9, 35:1, 44:17, 101:9, 101:13, 101:19, 102:1, 106:9, 121:13, 121:15, 121:19, 130:2 new 1:20, 2:12, 4:6, 7:16, 9:21, 190:9, 206:5, 206:7, 233:4, 234:17 next 21:11, 24:5, 24:13, 76:11, 115:11, 122:2, 171:6, 171:7, 171:8, 202:1, 202:22, 203:6, 203:9, 207:8, 210:6 nice 13:1, 115:15 niche 42:11 nih-funded 16:17 no-no 221:14 non-conservative 160:5	non-conserved 67:10, 67:20, 69:13, 71:6, 160:15 non-essential 54:12, 54:16, 54:17, 65:5, 65:7, 65:14, 65:18, 65:19, 65:21, 66:8, 66:9, 66:15, 66:18, 66:22, 67:1, 67:9, 67:13, 67:16, 67:19, 68:1, 68:4, 68:6, 68:10, 68:13, 68:17, 68:20, 69:3, 69:5, 69:8, 69:11, 69:14, 69:17, 70:6, 70:21, 71:7, 71:8, 71:12, 103:19, 116:1, 116:12, 116:16, 116:19, 118:12, 118:16, 119:3, 119:4, 135:18, 143:20 nonetheless 153:14 normal 192:22 normalization 152:7 normalizing 152:6 nos 1:12 notary 2:11, 233:1, 233:4, 234:16 note 147:16, 147:17, 148:13, 148:14, 148:15, 166:12 noted 122:4	nothing 9:10, 153:6, 153:12, 153:22, 160:15, 179:10 notice 2:10 noticeable 133:14 noticed 122:19, 174:20, 175:8 notified 178:9 noting 154:2 november 187:6 np 97:14 nuanced 202:15, 202:17 nucleotide 226:21 number 7:3, 18:6, 18:13, 18:19, 19:2, 20:10, 20:20, 23:10, 24:2, 24:20, 25:4, 25:5, 25:11, 25:13, 25:15, 25:17, 25:19, 29:9, 29:10, 29:11, 29:13, 30:6, 33:10, 34:8, 35:15, 38:13, 56:10, 56:15, 56:17, 57:3, 57:4, 57:7, 58:6, 78:13, 86:21, 91:2, 93:14, 93:15, 94:5, 94:7, 97:7, 97:13, 97:16, 97:19, 99:17, 100:19, 101:18, 102:8,
--	--	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

264

109:6, 109:11, 109:13, 109:15, 110:17, 111:20, 111:22, 112:7, 112:8, 113:11, 113:14, 113:15, 113:18, 128:22, 129:2, 130:3, 130:4, 133:8, 141:7, 146:5, 150:18, 150:19, 152:10, 161:15, 181:21, 183:21, 202:9, 202:10, 203:22, 204:2, 204:20, 205:14, 206:11, 212:7, 213:7, 216:6, 224:20, 231:15 numbers 7:7, 85:5, 97:3, 97:4, 97:7, 129:11, 151:4, 152:18, 162:5, 186:1, 231:6 nw 4:18 ny 2:6 O object 11:10, 120:14, 121:20, 229:8, 230:4, 230:6, 230:11, 230:13, 230:15 objecting 223:12 objection 14:12, 15:21, 16:13, 17:20, 28:18, 28:21, 33:4, 38:1, 38:12, 38:22, 39:16, 40:2, 40:12, 40:13,	41:17, 41:18, 43:5, 43:16, 45:14, 46:22, 52:14, 54:2, 57:18, 57:19, 58:18, 58:19, 59:14, 59:15, 62:21, 62:22, 63:6, 63:7, 64:11, 67:12, 71:10, 72:4, 72:5, 72:19, 72:20, 75:19, 79:2, 83:13, 84:13, 88:16, 89:8, 89:9, 92:3, 93:5, 93:12, 94:6, 94:16, 101:8, 101:15, 102:5, 102:12, 103:17, 106:8, 107:1, 107:12, 107:13, 108:9, 108:10, 114:19, 115:7, 121:14, 122:3, 122:9, 127:1, 130:1, 132:18, 135:4, 135:5, 136:1, 138:19, 139:21, 139:22, 140:10, 140:11, 141:11, 142:10, 142:12, 142:17, 145:16, 145:17, 149:1, 150:14, 156:8, 156:21, 158:1, 159:14, 159:15, 160:6, 162:1, 164:9, 166:2, 166:3, 166:10, 166:11, 167:6, 167:7, 172:12, 174:7, 178:18, 179:3, 181:17, 196:18, 197:8, 197:22, 200:7, 200:8,	202:7, 202:8, 203:11, 204:15, 208:10, 208:13, 208:14, 210:16, 210:17, 221:6, 222:15, 222:16, 223:1, 223:7, 226:11, 227:14, 227:21 objections 230:22 objective 135:10, 172:21, 173:7 objectively 172:18 obligated 61:1 observations 117:22 observe 64:22 obtained 79:7, 82:4, 109:12 obviously 129:3, 156:9, 192:19, 229:20, 229:22, 231:16 occasion 101:9 occupied 61:5, 62:19, 62:20, 63:5 occur 101:2, 170:5, 203:22, 206:2 occurred 101:19, 233:19 occurring 56:1, 116:7, 157:3 occurs 79:18, 114:1, 198:10 office 1:1, 7:6, 37:11, 37:12	offices 2:2, 233:19 often 54:11, 108:12, 153:9, 211:21 oftentimes 153:7 oh 19:16, 22:5, 23:15, 24:10, 27:4, 31:4, 37:18, 49:22, 63:11, 69:4, 69:6, 70:11, 82:1, 84:2, 85:2, 86:5, 94:20, 112:12, 113:2, 136:7, 136:8, 144:21, 147:20, 149:11, 152:13, 162:12, 162:19, 166:15, 185:3, 195:21, 210:15, 217:5 old 76:2 omega 6:22, 40:21, 41:11, 41:15, 50:11, 50:15, 51:7, 95:19, 95:21, 96:1, 96:8, 96:11, 100:11, 109:2 once 45:12, 45:15, 76:20, 91:1, 92:14, 100:10, 157:10, 173:15, 198:22 one's 108:2 one-minute 217:3 ones 13:22, 64:2, 99:4, 176:14, 189:12, 219:22
--	---	---	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

265

only 31:13, 36:12, 56:1, 78:21, 78:22, 79:4, 80:2, 99:11, 100:14, 142:14, 142:18, 142:21, 172:16, 172:19, 179:7, 179:8, 187:14, 192:9, 196:9, 196:14, 196:20, 198:13, 203:14, 212:5, 216:22, 220:4 onus 190:6 open 54:7 opened 47:13 opined 126:11 opinion 32:18, 68:19, 140:6 opinions 28:16, 29:4, 29:19, 32:15, 33:18, 172:4 opportunity 188:3, 189:18, 189:20 opposed 43:17, 44:6, 51:8, 51:22, 53:5, 53:18, 58:7, 66:12, 75:10, 97:20, 98:12, 144:9, 146:15, 190:3, 202:6, 219:12 opposing 192:22 opposite 69:14 option 85:19 options 179:16	orchestrated 222:18 order 93:10, 98:1, 98:8, 104:1, 117:18, 125:11, 130:6, 150:3, 172:10 ordinary 47:18, 48:1, 48:21, 49:2, 49:12, 51:21, 118:10, 140:7 organism 76:21 original 84:14, 85:11 originated 55:18 other 12:5, 12:17, 16:12, 17:16, 17:21, 21:1, 33:8, 34:1, 36:18, 39:3, 41:3, 41:13, 49:14, 50:18, 50:21, 51:6, 51:8, 51:14, 51:17, 52:1, 52:22, 53:8, 58:9, 59:2, 62:4, 68:18, 69:1, 76:14, 77:15, 88:11, 88:20, 92:14, 96:5, 99:5, 101:1, 103:6, 105:19, 107:16, 113:17, 114:21, 116:17, 128:20, 128:21, 129:7, 131:9, 138:7, 138:22, 139:6, 143:17, 143:19, 144:9, 144:16, 145:3, 145:11, 147:6, 154:2,	155:6, 159:6, 161:15, 164:20, 175:8, 175:17, 179:16, 192:13, 199:8, 200:5, 200:11, 201:8, 201:19, 202:15, 202:22, 203:6, 203:9, 204:2, 205:13, 206:3, 207:9, 208:19, 209:14, 210:6, 211:10, 226:13, 230:3, 231:17 others 43:1, 127:21, 208:17 otherwise 77:9, 117:8, 234:5 ourselves 40:3 out 24:17, 25:2, 42:5, 50:22, 52:1, 59:4, 79:8, 83:18, 88:21, 98:10, 111:11, 111:17, 130:13, 147:21, 148:8, 154:1, 161:17, 162:10, 168:21, 183:22, 186:14, 187:9, 187:15, 190:5, 202:5, 206:12, 217:16, 222:21 outcome 10:10, 234:6 output 109:1, 112:4, 151:2 outright 208:18 outside 15:1, 38:3, 67:17, 90:14, 129:15, 129:18,	133:19 over 11:6, 36:18, 47:3, 58:13, 59:1, 76:16, 76:20, 77:10, 84:10, 123:11, 123:12, 123:22, 176:12, 179:13, 190:8, 193:19, 207:14 overall 93:7, 127:9, 128:12, 133:12, 184:8 overlooked 206:20 overstatement 47:3 overwhelm 202:12 own 30:14, 121:1, 159:4, 223:11 owner 1:10, 4:3, 7:20, 187:7 ownership 36:16 P pa 3:19 page 6:2, 6:7, 6:12, 20:15, 28:2, 28:11, 29:8, 33:10, 34:7, 47:15, 108:16, 110:22, 113:8, 113:10, 115:11, 136:6, 151:1, 151:8, 151:18, 151:20, 152:4, 153:1, 162:15, 162:18, 179:18, 182:17, 183:1, 184:7, 185:14,
---	---	---	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

266

231:6 pages 1:25 paid 104:9 pair 223:13 pairs 56:11, 56:12 pairwise 96:13, 96:18 paper 45:10, 45:18, 152:16, 159:3, 161:6, 161:22, 163:13, 164:3, 194:18, 195:2, 217:16, 227:9, 227:15 papers 14:18, 14:20, 19:14, 46:3, 46:5, 159:6, 226:15, 226:20, 227:9, 227:19 paragraph 20:2, 21:3, 21:4, 21:5, 21:12, 21:13, 21:18, 21:22, 22:1, 22:3, 22:8, 22:9, 23:2, 23:3, 23:7, 23:8, 23:9, 23:10, 23:14, 24:6, 47:15, 54:8, 65:4, 68:9, 70:13, 70:16, 99:21, 100:1, 112:22, 113:3, 115:10, 115:13, 115:17, 126:19, 127:7, 127:8, 127:9, 127:13, 136:7, 138:14, 143:8, 158:8, 158:10, 158:15,	161:8, 161:9, 161:10, 162:15, 163:6, 163:7, 163:8, 163:21, 164:1, 164:2, 165:1, 165:2, 167:14, 177:3, 177:4, 177:5, 185:4, 195:19, 195:20, 215:7, 215:8, 215:11, 217:13, 217:14, 217:15, 218:2, 219:1, 225:4, 225:5, 225:6, 225:13 paragraphs 128:1, 167:15, 187:10, 187:11, 191:8 parallel 197:4 parameters 78:6 pardon 126:13 parentheses 22:10, 22:19, 23:4, 23:19 park 1:19, 2:1, 6:2, 6:7, 7:4, 9:16, 9:20, 9:22, 10:20, 11:4, 19:6, 26:13, 27:1, 27:6, 28:14, 36:10, 37:20, 46:18, 81:2, 88:1, 120:3, 122:13, 123:8, 155:22, 186:14, 195:19, 217:12, 228:17, 230:1, 232:10, 232:13, 233:7, 233:19 part 29:21, 54:18,	75:20, 108:21, 108:22, 118:22, 143:18, 151:19, 159:1, 162:16, 162:17, 168:12, 197:10, 205:17 participants 8:11, 8:13 participation 231:20, 231:22 particular 51:19, 53:6, 61:5, 62:4, 104:15, 104:17, 112:11, 135:9, 136:11, 137:21, 191:12, 201:22, 224:22, 227:1, 227:5, 227:12 particularly 134:2, 158:19 parties 234:2, 234:4 parts 206:10, 212:6 party 233:14 pass 230:18 passages 192:5 past 101:17, 123:2 patent 1:1, 1:3, 1:10, 1:15, 4:3, 6:14, 6:16, 6:18, 6:20, 7:6, 7:7, 7:20, 18:6, 18:13, 18:19, 19:2, 29:10, 29:13, 29:14, 29:15, 29:16, 29:17, 29:18, 29:22, 30:1, 30:2, 30:3, 30:5, 30:6, 30:8, 30:9,	30:11, 30:14, 30:18, 30:19, 30:21, 30:22, 31:1, 31:3, 31:6, 31:10, 31:13, 31:14, 31:17, 31:21, 31:22, 32:3, 32:6, 32:8, 32:10, 32:13, 33:10, 33:13, 33:15, 33:17, 33:21, 34:2, 34:4, 34:7, 34:11, 34:13, 34:14, 34:16, 35:2, 35:4, 35:7, 35:11, 35:13, 35:15, 35:19, 35:21, 35:22, 36:2, 36:7, 36:9, 36:11, 36:14, 36:21, 37:9, 37:10, 37:11, 37:12, 68:8, 68:11, 68:13, 70:10, 70:11, 70:16, 187:7 pay 147:20 paying 173:2 pbd 203:16, 204:11, 204:18, 205:8, 205:21 pdb 185:19, 185:21, 198:7 pdf 195:4 pending 11:18 people 36:18, 44:3, 91:8, 212:1 peptide 110:10
--	--	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

267

percent 57:6, 57:9, 58:15, 59:11, 84:11, 84:17, 86:2, 86:3, 86:21, 87:5, 87:6, 87:8, 90:20, 92:12, 92:13, 92:19, 93:1, 93:16, 93:20, 93:21, 94:2, 94:5, 94:8, 94:10, 94:14, 100:16, 100:17, 100:18, 101:3, 101:6, 101:11, 111:10, 111:11, 111:16, 111:18, 113:4, 113:21, 113:22, 114:7, 114:10, 139:8, 156:18, 157:1, 157:11, 157:13, 157:14, 170:2, 170:3, 176:20, 176:22, 181:7, 213:6, 213:7, 227:16 percent-ish 212:22 percentage 57:2, 85:7, 85:21, 86:9, 86:16, 87:7, 89:14, 90:9, 90:11, 90:13, 92:16, 92:19, 109:11, 110:2, 110:4, 114:2, 157:11, 170:6, 176:19 perception 128:17 perform 50:15, 69:12, 70:2, 101:12, 101:21, 102:9, 103:1	performed 16:8, 16:11, 20:6, 40:15, 71:4, 103:9, 156:12 performing 35:5 perhaps 34:18, 36:3, 42:21, 56:21, 85:9, 102:19, 129:18, 133:4, 171:15, 179:14 period 22:16, 22:17 person 47:18, 48:1, 48:7, 48:20, 49:2, 49:12, 50:14, 51:1, 51:9, 51:21, 72:22, 106:18, 108:4, 108:6, 114:17, 118:10, 118:15, 134:8, 140:6, 145:18, 145:19, 156:14, 199:16, 202:18, 225:21 person's 202:13 personal 147:16 personally 12:9, 51:18 persons 107:7 perspective 134:7, 141:17, 156:13, 190:20 petitioner 1:7, 3:3, 8:2 pgr 1:14, 6:13, 6:15, 6:17, 6:19, 7:8, 7:9, 18:6, 18:12, 18:18, 19:1,	28:1, 28:12, 29:7, 29:9, 33:12, 33:18, 34:6, 34:10, 35:15, 35:18 pgr- 1:12, 1:13 pgrs 18:3, 19:8, 37:2, 37:6, 41:4, 126:12, 190:8, 190:13 ph 4:15, 4:16, 13:21, 14:2, 14:9, 14:11, 14:13, 14:16, 15:4, 21:15, 21:16, 21:19, 21:20, 22:4, 22:6, 31:19, 34:1, 34:18, 34:22, 36:3, 39:10, 39:15, 48:3, 68:1, 73:10, 73:19, 74:1, 74:7, 74:14, 75:4, 77:13, 78:3, 78:10, 82:9, 82:17, 82:21, 83:7, 84:19, 88:21, 92:11, 92:17, 93:2, 97:16, 100:4, 109:5, 109:8, 110:6, 112:8, 112:19, 113:20, 113:22, 114:3, 114:6, 137:4, 161:4, 161:14, 161:21, 162:10, 162:13, 162:20, 163:1, 165:4, 165:9, 166:9, 167:4, 169:2, 169:5, 169:11, 170:7, 177:18,	177:19, 178:14, 181:1, 196:5, 197:2, 197:12, 197:18, 199:20, 203:5, 203:7, 204:10, 207:17, 212:21, 213:5, 213:10, 213:11, 213:13, 213:14, 213:18, 213:21, 213:22, 214:5, 214:6, 214:12, 214:20, 215:12, 215:18 ph-like 83:6 philadelphia 3:19 phrase 67:15, 71:18 pick 176:13, 176:14, 179:17 picked 98:12 piece 189:16, 194:3, 194:4 place 7:15, 93:22, 124:22, 184:1 places 159:9 planet 7:14, 9:3 plaza 2:5, 7:15 please 7:17, 9:6, 9:18, 10:22, 63:1, 105:14, 163:6, 195:3, 217:12 pllc 4:17 plotted 183:8 plus 56:11, 89:6,
--	---	--	---

89:20, 89:21, 89:22, 131:9, 134:14, 181:14 pocket 215:19, 216:1, 216:2, 216:18, 221:3, 223:18 point 30:20, 161:4, 163:12, 177:16, 178:6, 191:7, 192:18, 193:7, 194:1, 194:19, 208:6, 209:6, 209:16, 211:20, 212:2, 231:18, 232:5 pointed 187:9, 187:11, 187:15, 206:12, 217:16 polymorphisms 226:21 polypeptide 60:18, 61:20, 62:5, 63:10, 63:16, 70:21, 76:4 polypeptides 61:14, 72:16, 72:21 poor 225:14 populated 168:18 portal 203:15 portion 81:15, 86:12, 86:13, 203:18, 230:5 portions 99:7 posa 48:20, 49:4, 49:5, 49:9, 49:12, 49:14, 49:18, 50:5,	50:14, 50:18, 51:4, 51:12, 51:14, 68:19, 69:10, 69:22, 71:3, 71:11, 71:17, 71:20, 72:17, 72:22, 73:16, 94:7, 96:7, 96:13, 116:3, 116:4, 116:7, 129:5, 141:18, 144:13, 144:20, 144:21, 145:7, 145:12, 145:14, 145:18, 175:18, 176:4, 226:3 positions 56:15, 64:22, 65:12, 66:3, 66:10, 66:17, 67:20, 68:1, 68:2, 68:4, 68:5, 68:7, 68:13, 68:17, 69:2, 69:8, 71:8, 71:14, 100:12, 103:7, 104:9, 106:20, 112:6, 115:18, 115:20, 115:22, 116:5, 116:9, 116:11, 118:12, 118:18, 119:3, 119:12, 124:13, 135:18, 138:4, 139:8, 143:12, 143:14, 143:21, 165:16, 172:3, 182:7, 187:18, 188:16, 188:21, 190:2, 190:9, 190:11, 190:12, 193:16, 208:12, 209:1, 211:16, 220:17 positive 128:6, 128:20,	199:14 possibilities 63:14, 76:6, 143:7 possible 76:7, 76:8, 107:4, 137:22, 143:20, 152:11, 158:3, 169:13, 171:22, 172:16, 173:4, 189:7, 194:16, 196:8, 199:9, 202:11, 212:4, 221:22, 223:10 possibly 190:10 post-model 211:17 postdoctoral 48:3 potential 25:11, 62:18, 103:10, 128:10, 129:19, 133:19, 154:5, 154:7, 175:19, 178:1, 178:15, 178:19, 216:20, 230:6 potentially 66:11, 86:10, 86:21, 116:4, 118:17, 131:22, 132:16, 175:22, 230:3 powers 4:15, 7:22, 26:16, 26:19, 26:22, 191:19, 191:22, 193:9, 193:12 practical 173:9 practice 56:4 practitioner 60:9 practitioners 56:22, 57:5	pre 81:18 precedents 226:13 precise 45:3 precisely 137:7 precursor 82:22, 83:7, 83:8, 83:9, 83:11 predict 37:21, 38:10, 46:20, 47:1, 47:2, 54:1, 72:17, 223:5 predicted 189:7 prediction 43:4, 45:17 preference 100:21 prejudice 188:2, 232:2 prejudicial 229:9, 229:20 preliminary 187:8 preparation 29:2, 122:20 prepare 81:10, 81:13, 120:22, 123:9, 123:10, 124:1, 225:18 prepared 30:18, 30:20, 123:3 presence 136:10 present 5:3, 124:4, 125:19, 125:21 preservations 138:21 presumably 116:13, 120:22,
--	---	--	---

143:15, 213:9, 213:11 pretty 62:9, 91:16, 93:21, 101:3, 162:7, 168:17, 169:1, 179:15, 180:13, 181:1, 211:2, 211:5, 221:19 prevent 207:3 previous 63:20, 105:19 previously 6:10, 18:9, 18:15, 18:20, 19:3, 68:17, 81:5, 81:7, 173:20 principles 156:4, 156:9 prior 20:10, 22:9, 43:6, 102:19 probability 222:6 probably 26:12, 34:1, 46:8, 186:9 problem 198:10, 198:11, 198:12, 203:12, 205:10, 207:5, 207:6, 210:7, 212:5, 212:18, 212:19, 214:8 problems 221:4 proceed 126:21, 230:20 proceeding 20:2, 20:15, 21:2, 21:3, 21:4, 23:2, 24:5, 33:13, 34:10 proceedings 21:2, 21:13,	23:1 process 30:21, 167:20, 173:22, 231:5 processing 98:1 produce 187:3, 188:8 produced 95:20 product 193:3 production 48:9, 229:8, 231:3, 231:4 professor 10:8 profile 39:15 program 46:20, 47:7, 49:6, 51:6, 51:17, 98:12, 178:14, 210:11 programs 41:10, 43:4, 44:2, 49:18, 50:18, 50:22, 51:3, 51:5, 96:6 project 16:16, 16:17 prominent 220:6 promptly 231:19 propensity 225:7 properly 106:22, 220:18 properties 147:1, 148:19, 153:16, 198:17 property 198:18 propriety 230:22 protein's 136:12	proteins 16:5, 38:9, 38:13, 38:19, 38:20, 39:2, 39:3, 45:21, 48:10, 54:11, 55:16, 55:17, 56:2, 56:18, 57:1, 58:12, 60:10, 60:20, 67:7, 72:21, 74:11, 82:20, 87:21, 88:15, 89:2, 89:19, 90:5, 90:6, 93:16, 94:3, 94:13, 94:19, 94:21, 95:4, 95:7, 102:11, 106:5, 115:1, 115:19, 116:3, 116:7, 116:12, 116:13, 117:2, 118:13, 118:19, 143:13, 143:14, 156:18, 156:20, 156:22, 158:12, 163:9, 219:2 proven 143:5, 205:14, 212:1 provide 9:9, 45:7, 188:9, 194:6 provided 47:17, 48:1, 48:18, 169:17, 170:16, 170:18, 174:5, 192:17 provides 186:5 pseudo 117:12 psychically 190:4 ptab 37:9 public 2:11, 161:2,	233:1, 233:4, 234:16 publication 12:10, 81:17, 134:12, 180:17, 181:22, 212:1, 226:8, 226:9 publications 139:6, 226:8, 226:12 publish 134:9, 134:10 published 45:18, 46:5, 152:12, 152:16, 158:11 pubmed 226:17 pull 222:19 pulls 149:17 punitive 164:8, 164:19 purely 189:3 purify 45:6 purpose 52:16, 53:15, 67:14, 130:9 pursuant 2:10 put 94:7, 101:18, 102:8, 130:3, 130:4, 130:6, 131:18, 154:19, 155:2, 190:4, 190:6, 197:19, 203:17, 204:20, 230:9 putting 129:2 pymol 40:20, 41:10, 41:15, 42:3, 42:7, 42:12,
---	--	--	---

42:13, 44:9, 44:14, 150:6, 151:2, 196:16, 196:19, 197:5, 197:12, 215:12 pymol's 197:3	127:11, 137:19, 144:19, 161:18, 173:17, 191:14, 193:20, 218:15, 228:14, 228:20 questionable 91:5 questions 10:22, 11:11, 93:13, 192:1, 193:1, 232:6 quick 153:22, 228:4 quickly 33:7, 76:22, 196:22, 202:12, 203:20, 206:2, 206:12 quinn 4:9, 7:19, 7:21, 8:18 quintuple 209:7, 211:8 quite 103:20, 135:10, 180:20 quotation 136:10 quote 65:18, 65:21, 70:15, 70:19 quoted 68:9	145:22 range 90:3, 90:7, 90:9, 90:18 ranking 136:16 rapidly 193:20 rate 76:20 rather 108:21, 148:7 rating 129:22 rational 17:8 read 12:10, 14:18, 14:20, 19:21, 20:20, 21:8, 21:16, 21:18, 22:6, 22:10, 22:11, 24:4, 29:2, 30:2, 30:3, 30:10, 30:12, 30:19, 31:7, 31:13, 32:8, 32:9, 83:18, 123:10, 123:11, 126:9, 161:17, 179:8, 189:22, 191:7, 192:13, 193:14, 228:14 reader 58:10 reading 14:13, 16:1, 35:20, 83:15, 83:22, 88:10, 118:6, 122:19, 164:10, 230:7 reads 20:3, 21:14, 158:11 real 131:17 realize 173:16	really 73:5, 83:4, 91:12, 91:15, 107:14, 115:1, 131:12, 135:14, 135:15, 147:5, 148:19, 153:22, 154:1, 173:22, 179:7, 190:16, 190:17, 204:19 realm 90:14 realtime 196:20 reason 20:5, 77:11, 85:22, 98:16, 117:8, 144:4, 144:5, 144:8, 172:22, 203:21 reasonable 33:14, 49:13, 57:7, 59:2, 69:20, 140:4, 180:17, 181:4, 183:16, 201:3 reasonably 71:13 reasons 75:20, 83:16, 107:16, 110:8, 114:22 recall 10:16 recess 46:14, 80:15, 119:21, 155:18, 195:14, 217:8, 228:10, 231:11 recognition 164:17 recognize 70:19 recollection 84:15 recombinant 48:10 record 9:19, 18:4,
Q			
qm 180:19 qme 178:2, 178:3 qmean 181:9, 181:11, 182:9, 182:18, 182:19, 183:2, 183:7, 184:8, 184:11, 184:12, 185:7, 186:5, 196:6 qualitative 130:9, 181:11, 184:12, 189:4, 216:5 qualitatively 66:4 quality 178:2, 180:3, 182:19, 183:2, 183:20, 184:1, 184:10, 185:13 quantifying 149:15 quantitative 216:5 quantity 150:17 quarter 169:16, 171:21, 176:7, 176:9 question 11:12, 11:18, 11:19, 40:7, 47:4, 60:4, 63:1, 74:9, 82:17, 105:14, 105:15, 110:20,	R raechel 5:6 raise 9:6 raised 186:17, 231:1 ran 77:18 random 40:11, 61:21, 145:14 randomly 61:3, 66:2,		

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

271

46:13, 46:16, 80:14, 80:17, 119:20, 120:1, 122:4, 155:17, 155:20, 170:13, 186:14, 186:19, 187:1, 191:18, 192:15, 195:13, 195:16, 217:7, 217:10, 228:9, 228:12, 228:15, 230:10, 231:10, 231:13, 232:11, 233:11 recorded 174:9, 185:18 red 181:20 reduce 98:1, 166:9, 167:4 reduced 20:12, 165:4 redundancies 80:1 redundancy 98:3, 98:9 refer 48:20, 52:21, 55:20, 56:1, 67:20, 91:8, 110:14, 185:4, 219:21 reference 33:1, 33:3, 33:5, 128:14, 163:8 references 29:1, 32:16, 32:22, 33:10, 161:1, 161:5 referred 90:9, 143:9, 187:4 referring 38:2, 66:10, 84:21, 88:7, 102:13, 134:2,	169:4, 196:15 refers 55:15, 90:18 refine 174:1 regarding 18:6, 18:12, 18:18, 19:1, 124:8, 149:17, 231:3 regardless 74:14, 203:16, 216:10 regency 2:4, 233:20 region 54:17, 54:21, 66:9, 67:16, 67:20, 157:21, 158:4, 182:4 regions 54:12, 54:16, 65:5, 65:7, 65:14, 69:11, 70:21, 71:7, 71:13, 196:4 regularly 226:2 related 14:4, 55:3, 75:21, 76:1, 234:1 relating 73:3 relation 16:2 relationship 12:5, 22:11, 74:11, 90:13, 227:10 relative 151:9, 151:10, 182:18 relatively 198:15, 198:20, 198:21 relevant 32:17, 32:19,	32:21, 33:3, 33:6, 35:7, 48:4, 108:2, 191:15 reliability 185:7, 186:5 reliable 92:20, 93:7, 196:3, 196:5, 196:11, 197:1 relief 230:3 relies 230:16 religiously 58:9 rely 172:3, 174:4, 228:20 relying 191:16, 194:7 remain 140:5, 140:9 remainder 196:10 remember 43:2, 73:9, 87:8, 124:17, 161:3, 226:16 remote 8:10, 8:13 remotely 8:4 remove 121:22, 122:5 removed 79:6, 79:9, 79:13, 82:5 removing 78:20 repeat 63:1, 105:14, 118:22, 144:19 repeated 171:13 repetition 172:19 replaced 210:9	replies 187:8, 187:9, 187:12 report 159:7 reported 1:26, 151:5, 158:18, 158:19, 159:2, 159:6, 227:16 reporter 2:11, 9:2, 9:5, 9:8, 9:13, 12:16, 14:7, 14:15, 16:20, 17:10, 21:21, 24:12, 25:8, 28:9, 42:22, 45:20, 54:20, 62:15, 66:7, 78:4, 87:22, 101:4, 105:5, 107:19, 128:8, 144:18, 146:12, 149:12, 156:15, 167:8, 169:3, 176:10, 179:22, 182:5, 184:5, 185:6, 185:20, 200:13, 201:14, 211:1, 215:10, 219:6, 220:10, 222:8, 223:22, 225:16, 226:19, 233:1, 233:3 reports 159:12 represent 7:18 represented 79:21, 80:2, 233:15 representing 7:14, 9:3 reproduced 164:3 repulsion 25:12
--	--	---	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

272

request 125:12, 127:2, 174:12, 187:3, 230:2 require 102:7 required 43:21, 116:19, 130:10 requires 211:17 res 111:19, 112:10 research 12:2 researcher 135:8 reservation 131:17 reserve 230:2, 231:16 residue 103:19, 103:20, 105:3, 107:17, 108:5, 109:6, 109:19, 109:20, 110:3, 110:19, 110:20, 111:6, 111:13, 112:19, 113:11, 113:14, 113:15, 113:18, 113:20, 113:21, 113:22, 114:2, 114:3, 114:5, 114:6, 114:9, 115:2, 115:4, 116:18, 139:3, 141:9, 147:14, 149:18, 149:19, 150:6, 150:8, 153:18, 162:5, 170:7, 170:19, 182:2, 186:2, 186:3, 196:9, 196:14, 216:10, 217:21, 220:13, 220:15, 221:8, 224:22	residues 64:5, 64:9, 64:18, 65:10, 65:12, 66:1, 66:4, 66:15, 67:4, 67:10, 69:13, 69:18, 70:1, 70:4, 70:6, 71:6, 75:9, 76:16, 76:18, 77:5, 100:3, 100:4, 100:16, 101:7, 101:10, 101:14, 101:17, 101:22, 102:2, 102:7, 103:15, 103:18, 106:20, 107:15, 107:20, 112:14, 113:5, 113:9, 113:10, 114:13, 114:14, 114:16, 114:21, 115:2, 115:5, 116:13, 117:17, 118:16, 132:9, 137:8, 138:5, 138:9, 139:7, 140:14, 140:20, 141:3, 141:7, 142:7, 142:8, 142:14, 142:15, 142:18, 142:21, 143:4, 144:3, 144:9, 144:10, 154:5, 160:13, 161:11, 161:15, 162:3, 162:8, 162:10, 162:13, 163:1, 163:2, 164:12, 165:8, 165:18, 165:21, 167:4, 167:10, 187:14, 201:4, 202:22, 203:6, 203:9, 210:9, 211:11, 216:17, 222:10, 222:11	resources 44:3 respect 33:12, 35:18, 92:19, 127:1 respond 189:17 responded 192:16, 193:17 response 187:7, 231:16 responses 187:8 rest 138:6, 179:17 restrictions 74:22 restricts 61:6 resubmit 197:2 result 20:10, 75:8, 81:16, 87:12, 87:17, 153:13, 160:1, 167:11, 179:19, 179:20 resulting 79:15, 106:21, 118:19, 119:5, 155:1, 204:11, 227:13 results 99:17, 158:11, 163:11, 163:19, 164:4, 165:3, 167:3, 170:14, 199:14, 207:1 retained 6:11, 18:10, 18:16, 18:21, 19:4, 81:6, 81:8 return 78:13, 89:12, 90:15 returned 180:5 returning 89:11	review 121:2, 192:9 reviewing 230:14 revised 20:9 revisit 171:1 revisited 173:11 rhesus 213:5, 213:10, 213:12, 213:13, 213:21, 213:22, 214:8, 214:11 rid 77:10 rigorous 172:15 rl 163:15 role 138:12 rosetta 42:21, 43:11, 43:12, 43:15, 43:18, 44:6, 49:10, 49:16, 50:7 rotamer 210:20, 211:8, 211:9, 211:13 rotamers 210:21, 211:7 roughly 137:6, 171:21 routines 205:7 row 24:2, 24:19, 25:3, 25:4, 25:10, 25:13, 25:15, 25:17, 25:19, 83:20 rows 20:3, 20:4, 20:19, 21:8, 195:2, 229:15
--	--	---	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

273

rule 229:9, 230:11, 230:14 rules 194:6 run 43:18, 50:19, 78:11, 205:22 runs 178:8	93:17, 94:4, 98:6, 99:14, 117:15, 121:6, 121:16, 139:18, 139:19, 140:5, 140:9, 140:15, 144:8, 156:20, 157:2, 157:4, 159:22, 160:16, 173:6, 197:16, 211:10, 211:16, 213:13, 222:11, 229:13 sample 20:11, 64:14, 64:21, 65:1, 156:10 san 4:8, 42:6 sapiens 82:10 satisfy 93:10, 219:14, 220:8 saw 109:3 say 15:18, 23:5, 24:9, 24:22, 30:19, 30:22, 31:2, 31:12, 37:16, 38:18, 39:12, 49:12, 52:3, 52:10, 53:12, 54:10, 54:15, 55:14, 57:6, 57:9, 57:13, 58:15, 58:21, 59:11, 60:12, 65:20, 69:6, 72:2, 76:12, 85:22, 87:1, 88:6, 89:3, 100:1, 105:2, 106:18, 111:19, 116:10, 119:8, 123:2, 124:11, 124:20,	127:13, 128:9, 129:17, 130:7, 130:22, 131:18, 131:20, 132:22, 135:20, 136:22, 138:14, 153:6, 158:15, 159:2, 160:7, 168:12, 169:18, 175:3, 180:20, 189:16, 196:8, 196:14, 199:2, 199:20, 200:9, 200:14, 202:1, 202:18, 202:21, 207:8, 207:17, 210:8, 213:5, 215:9, 216:3, 217:15, 218:6, 219:12, 219:19, 219:22, 221:2, 222:9, 225:1, 225:6, 227:8, 229:6 saying 20:19, 57:6, 84:1, 84:2, 84:4, 95:7, 101:20, 191:16, 213:15 says 20:18, 22:3, 24:2, 24:8, 25:4, 25:6, 29:9, 70:19, 72:6, 84:15, 85:20, 110:2, 111:2, 146:18, 151:8, 181:8, 181:22, 184:21, 219:2 scale 170:11 scenario 135:7, 221:7, 221:11, 221:20, 223:14 scenarios 208:21	scheme 127:9 scientific 48:4, 158:18 scope 192:6 score 130:22, 132:14, 132:15, 132:19, 153:13, 154:3, 154:12, 171:6, 171:16, 173:5, 173:6, 173:11, 175:11, 175:14, 178:2, 178:3, 180:17, 183:7, 183:9, 184:8, 184:11, 185:8, 196:6 scored 132:9, 136:20, 170:10, 173:20 scores 171:1, 171:3, 185:5, 185:14 scoring 129:11, 129:14, 130:17, 141:15, 147:16, 167:16, 172:10, 172:20 screened 39:13, 39:21 script 98:8, 109:4, 151:6 scwrl 211:3, 211:11 se 101:11, 135:14, 203:13 search 51:22, 82:15, 161:2, 226:18 searches 102:10 searching 48:14 second 18:11, 46:1,
s 176:21 safe 93:21 said 47:17, 61:11, 63:21, 85:9, 90:16, 93:1, 96:7, 105:19, 123:15, 135:11, 140:13, 148:18, 167:18, 170:22, 171:22, 176:6, 176:7, 176:21, 187:12, 188:7, 189:1, 192:3, 192:8, 194:2, 194:3, 196:1, 212:5, 229:4 same 21:6, 21:12, 23:7, 24:1, 25:10, 25:11, 27:15, 27:17, 55:5, 60:1, 60:7, 60:12, 60:21, 61:9, 67:3, 72:17, 72:18, 72:22, 73:1, 73:14, 74:13, 74:19, 75:7, 75:8, 75:18, 76:8, 77:11, 79:15, 79:16, 79:20, 91:4, 91:19,			

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

274

68:4, 70:18, 109:8, 115:12, 115:13, 115:16, 127:12, 147:8, 174:19, 180:10, 202:3 secondary 146:4, 146:17, 147:8, 147:10, 148:2, 148:4, 148:7, 153:18, 183:5, 198:19 seconds 196:21 section 127:6 see 23:9, 23:12, 27:15, 27:18, 29:9, 29:12, 29:13, 32:10, 33:9, 51:5, 64:20, 66:18, 68:6, 68:11, 68:14, 69:1, 78:17, 82:19, 83:8, 84:2, 86:5, 91:12, 91:15, 99:19, 103:22, 109:16, 110:14, 119:9, 121:8, 127:8, 130:3, 130:5, 133:1, 133:12, 136:18, 137:10, 148:20, 153:11, 173:5, 191:3, 191:8, 196:20, 196:21, 200:18, 209:6, 215:22, 223:9, 223:10, 228:7 seed 78:2 seek 187:22 seem 86:3, 117:6	seemed 101:3 seems 33:14, 85:5, 87:8, 87:9, 93:21, 105:3, 193:12 seen 29:16, 29:17, 31:6, 31:7, 31:21, 33:15, 34:13, 34:14, 35:2, 35:21, 35:22, 37:5, 37:17, 37:18, 175:9, 191:2 sees 62:1, 68:19 segregation 115:18 selected 98:20, 178:20, 179:1 selecting 83:15 sense 64:13, 67:2, 67:5, 116:20, 143:7, 145:11, 198:9, 205:22 sentence 20:18, 22:3, 54:10, 54:14, 70:18, 71:20, 72:12, 100:9, 115:13, 115:16, 118:21, 118:22, 127:12, 218:4 separate 94:22, 95:12, 131:12 sequences 6:21, 20:7, 20:9, 20:11, 40:10, 51:11, 51:13, 51:16, 55:3, 55:6, 56:11, 57:1,	57:8, 58:14, 58:16, 59:12, 59:21, 59:22, 60:2, 60:5, 61:9, 63:22, 64:7, 64:12, 65:17, 67:3, 70:2, 71:5, 74:12, 74:14, 74:20, 75:2, 75:3, 75:21, 76:1, 76:22, 77:14, 77:16, 77:21, 78:1, 78:14, 78:17, 78:20, 78:22, 79:4, 79:7, 79:10, 81:17, 81:20, 81:22, 82:4, 82:6, 86:1, 87:12, 87:17, 87:18, 88:9, 90:15, 90:22, 91:18, 92:1, 92:4, 92:10, 92:14, 96:12, 96:18, 96:19, 96:20, 97:9, 97:10, 98:2, 98:6, 99:5, 99:7, 100:11, 103:1, 109:17, 109:18, 111:12, 119:10, 143:4, 143:18, 157:3, 205:17, 214:1 serially 190:8 service 43:17, 78:9, 78:16, 177:12, 179:8 services 41:2 set 57:4, 64:17, 64:18, 64:19,	78:6, 79:22, 80:3, 81:18, 81:22, 82:3, 85:22, 88:22, 98:2, 98:18, 108:20, 125:16, 131:3, 131:5, 168:11, 169:2, 169:5, 169:9, 171:17, 171:21, 172:4, 173:8, 173:9, 174:8, 202:19, 205:7, 209:5, 209:20, 209:21, 210:21, 211:8, 211:9, 228:22, 233:8, 234:8 sets 174:10, 205:16 setting 78:13, 192:22 seven 124:12, 124:13, 124:17, 154:10, 154:11, 155:6 several 23:8, 40:16, 84:10, 133:12, 180:5, 228:18 shape 73:5, 137:7, 219:9, 220:1, 220:5 shapes 61:19, 62:4 share 74:21, 156:20, 206:10 shared 67:7 sharp 1:6, 7:4, 233:15 sheer 212:6 sheet 225:8, 225:15
---	--	--	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

275

sheldon 1:19, 2:1, 6:2, 7:4, 9:20, 232:10, 232:12, 233:7, 233:19 short 46:9, 155:13 shortcomings 206:14, 207:1 shortfalls 206:14 shorthand 233:1 shortly 231:7 should 19:21, 20:3, 20:20, 21:8, 21:16, 21:18, 21:19, 22:6, 22:10, 22:11, 23:4, 23:8, 23:11, 23:19, 24:4, 24:9, 24:16, 24:22, 27:14, 56:3, 58:1, 95:13, 136:9, 146:22, 147:5, 148:19, 175:11, 187:22, 190:2, 190:21, 193:21, 194:9, 229:17, 231:6 shouldn't 89:15, 148:6 shown 163:21, 184:19, 185:17 shows 163:17 sic 26:16 side 62:10, 121:17, 185:17, 192:13, 210:18, 211:5, 219:4, 221:1, 221:2, 221:12	sidley 3:9 sidney 8:1, 8:5 sign 19:13, 44:1, 85:7, 86:10 signal 110:10, 110:11, 113:13, 113:17 signature-plkal 234:14 signed 19:11, 126:4, 126:5, 224:4 significant 101:1, 128:21, 141:6, 169:1, 209:17, 216:13 significantly 154:22 signing 126:6 similar 41:15, 42:6, 56:13, 57:1, 58:15, 58:21, 59:5, 59:13, 59:19, 60:22, 61:8, 72:16, 75:3, 78:2, 89:12, 91:1, 95:5, 153:8, 157:15, 175:9, 175:20, 181:1, 196:2, 226:14 similarities 87:4 similarity 55:5, 56:6, 56:7, 56:8, 56:17, 56:20, 57:2, 57:7, 57:9, 57:12, 57:13, 57:20, 57:21, 58:7, 58:17, 59:1, 59:3, 59:5,	59:12, 59:18, 59:22, 60:6, 60:11, 60:22, 65:17, 84:12, 85:15, 85:19, 85:21, 86:1, 86:22, 87:1, 87:13, 87:14, 90:8, 94:18, 157:1 similarly 92:18, 175:12, 179:13 simple 101:5 simply 22:11 simultaneous 204:1 simultaneously 209:2 since 10:5, 64:12, 69:14, 79:20, 174:12, 187:5 single 54:11, 70:20, 72:13, 136:11, 158:16, 163:9, 163:11, 165:4, 170:19, 171:18, 171:20, 172:9, 196:3, 198:14, 201:21, 202:3, 202:6, 208:6, 209:6, 209:16, 209:22, 211:20, 218:9, 219:3, 220:22, 226:21 sit 215:22 site 73:5, 73:12, 137:6, 138:5, 138:8, 138:10, 157:8, 161:11, 215:14, 215:17, 216:15	sites 204:5 situation 135:6, 206:2 size 64:21, 65:1, 76:4, 148:21, 153:8, 183:12, 184:18, 185:1, 185:2, 219:9, 221:13 skill 47:19, 48:1, 48:21, 49:2, 49:13, 51:21, 70:19, 118:10, 140:7 skilled 50:14, 51:9, 100:3, 106:18, 107:7, 108:3, 108:6, 114:17, 118:15, 156:13, 225:21 slight 57:22 slightly 58:6, 79:19, 90:8, 100:14, 173:18, 176:12 sliver 61:2 small 39:1, 39:2, 60:19, 61:1, 61:14, 62:3, 62:6, 62:14, 62:17, 63:3, 65:1, 76:2, 168:6, 229:14 smaller 64:17, 64:19, 151:14 snp 227:5 snps 226:20, 227:1, 227:16, 227:20
--	--	--	--

software 42:4, 42:5, 48:15, 49:14 solid 93:14 soluble 160:2 solved 44:18, 44:20, 45:13, 212:17, 212:18 solvent 149:16, 149:19, 150:1, 150:4, 150:5, 150:7, 150:11, 151:10, 151:13, 151:14, 151:19, 152:14, 152:15, 152:17, 183:5, 184:15, 219:12, 219:13, 220:7, 220:14, 220:18 solving 45:5, 45:22 some 11:10, 14:18, 19:17, 22:22, 24:17, 30:20, 36:17, 41:21, 42:1, 52:22, 56:13, 57:15, 57:22, 61:21, 64:22, 76:9, 76:20, 77:15, 83:16, 90:11, 90:12, 90:22, 107:15, 109:17, 114:21, 118:22, 119:6, 119:7, 124:13, 124:15, 124:19, 127:21, 130:13, 130:14, 135:2, 139:5, 139:11, 146:6, 159:9, 159:10, 159:18, 160:20, 161:2, 164:20,	168:5, 173:11, 174:21, 175:15, 176:8, 176:13, 179:13, 182:1, 183:7, 190:2, 195:2, 201:5, 208:16, 219:14, 220:8, 228:14 somebody 177:13 somehow 143:21, 190:4, 212:10, 213:18, 223:18 someone 8:12 something 14:4, 32:18, 51:7, 56:8, 63:13, 77:5, 77:8, 77:9, 80:9, 117:8, 117:18, 117:19, 118:1, 131:13, 131:17, 148:22, 152:10, 180:11, 195:1, 222:4 sometimes 43:22, 44:13, 90:9, 147:19, 161:5, 175:16, 182:2 somewhat 73:7, 150:15, 215:4 somewhere 20:3, 90:19, 92:13, 176:11 soon 194:16 sophisticated 43:20, 90:12 sorry 17:17, 22:1, 24:20, 25:3, 28:20, 39:18, 46:4, 70:11, 72:1, 73:22,	79:1, 79:6, 84:20, 113:2, 120:11, 126:17, 126:20, 146:2, 161:19, 166:15, 178:17, 204:14, 215:3 sort 69:6, 90:12, 90:20, 94:10, 147:21 sounds 46:11 space 60:17, 60:18, 61:2, 61:4, 61:13, 61:18, 62:11, 62:18, 63:4, 63:17, 63:18, 75:22, 76:3, 76:10, 77:1, 220:4 span 179:14 spatially 200:10 speak 12:19, 125:7, 125:8, 125:12 speaking 169:9, 198:21 specialist 177:14 specializes 51:2 specific 40:9, 74:15, 104:5, 187:14, 188:6 specifically 14:16, 40:20, 65:9, 230:12 specification 32:3 specificity 74:17 spectrum 56:8	spelling 8:8 sperm 82:22, 83:1 splicing 79:16, 79:17, 79:18 spreadsheet 24:15, 146:14, 170:16, 170:18, 174:4, 174:9, 174:12, 187:3, 188:8, 188:15, 189:8, 190:19, 190:20, 191:2, 191:3, 191:5, 194:10, 194:11, 194:12, 229:7, 229:8, 229:10, 229:13 st3gall 16:19, 16:21 stability 61:4, 129:7, 129:20, 131:10, 133:4, 133:7, 133:17, 145:21, 154:21, 228:1 stack 195:2 standard 60:8, 160:2, 183:10, 184:17, 184:21 stands 180:2, 181:11, 184:12 star 184:20, 184:21 start 26:19, 58:13, 69:5, 110:13, 173:8, 173:15, 198:22, 207:14, 216:17 started 15:3, 15:6, 15:11, 15:15,
---	---	--	--

16:3, 16:7, 17:13, 65:3, 76:9, 77:3, 170:1, 176:15, 176:19 starting 64:19, 86:13, 86:16, 161:4, 162:18, 169:21, 177:5, 177:16 starts 28:2, 66:14, 108:16 state 2:12, 7:18, 9:18, 161:10, 233:4, 234:17 stated 143:3 statement 209:20 states 1:1, 7:6, 210:21 statistical 64:13, 183:3 statistically 101:1 stay 144:1, 186:13, 186:18 steep 49:21 step 186:14, 203:17 step-by-step 177:10 steps 98:1, 226:16 steric 219:4 stern 158:20, 161:1 sterne 4:17, 7:22, 8:15 stewart 5:7, 8:6	stick 58:8 still 66:3, 116:13, 117:7, 119:5, 119:9, 120:8, 196:10, 205:17, 212:11, 213:11, 214:6, 219:14, 229:18 stone 57:4 stood 130:13, 153:22 stop 120:18 stopped 76:21 story 198:6 straightforward 198:15, 198:21, 208:17 street 3:10, 3:18, 4:18, 145:18 streptavidin 46:2, 104:12, 104:14, 104:19, 105:6, 106:1 strict 118:6 strictly 66:5, 116:18, 118:1 strike 15:2, 17:17, 36:20, 39:19, 40:8, 42:16, 46:4, 52:17, 55:21, 57:10, 58:13, 72:1, 73:22, 77:19, 82:18, 118:13, 125:20, 126:17, 142:5, 161:19, 218:1, 220:21 strong 154:16	structural 16:11, 138:21, 140:19, 158:17, 159:1, 159:2, 164:8, 164:19, 176:5, 177:14, 216:22, 219:8, 219:17, 219:20, 219:21 structurally 139:9 structures 16:4, 45:1, 45:2, 45:5, 60:16, 61:22, 62:20, 177:21, 179:9, 205:12, 205:16, 207:4, 214:22 struggle 212:16 struggling 212:21 students 40:5, 173:14 studies 68:18, 93:8, 101:17, 104:6, 104:22, 105:19 study 48:5, 75:1, 173:1 submit 96:18, 178:7, 198:1, 204:10 submitted 19:7, 19:10, 33:12, 34:10, 35:18, 123:14, 174:6, 194:9 subsequent 93:7, 198:8, 203:17, 231:18 subset 57:20, 75:2 substance 11:5, 21:5, 120:4, 126:3,	126:14, 156:1 substantial 72:8, 72:9, 155:1, 155:4 substantially 70:22, 71:8, 71:15, 71:18, 72:6, 72:15 substitute 146:10 substituted 149:5 substitution 54:5, 54:12, 58:2, 66:11, 66:13, 103:11, 107:9, 108:5, 127:20, 128:11, 129:19, 131:2, 131:6, 131:8, 131:15, 131:18, 131:19, 132:16, 132:19, 133:9, 133:11, 133:15, 133:20, 134:10, 134:20, 134:21, 135:1, 135:13, 137:2, 137:3, 137:14, 138:22, 139:15, 139:16, 140:3, 144:22, 145:7, 145:22, 146:22, 147:19, 151:4, 153:5, 153:7, 153:10, 154:3, 169:20, 170:10, 170:14, 171:5, 171:18, 171:20, 172:9, 172:22, 175:20, 175:22, 176:5, 198:13, 198:16, 200:17, 200:18, 202:4, 202:6, 216:19, 217:22, 218:9, 218:18, 220:14, 222:6, 226:6
---	--	--	---

substitutions 37:21, 38:11, 54:1, 57:16, 58:5, 66:19, 68:2, 68:5, 68:6, 68:12, 70:20, 71:7, 72:13, 106:5, 106:6, 116:5, 127:14, 127:18, 130:6, 130:11, 130:13, 130:21, 131:16, 132:21, 133:2, 133:3, 134:4, 134:5, 134:6, 134:13, 134:15, 134:17, 135:17, 135:21, 137:5, 139:11, 143:20, 145:11, 147:17, 153:9, 154:8, 154:11, 158:16, 159:5, 159:13, 160:18, 167:20, 168:2, 168:5, 168:8, 168:11, 168:14, 168:16, 168:19, 168:22, 169:10, 169:12, 169:14, 169:22, 170:4, 170:8, 171:7, 171:9, 171:22, 172:1, 172:17, 173:2, 173:12, 173:20, 174:3, 174:21, 176:12, 176:15, 176:17, 188:14, 188:17, 188:22, 189:9, 191:11, 196:4, 197:18, 197:20, 198:2, 199:7, 199:11, 199:21, 200:3, 201:16, 201:18, 204:22, 205:13, 206:16, 217:17, 218:14	substrate 74:17, 137:11, 137:21, 138:1, 164:7, 164:15, 164:17, 215:18, 215:19, 215:22, 216:9, 216:13 substrates 73:15 subtle 73:4, 74:16, 199:18 subtly 157:6 subtract 113:18 succeed 17:4 successful 211:22 sudden 209:2 suddenly 199:8 sufficient 118:4, 211:21 sufficiently 92:12, 93:3, 196:5, 216:8 suggest 87:20 suggested 165:16, 169:14, 169:21 suggests 65:17, 88:14, 117:17 suite 4:10 sulfuric 167:11 sullivan 3:7, 4:9, 8:5 sum 128:22, 184:13 summary 128:13 summers 4:7, 8:17	superposition 215:21 support 19:7, 118:4, 160:21, 225:7 supported 144:3 suppose 65:1, 172:13 supposed 56:12, 117:12, 145:19, 147:2 supposedly 231:3 sure 27:10, 32:12, 34:20, 35:1, 36:4, 36:5, 52:18, 55:11, 69:21, 83:14, 85:7, 88:3, 96:22, 119:17, 123:12, 124:12, 151:22, 152:2, 162:6, 162:7, 171:2, 174:16, 205:9, 216:6, 224:10, 228:5, 228:6 surface 149:13, 149:20, 149:21, 150:2, 150:4, 150:5, 150:7, 150:12, 150:22, 151:10, 151:14, 151:19, 152:8, 152:14, 152:15, 152:18 surmise 139:10 surprised 173:13 survived 143:22 swear 9:8 swiss-model 40:21, 41:10,	41:15, 42:16, 42:17, 43:4, 43:6, 43:14, 43:17, 44:5, 46:20, 47:2, 47:7, 49:6, 50:6, 52:3, 52:12, 52:21, 92:2, 92:7, 93:3, 93:11, 177:7, 177:11, 177:12, 178:13, 179:19, 185:22, 196:2, 197:2, 197:20, 198:2, 203:15, 204:10, 204:20, 205:4, 207:19, 210:18, 213:12, 213:17, 223:4, 223:8, 223:21 sworn 9:4, 233:9 synthesize 79:17 system 129:11, 129:13, 129:14, 130:18, 130:20, 131:3, 131:5, 141:16, 159:22, 167:16, 172:11, 172:20 systemically 205:15 T table 24:14, 24:19, 83:15, 100:6, 114:14, 162:11, 163:21, 164:10 tables 190:9 tabulate 212:10 tabulating 168:16 take 11:16, 11:17,
---	---	---	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

279

11:19, 36:15, 46:9, 80:7, 85:9, 118:5, 124:22, 155:13, 177:20, 186:11, 186:20, 195:9, 197:17, 204:17, 207:10, 217:3, 228:3, 231:8 taken 233:10 taking 7:15 talk 169:5, 229:22 talked 56:5, 113:3, 226:4 talking 18:3, 37:3, 53:7, 64:1, 135:6, 156:4, 214:14, 222:17 target 78:2, 78:10, 89:13 task 67:22, 68:2, 223:20 tasked 68:12, 69:8, 69:10, 69:22 tease 202:5 technically 50:1, 204:7 technician 5:6 techniques 22:13, 48:11, 48:13 tell 54:21, 55:2, 89:16, 126:6, 133:6, 183:13, 192:2, 204:21, 214:21 telling 187:17	tells 168:4, 183:15 template 178:4, 178:7, 178:21, 179:2, 179:4, 179:6, 179:7, 180:4, 180:5, 180:7, 180:10, 180:19, 197:12, 197:15, 197:21, 212:22, 214:3, 214:7 templates 178:1, 178:15, 178:20 tend 94:22 term 36:12, 48:20, 52:22, 55:20, 55:22, 58:9, 66:8, 67:9, 67:13, 67:19, 68:10, 68:20, 96:22, 100:8 termed 119:3 terminate 231:20 terminology 21:19, 52:19, 55:12, 136:5 terms 36:19, 58:8, 90:21, 91:7, 106:4, 129:16, 133:16, 136:16, 137:2, 148:21, 156:5, 159:3, 183:4, 183:6, 184:14, 191:1, 216:7, 219:8, 219:16, 227:11 test 86:17 tested 143:5 testimony 9:9, 126:15,	187:19, 230:16, 233:11 testing 144:9, 163:9, 164:4 th 4:18, 79:8, 234:9 thank 8:20, 8:21, 8:22, 9:13, 11:3, 11:9, 20:22, 22:7, 26:2, 26:5, 53:14, 70:8, 70:12, 88:4, 97:4, 127:4, 155:15, 166:22, 195:7, 215:2, 215:5, 224:11 thanks 50:9, 112:12, 185:3 themselves 7:18, 224:2 theoretical 63:14 theoretically 76:3, 89:15, 145:3 thereby 71:6 therefore 55:19, 57:2, 62:13, 69:15, 72:10, 73:15, 74:20, 75:1, 101:18, 106:16, 115:3, 138:2, 139:19, 143:6, 200:12 thing 56:20, 73:4, 73:17, 78:12, 147:22, 148:12, 191:13 things 68:3, 73:4,	119:11, 127:10, 133:8, 147:6, 160:8, 188:11, 192:20, 209:3, 209:7, 210:14, 226:14, 228:14 think 8:9, 8:19, 14:3, 14:5, 23:8, 23:10, 23:11, 30:14, 30:18, 35:7, 35:9, 39:6, 49:13, 51:18, 53:9, 59:18, 61:18, 69:3, 83:12, 85:18, 85:20, 86:4, 86:6, 87:7, 94:8, 100:20, 102:18, 106:3, 107:2, 115:8, 123:21, 125:1, 132:7, 133:14, 134:1, 140:4, 141:5, 141:14, 143:9, 147:6, 150:22, 154:20, 162:2, 173:22, 176:7, 176:20, 180:10, 180:16, 181:3, 181:18, 193:20, 193:21, 194:17, 194:18, 201:3, 206:18, 211:3, 212:18, 212:20, 216:11, 221:16, 221:20, 221:22, 222:6, 222:19, 223:14, 230:8, 230:17, 231:21, 232:2, 232:3 thinking 116:8, 175:13 third 18:17, 86:6, 97:15, 115:12,
---	---	--	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

280

115:13, 115:16, 146:18, 147:12, 152:19 thorough 172:15 thought 111:5, 131:11, 172:22, 173:7, 191:14 three 33:8, 86:20, 123:2, 146:16, 146:20, 147:15, 147:18, 153:15, 164:10, 193:4, 198:17, 209:1 three-dimensional 61:10 three-way 208:9 threshold 182:15, 184:9 through 13:21, 24:10, 78:7, 78:16, 83:17, 102:1, 104:21, 127:10, 128:4, 130:13, 167:20, 170:22, 172:19, 198:2, 201:20, 202:2, 203:15, 205:7, 205:15, 210:20, 215:21 throughout 48:19 thursday 1:21, 7:10, 233:20 time 7:11, 7:12, 10:19, 10:20, 11:16, 17:14, 25:11, 30:4, 41:9, 41:14, 43:8, 43:12, 44:8, 44:11, 46:13, 46:16,	46:19, 47:6, 47:19, 48:2, 49:1, 49:5, 49:9, 50:10, 50:19, 51:11, 51:15, 53:4, 71:3, 73:17, 76:17, 76:20, 77:10, 80:14, 80:17, 94:12, 98:4, 111:10, 111:11, 111:16, 114:7, 114:10, 119:16, 119:20, 120:1, 123:22, 133:22, 134:3, 134:4, 155:17, 155:20, 156:7, 156:11, 161:6, 171:14, 173:6, 175:18, 180:6, 187:1, 189:13, 190:8, 192:21, 195:16, 199:6, 217:7, 217:10, 222:11, 227:16, 228:3, 228:9, 228:12, 229:14, 231:10, 231:13 timeless 156:9 times 52:2, 52:5, 52:8, 52:15, 84:1, 109:22, 111:17, 171:2 tiny 183:21 today 7:13, 9:2, 9:9, 37:3, 42:4, 212:19 today's 7:10, 122:20, 230:16 together 76:1, 124:9, 201:16, 201:18,	206:9 told 190:3, 193:14, 193:15 tolerate 54:11, 66:11, 66:12, 66:19, 136:2, 136:9, 138:15, 160:18 tolerated 68:7, 115:19, 130:8, 135:17, 135:20, 137:4, 143:13, 154:10, 154:12, 154:15, 154:17, 218:9 took 98:1, 109:4, 149:6, 226:16 tool 42:9, 51:22 tools 22:13, 40:17, 40:18, 41:1, 41:3, 41:6, 41:13, 41:19, 41:22, 42:2, 48:13, 51:14, 52:1, 196:2 top 78:18, 97:13, 109:5, 110:1, 176:19, 184:7 torsion 183:4, 184:15 total 38:13, 167:11, 172:2, 183:7 totally 167:9, 190:15 toward 125:1 track 112:5, 165:17, 204:3, 206:7, 206:12, 212:8 tracked 199:16	trademark 1:1, 7:6 training 48:7 transcript 6:6, 27:2, 121:3, 230:7, 230:14 transferring 215:21 transfers 16:22 transforming 17:4 translates 181:3 treat 197:16, 199:4, 199:5 treated 200:12, 200:14, 201:9 trey 4:15, 7:22, 26:15, 194:3 trial 1:3, 7:7, 37:1 tried 106:6, 106:9, 106:12, 137:22 true 118:9, 140:12, 198:4, 206:10, 233:11 truncated 165:9 trust 184:2 truth 9:10, 9:11 try 103:7, 105:15, 106:17, 107:4, 107:8, 129:4, 137:12, 145:8, 145:10, 145:12, 145:22, 173:18, 207:14, 213:20,
---	--	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

281

227:4 trying 38:10, 64:13, 68:11, 83:17, 104:13, 105:22, 128:6, 128:11, 141:8, 148:11, 175:19, 190:3, 203:1, 207:9, 207:10, 210:1, 210:13, 216:3 turn 27:6, 47:10, 54:6, 54:8, 70:13, 99:20, 108:14, 112:21, 119:14, 126:8, 126:19, 141:21, 151:18, 161:8, 163:5, 163:6, 164:22, 167:13, 177:3, 194:18, 195:18, 195:19, 215:6, 217:12, 218:2, 225:4 turned 98:10 twenty 80:8 twice 171:17, 171:19 twilight 90:10, 90:17, 90:18, 91:6, 91:11 two 2:5, 7:15, 45:1, 45:2, 55:16, 55:17, 56:11, 56:18, 56:22, 57:8, 58:12, 58:14, 58:16, 59:12, 60:10, 68:3, 72:16, 72:21, 76:5, 90:4, 93:16, 94:2, 95:2, 95:12,	96:18, 98:5, 98:6, 100:20, 119:10, 125:6, 128:18, 130:12, 148:20, 156:22, 179:8, 197:18, 197:19, 198:2, 199:21, 200:19, 201:11, 201:15, 201:17, 202:21, 203:1, 203:6, 205:12, 206:10, 207:8, 207:13, 210:14, 212:6, 214:21, 216:21, 226:8, 226:12, 226:15, 227:8 type 12:4, 38:9, 114:3, 127:13 types 38:19, 167:19, 168:2, 168:4, 168:8, 168:14, 168:15, 168:19, 168:22, 191:9, 191:10, 208:15 typical 150:19, 224:21 typo 21:11 typographical 21:17, 24:6 tyr 161:13 tyrosine 161:14, 161:21 U uh-huh 16:15, 19:20, 20:17, 30:16, 38:6, 53:2, 58:3, 63:9, 65:20, 72:11, 73:13, 76:13, 102:20, 112:9, 119:1, 128:3,	136:4, 149:14, 152:5, 205:19, 221:10, 223:17 ultimate 134:8 ultimately 45:17, 112:4, 170:2, 176:16 unbiased 167:16 uncertainties 209:18 uncertainty 207:1 under 29:10, 122:9, 158:10, 194:6, 225:13, 229:9, 230:11, 230:14 undergo 79:17 undergraduate 48:3 underlying 147:10 understand 11:4, 11:8, 11:14, 11:15, 11:20, 31:18, 33:11, 34:9, 35:17, 37:1, 53:12, 58:11, 68:21, 71:4, 71:18, 73:16, 73:20, 92:22, 95:3, 99:15, 99:19, 107:8, 114:17, 118:11, 118:16, 121:9, 122:4, 135:16, 141:8, 144:13, 144:21, 145:20, 146:10, 148:11, 161:18, 203:2, 210:2, 210:13, 213:16, 216:4, 225:21 understanding 36:13, 65:6,	94:10, 111:9, 114:8, 115:21, 152:13, 163:14, 200:1, 201:17, 214:3 understood 31:11, 93:15, 95:14, 189:22, 226:2 unfavorable 127:22, 131:15, 133:21, 176:1, 202:11, 226:7 unfolded 160:1 unfortunately 57:5, 141:14, 198:5, 199:16, 204:19, 206:19, 209:8 unhappy 195:3 unique 22:22 united 1:1, 7:5 university 10:1, 10:4, 10:6 unknown 77:8 unless 11:12, 53:3, 139:2 unlike 173:14 unlikely 139:9, 216:10 unmuting 120:12 unpack 55:10 unquote 65:18, 65:21 unreasonable 190:15 unrelated 94:17, 95:6
--	---	--	---

unremarkable 153:6 until 11:6, 46:14, 80:15, 119:21, 155:18, 195:14, 217:8, 228:10, 231:11 untouched 140:3, 140:8 update 171:16 updated 173:21, 175:14 urge 154:1 urquhart 4:9 use 27:9, 39:9, 41:14, 42:5, 43:10, 43:11, 43:20, 44:11, 48:11, 48:20, 49:14, 49:18, 51:10, 51:12, 53:1, 53:22, 55:20, 58:9, 66:8, 67:9, 67:13, 67:19, 68:9, 77:15, 78:5, 91:8, 93:3, 93:10, 97:6, 97:7, 102:4, 129:13, 136:9, 141:2, 165:12, 165:14, 177:15, 178:1, 178:5, 179:2, 179:6, 213:17, 214:6, 224:18 useful 53:19, 159:3, 159:7, 159:10, 159:13, 159:16, 160:5, 160:7, 160:20, 166:5 uses 211:2	using 41:10, 41:12, 43:3, 44:9, 48:10, 51:3, 51:6, 52:18, 52:20, 55:22, 90:11, 92:2, 92:7, 95:19, 100:2, 112:3, 129:11, 170:11, 177:7, 177:11, 196:16, 197:12, 197:14, 197:21, 200:3, 203:14, 210:12, 213:12, 214:4, 215:12 V validate 172:10 value 78:15, 87:9, 149:22, 150:19, 180:15, 180:19, 181:5, 181:14, 182:8, 182:13, 185:19 values 62:9, 62:12, 152:16, 185:17 variable 104:1 variation 64:20, 66:18, 67:4, 116:1, 116:6, 116:17, 119:9, 119:12, 143:11 varied 67:2, 103:20, 150:13, 150:15 various 68:5, 103:7, 109:10, 134:3, 143:20, 159:9, 226:4, 227:20 vary 39:1, 56:14,	65:1, 65:15, 65:16 venom 215:20 versatile 51:20 version 163:1, 195:6, 229:18, 231:5 versions 13:18 versus 7:5, 82:17, 102:2, 208:6, 209:21, 221:17 viable 179:8 vice-versa 175:5 video 7:11, 7:14, 186:19, 186:20, 187:1 videographer 5:5, 7:2, 7:13, 8:22, 46:12, 46:15, 80:13, 80:16, 88:1, 88:4, 119:19, 119:22, 155:16, 155:19, 186:18, 186:22, 195:15, 217:6, 217:9, 224:3, 228:8, 228:11, 231:9, 231:12, 232:9 videotaped 1:18, 7:3, 232:12 view 50:5, 183:20 viewer 42:4 viewing 199:17 viewpoint 129:5 visit 177:19	visual 129:4, 211:20 visualized 215:9, 215:11 voice-identify 7:17 volume 220:1 vouch 172:21 W wait 32:13, 55:10, 193:22, 194:5, 207:13, 208:3 walk 78:7 wang 226:8, 227:9 want 8:10, 26:9, 26:18, 46:9, 57:11, 80:6, 87:1, 98:5, 121:22, 124:11, 155:13, 168:7, 174:14, 178:4, 186:11, 186:18, 187:4, 187:20, 188:9, 194:13, 195:9, 196:22, 228:3 wanted 19:17, 25:22, 78:17, 79:22, 96:13, 100:21, 103:22, 104:18, 123:20, 123:21, 127:8, 172:14, 216:21, 224:9 wants 192:19 washington 3:11, 4:19 waste 180:6, 192:21 watch 183:22
---	--	--	--

watching 232:1 way 34:12, 51:1, 53:8, 69:1, 70:3, 72:12, 72:17, 72:18, 72:22, 75:8, 75:18, 90:20, 91:20, 102:17, 110:6, 129:8, 132:13, 138:21, 149:15, 153:12, 160:2, 171:2, 171:10, 173:2, 175:17, 180:6, 183:7, 188:12, 189:4, 189:6, 189:7, 190:13, 197:16, 207:15, 213:13, 216:13, 220:3, 234:5 ways 100:20, 160:20, 164:21 we'll 195:8 we're 8:17, 18:3, 37:2, 53:6, 55:12, 103:8, 120:17, 126:21, 127:2, 135:6, 151:16, 187:2, 188:7, 214:14, 222:17, 230:9 we've 17:15, 46:8, 80:8, 113:3, 155:11, 156:4, 186:9, 193:14, 193:15, 228:2 web 41:1, 43:17, 78:9, 78:16, 177:12 website 177:19, 177:20,	178:13, 181:8 weeks 123:2 welcome 46:18, 81:1, 120:3, 155:22 well-defined 62:9 well-known 41:8, 51:1, 94:5, 104:7 went 68:16, 99:11, 123:12, 170:2, 170:22, 171:12, 173:11, 174:18, 177:10, 178:12, 192:7 weren't 103:18, 138:4 whatever 30:20, 62:3, 62:4, 85:9, 118:19 whereas 68:17, 98:11, 151:11 whereof 234:8 whether 54:21, 66:19, 85:10, 89:16, 90:4, 92:20, 103:22, 128:18, 129:5, 129:8, 129:19, 130:7, 133:20, 137:3, 137:17, 157:20, 159:18, 201:12, 202:18, 216:14, 218:8, 219:11, 223:9, 226:6 white 56:20, 229:16 whittled 78:20 whoever 224:1	whole 9:10, 56:15, 171:17, 179:16, 184:7, 212:16 wide 90:6 widely 41:8 wild-type 100:22, 109:7, 109:15, 111:2, 111:6, 112:6, 112:19, 113:12, 116:18, 131:13, 147:13, 150:10, 150:11, 151:3, 153:19, 154:22, 155:8, 166:13, 170:6, 197:16, 201:13, 203:7, 207:7, 207:12, 207:16, 208:3, 209:5 wile 114:3 willing 122:5, 187:2 wilson 4:15 withheld 193:9 withhold 193:10 within 59:3, 137:5, 215:12, 218:7, 219:5, 233:4 without 71:15, 71:21, 72:14, 116:9, 119:12, 129:2, 144:5, 173:2, 223:21 witness 9:3, 9:7, 9:12, 18:8, 18:14, 26:8, 27:4, 46:11, 80:11,	85:4, 88:3, 119:18, 120:16, 120:19, 122:9, 155:14, 186:12, 186:15, 228:5, 230:8, 230:18, 232:6, 233:7, 233:12, 234:8 word 55:13, 56:3, 136:2, 136:9, 203:14 words 24:17, 59:2, 88:11, 99:5, 107:2, 113:17, 116:17, 131:9, 138:7, 138:22, 143:17, 202:15, 204:2, 211:10 work 12:10, 14:9, 14:21, 15:1, 16:21, 17:11, 17:12, 17:16, 17:18, 37:20, 38:2, 38:3, 39:7, 41:9, 42:7, 43:3, 44:8, 44:15, 46:6, 52:12, 53:10, 67:10, 67:17, 101:7, 101:12, 101:20, 102:9, 102:13, 102:20, 105:10, 105:13, 106:4, 129:15, 129:17, 133:18, 135:15, 157:17, 172:14, 188:4, 188:7, 192:6, 192:12, 192:13, 193:3, 193:19, 223:6 worked 17:15, 17:21, 38:14, 38:20 working 15:3, 15:6,
--	--	--	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

284

15:11, 15:15, 16:3, 16:7, 16:16, 17:2, 103:8, 103:11, 104:3, 180:18 worried 131:18, 131:20 worry 138:13, 216:18 worse 201:13 worst 221:16 worthy 131:12 wouldn't 30:19, 49:19, 69:5, 76:15, 129:22, 134:4, 134:12, 134:18, 134:21, 145:8, 145:11, 145:12, 145:14, 145:22, 146:1, 154:20, 175:3, 193:5 wrap 24:16 written 42:5, 72:12, 151:6 wrote 12:14, 45:10, 45:17, 46:3 X x-ray 42:10 Y yeah 8:12, 19:16, 22:2, 23:16, 23:18, 24:18, 26:11, 26:22, 27:4, 30:12, 64:4, 74:19, 80:10, 80:11, 84:3, 91:16,	97:6, 97:22, 98:18, 102:20, 102:21, 108:16, 110:7, 112:3, 112:18, 117:22, 122:16, 127:6, 145:12, 151:21, 152:1, 194:2, 195:5, 195:10, 203:12, 217:5, 224:12 year 10:5, 20:8, 20:10, 43:7, 49:4, 77:17, 79:5, 125:1, 125:2, 176:2 years 17:15, 76:11 yf 163:15 york 1:20, 2:12, 4:6, 7:16, 9:21, 233:4, 234:17 yourself 80:19, 148:13, 224:7 yue 217:15, 226:9, 227:9 Z zach 4:7, 8:17 zhang 4:8, 158:20, 161:1, 163:9, 163:13, 163:20, 164:3 zone 90:10, 90:17, 90:18, 91:6, 91:7, 91:11, 91:14 zoom 120:8, 120:10, 120:13, 124:9,	124:10, 125:5, 125:10, 126:22 . .05 181:15 .17 150:12 .6 182:12, 184:1 .75 181:14 0 0.1 180:11 0.17 151:11 0.388 151:11 0.6 181:21, 181:22, 183:21 0.69 180:9, 180:14, 180:16, 181:3 0.75 181:18 00003 1:12, 6:13, 7:8, 18:6 00004 1:13, 6:15, 7:8, 18:12 00006 1:13, 6:17, 7:8, 18:18 00009 1:14, 6:19, 7:9, 19:1 003108.2 97:14 004 24:6 006 21:3 02199 4:11	03 23:2 035 35:19, 35:21, 35:22, 36:1, 36:7 04 80:15, 80:17, 119:20, 119:21, 155:17 05 119:15, 155:18 06 119:21, 120:1, 217:7, 217:8 07 231:11, 231:13 08 187:1, 217:8, 217:10, 232:11 09 232:13, 233:21 1 1 83:1, 97:16, 119:21, 120:1 1's 134:18 1,218,298 6:16, 18:13 10 4:18, 25:15, 38:18, 80:14, 80:15, 95:16, 170:2, 172:16, 176:20, 188:19, 188:20, 188:22 10.22 111:10, 111:11 100 23:7, 23:8, 23:9, 23:16, 78:14, 78:18, 89:6, 139:8, 189:2 1004 6:13, 6:15,
---	---	--	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

285

6:17, 6:19, 18:5, 18:9, 18:12, 18:15, 18:18, 18:20, 19:1, 19:3, 28:2, 28:3, 28:5 1005 30:6 101 165:1, 165:2 102 167:14, 167:15, 187:11, 191:8 103 167:15, 187:11, 191:8 1054 6:21, 80:5, 81:4, 81:5, 81:12, 81:14, 81:19, 81:22, 82:3, 82:8, 82:16, 82:19, 91:19, 92:1, 96:21, 97:10, 97:14, 97:21 1057 6:22, 80:5, 81:4, 81:7, 81:12, 95:16, 95:18, 96:20, 97:1, 97:8, 97:9, 97:13, 97:20, 109:3 107 215:7, 215:8, 215:11 109 23:2, 23:4, 23:12 11 25:17, 80:15, 80:17, 234:9 11,952,600 6:14, 18:7, 29:11 110 23:14	1101 4:18 111 4:10 113 166:8, 166:13, 166:17 12 21:22, 22:8, 22:9, 47:15, 119:15, 119:20, 119:21 12,018,298 33:10 12,123,035 1:15, 6:20, 19:2, 35:16 12,152,262 6:18, 18:19, 34:8 125 153:1 126 108:16 127 21:5 129 161:12, 163:15 13 25:19 131 161:13, 163:15 134 20:3, 20:12, 20:19, 20:20, 21:8, 24:6 14 98:14, 113:8, 113:10, 114:5, 114:9 14068 9:21 14202 2:6, 7:16 145 20:2 146 110:22, 161:13,	161:20 147 21:4 148 161:14, 161:21 149 177:3, 177:4, 177:5 15 155:18, 155:20 1501 3:10 151 21:3 153 185:4 16 109:22, 195:14 160 195:21, 195:22 161 195:19, 195:20 167 162:18 168 162:16 170 162:15 178 151:18, 151:20 179 152:1, 152:4 18 6:13, 6:15, 6:17, 234:12 18.18 110:1, 110:2 19 6:19, 145:3 19104 3:19 192 151:8 2 2 155:17, 155:18, 155:20	2's 134:17 2,800 229:15 2.83 184:8, 184:11, 184:16, 184:21 20 13:21, 14:2, 14:9, 14:11, 14:13, 14:16, 15:4, 21:15, 21:16, 21:19, 21:20, 22:4, 22:6, 31:19, 34:1, 34:18, 34:22, 36:3, 54:8, 65:4, 68:1, 73:10, 73:19, 74:1, 74:7, 74:14, 75:4, 77:13, 78:3, 78:10, 82:9, 82:17, 82:21, 83:6, 83:7, 84:19, 88:21, 90:19, 92:11, 92:17, 93:2, 97:16, 100:4, 109:5, 109:8, 110:6, 112:8, 112:19, 113:20, 113:22, 114:3, 114:6, 136:7, 137:4, 138:14, 161:4, 161:14, 161:21, 162:10, 162:13, 162:20, 163:1, 165:4, 165:9, 166:9, 167:4, 168:21, 168:22, 169:2, 169:5, 169:11, 170:7, 177:18, 177:19, 178:14, 181:1, 196:5, 197:2, 197:12, 197:18,
---	--	--	---

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

286

199:20, 203:5, 203:7, 204:10, 207:17, 212:21, 213:5, 213:10, 213:11, 213:13, 213:14, 213:18, 213:21, 213:22, 214:5, 214:6, 214:12, 214:20, 215:12, 215:18 20005 3:11, 4:19 2006 10:5 2011 20:9, 41:7, 41:9, 41:14, 42:2, 42:13, 42:18, 43:3, 43:6, 43:7, 44:8, 46:19, 47:6, 47:19, 48:2, 49:1, 49:4, 49:5, 49:9, 50:10, 50:14, 50:19, 51:11, 51:15, 67:10, 71:3, 71:11, 77:15, 77:17, 78:21, 79:5, 79:9, 81:18, 94:9, 94:12, 96:8, 96:14, 102:9, 102:15, 102:18, 133:22, 134:1, 156:7, 156:11, 156:14, 158:19, 175:18, 176:2, 196:2, 212:18, 225:2, 225:11, 225:21 2012 20:8 202 3:12, 4:20, 161:13, 163:15 2020 17:12	2021 17:13 2024 10:15 2025 1:12, 1:13, 1:14, 1:21, 6:13, 6:15, 6:17, 6:19, 7:8, 7:9, 7:11, 18:6, 18:12, 18:18, 19:1, 29:9, 233:21, 234:9 2026 234:12 2037 26:16, 26:19, 26:20, 26:21 2068 6:8, 27:1 2143 3:20 215 3:20 219 161:14, 161:21 234 1:25 247 163:15 2600 4:20 262 34:11, 34:13, 34:14, 34:15, 35:11 265 163:15 27 6:8, 228:9, 228:10 29 79:8 2929 3:18 298 33:13, 33:15, 33:17, 33:20,	34:3 3 3 29:9, 187:1, 195:14, 195:16 3,000 169:13, 172:1, 176:8 30 89:5, 93:15, 94:2, 94:4, 94:8, 94:10, 99:21, 100:1, 113:3 31 23:5, 24:9, 24:11, 93:20, 112:22, 115:10, 115:13, 115:17, 143:8 317 23:6 319 23:22 32 23:5, 68:9, 70:13, 70:16 320 24:2, 24:4, 110:15, 142:2, 142:6, 142:8, 143:14, 143:21, 144:15, 144:22, 145:2, 152:9, 154:6, 154:13, 154:19, 155:3, 192:9, 207:10, 207:11, 207:18, 207:19, 208:1, 208:4, 208:5, 208:12, 215:9, 215:11, 215:13, 215:16, 216:1, 216:10, 216:15 321 23:6, 207:21, 208:5, 208:12	323 23:19 324 23:6 34 23:5, 24:7, 24:8, 195:14, 195:16 341 165:9 35 90:19, 110:10, 110:11, 113:18 355 110:16, 110:18, 110:20, 111:2, 111:6, 112:13, 112:17, 112:19, 151:9 36 87:8, 89:5 37 89:5, 213:6, 213:7 371 4:20 372 21:16 374 21:14 380 168:22 394 111:19, 112:10 4 4 217:7, 217:8, 217:10, 228:9, 228:10, 228:12, 231:10, 231:11 40 86:2, 86:3, 87:6, 94:14, 212:21 40.24 181:7 400 177:1
--	---	--	--

Transcript of Dr. Sheldon Park
Conducted on August 7, 2025

287

41 92:12 42 21:18, 22:1, 22:2, 22:3, 46:13, 46:14 42.65 229:9 427 68:8, 70:9 429 30:5, 30:8, 30:9, 31:14, 32:8, 32:10, 32:13, 70:10, 70:11, 70:16 45 1:22, 7:11, 92:12, 93:1, 93:21, 233:21 450 176:20, 176:21 48 80:14, 80:15 495 98:15, 99:11, 110:7 5 231:11, 231:13, 232:11, 232:13, 233:21 5,000 78:16, 212:10 50 57:6, 59:3, 87:5, 179:14, 228:10, 228:12 500 59:4 506 46:1 509 98:11 51 111:17 511 98:10, 98:21,	99:4 52 217:13, 217:14, 217:15, 219:1 520 4:10 53 218:2 54 46:14, 46:16, 231:10, 231:11 57 95:16, 95:17 57.95 111:16, 111:18 594918 1:24 6 60 57:9, 58:15, 59:11 600 29:14, 29:16, 29:18, 29:22, 30:1, 31:17, 31:22, 32:3, 32:6 615 122:10, 230:12, 230:15 617 4:12 64 25:1, 25:9, 25:14 68 100:2, 114:12, 114:14, 114:16, 115:4 7 7,767,429 30:7 70 225:4, 225:5, 225:6, 225:13 7100 4:12	712 4:12 72 109:22 736 3:12 7th 7:10, 233:20 8 1:22, 7:11, 25:13, 233:21 80 20:15 800 176:12, 176:13, 190:2, 195:2 8000 3:12 81 6:21, 6:22 81.81 110:4 820 176:9, 188:13, 189:2, 189:8 830 176:9, 188:13, 189:2, 189:8 84 179:18 85 126:19, 127:7, 127:8, 127:9, 127:13 86 182:17, 183:1, 184:7, 185:14 88 79:10, 81:19, 82:5, 85:22, 98:2, 98:9, 98:13, 109:13, 110:1, 111:12, 111:18, 158:8, 158:10, 158:15 9 46:13, 46:14,	46:16 90 156:18, 157:1, 157:11, 157:13, 157:14, 227:16 91 161:8, 161:9, 161:10 95 20:4, 20:12, 20:20, 21:8, 79:7, 81:22, 82:1, 82:3, 86:1, 87:16, 91:18, 98:2, 100:16, 100:17, 100:18, 101:2, 101:6, 101:11, 113:4, 163:6, 163:7, 163:8 95.5 114:6, 114:9 97 21:13 99 28:2, 28:11, 163:21, 164:1, 164:2 994 3:20
--	---	---	--